prednisolone

Research Excerpts

Overview

Prednisolone (PRD) is an immunosuppressant and anti-inflammatory drug, although it may cause peptic ulcers as a side effect. It is a corticosteroid and one of the most important agents in the treatment of ALL.

Excerpt	Reference	Relevance
"Prednisolone (PRD) is an immunosuppressant and anti-inflammatory drug, although it may cause peptic ulcers as a side effect. "	( Multivariate Model Update Chemometric Methods for Determination of Prednisolone and Esomeprazole in Spiked Human Plasma: A Comparative Study. Abdelhamid, NS; Anwar, BH; Farid, NF; Magdy, MA, 2022)	2.4
"Prednisolone is a new treatment method for such patients."	( Prednisolone Treatment Is Effective for an Idiopathic Penile Abscess: A Case Report and Review. Konno, T; Kurokawa, M; Nishida, H; Tsuchiya, N; Yamagishi, A, 2021)	2.79
"Prednisolone is a widely used immunosuppressive and anti-inflammatory drug type that suffers from low aqueous solubility and bioavailability. "	( Orally Fast Disintegrating Cyclodextrin/Prednisolone Inclusion-Complex Nanofibrous Webs for Potential Steroid Medications. Celebioglu, A; Durgun, E; Kilic, ME; Uyar, T; Wang, N, 2021)	2.33
"Prednisolone (PN) is a glucocorticoid (GC) analog that is clinically used to treat allergic inflammation and autoimmune diseases. "	( Prednisolone induces sleep disorders via inhibition of melatonin secretion by the circadian rhythm in zebrafish. Feng, N; Gen, N; Jiang, Y; Lu, X; Wang, P, 2022)	3.61
"Prednisolone is a corticosteroid and one of the most important agents in the treatment of ALL."	( Early and Very Early GRIM19 and MCL1 Expression Are Correlated to Late Acquired Prednisolone Effects in a T-Cell Acute Leukemia Cell Line. Adamaki, M; G, L; Geronikolou, SA; Hatziagapiou, K; Tsartsalis, AN; Vlahopoulos, S, 2021)	1.57
"Prednisolone is an effective and well-tolerated medication for treating infantile spasms in Down syndrome. "	( Response to treatment and outcomes of infantile spasms in Down syndrome. Allen, NM; Gorman, KM; Harvey, S; King, MD; Lynch, B; Lynch, SA; O'Regan, M; O'Rourke, D; Shahwan, A; Webb, D, 2022)	2.16
"Prednisolone is a reported predisposing factor in humans with lipomatosis."	( Spinal epidural and synovial lipomatosis in a 3-year-old Eurasian dog receiving sustained steroid therapy. Cauzinille, L; Dally, C; Dumont, R; Gros, L; Le Boedec, K; Signoret, M, 2022)	1.44
"Prednisolone is a synthetic glucocorticoid used clinically for treating allergies, inflammation, and autoimmune diseases. "	( Effects of prednisolone on behavior and hypothalamic-pituitary-interrenal axis activity in zebrafish. Cheng, Y; Jiang, Y; Liu, S; Xin, N; Zhou, Y, 2020)	2.39
"Prednisolone acetate (PDN) is a corticosteroid anti-inflammatory liable to degradation under different conditions and used with antibiotics in eye drops. "	( Selective and Sensitive Chromatographic Methods for Determination of a Co-Formulated Binary Mixture in Antibacterial Eye Drops and Aqueous Humor in the Presence of Their Degradation Products and Potential Impurities. Abbas, SS; Abdelwahab, MH; Hegazy, MA; Hendawy, HAM; Weshahy, SA, 2019)	1.96
"Prednisolone is a corticosteroid and one of the most important agents in the treatment of acute lymphoblastic leukemia."	( Gene Expression and Resistance to Glucocorticoid-Induced Apoptosis in Acute Lymphoblastic Leukemia: A Brief Review and Update. Adamaki, M; Hatziagapiou, K; Lambrou, GI; Vlahopoulos, S, 2020)	1.28
"Prednisolone is a commonly used drug in cats and potential adverse effects include hyperglycaemia and diabetes mellitus. "	( Prednisolone-induced diabetes mellitus in the cat: a historical cohort. Boge, GS; Glanemann, B; Moberg, HL; Nerhagen, S, 2021)	3.51
"Prednisolone (PL) is a standard component of most immunosuppressive protocols after solid organ transplantation (Tx). "	( Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients. Andersen, AM; Åsberg, A; Bergan, S; Bjerre, A; Gustavsen, MT; Midtvedt, K; Skauby, RH; Vethe, NT, 2021)	3.51
"Prednisolone is an anti‑inflammatory drug used to treat a number of conditions, including liver disease and cancer. "	( γ‑irradiated prednisolone promotes apoptosis of liver cancer cells via activation of intrinsic apoptosis signaling pathway. Bai, HW; Chung, BY; Kang, BS; Kang, SH; Kawala, RA; Ramadhani, FJ, 2021)	2.43
"Prednisolone is a GC proven to be very effective in the treatment of nasal congestions and allergic rhinitis and its therapeutic use is allowed."	( Investigation of the urinary excretion of prednisolone and metabolites after nasal administration: Relevance to doping control. Deventer, K; Hooghe, F; Polet, M; Van Eenoo, P; Van Gansbeke, W; Van Hoecke, H, 2021)	1.61
"Prednisolone is a standard component of immunosuppressive protocols in renal transplantation (Tx) and despite standardized treatment regimens, adverse side effects are still frequent. "	( Prednisolone and Prednisone Pharmacokinetics in Pediatric Renal Transplant Recipients-A Prospective Study. Bergan, S; Bjerre, A; Bremer, S; Skauby, RH; Svarstad, A; Sæves, I; Vethe, NT, 2017)	3.34
"Prednisolone is a synthetic corticosteroid acting on both hydrosaline balance and metabolism that is liable to fraudulent administration to meat-producing animals for growth-promoting purposes. "	( Determination of prednisolone metabolites in beef cattle. Biolatti, B; Cannizzo, FT; Capra, P; Leporati, M; Nebbia, C; Vincenti, M, 2013)	2.17
"Prednisolone is a steroid belonging to the corticosteroid group. "	( Investigation on the origin of prednisolone in urine and adrenal glands of cows. Arioli, F; Bertocchi, L; Casati, A; Dusi, G; Fidani, M; Ghidelli, V; Hathaway, T; Nassuato, C; Pompa, G, 2013)	2.12
"Prednisolone (PLN) is a widely used corticosteroid in a variety of immune-mediated diseases. "	( Monitoring prednisolone and prednisone in saliva: a population pharmacokinetic approach in healthy volunteers. Ackermans, MT; Freijer, J; Guan, Z; Kist-van Holthe, JE; Nauta, J; Ruiter, AF; Teeninga, N; van Gelder, T, 2013)	2.22
"Prednisolone is a major risk factor for hyperglycaemia and new-onset diabetes after transplantation. "	( Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation. Cohney, SJ; Colman, PG; Fourlanos, S; Yates, CJ, 2014)	2.16
"Prednisolone is a member of synthetic glucocorticoids which are widely used to treat chronic inflammatory diseases. "	( Prednisolone induces microglial activation in the subnucleus caudalis of the rat trigeminal sensory complex. Endo, Y; Ichikawa, H; Iikubo, M; Kasahara, E; Sasano, T; Sato, T; Shimada, Y; Shoji, N, 2014)	3.29
"Prednisolone is a corticosteroid that has been used to treat inflammatory liver diseases such as autoimmune hepatitis and alcoholic hepatitis. "	( Opposing effects of prednisolone treatment on T/NKT cell- and hepatotoxin-mediated hepatitis in mice. Feng, D; Gao, B; Kwon, HJ; Park, O; Won, YS, 2014)	2.17
"Prednisolone is a potent anti-inflammatory glucocorticoid (GC) but chronic use is hampered by metabolic side effects. "	( Identification of gene signatures for prednisolone-induced metabolic dysfunction in collagen-induced arthritic mice. Bauerschmidt, S; Dokter, WH; Ellero-Simatos, S; Fleuren, WW; Toonen, EJ, 2014)	2.12
"Prednisolone (Prd) is a polymorphous synthetic corticosteroid that has three crystalline forms mediated by different solvents. "	( Solid-state NMR investigation of effect of fluorination and methylation on prednisolone conformation. Arco, S; Carillo, KD; Tzou, DL; Wang, CC, 2015)	2.09
"Prednisolone is a safe, effective first-line option for treatment of acute gout."	( Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial. Cheng, CH; Choi, YF; Graham, CA; Janssens, HJ; Lee, KH; Man, CY; Rainer, TH; Tam, LS; Yau, WH, 2016)	1.67
"Prednisolone is a commonly prescribed synthetic glucocorticoid which has been repeatedly detected in the environment."	( Physiological and Behavioral Effects of Exposure to Environmentally Relevant Concentrations of Prednisolone During Zebrafish (Danio rerio) Embryogenesis. McNeil, PL; Nebot, C; Sloman, KA, 2016)	1.37
"Prednisolone is an immunosuppressant shown to have anti-inflammatory and antiproliferative effects on PASMC."	( Prednisolone inhibits PDGF-induced nuclear translocation of NF-kappaB in human pulmonary artery smooth muscle cells. Firth, AL; Ogawa, A; Rubin, LJ; Yao, W; Yuan, JX, 2008)	2.51
"Oral prednisolone is a very effective medicine and symptoms and clinical findings disappear soon after the start of steroid therapy."	( [Autoimmune pancreatitis]. Shimosegawa, T, 2008)	0.8
"(1) Prednisolone monotherapy is a successful immunosuppressive modality in the treatment of SRMA; (2) protein markers are useful in identifying the potential for relapse."	( Steroid responsive meningitis-arteritis: a prospective study of potential disease markers, prednisolone treatment, and long-term outcome in 20 dogs (2006-2008). Anderson, TJ; Eckersall, PD; Lowrie, M; McLaughlin, M; Penderis, J, )	0.91
"Prednisolone is a glucocorticoid (GC) commonly used in the treatment of canine mast cell tumours (MCTs); however, resistance to GCs develops in many MCTs following repeated treatment. "	( Overexpression of P-glycoprotein, STAT3, phospho-STAT3 and KIT in spontaneous canine cutaneous mast cell tumours before and after prednisolone treatment. Chang, SC; Chiu, CY; Hsu, WL; Teng, SP; Wong, ML, 2012)	2.03
"Prednisolone is a synthetic glucocorticoid widely employed in bovine clinical practice that may also be used illegally as a growth promoter. "	( A field survey on the presence of prednisolone and prednisone in urine samples from untreated cows. Attucci, A; Barbarino, G; Capra, P; Gatto, S; Leporati, M; Nebbia, C; Vincenti, M, 2012)	2.1
"Prednisolone testing is an unreliable predictor of the benefit from inhaled fluticasone propionate in individual patients."	( Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Anderson, JA; Burge, PS; Calverley, PM; Jones, PW; Spencer, S, 2003)	2.48
"Prednisolone is an analgesic and anti-inflammatory drug. "	( Investigations of anti-inflammatory and analgesic activities of prednisolone solid dispersion prepared with skimmed milk. Librowski, T; Sahin, NO, )	1.81
"Prednisolone is a commonly prescribed corticosteroid used in the treatment of many diseases. "	( Prednisolone measurement in human serum using liquid chromatography tandem mass spectrometry. Gillingwater, S; Keevil, BG; Owen, LJ, 2005)	3.21
"Prednisolone is a safe antiinflammatory agent for the treatment of inflammatory diseases. "	( Inclusion complex of prednisolone with skimmed milk. Part I: Physicochemical characterization. Arslan, H; Sahin, NO, 2007)	2.1
"Prednisolone proved to be a strong drug-metabolizing enzyme inducer but it was less potent than PCN."	( Actions of prednisolone acetate, pregnenolone-16alpha-carbonitrile, and triamcinolone upon drug resistance and metabolism: a comparative study. Kourounakis, P; Selye, H, 1977)	1.37

Effects

Prednisolone has been used frequently in the treatment of acute lymphoblastic leukemia. It has been suggested as a treatment for olfactory disorders after COVID-19, but evidence is scarce. Prednislone has become the principal agent for treating patients with severe AH.

Excerpt	Reference	Relevance
"Prednisolone has been used frequently in the treatment of acute lymphoblastic leukemia. "	( Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia. Aksoylar, S; Alpay, A; Bagca, BG; Cogulu, O; Durmaz, B; Gunduz, C; Susluer, SY, 2021)	2.3
"Prednisolone has been suggested as a treatment for olfactory disorders after COVID-19, but evidence is scarce. "	( Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial. Blijleven, EE; Boek, WM; Boesveldt, S; Kamalski, DMA; Schepens, EJA; Stegeman, I; Stokroos, RJ, 2022)	3.61
"Prednisolone therapy has shown modest survival benefits over placebo at 28 but not 90 days."	( Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial. Arora, V; Dore, J; Jagdish, R; Khillan, V; Kumar, G; Kumar, M; Mondot, S; Pande, A; Rastogi, A; Sarin, SK; Sharma, S; Shasthry, SM; Vijayaraghavan, R, 2023)	1.89
"Prednisolone has been recommended rather than hydrocortisone for glucocorticoid replacement in adrenal insufficiency due its longer duration of action and lower cost."	( Mortality Risk in Patients With Adrenal Insufficiency Using Prednisolone or Hydrocortisone: A Retrospective Cohort Study. Cox, J; Godsland, IF; Johnston, DG; Majeed, A; Ngaosuwan, K; Oliver, N; Quint, JK; Robinson, S, 2021)	2.31
"Oral prednisolone has more favourable pharmacokinetics in cats than prednisone; therefore, lower doses of prednisolone may be effective in treating feline PF."	( Use of prednisolone as monotherapy in the treatment of feline pemphigus foliaceus: a retrospective study of 37 cats. Burton, GG; Simpson, DL, 2013)	1.3
"Prednisolone has been gradually reduced."	( Florid urticarial vasculitis heralding a flare up of ulcerative colitis. Boules, E; Lyon, C, 2014)	1.12
"Prednisolone has become the principal agent for treating patients with severe AH."	( Acute Alcoholic Hepatitis: Therapy. Lucey, MR; Phillips, PK, 2016)	1.16
"Prednisolone (PSL) has been suggested to be useful for the treatment of Kawasaki disease (KD) resistant to i.v. "	( Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease. Akiyama, N; Asakura, I; Fukuoka, T; Harazaki, M; Iwashima, S; Kamimaki, T; Kimura, M; Meguro, T; Morishita, H; Ohkawara, I; Sakai, H; Seto, S; Shimomura, M; Tsurui, S, 2017)	2.24
"Prednisolone monotherapy has been the standard systemic treatment in many patients with androgen- independent prostate cancer and should today be compared to treatment with Taxotere plus prednisolone. "	( A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer. Fosså, SD, 2008)	2.03
"Prednisolone has been widely used due to its relatively short pituitary inhibition and its moderate potency. "	( Sub-maximal exercise altered the prednisolone absorption pattern. Chen, TT; Chien, KY; Hsu, J; Hsu, MC; Kuo, CH; Li, JH; Pan, RN, 2010)	2.08
"Prednisolone has no significant effect on reducing the prevalence of post-bronchiolitis wheezing and on improving the acute course of illness in hospitalized infants with bronchiolitis."	( Long and short-term effect of prednisolone in hospitalized infants with acute bronchiolitis. Auler, MI; Bonfanti, T; Costa, MM; D'avila, NE; Faria, CS; Ferruzzi, E; Zhang, L, )	1.86
"Prednisolone has unknown growth-suppressing effects relative to other steroids. "	( Prednisolone in the treatment of adrenal insufficiency: a re-evaluation of relative potency. Legault, L; Polychronakos, C; Punthakee, Z, 2003)	3.2
"Prednisolone has been shown to reduce the rate of hand joint destruction as seen on radiography but has not been shown to reduce the rate of hand bone loss."	( Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Haugeberg, G; Kirwan, JR; Kvien, TK; Strand, A, 2005)	1.32
"Prednisolone has similar pharmacokinetic properties and has a significant advantage in that it is commercially available in liquid preparations."	( Prednisolone versus dexamethasone in croup: a randomised equivalence trial. Geelhoed, G; Sparrow, A, 2006)	2.5
"Prednisolone has no effect on withdrawal headache in unselected patients with chronic daily headache and medication overuse."	( Prednisolone does not reduce withdrawal headache: a randomized, double-blind study. Bøe, MG; Mygland, A; Salvesen, R, 2007)	3.23
"Prednisolone has stable oral pharmaceutical formulations commercially available, with the advantage of a single daily dose."	( [Comparative study of prednisolone versus hydrocortisone acetate for treatment of patients with the classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency]. Borghi, M; Calliari, LE; Faria, CD; Kochi, C; Leite, FM; Longui, CA; Monte, O, 2008)	1.38
"Prednisolone suppositories have been used successfully for the treatment of ulcerative colitis in hospital settings. "	( [Controlled release of prednisolone from suppository prepared using powder of pulverized tablet]. Hamaguchi, T; Kadobayashi, M; Kobayashi, Y; Muraoka, R; Nakamoto, T; Oda, S; Shikata, T; Tagawa, N; Takahashi, Y; Tanaka, K; Tatsumi, A; Tatsumi, S, 2008)	2.1
"The prednisolone has got a devastating effect on the creatine content of muscle when it is tenotomised. "	( Creatine of tenotomised muscle under influence of prednisolone treatment. Dastidar, AG; Mandal, SK, )	0.94
"Prednisolone serum levels have been measured by radio-immunoassay in 12 steroid-dependent asthmatic patients. "	( Prednisolone pharmacokinetics in asthmatic patients. Bochner, F; Caffin, JA; Halliday, JW; May, CS, 1980)	3.15
"Prednisolone has been shown to improve strength in Duchenne dystrophy, the improvement starting within 10 days of treatment and reaching a maximum by 3 months, and then plateauing. "	( Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule. Dubowitz, V; Royston, P; Sansome, A, )	1.57
"Prednisolone priming has been found to be beneficial over treatment with interferon alone in these subjects."	( Treatment of hepatitis B surface antigen carriers in the early stage of the infection using recombinant alpha-interferon with steroid priming. Guan, R; Ho, KY; Kang, JY; Ng, C; Smith, R; Tan, CC; Wee, A; Yap, I, 1995)	1.01
"Prednisolone has not been previously used to treat patients with hyperthyroidism who have not responded to thionamide drugs."	( Treatment of thyrotoxicosis resistant to carbimazole with corticosteroids. Dale, J; Dodson, PM; Jude, EB; Kumar, S, 1996)	1.02
"Prednisolone has no effect on a neuromuscular block caused by choline, decamethonium, physostigmine, d-tubocurarine, and a high or low calcium ion concentration."	( Effect of corticosteroids on the phrenic nerve-diaphragm of preparation treated with hemicholinium. A possible model of myasthenia gravis. Leeuwin, RS; Wolters, MJ, 1976)	0.98
"Prednisolone has no effect on the reaction after this phase."	( Effect of prednisolone on cell-mediated cytotoxicity in vitro. Demonstration of a short sensitive induction phase. Franks, D; Sanderson, CJ, 1975)	1.38
"Low prednisolone doses have been quite effective in therapy of this condition."	( [Clinical variants of Wegener's granulomatosis]. Batishchev, EV; Rodionov, AN; Samtsov, AV, 1989)	0.76

Actions

Pradnisolone displays significant pharmacokinetic variability and exposure-outcome relationships in renal transplant recipients. Prednisolones can suppress ischemia-reperfusion injury of the rat liver.

Excerpt	Reference	Relevance
"Prednisolone displays significant pharmacokinetic variability and exposure-outcome relationships in renal transplant recipients, suggesting a role for drug monitoring in some scenarios. "	( Prednisolone Concentrations in Plasma (Total and Unbound) and Saliva of Adult Kidney Transplant Recipients. Brooks, E; Isbel, NM; McWhinney, B; Staatz, CE; Tett, SE, 2019)	3.4
"Prednisolone can suppress ischemia-reperfusion injury of the rat liver. "	( Protective effect of prednisolone on ischemia-induced liver injury in rats. Chen, X; Li, XF; Shen, F; Shi, LH; Wang, M; Wu, MC; Xi, T, 2008)	2.11
"Prednisolone may cause hyperglycemia after organ transplantation. "	( Role of prednisolone pharmacokinetics in postchallenge glycemia after renal transplantation. Bergrem, H; Bergrem, HA; Hartmann, A; Hjelmesaeth, J; Jenssen, T, 2008)	2.22
"Prednisolone did not inhibit either of these responses."	( The suppressive effects of YM-58483/BTP-2, a store-operated Ca2+ entry blocker, on inflammatory mediator release in vitro and airway responses in vivo. Ishikawa, J; Ohga, K; Shimizu, Y; Takezawa, R; Yamada, T; Yoshino, T, 2008)	1.07
"Prednisolone was found to suppress the development of arthritis which, in turn, decreased the increased activity of collagenase and lysosomal enzymes cathepsin B1 and D in tissues and serum of arthritic rats."	( Effect of adjuvant arthritis on collagenase and certain lysosomal enzymes in relation to the catabolism of collagen. Bose, SM; Kuberasampath, T, 1980)	0.98
"Prednisolone may enhance the degree of mucosal protection afforded by this mechanism."	( Influence of prednisolone on ethanol-induced gastric injury in the rat. Derelanko, MJ; Long, JF, 1982)	1.35
"Prednisolone could cause dramatic increase in activity of ALP, but no change in ALP isozyme spectrum and concomitant increase in lactic dehydrogenase activity were found after prednisolone treatment."	( [Expression of placental alkaline phosphatase in esophageal cancer cell line Eca109]. Yan, X; Zhang, F; Zhang, M, 1996)	1.02
"Prednisolone could not inhibit PGE2 synthesis in these cells in our experimental conditions."	( PGE2 synthesis by corneal endothelial cells: effect of glucocorticoids and NSAIDs. Bellot, JL; García-Cabanes, C; Orts, A; Palmero, M, 1999)	1.02

Treatment

Prednisolone treatment decreased collagen type-II degradation in immature cartilage, whereas glucocorticoids did not affect collagentype-II in mature cartilage. Prednisolones were gradually withdrawn and was completely stopped at 9 months post-KTX.

Excerpt	Reference	Relevance
"Prednisolone is a new treatment method for such patients."	( Prednisolone Treatment Is Effective for an Idiopathic Penile Abscess: A Case Report and Review. Konno, T; Kurokawa, M; Nishida, H; Tsuchiya, N; Yamagishi, A, 2021)	2.79
"Six prednisolone and six fMSC treatment cats completed the study. "	( Comparing adipose-derived mesenchymal stem cells with prednisolone for the treatment of feline inflammatory bowel disease. Webb, CB; Webb, TL, 2022)	1.53
"Prednisolone, a routine treatment, is intolerable in almost one-third of children, requiring repeated dosing, which may prolong length of stay (LOS)."	( Reducing oral steroid intolerability and drug costs for acute wheezers: A retrospective evaluation of a clinical management algorithm in a Pediatric Emergency Department. Bartholome, B; Davison, G; Kennedy, B; McCann, J; McDonald, R; Mullen, S; O'Neill, V; Ruddell, J; Shields, MD; Steen, H; Trouton, M, 2023)	1.63
"The prednisolone treatment duration was significantly longer in the PIO patient group than in the non-PIO patient group."	( Analysis of Prednisolone-Induced Osteoporosis Using the Japanese Adverse Drug Event Report Database. Hasegawa, S; Inoue, M; Iwata, M; Maezawa, M; Masuta, M; Matsumoto, K; Nakamura, M; Oura, K; Satake, R; Suzuki, T; Tanaka, M; Uranishi, H; Wakabayashi, W; Yoshida, Y, 2022)	1.58
"Oral prednisolone was added to treatment 5 days after antiviral therapy."	( Human Adenovirus: An Unusual Causative Agent for Acute Retinal Necrosis Presented with Central Retinal Vascular Occlusion. Özdal, PÇ; Özdemir, HB, 2020)	1.01
"Prednisolone treatment significantly improved her myositis."	( Drop Head Syndrome as a Rare Complication in Mixed Connective Tissue Disease. Akagi, M; Endo, Y; Fukui, S; Hara, K; Hashisako, M; Ichinose, K; Igawa, T; Iwamoto, N; Kawakami, A; Kawashiri, SY; Koga, T; Nakamura, H; Niino, D; Origuchi, T; Shimizu, T; Takatani, A; Tamai, M; Tsuji, S; Umeda, M, 2020)	1.28
"Prednisolone as preemptive treatment did not lead to an increase in relapse (20.2% in the placebo and 14.0% in the prednisolone group (P = 0.46))."	( A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy. Baurmann, H; Bethge, W; Beutel, G; Bunjes, DW; Ehrlich, S; Ganser, A; Hambach, L; Hamwi, I; Heidenreich, D; Holler, E; Jonigk, D; Klein, S; Krauter, J; Kreipe, HH; Messinger, D; Metzger, J; Papkalla, A; Raad, J; Rank, A; Schäfer-Eckart, K; Schetelig, J; Schleuning, M; Schmid, C; Stadler, M; Stolzl, F; Türüchanow, I; von der Leyen, H; von Harsdorf, S; Wagner-Drouet, EM; Weissinger, EM; Westphal, K, 2021)	1.34
"No prednisolone treatment (control group) and B."	( Prednisolone treatment in acute interstitial nephritis (PRAISE) - protocol for the randomized controlled trial. Bech, JN; Birn, H; Hoffmann-Petersen, N; Mose, FH, 2021)	2.58
"Prednisolone treatment successfully induced clinical remission and mucosal healing."	( A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine. Akemoto, Y; Asari, T; Chinda, D; Fukuda, S; Fukutoku, Y; Hasui, K; Hiraga, H; Kikuchi, H; Mikami, T; Murai, Y; Sakuraba, H; Sawaya, M; Tanaka, M; Tatsuta, T, 2019)	1.24
"Prednisolone treatment increased the chance of Lille response if the NLR was  ≥ 5 (56.5% cf."	( Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis. Allison, M; Atkinson, SR; Austin, A; Dhanda, A; Forrest, EH; Fraser, A; Hayes, PC; Katarey, D; Masson, S; McCune, A; Parker, R; Potts, J; Richardson, P; Ryder, S; Sinha, R; Storey, N; Thursz, MR; Vergis, N; Verma, S, 2019)	1.24
"Each prednisolone-treated cat was matched to a healthy control cat on the basis of sex, neuter status, age (± 1 year), and body weight (± 10%)."	( Clinicopathologic, hemodynamic, and echocardiographic effects of short-term oral administration of anti-inflammatory doses of prednisolone to systemically normal cats. Berger, DJ; Khelik, IA; Mochel, JP; Palerme, JS; Seo, YJ; Ward, JL; Ware, WA, 2019)	1.18
"Prednisolone-treated cats had expected clinicopathologic alterations (mild increases in neutrophil and monocyte counts and serum concentrations of albumin, cholesterol, and triglycerides) but systolic arterial blood pressure; blood glucose, serum potassium, and cardiac biomarker concentrations; urinary sodium excretion; and echocardiographic variables did not differ significantly from baseline at any time. "	( Clinicopathologic, hemodynamic, and echocardiographic effects of short-term oral administration of anti-inflammatory doses of prednisolone to systemically normal cats. Berger, DJ; Khelik, IA; Mochel, JP; Palerme, JS; Seo, YJ; Ward, JL; Ware, WA, 2019)	2.16
"Oral prednisolone treatment provided temporary remission."	( Spinal dural ossification causing neurological signs in a cat. Antila, JM; Anttila, M; Cizinauskas, S; Jeserevics, J; Rakauskas, M, 2013)	0.84
"Prednisolone treatment further impedes regeneration through a shift in the time profiles of osteoblast and osteoclast genes that commensurates with an osteoporosis-like imbalance in bone formation."	( Prednisolone induces osteoporosis-like phenotype in regenerating zebrafish scales. de Vrieze, E; Flik, G; Metz, JR; Peters, HM; Spanings, FA; van Kessel, MA, 2014)	2.57
"Prednisolone treatment was well tolerated; none of the participants left the study."	( Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure: a randomised controlled trial. Diamant, M; Eringa, EC; Guigas, B; Ijzerman, RG; Linssen, MM; Ouwens, DM; Serné, EH; van Raalte, DH, 2013)	1.11
"Prednisolone treatment normalized coagulopathies associated with chronic idiopathic hepatitis within one week in all 10 dogs that had coagulopathies at initial diagnosis."	( A retrospective study of oral prednisolone treatment in canine chronic hepatitis. Favier, RP; Penning, LC; Poldervaart, JH; Rothuizen, J; van den Ingh, TS, 2013)	1.4
"Prednisolone treatment prevents T/NKT cell hepatitis but exacerbates hepatotoxin-induced liver injury by inhibiting macrophage- and neutrophil-mediated phagocytic and hepatic regenerative functions. "	( Opposing effects of prednisolone treatment on T/NKT cell- and hepatotoxin-mediated hepatitis in mice. Feng, D; Gao, B; Kwon, HJ; Park, O; Won, YS, 2014)	2.17
"Prednisolone treatment further upregulated urea synthesis, which increases the hepatic loss of nitrogen and promotes body catabolism. "	( Prednisolone but not infliximab aggravates the upregulated hepatic nitrogen elimination in patients with active inflammatory bowel disease. Aagaard, NK; Agnholt, J; Christensen, LA; Dahlerup, JF; Frystyk, J; Grønbæk, H; Thomsen, KL; Vilstrup, H, 2014)	3.29
"Prednisolone-treated patients presented with more advanced disease compared to controls (Class IIB or greater, 42 [60.0%] versus 7 [11.3%], respectively; P < 0.001). "	( Efficacy of perioperative high-dose prednisolone therapy during thymectomy in myasthenia gravis patients. Iwata, T; Kawaguchi, N; Mizobuchi, T; Suzuki, H; Tagawa, T; Yamada, Y; Yoshida, S; Yoshino, I, 2013)	2.11
"Prednisolone treatment reduced circulating IL-6 and creatinine plasma levels but not serum AST, ALT or LDH. "	( Prednisolone has a positive effect on the kidney but not on the liver of brain dead rats: a potencial role in complement activation. Akhtar, MZ; Leuvenink, HG; Liu, B; Ottens, PJ; Ploeg, RJ; Rebolledo, R; Zhang, JN, 2014)	3.29
"Prednisolone treatment caused an appreciable decrease in calcium levels both in the bone and serum and also in bone dry weight, BMC, and BMD in rats."	( Moderate zinc supplementation during prolonged steroid therapy exacerbates bone loss in rats. Bansal, SC; Dhawan, DK; Kamal, R; Khandelwal, N; Rai, DV, 2014)	1.12
"The prednisolone co-treatment may improve the clinical pregnancy rate and reduce the miscarriage rate after IVF in women affected by thyroid autoimmunity."	( In women with thyroid autoimmunity, does low-dose prednisolone administration, compared with no adjuvant therapy, improve in vitro fertilization clinical results? Arrivi, C; Greco, E; Litwicka, K; Mencacci, C; Varricchio, MT, 2015)	1.15
"In prednisolone-treated eyes, corneal epithelial thickness was decreased, and apoptosis of corneal epithelial cells was increased."	( Comparison of Topical Application of TSG-6, Cyclosporine, and Prednisolone for Treating Dry Eye. Kim, MK; Kim, YJ; Ko, JH; Lee, HJ; Oh, JY; Park, SY; Ryu, JS; Wee, WR, 2016)	1.19
"Prednisolone treatment of patients with subacute thyroiditis was superior to nonsteroidal anti-inflammation drugs with regard to resolution of symptoms."	( Comparison of the therapeutic effects of prednisolone and nonsteroidal anti-inflammatory drugs in patients with subacute thyroiditis. Goto, H; Himuro, M; Honda, A; Komiya, K; Sato, J; Suzuki, R; Takeno, K; Uchida, T; Watada, H, 2017)	1.44
"Prednisolone treatment ameliorated diarrhea and hypoproteinemia."	( A unique case of collagenous colitis presenting as protein-losing enteropathy successfully treated with prednisolone. Inoue, T; Kubo, Y; Nakamura, T; Nishio, M; Okawa, K; Sano, S; Tanaka, A; Ueda, W; Yamagami, K; Yoshioka, K, 2008)	1.28
"In prednisolone treated rats Ipamorelin reduced CUNS by 20% (p<0.05), decreased the expression of urea cycle enzymes, neutralised N-balance, and normalized or improved organ N-contents."	( Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Aagaard, NK; Greisen, J; Grøfte, T; Grønbaek, H; Johansen, PB; Malmlöf, K; Tygstrup, N; Vilstrup, H; Ørskov, H, 2009)	0.87
"Prednisolone treatment ablated eosinophilia and MuSC in adult Scnn1b-Tg mice, but did not decrease mucus plugging or neutrophilia."	( Airway and lung pathology due to mucosal surface dehydration in {beta}-epithelial Na+ channel-overexpressing mice: role of TNF-{alpha} and IL-4R{alpha} signaling, influence of neonatal development, and limited efficacy of glucocorticoid treatment. Boucher, RC; Grubb, BR; Hudson, EJ; Livraghi, A; Mall, MA; O'Neal, WK; Randell, SH; Sheehan, JK; Wilkinson, KJ, 2009)	1.07
"Prednisolone treatment in patients with inflammatory bowel disease is associated with a delayed onset and a shorter duration of action of rocuronium. "	( Attenuation of a rocuronium-induced neuromuscular block in patients receiving prednisolone. Diefenbach, C; Mencke, T; Molter, GP; Soltész, S; Stunz, M; Ziegeler, S, 2009)	2.02
"Prednisolone pre-treatment did not alter the summed or peak immediate headache responses to GTN significantly (P = 0.08, P = 0.07), whereas the peak headache scores during the following 12 h were significantly lower after prednisolone pre-treatment (median peak score = 1, range 0-8) compared with placebo (median = 4, range 0-8) (P < 0.01)."	( Prednisolone reduces nitric oxide-induced migraine. Daugaard, D; Iversen, HK; Lassen, LH; Olesen, J; Tfelt-Hansen, P, 2009)	2.52
"Prednisolone treatment did not affect force loss during eccentric contractions or recovery of force following injury."	( Effects of prednisolone on skeletal muscle contractility in mdx mice. Baltgalvis, KA; Call, JA; Lowe, DA; Nikas, JB, 2009)	1.46
"Prednisolone treatment increased fasting blood glucose and plasma insulin concentrations, but this apparently reduced insulin sensitivity could not be confirmed in hyperinsulinemic euglycemic clamp studies."	( Chronic prednisolone treatment reduces hepatic insulin sensitivity while perturbing the fed-to-fasting transition in mice. Bloks, VW; Dokter, WH; Grefhorst, A; Groen, AK; Kuipers, F; Laskewitz, AJ; Reijngoud, DJ; van Dijk, TH; van Lierop, MJ, 2010)	1.52
"Prednisolone treatment resulted in reduction (P < 0.05) and indomethacin treatment produced raise (P < 0.01) in synovial tissue kallikrein levels."	( Modifications in tissue kallikrein activity with indomethacin and prednisolone treatment in arthritic rats. Sharma, JN, 2010)	1.32
"Prednisolone treatment was strongly associated with negative TST, adjusted odds ratio (AOR) 0.22 (0.1-0.8; P = 0.018), and with an increased risk of indeterminate QFT-IT results AOR 16.1 (4.1-63.2; P < 0.001), whereas no negative effect was found for long-acting corticosteroids."	( Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Bélard, E; Brylov, A; Hetland, ML; Jensen, FK; Nordgaard-Lassen, I; Ravn, P; Ruhwald, M; Semb, S; Soborg, B; Thomsen, H; Werlinrud, AM, 2011)	2.53
"Prednisolone treatment provided relief of pain within 2 days."	( [Atypical presentation of subacute thyroiditis]. Janssen, OE, 2011)	1.09
"The prednisolone-treated patients were assigned to one of five regimens: 0.5 mg/kg/day given for the first 10 days of every month (n = 6), 0.75 mg/kg/day given for the first 10 days of every month (n = 3), 0.5 mg/kg on alternate days (n = 1), 0.75 mg/kg on alternate days (n = 1), or 5 mg/kg twice a week (n = 3)."	( [Prednisolone treatment for Duchenne muscular dystrophy]. Fujii, T; Kimura, N; Kumada, T; Miyajima, T; Oda, N; Saito, K; Shimomura, H, 2011)	1.76
"Prednisolone treatment was gradually withdrawn and was completely stopped at 9 months post-KTX."	( Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data. Ahlenstiel, T; Blume, C; Lehner, F; Pape, L, 2011)	1.09
"Prednisolone treatment decreased collagen type-II degradation in immature cartilage, whereas glucocorticoids did not affect collagen type-II in mature cartilage. "	( Glucocorticoids exert context-dependent effects on cells of the joint in vitro. Andreassen, KV; Bay-Jensen, AC; Christensen, ST; Henriksen, K; Karsdal, MA; Madsen, SH; Sverdrup, FM, 2011)	1.81
"Prednisolone treatment reduces endometrial vascular maturation and angiogenic growth factor expression in women with RM with increased uNK cells."	( Prednisolone treatment reduces endometrial spiral artery development in women with recurrent miscarriage. Bulmer, JN; Drury, JA; Innes, BA; Lash, GE; Quenby, S; Robson, SC, 2011)	3.25
"Prednisolone treatment showed significant lower osteocalcin levels and lower Z-scores for lumbar spine and femoral neck compared to PAI patients on hydrocortisone."	( Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. Diederich, S; Koetz, KR; Quinkler, M; Ventz, M, 2012)	1.1
"The prednisolone-treated group showed significantly greater improvements in all nasal symptoms, nasal flow and polyp size than the placebo-treated group (p < 0.001, all). "	( Clinical efficacy of a short course of systemic steroids in nasal polyposis. Kirtsreesakul, V; Ruttanaphol, S; Wongsritrang, K, 2011)	0.93
"Prednisolone treatment that caused a marked reduction in tumour volume was correlated with reduced pSTAT3 expression."	( Overexpression of P-glycoprotein, STAT3, phospho-STAT3 and KIT in spontaneous canine cutaneous mast cell tumours before and after prednisolone treatment. Chang, SC; Chiu, CY; Hsu, WL; Teng, SP; Wong, ML, 2012)	1.31
"Prednisolone treatment delayed the half-emptying time (184 ± 45 min) compared with that of controls (137 ± 19 min), and coadministration of mosapride improved this gastric-emptying delay (143 ± 29 min)."	( Effect of mosapride on prednisolone-induced gastric mucosal injury and gastric-emptying disorder in dog. Fujino, Y; Fukushima, K; Hori, M; Maeda, S; Nakashima, K; Ohno, K; Tsujimoto, H; Tsukamoto, A, 2012)	1.41
"Prednisolone treatment, by contrast, resulted in decreased BW, decreased feed efficiency, increased FHS index, and elevated blood lipid levels."	( Effects of high fat diets or prednisolone treatment on femoral head separation in chickens. Clark, FD; Coon, CC; Durairaj, V; Huff, GR; Huff, WE; Okimoto, R; Rath, NC, 2012)	1.39
"Prednisolone treatment aggravated fasting hyperglycemia and hyperinsulinemia caused by high-fat feeding, resulting in a higher homeostatic assessment model of insulin resistance."	( Chronic prednisolone treatment aggravates hyperglycemia in mice fed a high-fat diet but does not worsen dietary fat-induced insulin resistance. Bloks, VW; Dokter, WH; Grefhorst, A; Groen, AK; Kuipers, F; Laskewitz, AJ; Reijngoud, DJ; Schreurs, M; van Dijk, TH; van Lierop, MJ, 2012)	1.53
"Prednisolone treatment resulted in higher complete recovery rates, regardless of severity at baseline. "	( Bell's palsy - the effect of prednisolone and/or valaciclovir versus placebo in relation to baseline severity in a randomised controlled trial. Axelsson, S; Berg, T; Engström, M; Jonsson, L; Kanerva, M; Stjernquist-Desatnik, A, 2012)	2.11
"Prednisolone treatment resulted in a statistically longer survival time compared to UDCA."	( Retrospective comparison of prednisolone and ursodeoxycholic acid for the treatment of feline lymphocytic cholangitis. Favier, RP; Otte, CM; Penning, LC; Rothuizen, J, 2013)	1.41
"Prednisolone treatment reduced IGF1 bioactivity by 12.6% from 2.22±0.18 to 1.94±0.15 μg/l (P=0.01) compared with placebo. "	( Prednisolone reduces the ability of serum to activate the IGF1 receptor in vitro without affecting circulating total or free IGF1. Flyvbjerg, A; Frystyk, J; Heuck, C; Lyngholm, M; Schou, AJ; Vorum, H; Wolthers, OD, 2013)	3.28
"Oral prednisolone treatment was initiated at 60 mg daily together with oral cyclosporin A (100-150 mg daily)."	( [A case of nonspecific interstitial pneumonia associated with amyopathic dermatomyositis efficiently treated with a combination of cyclosporin A and prednisolone]. Abe, S; Harada, H; Hiraga, Y; Inoue, N; Morikawa, Y; Ohmichi, M; Sasaki-Date, H; Shijubo, N; Takahashi, H, 2002)	0.97
"Oral prednisolone treatment markedly reduced the tumor and improved not only abnormal laboratory data such as C-reactive protein, but also the hoarseness."	( [A case of fibrosing mediastinitis manifesting recurrent nerve palsy]. Asai, M; Iwahori, K; Kido, T; Komuta, K; Minami, S; Utsumi, T, 2002)	0.77
"Prednisolone treatment was associated with decreases in the total thickness of the cutis and subcutis in the thigh (0.28 mm) and forearm (0.15 mm), and an increase in the abdomen (0.23 mm)."	( Differential effects of short-term prednisolone treatment on peripheral and abdominal subcutaneous thickness in children assessed by ultrasound. Heuck, C; Schou, AJ; Wolthers, OD, 2003)	1.32
"In prednisolone-treated animals, 40.5% of the hypertrophic chondrocytes was apoptotic (P<0.02), with apoptotic chondrocytes also appearing higher in the hypertrophic zone."	( Short-term glucocorticoid treatment of piglets causes changes in growth plate morphology and angiogenesis. Buchholz, IM; Christis, C; de Meer, K; Hamers, N; Koedam, JA; Sakkers, RJ; Smink, JJ; van Buul-Offers, SC; van Tilburg, CM, 2003)	0.83
"Oral prednisolone is the treatment of choice for the most severe asthma exacerbations, given together with oxygen and beta-2 agonists."	( [Treatment of acute asthma attack in the emergency department]. Volovitz, B, 2003)	0.77
"Oral prednisolone treatment initiated at 20 mg daily, combined with oral cyclophosphamide at 50 mg daily markedly improved not only the clinical symptoms, but also the mass shadows in the left upper lobe."	( [A case of the limited from of Wegener's granulomatosis without c-ANCA]. Bandoh, S; Fujita, J; Horiike, A; Ishida, T; Ishii, T; Kubo, A; Tojo, Y; Yokomise, H, 2003)	0.77
"Prednisolone treatment of sensory impairment of the ulnar and posterior tibial nerves detectable with the monofilament test, but not with the ballpen test, did not improve the long-term outcome in terms of recovery of touch sensibility, not did it reduce the risk of leprosy reactions or nerve function impairment beyond the initial 4-month treatment phase."	( The prognostic importance of detecting mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2). Anderson, AM; Croft, RP; Nicholls, PG; Richardus, JH; Smith, WC; Van Brakel, WH; Withington, SG, 2003)	1.04
"Prednisolone-treated mice also exhibited decreased vascular P-selectin (-82%) and ICAM-1 (-52%) expression and fewer L-selectin (-79%) and ICAM-1 (-57%) expressing mononuclear cells in quadriceps."	( Prednisolone decreases cellular adhesion molecules required for inflammatory cell infiltration in dystrophin-deficient skeletal muscle. Lee, JJ; Tidball, JG; Wehling-Henricks, M, 2004)	2.49
"Prednisolone treatment was administered orally to patients at 30 mg for 7 days, 15 mg for 4 days, and 5 mg for 3 days."	( Efficacy of steroid treatment for sensory impairment after orthognathic surgery. Seo, K; Someya, G; Tanaka, Y; Terumitsu, M, 2004)	1.04
"Prednisolone treated patients had an increased percentage body fat (SDS +0.46; P < 0.05) and increased body mass index (SDS 0.88; P < 0.01) compared to normal."	( No difference between prednisolone and dexamethasone treatment in bone mineral density and growth in long term survivors of childhood acute lymphoblastic leukemia. de Muinck Keizer-Schrama, SM; Hakvoort-Cammel, FG; Krenning, EP; Pieters, R; van Beek, RD; van den Heuvel-Eibrink, MM; van der Sluis, IM, 2006)	1.37
"Prednisolone treatment significantly reduced the number of CD56 cells in the endometrium, from a median of 14% (before) to 9% (after) (P=.0004)."	( Prednisolone reduces preconceptual endometrial natural killer cells in women with recurrent miscarriage. Bates, M; Farquharson, R; Kalumbi, C; Quenby, S; Vince, G, 2005)	2.49
"Prednisolone treatment did not influence the responses."	( Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Geborek, P; Jönsson, G; Kapetanovic, MC; Saxne, T; Sjöholm, A; Truedsson, L, 2006)	1.32
"Prednisolone treatment alone was not successful."	( Satoyoshi syndrome: a rare multisystemic disorder requiring systemic and symptomatic treatment. Heger, S; Kuester, RM; Sippell, WG; Stephani, U; Volk, R, 2006)	1.06
"Prednisolone treated patients and controls became chair bound at the mean age of 169 +/- 9 and 132 +/- 8 months respectively."	( Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. Ghosh, D; Kumar, A; Mittal, B; Pandey, CM; Pradhan, S; Singh, U; Srivastava, NK, 2006)	2.5
"Prednisolone treatment was associated with progressive reduction in height standard deviation score, which became statistically significant after 3 years (p<0.05)."	( Follow-up of linear growth of body height in children with nephrotic syndrome. Hung, YT; Yang, LY, 2006)	1.06
"Prednisolone treatment of patients with reactions is associated with an upregulation of 11beta-HSD2 expression in skin."	( Alteration of the cortisol-cortisone shuttle in leprosy type 1 reactions in leprosy patients in Hyderabad, India. Andersson, AK; Atkinson, SE; Chaduvula, M; Jain, S; Khanolkar-Young, S; Lockwood, DN; Suneetha, L; Suneetha, S, 2007)	1.06
"Prednisolone treatment increased the frequency of muscle calcification, while RAG2 genotype had no effect."	( Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout. Connolly, AM; Golumbek, PT; Keeling, RM, 2007)	1.06
"Prednisolone treatment, which is known to retard bone formation activity, led to a significant decrease in PINP, whereas PTH treatment dose-dependently increased PINP."	( Development of a highly sensitive, high-throughput, mass spectrometry-based assay for rat procollagen type-I N-terminal propeptide (PINP) to measure bone formation activity. Copeland, M; Geiser, AG; Hale, JE; Hale, LV; Han, B; Harvey, A; Ma, YL; Powers, CS; Sato, M; You, J, 2007)	1.06
"Prednisolone treatment reduced the influx of inflammatory cells into the BALF, but not significantly, had no effect on pulmonary function, and did not reduce of airway hypersensitivity."	( Characterisation of the acute and reversible airway inflammation induced by cadmium chloride inhalation in healthy dogs and evaluation of the effects of salbutamol and prednisolone. Bolognin, M; Clercx, C; De Buscher, V; Gustin, P; Kirschvink, N; Leemans, J; Peeters, D; Snaps, F, 2009)	1.27
"Prednisolone treatment (50 mg daily) resulted in dramatic regression of recurrent mediastinal and pleural tumors, as well as improvement of pure red cell aplasia."	( [Successful corticosteroid therapy of a recurrent thymoma with pure red cell aplasia]. Koshio, J; Maeda, T; Nagasawa, Y; Tsukada, H; Yokoyama, A, 2007)	1.06
"Prednisolone treatment of infected animals did not affect the concanavalin A response, and lipopolysaccharide stimulation decreased more slowly and to a lesser extent than it did in mice treated with antilymphocyte globulin or both agents."	( Immediate loss of cell-mediated immunity to murine cytomegalovirus upon treatment with immunosuppressive agents. Balfour, HH; Howard, RJ; Mattsson, DM, 1980)	0.98
"Prednisolone treatment did not alter the number of somatic cells in milk or reduce the inflammatory response of experimentally infected cows."	( Excretion of [3H]prednisolone in clinically normal and experimentally infected bovine udders. Geleta, JN; Mercer, HD; Shimoda, W, 1984)	1.33
"83 prednisolone-treated and 57 control children of a previous study demonstrating benefits of antenatal steroid prophylaxis of IRDS were reexamined at the age of 6 years. "	( Normal physical and mental development of 6-year-old children whose mothers were treated antenatally with prednisolone. Adamovich, K; Arató, J; Horváth, I; Ostorharics-Horváth, G; Papp, K, 1984)	1.1
"Prednisolone treatment also had deleterious effect on cartilage proteoglycan metabolism determined both histologically and biochemically."	( Some further effects of prednisolone and triamcinolone hexacetonide on experimental arthritis in rabbits. Hunneyball, IM, 1981)	1.29
"Prednisolone treatment produced no important beneficial effect on any of the hepatic biochemical tests."	( Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Boyer, T; Depew, W; Omata, M; Redeker, A; Reynolds, T, 1980)	1.26
"Prednisolone treatment did not alter fecundity in primary or secondary infections."	( Effects of prednisolone on murine strongyloidiasis. Dawkins, HJ; Grove, DI, 1981)	1.37
"Prednisolone treatment did not increase the risk of treatment failure, nor did decreasing the total dose of melarsoprol from 12 to 9 injections for patients with > or = 100 white blood cells/mm3 of CSF."	( Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy. Khonde, A; Loko, L; Milord, F; Mpia, B; Niyonsenga, T; Pépin, J, )	0.85
"Prednisolone treatment (> or = 2 mg.kg-1 x day-1) resulted in a significant reduction in phosphofructokinase activity (expressed as microM substrate.min-1 x mg protein-1) and an increase in 3-hydroxyacyl-CoA dehydrogenase activity in the plantaris muscle."	( Exercise and glucocorticoid-induced diaphragmatic myopathy. Chen, CL; Criswell, D; Herb, RA; Lieu, FK; Martin, D; Powers, SK; Stainsby, W; Wood, C, 1993)	1.01
"Prednisolone pretreatment resulted in decreased covalent binding of the toxic metabolite in vivo and an increased urinary excretion of glutathione-derived conjugates of acetaminophen, indicating an enhanced detoxification of the reactive metabolite by glutathione."	( Prednisolone stimulates hepatic glutathione synthesis in mice. Protection by prednisolone against acetaminophen hepatotoxicity in vivo. Lauterburg, BH; Schranz, C; Speck, RF, 1993)	2.45
"When prednisolone- and placebo-treated groups were compared there was a decrease in airway methacholine responsiveness (p < 0.01) and an increase in FEV1 (p < 0.05) after prednisolone."	( Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Assoufi, B; Bentley, AM; Durham, SR; Hamid, Q; Kay, AB; Meng, Q; Robinson, DS; Schotman, E, 1996)	2.19
"Prednisolone treated patients had significantly fewer days with liquid stools than mesalazine patients, with a median of 0 and 1 days respectively by week 4 (p = 0.001)."	( A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Daniels, S; Grace, RH; Jewell, DP; Keighley, MR; Kingston, RD; Lee, FI; Mani, V; Patterson, J; Record, CO; Smith, K, 1996)	1.28
"Prednisolone pre-treatment tended to be more effective in patients with higher transaminase levels and in patients with low levels of HBV DNA."	( Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group. Bassendine, M; Benhamou, JP; Berthelot, P; Bindslev, N; Enriquez, J; Krogsgaard, K; Lindberg, J; Marcellin, P; Ouzan, D; Ring-Larsen, H; Sanchez-Tapias, JM; Tran, A; Trepo, C, 1996)	2.46
"Prednisolone pre-treatment significantly enhanced the treatment effect of lymphoblastoid interferon in terms of HBeAg clearance and seroconversion to anti-HBe. "	( Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group. Bassendine, M; Benhamou, JP; Berthelot, P; Bindslev, N; Enriquez, J; Krogsgaard, K; Lindberg, J; Marcellin, P; Ouzan, D; Ring-Larsen, H; Sanchez-Tapias, JM; Tran, A; Trepo, C, 1996)	3.18
"Oral prednisolone treatment was started and the retinopathy was improved, but was complicated by acute interstitial pneumonia."	( [A case of dermatomyositis with severe retinopathy in a patient who died of acute interstitial pneumonia]. Enoki, T; Murakami, A; Nakabayasi, I; Nakagami, T; Okisaka, S; Yoshizawa, N, 1997)	0.75
"The prednisolone-treated patients had a median length of hospital stay (secondary end-point) of 5 days vs 6 for the placebo-treated (p < 0.01)."	( Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study. Bergkvist, PI; Sjöbeck, K, 1997)	1.13
"Prednisolone treatment significantly prevented the increase in urinary protein and albumin excretion and glomerular cell proliferation in ATS-induced GN, indicating the beneficial effects of prednisolone on this GN."	( Effects of prednisolone on glomerular signal transduction cascades in experimental glomerulonephritis. Hamaguchi, A; Iwao, H; Kim, S; Masuda, T; Nakamura, Y; Seto, M; Yamanaka, S; Yoshifusa, H, 1998)	1.41
"Prednisolone pre-treatment, enhances the effect of lymphoblastoid interferon in chronic hepatitis B."	( [Pretreatment with prednisolone enhances the effect of human lymphoblastoid interferon in chronic hepatitis B]. Bassendine, M; Benhamou, JP; Berthelot, P; Bindslev, N; Enriquez, J; Krogsgaard, K; Lindberg, J; Marcellin, P; Ouzan, D; Ring-Larsen, H; Sanchez-Tapias, JM; Tran, A; Trepo, C, 1998)	1.35
"Prednisolone treated patients had higher exhaled NO levels than patients only requiring inhaled corticosteroids (17.5 ppb, 95% CI 11.1 to 24.0 versus 7.2 ppb, 95% CI 4.6 to 9.8; p = 0.016), suggesting greater disease severity in this group."	( Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids. Asthma and Allergy Group. Barnes, PJ; Campbell, D; Chung, KF; Durham, SR; Kharitonov, SA; Robinson, DS; Stirling, RG, 1998)	1.02
"Prednisolone treatment had no effect on any of the outcome measures."	( Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants. Bonde-Hansen, ME; Bülow, SM; Friis, B; Holm, JC; Levin, E; Moller, T; Nielsen, HE; Nielsen, JE; Nir, M; Thomsen, LL, 1999)	3.19
"Prednisolone treatment decreased the serum concentration of lysozyme and MPO."	( Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis. Arvidson, NG; Gudbjörnsson, B; Hâkansson, L; Hällgren, R; Torsteinsdóttir, I; Venge, P, 1999)	1.02
"Prednisolone treatment induced a complete remission of both clinical and hematological findings after two months, while Coombs' tests became negative after three months."	( [Autoimmune hemolytic anemia in chronic hepatitis C virus infection treated with alpha-interferon: a therapy-related event or extra-hepatic immunologic manifestation?]. Antonaci, S; Giannoccaro, F; Pace, L; Schiraldi, O, 1999)	1.02
"Prednisolone pretreatment resulted in an increase in the proportion of mutant in patients with initially low percentages (< or = 25%) of mutant."	( Olone modulates the therapeutic effect of interferon to eliminate preferentially the hepatitis B virus precore stop mutant. Chen, TC; Chu, CM; Hsieh, SY; Liaw, YF; Sheen, IS; Yeh, CT, 2000)	1.03
"The prednisolone treated patients were compared to 30 newly diagnosed PMR (n = 26) or TA patients (n=4) examined prior to start of prednisolone, and 70 healthy controls."	( No permanent reduction in bone mineral density during treatment of polymyalgia rheumatica and temporal arteritis using low dose corticosteroids. Dovland, H; Gran, JT; Haugeberg, G; Mikkelsen, B; Myklebust, G, 2000)	0.79
"Prednisolone treatment had no effect on any of the outcome measures. "	( [Prednisolone treatment of respiratory syncytial virus infection. A randomized, controlled trial of 147 children]. Bonde-Hansen, MB; Bülow, SL; Friis, B; Holm, JC; Levin, EF; Nielsen, HE; Nielsen, JE; Nir, M; Pedersen, TM; Thomsen, LL, 2000)	2.66
"The prednisolone treatment led to an increase in the content of oxyproline (a marker of bone resorption), calcium, and inorganic phosphates in the urine."	( [Comparative study of dimephosphon and xidiphone efficacy in steroid-induced osteoporosis in rats]. Burnasheva, ZA; Galiautdinova, AIu; Samoĭlova, NS; Valeeva, IKh; Ziganshina, LE, )	0.61
"In prednisolone-treated patients there was no correlation between clinical synovitis and change in Larsen score (r=0.029) and only a slight and non-significant correlation with joint space narrowing (r=0.127)."	( The relationship between soft tissue swelling, joint space narrowing and erosive damage in hand X-rays of patients with rheumatoid arthritis. Byron, M; Kirwan, J; Watt, I, 2001)	0.82
"Prednisolone treatment had little effect at day 7, but by day 28 significant decreases were found in cytokine levels."	( Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Coulthart, A; Khanolkar-Young, S; Little, D; Lockwood, DN; Suneetha, S, 2001)	1.22
"Oral prednisolone treatment improved the pulmonary nodular lesion, the abnormal laboratory data, and the uveitis."	( [A case of pulmonary inflammatory pseudotumor with hypergammaglobulinemia, elevated ANA, and uveitis]. Gejyo, F; Kaizu, C; Kuwabara, K; Moriyama, H; Saito, Y; Suzuki, E; Takada, T; Terada, M, 2001)	0.77
"Prednisolone or saline treatment was continued until the rabbits were killed either 6 weeks or 8 weeks after creation of the osteotomy."	( Recombinant human bone morphogenetic protein-2 enhances osteotomy healing in glucocorticoid-treated rabbits. Ammirati, KM; Blake, CA; Bouxsein, ML; Luppen, CA; Seeherman, HJ; Stevens, ML; Wozney, JM, 2002)	1.04
"Prednisolone treatment led to insulin resistance as expected (HOMA-S; prednisolone vs placebo; 1.85 +/- 0.26 vs 1.02 +/- 0.10; p < 0.01) with exaggerated first-phase insulin secretion (3016 +/- 468 pmol/l vs 1688 +/- 207 pmol/l; p < 0.01), suggesting a stable disposition index. "	( Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. Dall, R; Hollingdal, M; Juhl, CB; Pørksen, N; Schmitz, O; Sturis, J; Veldhuis, JD, 2002)	1.76
"Prednisolone treatment caused immunosuppression in one monkey; this was accompanied by a progressive loss of humoral antibody to HVS-associated antigens, but neoplastic disease did not develop."	( Infection of capuchin monkeys (Cebus albifrons) with Herpesvirus saimiri. Cicmanec, JL; Neubauer, RH; Orr, TW; Pearson, GR; Rabin, H; Wallen, WC, 1975)	0.98
"Prednisolone treatment of thymocytes before their injection cancelled the suppressive effect of autologous thymocytes."	( [Suppressive effect of autologous thymocytes abolished by prednisolone]. Giulling, EV; Mel'nikov, OF, 1978)	1.22
"Prednisolone treatment did not result in significantly increased P50 values."	( Effect of prednisolone treatment on selected respiratory parameters and cardiac output in prematurely delivered neonatal lambs. Culver, DH; Thompson, FN; van Kampen, M, 1978)	1.38
"Prednisolone treatment elicited a quantitative increase in galactosamine (30.2%), uronic acid (76.2%), and sulphate (9.1%), while no difference was observed in sialic acid content between the treated and untreated groups."	( Effect of prednisolone on the glycosaminoglycan components of the regenerating articular cartilage. Kostenszky, KS; Oláh, EH, 1976)	1.38
"Prednisolone treatment (40 mg daily) resulted in a dramatic improvement of renal function as well as other clinical abnormalities due to sarcoidosis, without any significant changes in liver function."	( [An autopsy case of sarcoidosis associated with renal failure]. Ishii, A; Ito, K; Kobayashi, N; Miyamoto, T; Ohta, K; Okudaira, H; Suzuki, S; Takizawa, H, 1992)	1
"prednisolone (PSL) treated nephrotic stage, 3."	( Two-color analysis of lymphocyte subpopulations in patients with nephrotic syndrome due to membranous nephropathy. Koide, H; Nakayama, S; Ozaki, T; Tomino, Y, 1992)	1
"In prednisolone-treated arthritic rats, there was a sustained decrease in plasma copper starting after 2 weeks of treatment which could be correlated with an improvement of the clinical and biochemical signs of inflammation."	( Effects of chronic prednisolone administration on plasma copper in rats with adjuvant arthritis. Famaey, JP; Fontaine, J; Neve, J; Pelen, F; Peretz, A, 1991)	1.12
"Prednisolone treatment leads to diminution of ACTH and cortisol levels, elevation of glucose, insulin and C-peptide concentrations in plasma compared to prednisolone-untreated patients, producing insignificant effect on plasma levels of STH, vasopressin, aldosterone, area and creatinine."	( [Effect of glucocorticoid hormones on the status of the hypothalamo-hypophyseal-adrenal system and endocrine function of the pancreas in patients with hemorrhagic fever with renal syndrome]. Bystrovskiĭ, VF, 1990)	1
"Prednisolone treatment is not recommended when the reliability of the treatment cannot be guaranteed, as the hazard of harm would exceed the expected benefit."	( Corticosteroids in primary tuberculosis with bronchial obstruction. Dab, I; Derde, MP; Malfroot, A; Spehl, M; Toppet, M; Toppet, V, 1990)	1
"Prednisolone treatment reduced POMC mRNA below the levels detected in untreated animals, with no detectable response to stress.(ABSTRACT TRUNCATED AT 250 WORDS)"	( Stress responsiveness of hypothalamic corticotrophin-releasing factor and pituitary pro-opiomelanocortin mRNAs following high-dose glucocorticoid treatment and withdrawal in the rat. Gillham, B; Harbuz, MS; Lightman, SL; Nicholson, SA, 1990)	1
"Only prednisolone-treated eyes had an extended period of virus shedding, and the rabbit mortality rate in this group was slightly higher."	( Assessment of diclofenac on herpes keratitis in rabbit eyes. Barlow, WE; McGuigan, LJ; Trousdale, MD, 1989)	0.73
"Prednisolone treatment effected the state of neutrophils manifested in a reduced acid phosphatase activity; the production of lysozyme increased, the absorptive capacity normalized."	( [The effect of prednisolone on the functional status of phagocytic cells in the peripheral blood of patients with pulmonary sarcoidosis]. Tyshko, NA, 1989)	1.35
"Prednisolone treatment merits further assessment in primary biliary cirrhosis over a longer period, with attention to selection of patients most likely to benefit and continuing observation of bone mass to better establish the "cost/benefit" ratio."	( A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Bassendine, MF; James, OF; Malcolm, AJ; Mitchison, HC; Record, CO; Watson, AJ, 1989)	1.25
"Prednisolone treatment of eleven asthmatics and beclomethasone treatment of five asthmatics did not inhibit the early response but only the late response."	( Drug effects on exercise-induced late asthmatic responses. Iikura, Y; Inui, H; Kay, AB; Lee, TH; Nagakura, T; Obata, T; Sugimoto, H, )	0.85
"Prednisolone pretreatment (2 mg/kg, s.c.) also prolonged baclofen-induced muscle relaxation."	( [Enhancement of the muscle relaxant action of baclofen by glucocorticoids]. Wakayama, K, 1987)	0.99
"In prednisolone-treated cells, the processing of 61.5 K to the 64.5 K monomer was accelerated, and the presence of the 61.5 K precursor could only be detected by either neuraminidase or monensin treatment."	( Control of placental alkaline phosphatase gene expression in HeLa cells: induction of synthesis by prednisolone and sodium butyrate. Chou, JY; Takahashi, S, 1987)	1
"Prednisolone treatment reduced intestinal calcium transport and increased phosphate excretion, causing a reduction in serum phosphate."	( The effect of 1 alpha-hydroxyvitamin D2 on calcium metabolism in glucocorticoid-treated rats. DeLuca, HF; Lindgren, JU; Sjödén, GO, 1985)	0.99
"Treatment with prednisolone (PSL), mycophenolate mofetil (MMF), and tacrolimus (TAC) resulted in improved SLE activity and glucose intolerance with the reduction of anti-insulin receptor autoantibodies."	( Effect of a multitarget therapy with prednisolone, mycophenolate mofetil, and tacrolimus in a patient with type B insulin resistance syndrome complicated by lupus nephritis. Asano, T; Fujita, Y; Furuya-Yashiro, M; Kiko, Y; Kobayashi, H; Matsumoto, H; Matsuoka, N; Migita, K; Oda, A; Saito, K; Sasajima, T; Sato, S; Shimabukuro, M; Shio-Yano, K; Tanabe, H; Temmoku, J; Watanabe, H, 2022)	1.33
"Treatment with prednisolone alone within 72 hours after onset still is the cornerstone of the treatment."	( [Diagnostics and Therapy of Idiopathic Facial Palsy (Bell's Palsy)]. Guntinas-Lichius, O; Kuttenreich, AM; Thielker, J; Volk, GF, 2021)	0.96
"Treatment with prednisolone upregulated expression of CD20 and an apoptosis-inducing protein BIM, which might augment perforin/granzyme B-mediated cell death."	( Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies. Fujimura, T; Harada, N; Kawasaki, N; Kondoh, O; Yamashita-Kashima, Y; Yoshimura, Y; Yoshiura, S, 2022)	1.06
"Treatment with prednisolone 15 mg daily was instituted."	( Remitting seronegative symmetrical synovitis with pitting edema: a case report. Kitamoto, K; Kohchi, K; Tanaka, Y, 2022)	1.06
"Treatment with prednisolone and furosemide was initiated, but then dialysis was initiated due to AKI."	( Rehabilitation of a Patient With Minimal Change Nephrotic Syndrome and Acute Kidney Injury: A Case Report. Hirano, Y; Kono, K; Yamauchi, K; Yasuda, H, 2022)	1.06
"Treatment with prednisolone (PSL) reduced urinary protein from 7.8 g/gCre to approximately 1 g/gCre but did not lead to complete remission."	( Complete remission of primary membranous nephropathy following hepatitis E infection. Igarashi, H; Kitayama, Y; Koyano, A; Rachi, H; Shimasaki, M; Shiratori, K; Sugiura, T; Takanohashi, S; Togawa, A; Ueno, T, 2023)	1.25
"Treatment by prednisolone eye drops was initiated every 30 minutes for 1 day with a gradual decrease for 6 weeks."	( Preventive Inflammation Management with Steroids before Retreatment with Anti-VEGF after Severe Inflammation due to Brolucizumab. Ambresin, A; Castro, DG; Karmy, BE, 2023)	1.26
"Treatment with prednisolone, in combination with theophylline, curcumin or resveratrol increases SIRT1 expression, restores steroid sensitivity, and inhibits pro-inflammatory cytokine production from these cells and may reduce systemic inflammation in COPD."	( Lymphocyte senescence in COPD is associated with decreased sirtuin 1 expression in steroid resistant pro-inflammatory lymphocytes. Hodge, G; Hodge, S; Jersmann, H; Reynolds, PN; Tran, HB, )	0.47
"Treatment with prednisolone rapidly ameliorated the symptoms, and the serum CK level normalized."	( [A case of anti-titin antibody positive nivolumab-related necrotizing myopathy with myasthenia gravis]. Fujita, N; Isami, A; Kawachi, I; Shimaoka, Y; Suzuki, S; Uchiyama, A, 2019)	0.85
"Treatment with prednisolone resolved the clinical signs and laboratory abnormalities."	( Diagnosis and management of atypical hypoadrenocorticism in a variable flying fox (Pteropus hypomelanus). Brock, AP; Cooke, KL; Emerson, JA; Hall, NH; Reese, DJ; Wellehan, JF, 2013)	0.73
"Treatment with prednisolone, sirolimus, and regular ureteric stent revision was initiated to achieve adequate urinary tract drainage."	( Erdheim-Chester disease: an uncommon cause of upper urinary tract obstruction. Cheung, H; Lee, YW; Liu, PL; Tsu, JH; Yuen, SK, 2013)	0.73
"Treatment with prednisolone was well tolerated."	( Comparison of methods for evaluation of the suppressive effects of prednisolone on the HPA axis and bone turnover: changes in s-DHEAS are as sensitive as the ACTH test. Gruvstad, E; Hedner, LP; Höglund, P; Luts, A; Norjavaara, E, 2014)	0.98
"Treatment with prednisolone and MMF led to a significant drop in IgG after two weeks, reaching a nadir at eight weeks, followed by gradual normalization."	( Serum immunoglobulin G level in patients with lupus nephritis and the effect of treatment with corticosteroids and mycophenolate mofetil. Chan, GC; Chan, TM; Kwan, LP; Ma, MK; Mok, MM; Yap, DY; Yung, S, 2014)	0.74
"Treatment with prednisolone and MMF does not result in clinically important suppression of IgG."	( Serum immunoglobulin G level in patients with lupus nephritis and the effect of treatment with corticosteroids and mycophenolate mofetil. Chan, GC; Chan, TM; Kwan, LP; Ma, MK; Mok, MM; Yap, DY; Yung, S, 2014)	0.74
"Treatment with prednisolone and azathioprine was initiated."	( Pneumomediastinum in a patient with microscopic polyangiitis preceded by interstitial pneumonia. Hanafusa, T; Ishida, T; Isoda, K; Makino, S; Takeuchi, T, 2014)	0.74
"Treatment with prednisolone (60 mg/d) along with WHO MDT-MB continued."	( Optic nerve involvement in a borderline lepromatous leprosy patient on multidrug therapy. Abhinav, C; Chander, B; Chauhan, PS; Khatri, G; Mahajan, VK; Mehta, KS; Prabha, N; Sharma, SK; Sharma, V; Tuli, R, 2013)	0.73
"Treatment with prednisolone (PSL) 60 mg/day resulted in resolution of the AIHA, and the treatment was completed in November 2011."	( A case of recurrent autoimmune hemolytic anemia during remission associated with acute pure red cell aplasia and hemophagocytic syndrome due to human parvovirus B19 infection successfully treated by steroid pulse therapy with a review of the literature. Imai, H; Komatsu, N; Nakamura, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Shimada, A; Sugimoto, K; Wakabayashi, M, 2014)	0.74
"Treatment with prednisolone for 2 months resulted in a significant improvement of the skin and joint symptoms, but was discontinued due to his significant enlargement and extensive metastases of the liver carcinoma."	( Erythema, papules, and arthralgia associated with liver cancer: report of a rare case of multicentric reticulohistiocytosis. Cheng, LP; Hao, QS; Hu, L; Mei, JH; Wu, YH; Xia, J, 2015)	0.76
"Treatment with prednisolone achieved good clinical response."	( Idiopathic pulmonary hemosiderosis complicated by Down syndrome. Abe, Y; Ayusawa, M; Chou, A; Izumi, H; Kamiyama, H; Kato, M; Komori, A; Matsumura, M; Takahashi, S; Watanabe, H, 2015)	0.76
"Treatment with prednisolone was associated with a 3.2-fold increase in HIV viral load (p < 0.0001)."	( Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial. Dölken, L; Gschmack, E; Hain, J; Hofmann, D; Horn, A; Kabyemera, R; Kalluvya, S; Kasang, C; Klinker, H; Kongola, G; Koutsilieri, E; Magambo, K; Majinge, C; Massawe, I; Mlewa, M; Müller, A; Preiser, W; Rethwilm, A; Scheller, C; Stich, A; Ulmer, A; Weissbrich, B, 2016)	1.16
"Treatment with prednisolone at 125 μg/L to 1000 μg/L resulted in significant decline in growth, survival, and heart rate, as well as notable abnormalities in embryonic development."	( Prednisolone impairs embryonic and posthatching development and shell formation of the freshwater snail, Physa acuta. Bal, N; Du, J; Kumar, A; Nugegoda, D, 2016)	2.22
"Treatment with prednisolone resulted in improvement of the skin and other lesions along with a decrease in IgG4 serum levels."	( Immunoglobulin G4-related disease presenting with prurigo: Circulating T-helper 2 cells may be involved in the pathogenesis. Suyama, T; Takamura, S; Teraki, Y, 2016)	0.77
"Treatment with prednisolone resulted in an amelioration of the symptoms."	( A case of systemic lupus erythematosus (SLE) following Human papillomavirus (HPV) vaccination. Furuya, K; Hirai, K; Ito, H; Kurosaka, D; Noda, K; Ukichi, T, 2016)	0.77
"Treatment with prednisolone followed by methotrexate resolved the cutaneous symptoms and the arthralgia completely."	( [Primary cutaneous manifestation of Wegener's granulomatosis]. Bramsiepe, I; Danz, B; Fiedler, E; Heine, R; Holzhausen, HJ; Marsch, WC; Taube, KM, 2008)	0.69
"Treatment with prednisolone combined with the NO-donor DETA-NONOate led to a greater inhibition of the eosinophilia and Cys-LT generation as compared with either drug alone."	( Suppressive effects of nitric oxide-releasing prednisolone NCX-1015 on the allergic pleural eosinophil recruitment in rats. Cordeiro, RS; de O Barreto, E; e Silva, PM; Ferreira, TP; Lagente, V; Martins, MA; Oliveira, MS; Pires, AL; Wallace, JL; Zamuner, S, 2008)	0.94
"Treatment with prednisolone combined with valsartan effectively decreased both chymase-positive mast cells and RI, displaying a significant correlation between these biomarkers (rho=0.85, p=0.016)."	( Evidence for abundant presence of chymase-positive mast cells in the kidneys of patients with immunoglobulin A nephropathy: effect of combination therapy with prednisolone and angiotensin II receptor blocker valsartan. Imanishi, M; Kitabayashi, C; Konishi, Y; Maeda, I; Miyazaki, M; Morikawa, T; Nishiyama, A; Okada, N; Okumura, M; Takai, S; Ueda, M; Yoshioka, K, 2008)	0.88
"Treatment of prednisolone-resistant Jurkat and Molt4 cells with 2-deoxy-D-glucose (2-DG), lonidamine (LND), or 3-bromopyruvate (3-BrPA) increased the in vitro sensitivity to glucocorticoids, while treatment of the prednisolone-sensitive cell lines Tom-1 and RS4; 11 did not influence drug cytotoxicity."	( Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Broekhuis, MJ; Den Boer, ML; Evans, WE; Holleman, A; Hulleman, E; Kazemier, KM; Pieters, R; Rudin, CM; VanderWeele, DJ, 2009)	0.98
"Treatment with prednisolone resulted in a rapid improvement and recovery of his hearing."	( Cogan's syndrome: a rare cause of meningoencephalitis. Ferrie, CD; Long, V; Pysden, KS, 2009)	0.69
"Pre-treatment with prednisolone did not reduce the immediate GTN-induced headache, did not inhibit the frequency of delayed headache but significantly decreased the intensity of delayed GTN-induced headache. "	( Prednisolone reduces nitric oxide-induced migraine. Daugaard, D; Iversen, HK; Lassen, LH; Olesen, J; Tfelt-Hansen, P, 2009)	2.12
"Treatment with prednisolone, 100 mg/day, had no significant effect. "	( [Severe corticoid-refractory autoimmune thrombocytopenia associated with mixed connective tissue disease (Sharp's syndrome). Treatment with rituximab]. Hrdlicka, P; Kouba, M; Rudolph, SE, 2009)	0.71
"Treatment with prednisolone was also associated with a 16% reduction in the night time symptom score (geometric mean ratio 0.84, 95% CI 0.70 to 1.00; P=0.050), a reduced risk of health resource use (odds ratio 0.54, 95% CI 0.34 to 0.86; P=0.010), and reduced school absenteeism (mean difference -0.4 days, 95% CI -0.8 to 0.0 days; P=0.045)."	( Parent initiated prednisolone for acute asthma in children of school age: randomised controlled crossover trial. Biscan, MI; Brennan, SL; Carlin, JB; Robertson, CF; South, M; Vuillermin, PJ, 2010)	1.04
"Treatment with prednisolone and azathioprine resulted in complete or partial remission in majority of the patients (54.8%)."	( Autoimmune hepatitis: Single-center experience of clinical presentation, response to treatment and prognosis in Saudi Arabia. Akbar, HO; Fallatah, HI; Qari, YA, )	0.47
"Treatment with prednisolone improves IS along with normalization of cytokine and adipokine levels and physical activity."	( Insulin sensitivity and related cytokines, chemokines, and adipokines in polymyalgia rheumatica. Galbo, H; Kreiner, F, 2010)	0.7
"Oral treatment with prednisolone results in a reduction of effective thyroidal (131)I half-life in Graves disease, especially at higher doses."	( Qualitative and quantitative impact of protective glucocorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves disease. Beu, M; Hautzel, H; Müller, HW; Pisar, E; Schott, M; Yazdan-Doust, N, 2010)	0.68
"Treatment with prednisolone within 48 hours of onset of palsy resulted in significantly higher complete recovery rates and less synkinesis compared with no prednisolone."	( Prednisolone in Bell's palsy related to treatment start and age. Axelsson, S; Berg, T; Engström, M; Jonsson, L; Kanerva, M; Pitkäranta, A; Stjernquist-Desatnik, A, 2011)	2.16
"Oral treatment with prednisolone (30 mg/day) resulted in rapid disappearance of the infiltrative shadow."	( A case of adult onset Still's disease complicated with cryptogenic organizing pneumonia. Haraoka, H; Kobayashi, Y; Nishio, S; Onishi, T; Sato, H; Takao, T; Yokoe, I, 2011)	0.68
"Treatment with prednisolone and azathioprine led to fast and durable resolution of symptoms."	( [Protein-losing enteropathy: a cause of hypoalbuminaemia in patients with systemic lupus erythematosus]. Briem, S; Fiehn, C; Mühleisen, H; Weis, D; Xanthouli, P, 2011)	0.71
"Treatment with prednisolone led to improvement of both AIHA and IIP."	( [Autoimmune hemolytic anemia in a patient with idiopathic interstitial pneumonia]. Chiba, S; Fukuda, K; Kamada, Y; Suzukawa, K; Taoka, K; Yokoyama, Y, 2011)	0.71
"Treatment of prednisolone-induced hyperglycemia should be targeted at this time period."	( Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. Aguilar-Loza, NR; Burt, MG; Frith, P; Roberts, GW; Stranks, SN, 2011)	0.95
"Treatment with prednisolone successfully prevented inflammatory infiltration over significant regions of the OE. "	( The role of TNF-α in inflammatory olfactory loss. Lane, AP; May, LA; Sultan, B, 2011)	0.72
"Treatment with prednisolone at both dosages reduced CRP levels significantly."	( Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Bijlsma, JW; den Uyl, D; Diamant, M; Dijkmans, BA; Hoes, JN; Lems, WF; Nurmohamed, MT; van Raalte, DH, 2012)	1
"Treatment with prednisolone and vinblastin resulted in settling of fever and resolution of respiratory symptoms and signs."	( Pulmonary langerhans cell histiocytosis masquerading as tuberculosis in an infant. De Silva, MV; Mettananda, S; Senanayake, MP, 2011)	0.71
"Treatment of prednisolone-induced hyperglycaemia should be directed at the postprandial period."	( Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study. Ahern, MJ; Burt, MG; Petersons, CJ; Smith, MD; Stranks, SN; Willenberg, VM, 2012)	0.95
"Treatment with prednisolone does not improve short-term outcome in patients with IFP in an unselected clinical setting. "	( No effect of corticosteroid treatment for idiopathic facial paralysis. Andreassen, CS; Christensen, KF; Ovesen, T, 2012)	0.73
"Treatment with prednisolone resulted in resolution of the lesions."	( Pemphigus foliaceus in a juvenile Cashmere goat, and outcome after prednisolone and methylprednisolone therapy. Janzen, AM; Marqués, FJ; Myers, S; Wiles, D, 2011)	0.95
"Treatment with prednisolone and mycophenolate mofetil led to considerable clinical improvement."	( Generalised lymphadenopathy as the first manifestation of lupus nephritis. Al-Hashimi, H; Bhowmik, A, 2010)	0.7
"Treatment with prednisolone, vinblastine and methotrexate was successful with regression of skin and CNS lesions."	( Systemic juvenile xanthogranuloma with multiple central nervous system lesions. Hamdi, A; Meshkini, A; Mirzayan, J; Shahzadi, S; Tajeddini, A; Zali, A, )	0.47
"Treatment with prednisolone at 60 mg/day resulted in dramatic improvement of both the symptoms and the radiologic abnormalities."	( Chronic eosinophilic pneumonia presenting with acute onset. Hashimoto, S; Kobayashi, T; Koyama, D; Kumasawa, F; Mizumura, K; Nishinarita, S; Noda, A; Oki, T; Sawada, T; Shintani, Y, 2012)	0.72
"Treatment with prednisolone induced insulin resistance (Homeostasis Model Assessment index: placebo vs. "	( Preferential stimulation of abdominal subcutaneous lipolysis after prednisolone exposure in humans. Christiansen, JS; Dall, R; Gravholt, CH; Møller, N; Schmitz, O, 2002)	0.9
"The treatment with prednisolone and cyclophosphamide reduced his symptoms and laboratory data including serum C-ANCA."	( [A case of Wegener's granulomatosis complicated with cytomegalovirus pneumonia during the treatment with immunosuppressants]. Izaki, K; Kawano, T; Kohno, S; Kondo, Y; Machida, I; Matsuse, H; Shimoda, T; Tomari, SY, 2002)	0.63
"Treatment with prednisolone induced a prompt improvement with normalization of serum concentrations of ionized calcium and 1,25-(OH)2D3."	( A patient with sarcoidosis presenting with acute renal failure: implication for granulomatous interstitial nephritis and hypercalcemia. Fujigaki, Y; Hirano, M; Hishida, A; Kato, A; Ohashi, N; Takahashi, S; Yamamoto, T; Yonemura, K, 2002)	0.65
"Treatment with prednisolone and azathioprine is beneficial in ameliorating the clinical course of a subset of IgAN patients with heavy proteinuria or impaired renal function. "	( Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study. Ahuja, M; Brown, CB; Davlouros, P; El Nahas, AM; Goumenos, DS; Shortland, JR; Vlachojannis, JG, 2003)	2.11
"Treatment with prednisolone resulted in remission of neurological symptoms and a rapidly normalization of the eosinophil count."	( [A case of hypereosinophilic syndrome associated with paraplegia]. Endo, C; Miyake, S, 2003)	0.66
"Treatment with prednisolone resulted in a reduction in pulmonary arterial pressure and CXR findings improved 2 months later, but no further effect was observed."	( A case of pulmonary veno-occlusive disease associated with systemic sclerosis. Ito, K; Oka, T; Saito, A; Takizawa, H; Yamamoto, K, 2003)	0.66
"Treatment with prednisolone alone caused loss of bone mineral density, which could be fully prevented in groups D, K, and D + K. "	( Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine. Fujigaki, Y; Fukasawa, H; Hishida, A; Yonemura, K, 2004)	0.94
"Treatment with prednisolone (2 mg/kg/day) for 14 days resulted in dramatic improvement of the thrombocytopenia."	( Neonatal lupus erythematosus with cholestatic hepatitis. Chuo, HT; Huang, LH; Lee, HC; Lin, SC; Shyur, SD; Wu, JY, 2004)	0.66
"Treatment with prednisolone lowered (p < 0.001) trabecular thickness (TbTh) and number (TbN), while increasing (p < 0.001) the gap between trabeculae."	( Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague-Dawley rats. León, F; Más, R; Mendoza, N; Mendoza, S; Noa, M, 2004)	0.89
"Treatment with prednisolone and immunoglobulin resulted in a relative increase in the platelet count."	( Immune-mediated thrombocytopenic purpura associated with Toxoplasma gondii infection in an immunocompetent patient. Belegrati, M; Deutsch, M; Dourakis, SP; Kalmantis, T; Kountouras, D; Nezi, V, 2004)	0.66
"Treatment with prednisolone quickly brought remission of systemic and laryngeal symptoms as well as improvement in the results of video-laryngostroboscopic tests."	( Cricoarytenoid arthritis in Sjögren's syndrome. Broussolle, C; Bui-Xuan, C; Charhon, A; Poupart, M; Sève, P, 2005)	0.67
"Treatment with prednisolone was without effect, but 3 weeks after i.v."	( Aplastic anemia successfully treated with rituximab. Hansen, PB; Lauritzen, AM, 2005)	0.67
"Treatment with prednisolone resulted in an increase in p-gp expression (P=0.005)."	( P-glycoprotein expression in lamina propria lymphocytes of duodenal biopsy samples in dogs with chronic idiopathic enteropathies. Allenspach, K; Bergman, PJ; Doherr, MG; Gaschen, F; Gröne, A; Sauter, S, 2006)	0.67
"Treatment with prednisolone and azathioprine caused rapid and complete healing."	( [Desmoglein 1-negative, desmoglein 3-positive pemphigus herpetiformis with involvement of oral mucous membranes]. Brod, C; Fierlbeck, G; Metzler, G; Röcken, M; Schaller, M; Sönnichsen, K, 2005)	0.67
"Treatment with prednisolone, erythropoietin and danocrine was without effect."	( [Refractory anaemia successfully treated with thalidomide]. Hansen, M; Hansen, PB, 2006)	0.67
"Treatment with Prednisolone priming and Interferon, improved both the time and rate of seroconversion compared to no treatment or Interferon alone, suggesting that this combination of drugs might have an immunomodulatory effect."	( Long-term follow-up of hepatitis B carrier children treated with interferon and prednisolone. Ballard, AL; Boxall, EH; Davies, P; Kelly, DA; Sira, J, 2006)	0.9
"Treatment with prednisolone and azathioprine seems to be of no long-term benefit in ameliorating the clinical course of nephrotic patients with membranous nephropathy. "	( Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study. Ahuja, M; Brown, CB; Davlouros, P; El Nahas, AM; Goumenos, DS, 2006)	2.13
"Treatment with prednisolone and endoscopic variceal ligation resulted in improvement of her symptoms."	( A case of systemic sclerosis complicated by idiopathic portal hypertension: case report and literature review. Akimoto, K; Kawai, S; Nishio, S; Takagi, K; Yoshino, T, 2006)	0.67
"With treatment of prednisolone, an angiotensin-converting enzyme inhibitor, and an angiotensin II receptor-blocker, his proteinuria markedly decreased and renal function was stabilized."	( Nephrotic syndrome and IgA nephropathy in polycystic kidney disease. Gejyo, F; Hiura, T; Kawabe, S; Miyamura, S; Nishi, S; Saeki, T; Ueno, M; Yamazaki, H, 2006)	0.66
"The treatment with prednisolone was started, which was effective on each disease."	( [A case of autoimmune pancreatitis complicated with immune thrombocytopenia]. Fukushima, H; Katou, E; Nagayama, K; Sata, M; Shirachi, A, 2006)	0.65
"Treatment with prednisolone and hydroxychloroquine followed by inhaled corticosteroids may improve survival in children with IPH."	( Idiopathic pulmonary hemosiderosis: clinical profile and follow up of 26 children. Bhargava, S; Kabra, SK; Lodha, R; Satyavani, A; Walia, M, 2007)	0.69
"Treatment with prednisolone (1.5 mg/kg) or indomethacin (5 mg/kg) had no effect on the serum calcium level of these mice."	( Association of hypercalcemia with tumors producing colony-stimulating factor(s). Asano, S; Kondo, Y; Kosaka, K; Mori, M; Ohkawa, H; Ohsawa, N; Okabe, T; Sato, K; Sato, N; Ueyama, Y, 1983)	0.61
"Treatment with prednisolone and clofazimine produced an excellent clinical response."	( Pyoderma gangrenosum associated with selective hereditary IgA deficiency. Bundino, S; Zina, AM, 1984)	0.61
"Treatment with prednisolone alone or with a prednisolone/azathioprine combination resulted in an equal five-year survival (82%) and a similar overall preservation of renal function."	( Renal involvement in systemic lupus erythematosus. Atkins, RC; Boyce, NW; Holdsworth, SR; Thomson, NM, 1984)	0.61
"Mice treated with prednisolone for 1 week had delayed clearance at 22h, and mice treated for 2 days had normal clearance."	( Chronic glucocorticosteroid therapy impairs staphylococcal clearance from murine lungs. Nugent, KM; Pesanti, EL, 1982)	0.59
"Treatment with prednisolone gave rapid relief of pain and allowed the patient to become mobile again."	( Engelmann's disease and the effect of corticosteroids. A case report. Fitton, JM; Forsythe, WI; Hardy, GJ; Minford, AM; Rowe, VL, 1981)	0.6
"Treatment with prednisolone was tried in some cases with excellent results."	( Sinus histiocytosis with massive lymphadenopathy and epidural involvement. Haas, RJ; Helmig, MS; Meister, P, 1981)	0.6
"Treatment with prednisolone largely normalized the lung functions in case 2, completely in case 1, and renal functions in both."	( [Sarcoidosis in monozygotic twins]. Jany, B; Kneitz, C; Kraus, MR; Tony, HP; Tschammler, A; Wilhelm, M, 1995)	0.63
"Treatment with prednisolone resulted in an improvement in the chest X-ray findings, as well as a diminished polyclonal hypergammaglobulin level."	( Lymphoid interstitial pneumonia as a pulmonary lesion of idiopathic plasmacytic lymphadenopathy with hyperimmunoglobulinemia. Kawabata, Y; Miwa, T; Ogawa, K; Takagi, K; Torii, K; Yokoi, T, 1994)	0.63
"Oral treatment with prednisolone and cyclosporin A of zymosan-challenged animals showed a dose-dependent reduction of IL-1 beta concentrations, but no effect of indomethacin."	( Interleukin-1 (IL-1) production in a mouse tissue chamber model of inflammation. II. Identification of (tissue) macrophages as the IL-1 producing cells and the effect of anti-inflammatory drugs. Chaplin, D; Dawson, J; Geiger, T; Kunz, S; Nguyen, H; Rordorf-Adam, C; Towbin, H; Vosbeck, K; Zingel, O, 1993)	0.6
"Treatment with prednisolone markedly improved her symptoms."	( Anticardiolipin antibody-induced sudden profound sensorineural hearing loss. Hisashi, K; Komune, S; Sadoshima, S; Taira, T; Tsuda, H; Uemura, T, )	0.47
"Treatment with prednisolone and melphalan resulted in improvement of clinical findings such as anemia, lymph node swelling and hypergammaglobulinemia in concurrence with decrease in serum levels of IL-6."	( [Chromosomal abnormalities in Castleman's disease with high levels of serum interleukin-6]. Hashimoto, S; Ishii, A; Kawano, E; Kogure, K; Matsuura, Y; Nakamura, H; Nakaseko, C; Nishimura, M; Oh, H; Yoshida, S, 1993)	0.63
"The treatment with prednisolone rapidly and progressively decreased serum levels of thyroglobulin, T4, and C-reactive protein and the erythrocyte sedimentation rate."	( Dissociation between serum interleukin-6 rise and other parameters of disease activity in subacute thyroiditis during treatment with corticosteroid. Aizawa, T; Sato, A; Yamada, T, 1996)	0.61
"Treatment with prednisolone (15 mg/day), chloroquine phosphate (200 mg/ day), cyclosporine (5 mg/kg daily), and gold (10 mg/day) failed to reduce pruritic plaque formation, and pulse methylprednisolone therapy led to only a transient remission."	( Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy. Hatta, N; Imai, T; Sakai, H; Takata, M; Takehara, K; Tsutsui, K, 1996)	0.63
"Treatment with prednisolone for DM and acetylspiramycin for toxoplasmosis was successful."	( [A case of toxoplasmosis with dermatomyositis]. Fujisaki, T; Hayashi, J; Kashiwagi, S; Kawakami, Y; Tani, Y; Yamaga, S, 1995)	0.63
"Treatment with prednisolone and cyclophosphamide."	( Polyarteritis nodosa--a few unusual findings. Bajwa, RP; Joshi, K; Kumar, L; Malik, N; Sarkar, B; Singh, S, 1996)	0.65
"Treatment with prednisolone (7.5 mg/day) and aspirin (40 mg/day) was continued."	( [A case of antiphospholipid antibody syndrome successfully treated with prednisolone and low-dose aspirin, with subsequent normal pregnancy]. Maeda, T; Maesima, E; Yamada, Y; Yamamoto, M; Yukawa, S, 1997)	0.87
"Treatment with prednisolone, but not placebo, significantly reduced asthma symptoms (from mean +/- SEM total weekly score of 34 +/- 6.2 to 15.7 +/- 3.2, p = 0.02) and albuterol usage (from mean +/- SEM number of puffs/wk of 29.7 +/- 6.2 to 18.2 +/- 3.7, p = 0.01) and significantly increased FEV1 (from 89.8 +/- 4.4% to 99.3 +/- 4.1% of predicted, p = 0.03)."	( The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation. Djukanović, R; Gratziou, C; Holgate, S; Homeyard, S; Howarth, P; Madden, J; Montefort, S; Peroni, D; Polosa, R; Walls, A, 1997)	0.64
"Treatment with prednisolone, a glucocorticoid hormone, prevented activation of both NF-kappa B and AP-1 in glomeruli and subsequent mRNA expression of NF-kappa B- and AP-1-regulated genes."	( Suppression of NF-kappa B and AP-1 activation by glucocorticoids in experimental glomerulonephritis in rats: molecular mechanisms of anti-nephritic action. Hisada, Y; Ishizuka, T; Kawashima, K; Sakurai, H; Shigemori, N; Sugita, T, 1997)	0.64
"Treatment with prednisolone alone did not prevent progression to overt hepatic failure."	( Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Chamuleau, RA; de Man, RA; Jones, EA; Rietbroek, RC; Smorenburg, S; ter Borg, F, 1998)	0.64
"Treatment with prednisolone and melphalan for one year has stabilised the condition."	( [Localized diffuse pulmonary AL-amyloidosis]. Abdulla, J; Birgens, H; Maltboek, N, 1998)	0.64
"Treatment with prednisolone, azathioprine, heparin-warfarin, and dipyridamole early in the course of disease may prevent immunologic renal injury in children with severe IgA nephropathy."	( A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. Awazu, M; Hattori, S; Honda, M; Iitaka, K; Ito, H; Ito, K; Koitabashi, Y; Matsuyama, S; Nakagawa, K; Nakamura, H; Ninomiya, M; Sakai, T; Seino, Y; Takeda, N; Takekoshi, Y; Yamaoka, K; Yoshikawa, N, 1999)	0.64
"Treatment with prednisolone and azathioprine was initiated."	( [Pyoderma gangrenosum and portal vein thrombosis in a 33-year-old female patient]. Berr, F; Halm, U; Mössner, J; Paasch, U; Pönisch, W; Schiefke, I, 1999)	0.64
"Mice treated with prednisolone after auditory threshold elevations demonstrated significant improvement and stabilization of thresholds compared with untreated controls."	( Steroid-responsive cochlear dysfunction in the MRL/lpr autoimmune mouse. Kempton, Jb; Trune, DR; Wobig, RJ, 1999)	0.63
"Treatment with prednisolone and cyclophosphamide resulted in the disappearance of the skin lesions and the improvement of laboratory data."	( [The radiographic report of soft tissue tumor on the legs in a case of cutaneous polyarteritis nodosa]. Saegusa, J; Sinzato, I; Sugimoto, K; Yabe, H, 2000)	0.65
"Treatment with prednisolone and cyclophosphamide induced a rapid recovery from acute renal failure."	( A case with acute renal failure complicated by Waldenström's macroglobulinemia and cryoglobulinemia. Fujigaki, Y; Hishida, A; Ikegaya, N; Sano, K; Suzuki, T; Yonemura, K, 2000)	0.65
"Pre-treatment with prednisolone decreased the cell attracting effect of ICAM-1 in a dose-dependent manner to 72% of the basal migration (P<0.001)."	( Chemotactic properties of ICAM-1 and PECAM-1 on neutrophil granulocytes in ulcerative colitis: effects of prednisolone and mesalazine. Nielsen, OH; Vainer, B, 2000)	0.84
"Treatment with prednisolone subsequently improved insulin secretion and glycaemic control in these patients."	( Corticosteroid-responsive diabetes mellitus associated with autoimmune pancreatitis. Hashimoto, M; Kobayashi, T; Murase, T; Nakanishi, K; Okubo, M; Takeuchi, K; Tanaka, S, 2000)	0.65
"Treatment with prednisolone (1 mg/kg/d) began on approximately day 300."	( Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. Kuwana, M; Mashima, Y; Mori, T; Nakajima, T; Ogawa, Y; Oguchi, Y; Okamoto, S; Tsubota, K; Watanabe, R; Yamada, M, 2001)	0.65
"Treatment with prednisolone resulted in marked improvement of biochemical, hematological and dermatological abnormalities."	( Autoimmune hepatitis concomitant with hypergammaglobulinemic purpura, immune thrombocytopenia, and Sjögren's syndrome. Kamimoto, H; Nakasho, K; Park, SY; Shintani, S; Wada, M, 2001)	0.65
"Treatment with prednisolone largely prevents the microcirculatory alterations in the small bowel induced by extracorporeal circulation."	( Influence of steroids on microvascular perfusion injury of the bowel induced by extracorporeal circulation. Dollner, R; Gebhard, MM; Hagl, S; Reidenbach, B; Sack, FU; Schledt, A, 2001)	0.66
"Treatment with prednisolone 10 mg tid rapid resolved nausea and vomiting, allowing discharge in 3 (range 1-6.5) days. "	( Management of hyperemesis gravidarum: the importance of weight loss as a criterion for steroid therapy. Moran, P; Taylor, R, 2002)	0.67
"Retreatment with prednisolone and azathioprine has resulted in its improvement."	( [Interstitial pneumonia associated with chronic thyroiditis]. Hashizume, T; Matsushita, K; Numata, H, 2002)	0.64
"Treatment with prednisolone (40 mg/day) started and the bleeding tendency gradually improved."	( Acquired type 3-like von Willebrand syndrome preceded full-blown systemic lupus erythematosus. Hasegawa, H; Hayashi, Y; Kushiro, M; Niiya, K; Niiya, M; Takazawa, Y; Tanimizu, M; Tanimoto, M; Tanio, Y, 2002)	0.65
"Treatment with prednisolone may be applied to any form of myasthenia gravis, particularly those which do not react to anticholinesterasic agents in moderate dosages."	( [Long term administration of oral prednisone or prednisolone in treatment of myasthenia gravis. Report of five cases (author's transl)]. Contamin, F; Ecoffet, M; Mignot, B; Offenstadt, G; Singer, B, )	0.73
"Pretreatment with prednisolone 10 mg/kg or cortisone acetate 10 mg/kg given subcutaneously significantly suppressed the aggravated ulceration in response to 20 mg/kg of indomethacin in these adrenalectomized rats."	( The mechanism of aggravation of indomethacin-induced gastric ulcers by adrenalectomy in the rat. Kasuya, Y; Okabe, S; Urushidani, T, 1979)	0.58
"Treatment with prednisolone increased the concentrations of thiamine mono-, di- and triphosphates in both of these tissues in adrenalectomized rats, compared with unoperated control animals."	( Effects of adrenalectomy and prednisolone on the absorption and phosphorylation of thiamine in rats. Lazarov, J, 1978)	0.89
"Treatment with prednisolone did not appear to have any effect on the length of the follicular phase or on ovulation."	( Urinary oestrogen excretion, oestrous behaviour and ovulation in heifers treated with prednisolone during pro-oestrus and oestrus. Tomasgard, G, 1976)	0.82
"Treatment with prednisolone or dexamethasone is followed by an increase in renal excretion of p-aminohippurate (PAH) and in accumulation of PAH in renal cortical slices, particularly in 5- and 10-day-old rats with immature kidney function. "	( Stimulation of renal tubular transport of p-aminohippurate in rats of different ages by treatment with adrenocortical steroids. Bräunlich, H; Rassbach, H; Vogelsang, S, 1992)	0.64
"Treatment with prednisolone improves the short-term survival of patients with severe biopsy-proved alcoholic hepatitis."	( A randomized trial of prednisolone in patients with severe alcoholic hepatitis. Benhamou, JP; Chaput, JC; Mathurin, P; Poynard, T; Ramond, MJ; Rueff, B; Théodore, C, 1992)	0.95
"Treatment with prednisolone or cytostatic drugs as single therapy for up to 6 months increased the risk of improvement of the disease, and had no significant effect on deterioration."	( Prognosis in glomerulonephritis. III. A longitudinal analysis of changes in serum creatinine and proteinuria during the course of disease: effect of immunosuppressive treatment. Report from Copenhagen Study Group of Renal Diseases. Balsløv, JT; Brahm, M; Brammer, M; Brun, C; Gerstoft, J; Jørgensen, HE; Lorenzen, I; Thomsen, AC, 1992)	0.62
"Treatment with prednisolone 60 mg daily was started."	( [A case of mixed connective tissue disease (MCTD) associated with transverse myelitis responding to pulse therapy]. Obara, K; Tanaka, K, 1991)	0.62
"was treated with prednisolone following the recommendation of Rubinstein."	( [Initial therapeutic experiences in AIDS in childhood]. Eitelberger, F; Tulzer, W, 1990)	0.61
"Pretreatment with prednisolone was started as therapy for leukemia, and 2 days later, the patient underwent surgery."	( Intestinal obstruction at the onset of acute lymphoblastic leukemia in a child. Ballati, G; Cozzi, F; Digilio, G; Iacobini, M; Lemmo, M; Multari, G; Roggini, M; Sirignano, A; Werner, B, 1990)	0.6
"Treatment with prednisolone and acetylsalicylic acid (ASA) during pregnancy should be given to only those women who have high levels of anti-cardiolipin antibodies concomitant with high APTT values, and low values of complement C4."	( The results of investigations for blocking antibody and autoantibodies help to choose between different immunological treatments for recurrent abortion. Arfors, L; Haeger, M; Lindholm, A; Norberg, R; Siösteen, C; Stigendal, L; Unander, AM; Wenneström, H, )	0.47
"Treatment with prednisolone resulted in striking improvement in both patients."	( Allergic bronchopulmonary aspergillosis with coexistent aspergilloma: a long-term followup. Chaturvedi, S; Jaggi, OP; Khan, ZU; Ramchandran, S; Randhawa, HS; Shah, A, 1989)	0.62
"Treatment with prednisolone brought relief."	( Endobronchial pseudolymphoma associated with Sjögren's syndrome. Report of a case. Kajiki, A; Kido, M; Kuroiwa, A; Miyazaki, N; Yamazaki, H; Yoashihara, S, 1989)	0.62
"Treatment with prednisolone produced marked reductions in body weight gain, adrenal weight and pituitary ACTH content, but no significant change in hypothalamic corticotrophin-releasing factor (CRF) bio- or immunoreactivity."	( Recovery of the components of the hypothalamo-pituitary-adrenocortical axis in the rat after chronic treatment with prednisolone. Campbell, EA; Gillham, B; Jones, MT; Nicholson, SA, 1987)	0.82
"Treatment with prednisolone, cytotoxic drugs, and plasma exchange hastened the time to clearance of autoantibody and improved the outlook of patients who were not dependent on dialysis and those with lung haemorrhage."	( Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Bowman, C; Lockwood, CM; Pusey, CD; Rees, AJ; Savage, CO, 1986)	0.61
"Treatment with prednisolone resulted in a marked improvement in both clinical condition and renal function."	( Reversible acute renal failure due to Churg-Strauss syndrome. Davenport, A; Goldsmith, HJ; McDicken, I, 1988)	0.61
"Treatment with prednisolone should be given for at least two years, with adjustment of dosage according to the serum levels of aspartate transaminase; maintenance does should be 8-12 mg a day."	( Treatment of chronic active hepatitis and other liver diseases with corticosteroid agents. Mackay, IR, 1987)	0.61
"Treatment with prednisolone hemisuccinate sodium (0.25 mumol/egg) produced an elevation in the level of LPO in the lens but that with cortisone hemisuccinate sodium or cortexolone hemisuccinate sodium did not change the level of LPO in the lens."	( The alteration of lipid peroxide in glucocorticoid-induced cataract of developing chick embryos and the effect of ascorbic acid. Iwatsuru, M; Lee, JW; Nishigori, H; Yamauchi, Y, 1986)	0.61
"Treatment with prednisolone or with maintenance doses of carbohydrate-active steroids returned auditory detection and perception to normal in every patient tested."	( Auditory detection and perception in normal man and in patients with adrenal cortical insufficiency: effect of adrenal cortical steroids. Daly, RL; Henkin, RI, 1968)	0.59
"Treatment with Prednisolone(R) did not change the magnitude of the initial response to 1,25-dihydroxyvitamin D(3) at 7 hr, but did decrease the response at 24 and 48 hr after a single dose of 1,25-dihydroxyvitamin D(3)."	( The effect of Prednisolone upon the metabolism and action of 25-hydroxy-and 1,25-dihydroxyvitamin D3. Ayigbedé, O; Carré, M; Miravet, L; Rasmussen, H, 1974)	0.95

Toxicity

MMF seems safe and effective as first-line therapy in inducing and maintaining remission in treatment-naive patients with AIH. Incidence rates per 1000 person-years of potential corticosteroid-related adverse events in patients with new current use of oral prednisolone ranged from 1 to 2.

Excerpt	Reference	Relevance
" No toxic effects of the drug have been found."	( The therapeutic value of oral long-term treatment with terbutaline (Bricanyl) in asthma. A follow-up study of its efficacy and side effects. Formgren, H, 1975)	0.25
"03 mg/kg/day group, ther were no toxic signs."	( [A 13-week subcutaneous toxicity study of prednisolone farnesylate (PNF) in rats]. Anabuki, K; Hoshiya, T; Okazaki, S; Tamura, K; Tanaka, G; Tanaka, H; Yamazaki, E, 1992)	0.55
" In the groups that received less than 1 mg/kg/day of PNF gel, there were no toxic signs induced by the drug."	( [A 13-week dermal toxicity study of prednisolone farnesylate (PNF) gel in rats with a recovery period of 5 weeks]. Anabuki, K; Hoshiya, T; Okazaki, S; Tamura, K; Tanaka, G; Tanaka, H; Yamazaki, E, 1992)	0.56
"125 mg/kg/day group, there were no toxic signs induced by the drug."	( [A 52-week dermal toxicity study of prednisolone farnesylate (PNF) gel in rats with a recovery period of 8 weeks]. Aikawa, T; Hatayama, K; Nishimura, S; Okazaki, S; Tamura, K; Tanaka, G; Tanaka, H, 1992)	0.56
" Main side-effect shown was osteoporosis (n = 7), other known steroid-side effects were quite seldom (less than 5%)."	( [Polymyalgia rheumatica and giant cell arteritis; diagnosis and side effects of low-dose long-term glucocorticoid therapy]. Hatz, HJ; Helmke, K, )	0.13
" An animal model is presented to assess these adverse effects on growth."	( An animal model to study toxicity of central nervous system therapy for childhood acute lymphoblastic leukemia: effects on growth and craniofacial proportion. Howes, A; Mullenix, PJ; Schunior, A; Tarbell, NJ; Tassinari, MS; Zengel, AE, 1990)	0.28
" From the direction and magnitude of these changes it was concluded that they did not reflect any toxic actions of the preparation."	( Target animal safety test of a dexamethasone-prednisolone combination in horses. Laczay, P; Lehel, J; Móra, Z; Simon, F, 1990)	0.54
"Six patients with histologically proven HBsAg-negative chronic active hepatitis (CAH), who were initially treated successfully with prednisolone with or without azathioprine, developed unacceptable adverse effects due to prednisolone."	( D-penicillamine therapy in patients with HBsAg-negative chronic active hepatitis and major prednisolone-induced adverse effects. Callender, ME; McClements, BM, 1990)	0.7
"In contrast to its importance in improving renal graft survival, nephrotoxicity is the most serious side effect of cyclosporine."	( Amplification of the nephrotoxic effect of cyclosporine by preexistent chronic histological lesions in the kidney. Bosman, FT; Kootstra, G; Leunissen, KM; Nieman, FH; Noordzij, TC; van Hooff, JP; Vromen, MA, 1989)	0.28
"Prednisolone, given orally or intraperitoneally before challenge, protected mice against the lethal effect of a crude cell extract of Bordetella pertussis containing heat-labile toxin (HLT) as the major toxic component."	( Effect of prednisolone on the toxicity of Bordetella pertussis for mice. Parton, R, 1985)	2.11
"Some widely used ototopical preparations are potentially toxic to the middle and inner ear."	( Ototoxicity of Vasocidin drops applied to the chinchilla middle ear. Brown, OE; Masaki, M; Meyerhoff, WL; Wright, CG, 1988)	0.27
"A retrospective analysis of 350 treatment courses using high dose pulsed intravenous methylprednisolone for relapses of multiple sclerosis revealed a low number of adverse effects."	( Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects. Lyons, PR; Newman, PK; Saunders, M, 1988)	0.98
" These findings suggest that the action site(s) of steroidal anti-inflammatory agents is involved in the development of the toxic actions of T-2 toxin, and the implications of the results with bioamines and opioids are also discussed."	( Effects of drugs and metabolic inhibitors on the acute toxicity of T-2 toxin in mice. Ryu, JC; Shiraki, N; Ueno, Y, 1987)	0.27
" From the above evidence, it was concluded that HBP ointment was less toxic than the other topical corticosteroids."	( Comparative toxicity study of hydrocortisone 17-butyrate 21-propionate (HBP) ointment and other topical corticosteroids in rats. Kimura, M; Nakane, S; Otomo, S; Tarumoto, Y, 1986)	0.27
" To determine if both groups of substances act through similar biologic mechanisms, their capacity to protect macrophages from the direct toxic effects of LPS was examined in vitro."	( Inhibition of LPS toxicity for macrophages by metallothionein-inducing agents. Costa, M; Lewis, VM; Patierno, SR; Peavy, DL, 1983)	0.27
" To evaluate the role of direct toxic action of drugs on hepatocytes, the effects of salicylate, chloroquine, prednisolone and indomethacin on LDH leakage from cultured rat hepatocytes were studied."	( Hepatotoxic effects of anti-rheumatic drugs in cultured rat hepatocytes. Akesson, A; Akesson, B, 1984)	0.48
" Adverse effects are rarely if ever associated with short courses of steroids used for this purpose."	( Safety of oral corticosteroids. Weinberger, M, 1982)	0.26
" In 59 patients with advanced disease who received no other treatment, a 5-year survival rate of 66% was comparable with that achieved by more toxic mustine-containing combinations."	( Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease. Austin, DE; Barrett, A; Dady, PJ; McElwain, TJ; Peckham, MJ, 1982)	0.26
"To determine whether intermittent rather than daily administration of D-penicillamine (D-Pen) would effectively reduce the incidence of adverse effects without significantly diminishing the clinical benefits."	( Intermittent treatment with D-penicillamine is effective in lower doses and with fewer adverse effects in patients with rheumatoid arthritis. Akahoshi, T; Hakoda, M; Kamatani, N; Kashiwazaki, S; Taniguchi, A, 1994)	0.29
" The incidence of adverse effects was significantly lower in the intermittent group."	( Intermittent treatment with D-penicillamine is effective in lower doses and with fewer adverse effects in patients with rheumatoid arthritis. Akahoshi, T; Hakoda, M; Kamatani, N; Kashiwazaki, S; Taniguchi, A, 1994)	0.29
" Prednisolone pretreatment resulted in decreased covalent binding of the toxic metabolite in vivo and an increased urinary excretion of glutathione-derived conjugates of acetaminophen, indicating an enhanced detoxification of the reactive metabolite by glutathione."	( Prednisolone stimulates hepatic glutathione synthesis in mice. Protection by prednisolone against acetaminophen hepatotoxicity in vivo. Lauterburg, BH; Schranz, C; Speck, RF, 1993)	2.64
" However on multivariate analysis only the presence of bulky disease and of B symptoms were independent adverse factors for response and for survival."	( EPIC: an effective low toxicity regimen for relapsing lymphoma. Ashley, S; Catovsky, D; Cunningham, D; Gore, ME; Hickish, T; Mansi, J; Nicolson, V; Roldan, A; Smith, IE, 1993)	0.29
"Rimexolone 1% ophthalmic suspension is safe and effective for the treatment of uveitis."	( Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis. Alter, G; Crabb, JL; DeBarge, LR; Feiler, LS; Foster, CS; Friedlaender, MH; Raizman, MB; Santos, CI, 1996)	0.53
" depot bromocriptine (Parlodel-LAR, Sandoz, Basel, Switzerland), but adverse effects following the first injection may still be a significant problem."	( Oral prednisolone supplement abolishes the acute adverse effects following initiation of depot bromocriptine therapy. Besser, GM; Grossman, AB; Jain, A; Jenkins, PJ; Jones, SL, 1996)	0.81
"Concurrent oral administration of prednisolone significantly reduces the incidence of acute adverse effects following depot bromocriptine."	( Oral prednisolone supplement abolishes the acute adverse effects following initiation of depot bromocriptine therapy. Besser, GM; Grossman, AB; Jain, A; Jenkins, PJ; Jones, SL, 1996)	1.09
" Additionally, the toxic effect of amiodarone on the cells was depressed by pretreatment of them with docosahexaenoic acid (DHA) or alpha-tocopherol for 2 days and co-treatment with these agents for 1 day, but not with prednisolone or indomethacin co-treatment."	( Toxicity of amiodarone on mouse pulmonary endothelial cells cultured with or without alveolar macrophages. Futamura, Y, 1996)	0.48
" There were no significant adverse effects."	( Efficacy and safety of one year of growth hormone therapy in steroid-dependent nephrotic syndrome. Chao, SM; Lee, KO; Loke, KY; Tan, SP; Yap, HK; Zhou, X, 1997)	0.3
" However, the induction phase is toxic and a 3-weekly interval appears more appropriate."	( Feasibility, toxicity, and activity of LNH84-derived chemotherapy in the management of aggressive lymphomas. Alberto, P; Bauer, J; Iten, PA; Laurencet, FM; Mermillod, B; Zulian, GB, 1997)	0.3
" The drop-out rate due to adverse events was surprisingly higher in the placebo group (41%) than in the auranofin group (10%) and, as expected, higher due to lack of effect (29 and 16%)."	( Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. Andrup, O; Brodin, U; Clarke-Jenssen, O; Glennås, A; Karstensen, B; Kvien, TK, 1997)	0.3
"Deflazacort (DFZ) is claimed to have fewer adverse bone effects than prednisone (PDN) at doses with equivalent anti-inflammatory activity (5 mg PDN = 6 mg DFZ)."	( The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis. Imbimbo, B; Milani, S; Riboldi, A; Rizzato, G; Torresin, A, 1997)	0.3
" Our initial studies have demonstrated a direct adverse effect of individual glucocorticoids and cytotoxic agents on the proliferative capacity of rat tibial growth-plate chondrocytes in vitro."	( Glucocorticoid pretreatment reduces the cytotoxic effects of a variety of DNA-damaging agents on rat tibial growth-plate chondrocytes in vitro. Anderson, E; Eden, O; Isaksson, O; Robson, H; Shalet, S, 1998)	0.3
" Adverse events were similar between groups (P = ."	( The efficacy and safety of diclofenac 0.1% versus prednisolone acetate 1% following trabeculectomy with adjunctive mitomycin-C. Cate, EA; Dubiner, HB; Kent, AR; Mundorf, TK; Stewart, JA; Stewart, WC; Whitaker, R, 1998)	0.55
"To appraise the adjunctive role of prednisolone (PN) in pulmonary tuberculosis (PTB) with toxic reactions."	( Prednisolone: a beneficial and safe adjunct to antituberculosis treatment? A randomized controlled trial. Bilaçeroğlu, S; Büyükşirin, M; Celikten, E; Perim, K, 1999)	2.02
"Prednosolone is a beneficial and safe adjunct to 12-month antituberculosis treatment in advanced PTB causing toxic reactions, provided that close clinical, radiographic and bacillary monitoring is exercised."	( Prednisolone: a beneficial and safe adjunct to antituberculosis treatment? A randomized controlled trial. Bilaçeroğlu, S; Büyükşirin, M; Celikten, E; Perim, K, 1999)	1.75
"To appraise the data on systemic adverse effects of inhaled corticosteroids."	( Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Lipworth, BJ, 1999)	0.3
"All inhaled corticosteroids exhibit dose-related systemic adverse effects, although these are less than with a comparable dose of oral corticosteroids."	( Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Lipworth, BJ, 1999)	0.3
" No adverse events were reported, and there were no significant changes in intraocular pressure in either group."	( Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. Jenkins, JE; Pendelton, RA; Simone, JN, 1999)	0.54
" There were no toxic deaths."	( Epic as an effective, low toxicity salvage therapy for patients with poor risk lymphoma prior to beam high dose chemotherapy and peripheral blood progenitor cell transplantation. Cavenagh, JD; Eden, AG; Hughes, A; Kelsey, SM; Lamont, A; McBride, NC; Mills, MJ; Newland, AC; Ward, MC, 1999)	0.3
"Systemic toxic effects may develop as a result of topical and local use of ophthalmic corticosteroid preparations in susceptible patients."	( Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year-old male with posterior uveitis. Cheng, L; Freeman, WR; Levi, L; Ozerdem, U; Scher, C; Song, MK, 2000)	0.31
"The adverse effects of oral corticosteroids are widely recognised but there are few quantitative data on which to base advice to patients."	( Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Cooper, S; Hubbard, R; Lewis, SA; Oborne, J; Pringle, M; Tattersfield, AE; Walsh, LJ; Wong, CA, 2001)	0.31
"Data on oral corticosteroid use, lifestyle, fractures, and other possible adverse effects were collected by questionnaire and compared between a community based cohort of patients taking continuous or frequent intermittent oral corticosteroids for asthma, chronic obstructive pulmonary disease, or alveolitis and age and sex matched control subjects."	( Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Cooper, S; Hubbard, R; Lewis, SA; Oborne, J; Pringle, M; Tattersfield, AE; Walsh, LJ; Wong, CA, 2001)	0.31
" The principal adverse reactions to FK 506 therapy were hyperglycaemia, renal dysfunction and hyperkalaemia."	( Two-year follow-up study of the efficacy and safety of FK 506 in kidney transplant patients. Japanese FK 506 Study Group. , 1994)	0.29
" Oral administration of prednisolone (1 mg/kg of body weight) resulted in resolution of adverse effects in all 8 dogs."	( Evaluation of the safety of an abbreviated course of injections of allergen extracts (rush immunotherapy) for the treatment of dogs with atopic dermatitis. Bettenay, SV; Mueller, RS, 2001)	0.62
"Rush immunotherapy performed by personnel at a veterinary hospital is a safe method for treatment of dogs with atopic dermatitis."	( Evaluation of the safety of an abbreviated course of injections of allergen extracts (rush immunotherapy) for the treatment of dogs with atopic dermatitis. Bettenay, SV; Mueller, RS, 2001)	0.31
" We have concluded that, in selected patients with cyclosporine nephrotoxicity, CsA withdrawal with concomitant use of MMF is safe and effective in the improvement of graft function and arterial hypertension."	( [Use of mycophenolate mofetil in patients with a transplanted kidney and cyclosporin nephrotoxicity]. Dimitrijević, J; Drasković-Pavlović, B; Dujić, A; Elaković, D; Hrvacević, R; Ignjatović, Lj; Kronja, G; Marić, M; Vavić, N, )	0.13
" In this study, the PDsuc-appended alpha-CyD ester conjugate (PDsuc/alpha-CyD conjugate) was intracolonically administered to rats with 2,4,6-trinitrobenzensulfonic acid-induced colitis, and its antiinflammatory and systemic adverse effects were compared with those of prednisolone (PD) alone and the PD/2-hydroxypropyl-beta-CyD complex (PD/HP-beta-CyD complex), which is a noncovalent inclusion complex."	( Prednisolone-appended alpha-cyclodextrin: alleviation of systemic adverse effect of prednisolone after intracolonic administration in 2,4,6-trinitrobenzenesulfonic acid-induced colitis rats. Arima, H; Hirayama, F; Uekama, K; Yano, H, 2001)	1.93
" The most significant side effect is nephrotoxicity, which may present differently at different times after transplantation."	( Cyclosporine nephrotoxicity: associated allograft dysfunction at low trough concentration. Druskis, V; Jankauskiene, A; Laurinavicius, A, 2001)	0.31
" In this study, the anti-inflammatory effect and systemic side effect of the PD succinate/alpha-cyclodextrin (PDsuc/alpha-CyD) ester conjugate after oral administration were studied using IBD model rats."	( Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. Arima, H; Hirayama, F; Kamada, M; Uekama, K; Yano, H, 2002)	0.61
"A major thrust of transplantation research is to find more effective and less broadly toxic immunosuppressive agents."	( Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients. Koch, M; Kuse, ER; Light, S; Nashan, B; Niemeyer, G, 2002)	0.31
"Intravenous pulse cyclophosphamide may be a safe and effective treatment in patients with severe IBD unresponsive to steroid treatment and merits evaluation in a controlled trial."	( Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Duchmann, R; Fischinger, J; Moser, C; Stallmach, A; Wittig, BM; Zeitz, M, 2003)	0.32
"CHOP-14 with the addition of rhG-CSF is safe and practicable in a large multicentre setting in patients aged 18-75 years."	( Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Bittner, S; Kloess, M; Loeffler, M; Pfreundschuh, M; Reiser, M; Rudolph, C; Schmalenberg, H; Schmits, R; Truemper, L; Wunderlich, A, 2003)	0.32
" Prednisolone, dexamethasone and their photoproducts have been tested to evaluate their acute and chronic toxic effects on some freshwater chain organisms."	( Toxicity of prednisolone, dexamethasone and their photochemical derivatives on aquatic organisms. DellaGreca, M; Fiorentino, A; Isidori, M; Lavorgna, M; Previtera, L; Rubino, M; Temussi, F, 2004)	1.61
" For this reason, one goal of research in the GC field is the development of new drugs, which show a reduced side-effect profile while maintaining the antiinflammatory and immunosuppressive properties of classical GCs."	( Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Asadullah, K; Döcke, WD; Hennekes, H; Jaroch, S; Rehwinkel, H; Schäcke, H; Schmees, N; Schottelius, A; Strehlke, P, 2004)	0.32
" Safety concerns led to an assessment of adverse events of corticosteroids, based on data of three trials studying prevention of NFI (the TRIPOD study)."	( Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials. Anderson, AM; Croft, RP; Nicholls, PG; Richardus, JH; Smith, WC; Van Brakel, WH; Withington, SG, 2003)	0.32
" There were no significant differences between the tacrolimus groups and placebo group in the incidence of adverse events."	( Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. Abe, T; Hara, M; Hashimoto, H; Irimajiri, S; Kondo, H; Sugawara, S; Uchida, S, 2004)	0.32
" Safety of the rimexolone was evaluated by IOP values and the presence of adverse effects."	( Efficacy and safety of rimexolone 1% versus prednisolone acetate 1% in the control of postoperative inflammation following phacoemulsification cataract surgery. Ozbay, D; Ozden, S; Tatlipinar, S; Yaylali, V; Yildirim, C, 2004)	0.58
"Rimexolone 1% ophthalmic suspension is both an effective and safe topical steroid in controlling postoperative inflammation after cataract extraction with phacoemulsification."	( Efficacy and safety of rimexolone 1% versus prednisolone acetate 1% in the control of postoperative inflammation following phacoemulsification cataract surgery. Ozbay, D; Ozden, S; Tatlipinar, S; Yaylali, V; Yildirim, C, 2004)	0.58
" While many effects on the immune system's components can be found as a result of a drug treatment or chemical exposure, true immunotoxicity occurs when such treatment results in adverse effects or defects in the immune response."	( Adequate immunotoxicity testing in drug development. Gore, ER; Herzyk, DJ, 2004)	0.32
"Glucocorticoid treatment for steroid-dependent nephrotic syndrome (NS) is associated with severe adverse effects, such as bone fractures and epidural lipomatosis."	( Effectiveness of high trough levels of cyclosporine for 5 months in a case of steroid-dependent nephrotic syndrome with severe steroid toxicity. Arisaka, O; Kano, K; Nishikura, K; Shimizu, A; Shiraiwa, T; Tomita, S; Ueda, Y; Yamada, Y, 2004)	0.32
" Low doses of MMF were chosen to minimize adverse effects and to reduce levels of CNIs without the attendant risks of under-immunosuppression."	( Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Afzali, B; Chowdhury, P; Goldsmith, D; O'sullivan, H; Shah, S; Taylor, J, 2005)	0.33
" There was no significant difference between groups in terms of infection or serious adverse events."	( Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. Bradley, JA; Bradley, JR; Calne, R; Firth, J; Friend, PJ; Hale, G; Jamieson, NV; Smith, KG; Taylor, CJ; Thiru, S; Waldmann, H; Watson, CJ, 2005)	0.33
" Lipid profile, oral glucose tolerance, and adverse events were monitored."	( Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial. Abramowicz, D; Kuypers, D; Meurisse, M; Mourad, M; Squifflet, JP; Vanrenterghem, Y; Wissing, M, 2005)	0.33
"Steroid administration currently plays a central role in the medical management of ulcerative colitis (UC); however, long-term steroid usage causes adverse effects, which necessitates stoppage of drug intake, leading to worsening of the disease."	( Leukocytapheresis therapy for steroid-naïve patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. Abe, T; Aoyama, N; Fukagawa, M; Kasuga, M; Maekawa, S; Nakahara, T; Nishioka, C; Shirasaka, D; Tamura, T; Umezu, M, 2005)	0.33
" As for the treatment complications, three major adverse effects were observed in the PSL group, but none were observed in the LCAP group."	( Leukocytapheresis therapy for steroid-naïve patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. Abe, T; Aoyama, N; Fukagawa, M; Kasuga, M; Maekawa, S; Nakahara, T; Nishioka, C; Shirasaka, D; Tamura, T; Umezu, M, 2005)	0.33
"The results of this study suggest that the efficacy and safety of LCAP are equivalent, and in terms of severe adverse effects, superior to those of steroid therapy."	( Leukocytapheresis therapy for steroid-naïve patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. Abe, T; Aoyama, N; Fukagawa, M; Kasuga, M; Maekawa, S; Nakahara, T; Nishioka, C; Shirasaka, D; Tamura, T; Umezu, M, 2005)	0.33
" We evaluated total Quantitative MG (Q-MG) score, anti-acetylcholine receptor (AChR) antibody titer in the blood, interleukin 2 (IL-2) production in peripheral blood mononuclear cells (PBMCs), administration dosage of prednisolone (PSL), and adverse effects of FK506."	( Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. Igarashi, S; Naruse, S; Nishizawa, M; Onodera, O; Oyake, M; Shimohata, T; Tada, M; Tanaka, K; Tsuji, S, 2006)	0.52
" Although adverse effects were observed in three patients (33."	( Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. Igarashi, S; Naruse, S; Nishizawa, M; Onodera, O; Oyake, M; Shimohata, T; Tada, M; Tanaka, K; Tsuji, S, 2006)	0.33
"Our study indicates that low-dose FK506 treatment may be efficacious not only in controlling intractable myasthenic symptoms, but also in reducing steroid dosage, and that FK506 is safe as an adjunctive drug to PSL for MG treatment for a maximum of 3 years."	( Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. Igarashi, S; Naruse, S; Nishizawa, M; Onodera, O; Oyake, M; Shimohata, T; Tada, M; Tanaka, K; Tsuji, S, 2006)	0.33
"A retrospective cohort study involving 29 Japanese patients with autoimmune hepatitis (AIH) was performed to clarify factors that predict the efficacy of prednisolone and the occurrence of various serious adverse effects."	( Efficacy and safety of prednisolone in patients with autoimmune hepatitis. Honda, E; Inawari, M; Kiuchi, Y; Kogo, M; Mitamura, K; Shibata, M; Yoneyama, K, )	0.64
"We examined the efficacy and adverse effects of rituximab with CHOP (cyclophosphamide, doxorubicin, vincristin, prednisone) or THP-COP (pirarubicin, cyclophosphamide, vincristin, prednisone) in previously untreated old-old and extremely old patients with diffuse large B cell lymphoma (DLBCL)."	( [The efficacy and adverse effects of rituximab with CHOP or THP-COP in old-old and extremely old patients with diffuse large B cell lymphoma]. Abe, S; Fujii, H; Iwamoto, T; Kanaya, K; Kikukawa, M; Kiuchi, A; Miyazaki, K; Shin, K, 2006)	0.33
" The most frequent adverse effect was bone marrow suppression, observed in 9 patients (69."	( [The efficacy and adverse effects of rituximab with CHOP or THP-COP in old-old and extremely old patients with diffuse large B cell lymphoma]. Abe, S; Fujii, H; Iwamoto, T; Kanaya, K; Kikukawa, M; Kiuchi, A; Miyazaki, K; Shin, K, 2006)	0.33
"This result suggested that both CHOP and THP-COP combined with rituximab were safe and effective for old-old and extremely old patients."	( [The efficacy and adverse effects of rituximab with CHOP or THP-COP in old-old and extremely old patients with diffuse large B cell lymphoma]. Abe, S; Fujii, H; Iwamoto, T; Kanaya, K; Kikukawa, M; Kiuchi, A; Miyazaki, K; Shin, K, 2006)	0.33
" After the treatment, each treatment modality was evaluated by the response rate, relapse rate, and side effect profile."	( A comparison of the efficacy, relapse rate and side effects among three modalities of systemic corticosteroid therapy for alopecia areata. Aiba, S; Kawamura, M; Kurosawa, M; Mizuashi, M; Nakagawa, S; Saito, M; Sasaki, Y, 2006)	0.33
" It had minimum adverse effects, however, MZR therapy does not sufficiently suppress the relapse of FRNS."	( [Beneficial and adverse effects of high-dosage MZR therapy in the management of children with frequently relapsing nephrotic syndrome]. Goto, M; Hamasaki, Y; Hataya, H; Honda, M; Ikeda, M; Ishikura, K, 2006)	0.33
" No other adverse effect was observed."	( [Beneficial and adverse effects of high-dosage MZR therapy in the management of children with frequently relapsing nephrotic syndrome]. Goto, M; Hamasaki, Y; Hataya, H; Honda, M; Ikeda, M; Ishikura, K, 2006)	0.33
"High-dose MZR therapy in the management for FRNS may provide more beneficial effects without significant adverse effects."	( [Beneficial and adverse effects of high-dosage MZR therapy in the management of children with frequently relapsing nephrotic syndrome]. Goto, M; Hamasaki, Y; Hataya, H; Honda, M; Ikeda, M; Ishikura, K, 2006)	0.33
" In addition, we have found that it is critical to pay attention to patient-reported adverse reactions."	( Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Hara, M; Inoue, E; Kamatani, N; Nakajima, A; Tanaka, E; Taniguchi, A; Terai, C; Tomatsu, T; Yamanaka, H, 2007)	0.34
" Both therapeutic agents were suspected as a possible cause of this adverse event."	( Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Boeck, S; Hausmann, A; Heinemann, V; Reibke, R; Schulz, C, 2007)	0.34
" The most frequently reported adverse event during the study was headache (52% in CRx-102 vs 15% in the placebo group)."	( Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis. Borisy, AA; Fjeld, E; Kvien, TK; Lessem, J; Mikkelsen, K; Nichols, M; Palm, Ø; Prøven, A; Slatkowsky-Christensen, B; Zhang, Y, 2008)	0.35
" It was demonstrated that Ch-SP-MS/EuL enhanced effectiveness of PD and reduced toxic side effects of PD greatly."	( Efficacy and toxicity of Eudragit-coated chitosan-succinyl-prednisolone conjugate microspheres using rats with 2,4,6-trinitrobenzenesulfonic acid-induced colitis. Machida, Y; Onishi, H; Oosegi, T, 2008)	0.59
"To assess the incidence and severity of disease modifying antirheumatic drug (DMARD)-induced adverse effects (AE) in patients with rheumatoid arthritis (RA) taking/not taking glucocorticoids (GC)."	( Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. Arnold, S; Baerwald, CG; Häntzschel, H; Malysheva, OA; Pierer, M; Wagner, U; Wahle, M, 2008)	0.76
"Fourteen members of the Japanese Society for Pediatric Inflammatory Bowel Disease reported 35 retrospective cases that received AZA/6-MP and were evaluated for adverse drug effects."	( Efficacy and safety of azathioprine and 6-mercaptopurine in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease. Etani, Y; Kobayashi, A; Konno, M; Maisawa, S; Nakacho, M; Sasaki, M; Shimizu, T; Sumazaki, R; Tajiri, H; Tomomasa, T; Toyoda, S; Ushijima, K; Yoden, A, 2008)	0.35
"AZA or 6-MP was safely used in 21 of 35 patients (60%) without adverse drug effects."	( Efficacy and safety of azathioprine and 6-mercaptopurine in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease. Etani, Y; Kobayashi, A; Konno, M; Maisawa, S; Nakacho, M; Sasaki, M; Shimizu, T; Sumazaki, R; Tajiri, H; Tomomasa, T; Toyoda, S; Ushijima, K; Yoden, A, 2008)	0.35
" However, 40% experienced adverse drug effects, mainly myelosuppression."	( Efficacy and safety of azathioprine and 6-mercaptopurine in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease. Etani, Y; Kobayashi, A; Konno, M; Maisawa, S; Nakacho, M; Sasaki, M; Shimizu, T; Sumazaki, R; Tajiri, H; Tomomasa, T; Toyoda, S; Ushijima, K; Yoden, A, 2008)	0.35
"It is safe for patients with CAN to use substitute sirolimus for CNI; the incidence of acute rejection did not increase."	( Observation of efficacy and safety of converting the calcineurin inhibitor to sirolimus in renal transplant recipients with chronic allograft nephropathy. Chen, J; Cheng, D; Cheng, Z; Ji, S; Li, L; Liu, Z; Sha, G; Sun, Q; Tang, Z; Wen, J, 2008)	0.35
"5-month-old infant with IPP is presented, who was successfully treated with systemic retinoid therapy, which appears to be a safe and effective option for this challenging pustular eruption of childhood."	( Acitretin is a safe treatment option for infantile pustular psoriasis. Ergin, S; Ersoy-Evans, S; Ozkaya, O; Sahin, S, 2008)	0.35
" Main Outcome Measure Severe adverse effects were defined as those judged serious enough that azathioprine therapy be discontinued in 139 patients treated with azathioprine."	( Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris. Chams-Davatchi, C; Firooz, A; Ghandi, N; Hallaji, Z; Karbakhsh Davari, M; Valikhani, M, 2008)	0.35
" Serious adverse effects occurred in 14 patients (10."	( Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris. Chams-Davatchi, C; Firooz, A; Ghandi, N; Hallaji, Z; Karbakhsh Davari, M; Valikhani, M, 2008)	0.35
" There seems to be a boost and extension of the glucocorticoid effect by the combination, without a clear increase of adverse effects, potentially allowing the application of lower dosages."	( Innovative combination strategy to enhance effect and diminish adverse effects of glucocorticoids: another promise? Bijlsma, JW; Jacobs, JW, 2009)	0.35
" Toxicity was assessed by number of the patients withdrawn for adverse events (AEs), and the numbers of serious adverse events (SAEs) and AEs."	( Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis. Choy, EH; Rachapalli, S; Ravindran, V, 2009)	0.35
" However, long-term efficacy and adverse events are barely known."	( Maintenance immunosuppression with mycophenolate mofetil: long-term efficacy and safety after heart transplantation. Dandel, M; Hetzer, R; Jasaityte, R; Knosalla, C; Lehmkuhl, H, )	0.13
" We analyzed the survival, number, and severity of ARE, development of coronary allograft vasculopathy (CAV), and main adverse effects (infections, tumors)."	( Maintenance immunosuppression with mycophenolate mofetil: long-term efficacy and safety after heart transplantation. Dandel, M; Hetzer, R; Jasaityte, R; Knosalla, C; Lehmkuhl, H, )	0.13
"Initial remission targeted therapy with the FIN-RACo DMARD combination in early RA is safe for kidneys and does not induce more short- or long-term renal complications compared to traditional therapy with a single DMARD."	( Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial. Hannonen, PJ; Kaipiainen-Seppänen, OA; Karjalainen, AH; Karstila, KL; Korpela, MM; Leirisalo-Repo, M; Möttönen, TT; Mustonen, JT; Rantalaiho, VM, )	0.13
", re-introduction of CNI), incidence of adverse events, and mortality up to one year after OLT."	( A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT. Goralczyk, AD; Lorf, T; Obed, A; Ramadori, G; Schnitzbauer, A; Tsui, TY, 2010)	0.36
" When the two agents were combined, all the adverse effects of glucocorticoid excess on bone were prevented."	( Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Almeida, M; Jilka, RL; Manolagas, SC; Roberson, PK; Weinstein, RS, 2010)	0.36
"Remission and complete response (primary outcome measures), frequency of uveitis attacks, visual acuity (VA), and adverse effects (secondary outcome measures)."	( Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments. Bayer, A; Bayraktar, MZ; Durukan, AH; Erdem, U; Erdurman, C; Karagul, S; Köksal, S; Sobaci, G, 2010)	0.36
"6%) developed severe adverse effects, including psoriasis, epileptic seizure, and extreme tiredness."	( Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments. Bayer, A; Bayraktar, MZ; Durukan, AH; Erdem, U; Erdurman, C; Karagul, S; Köksal, S; Sobaci, G, 2010)	0.36
" Adverse reactions responsible for discontinuation included gastrointestinal symptoms, renal dysfunction, and infection."	( Efficacy and safety of tacrolimus in 101 consecutive patients with rheumatoid arthritis. Inoue, E; Kaneko, H; Kitahama, M; Koseki, Y; Momohara, S; Okamoto, H; Taniguchi, A; Yamanaka, H, 2010)	0.36
" Adverse events occurring immediately after the procedure and within the first month were collected."	( Feasibility and safety of ultrasound-guided caudal epidural glucocorticoid injections. Berthelot, JM; Blanchais, A; Glemarec, J; Guillot, P; Le Goff, B; Maugars, Y, 2010)	0.36
"Mizoribine (MZR) is an immunosuppressant that inhibits nucleic acid metabolism and is a relatively safe disease-modifying anti-rheumatic drug (DMARD)."	( Efficacy and safety of mizoribine by one single dose administration for patients with rheumatoid arthritis. Aramaki, T; Arima, K; Eguchi, K; Fujikawa, K; Ichinose, K; Ida, H; Iwamoto, N; Kamachi, M; Kawakami, A; Kawashiri, SY; Nakamura, H; Origuchi, T; Tamai, M; Tsukada, T; Ueki, Y, 2010)	0.36
" We show that MZR may be a useful and relatively safe therapy for patients in this group."	( Efficacy and safety of mizoribine by one single dose administration for patients with rheumatoid arthritis. Aramaki, T; Arima, K; Eguchi, K; Fujikawa, K; Ichinose, K; Ida, H; Iwamoto, N; Kamachi, M; Kawakami, A; Kawashiri, SY; Nakamura, H; Origuchi, T; Tamai, M; Tsukada, T; Ueki, Y, 2010)	0.36
"Neurotoxicity is an unwanted acute side effect of aggressive chemotherapy."	( Evidence for acute neurotoxicity after chemotherapy. Cornelissen, J; Filippi, M; Giovannoni, G; Hintzen, R; Kappos, L; Kuhle, J; Lowenberg, B; Mondria, T; Petzold, A; Rocca, MA; te Boekhorst, P, 2010)	0.36
"MMF seems safe and effective as first-line therapy in inducing and maintaining remission in treatment-naive patients with AIH, having a significant and rapid steroid sparing effect as attested by the fact that so far, 37% (22/59) of AIH patients achieved CR off prednisolone."	( Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. Dalekos, GN; Gatselis, N; Papadamou, G; Rigopoulou, EI; Zachou, K, 2011)	0.55
" SbV has a side effect profile that requires treatment interruption in up to 28% of patients."	( Glucocorticoids as a novel approach to the treatment of disabling side effects of sodium stibogluconate. Brostoff, JM; Lockwood, DN, 2012)	0.38
" Therapy is safe because it is limited to several months and the dosage is continually weaned as the infant gains weight."	( Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. Couto, RA; Greene, AK, 2011)	0.88
"Bendamustine is a safe and useful addition to the drug arsenal against lymphoproliferative disorders."	( Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect. Ganesan, P; Malipatil, B; Sagar, TG; Sundersingh, S, 2011)	0.37
" It can be considered as a safe alternative for management of aggressive nasal polyposis refractory to traditional treatment strategies."	( Examining the safety of prednisolone acetate 1% nasal spray for treatment of nasal polyposis. Liang, J; Strong, EB, )	0.44
" None of the patients in the study and control group experienced any adverse reaction and complications, neither after routine treatment nor after cell transplantation."	( Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients. Eskandary, H; Karamouzian, S; Nakhaee, N; Nematollahi-Mahani, SN, 2012)	0.38
"We conclude that transplantation of autologous BMC via LP is a feasible and safe technique, but at the moment, no clear answer can be given regarding the clinical potential, despite a potential tendency to treat SCI patients, observed through statistics."	( Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients. Eskandary, H; Karamouzian, S; Nakhaee, N; Nematollahi-Mahani, SN, 2012)	0.38
" Adverse event reports including elevation of intraocular pressure (IOP) were recorded."	( Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety. Alakuş, MF; Işcan, Y; Oner, V; Taş, M; Türkcü, FM, 2012)	0.38
" Rituximab's adverse effects generally could be controlled with an effective dosing regimen."	( Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis. Chen, JH; Han, F; Lan, L, 2012)	0.38
" Vidofludimus was well tolerated, no drug-related serious adverse events were observed."	( Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. Ammendola, A; Diculescu, M; Dietrich, B; Fellermann, K; Hartmann, H; Hentsch, B; Herrlinger, KR; Howaldt, S; Nikolov, R; Otte, JM; Petrov, A; Reindl, W; Stange, EF; Stoynov, S; Strauch, U; Sturm, A; Voiosu, R, 2013)	0.39
"To assess the current use of glucocorticoids (GCs) in Duchenne muscular dystrophy in the UK, and compare the benefits and the adverse events of daily versus intermittent prednisolone regimens."	( Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Manzur, AY; Muntoni, F; Quinlivan, R; Ricotti, V; Ridout, DA; Robb, SA; Scott, E, 2013)	0.58
" Moderate to severe side effects were more commonly reported and observed in the daily regimen, including Cushingoid features, adverse behavioural events and hypertension."	( Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Manzur, AY; Muntoni, F; Quinlivan, R; Ricotti, V; Ridout, DA; Robb, SA; Scott, E, 2013)	0.39
" The study also highlights the importance of collecting longitudinal natural history data on patients treated according to standardised protocols, and clearly identifies the benefits and the side-effect profile of two treatment regimens, which will help with informed choices and implementation of targeted surveillance."	( Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Manzur, AY; Muntoni, F; Quinlivan, R; Ricotti, V; Ridout, DA; Robb, SA; Scott, E, 2013)	0.39
"Patients with ulcerative colitis (UC) are treated with prednisolone (PSL), which causes adverse side effects."	( Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. Hiraishi, H; Hoshino, M; Kanke, K; Nakano, M; Tominaga, K, 2013)	0.84
" In the GMA group, 5 transient adverse events were observed vs 10 steroid related adverse events in the PSL group (P<0."	( Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. Hiraishi, H; Hoshino, M; Kanke, K; Nakano, M; Tominaga, K, 2013)	0.6
"Amiodarone pulmonary toxicity (APT) is the most serious side effect of amiodarone."	( Successful treatment of severe amiodarone pulmonary toxicity with polymyxin B-immobilized fiber column direct hemoperfusion. Goto, E; Horio, Y; Ichiyasu, H; Kohrogi, H; Kojima, K; Masunaga, A; Sato, N, 2013)	0.39
" Here, we investigated the contribution of microvascular dysfunction to the development of these adverse effects in healthy men."	( Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure: a randomised controlled trial. Diamant, M; Eringa, EC; Guigas, B; Ijzerman, RG; Linssen, MM; Ouwens, DM; Serné, EH; van Raalte, DH, 2013)	0.39
" We propose that GC-induced impairments of microvascular function may contribute to the adverse effects of GC treatment on glucose metabolism and blood pressure."	( Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure: a randomised controlled trial. Diamant, M; Eringa, EC; Guigas, B; Ijzerman, RG; Linssen, MM; Ouwens, DM; Serné, EH; van Raalte, DH, 2013)	0.39
" Two cases of serious adverse events were associated with cytomegalovirus infection in the multi-target group, namely gastric ulcer and pancytopenia, both of which were successfully treated by antiviral therapy."	( Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. Hiromura, K; Ikeuchi, H; Kaneko, Y; Kuroiwa, T; Maeshima, A; Mishima, K; Nojima, Y; Sakairi, T; Sakurai, N; Takahashi, S, 2014)	0.4
" Number of cabazitaxel cycles, dose reductions for any cause, dose delays possibly related to cabazitaxel adverse events, and tolerability were similar in the three age groups."	( Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Bracarda, S; Climent, MA; Fossa, S; Heidenreich, A; Hitier, S; Mason, M; Ozen, H; Papandreou, C; Sengelov, L; Van Oort, I, 2014)	0.4
" The primary outcome was death and secondary outcome measures were 6 month disability, repeat MRI changes and serious adverse events (SAEs)."	( Safety and efficacy of levofloxacin versus rifampicin in tuberculous meningitis: an open-label randomized controlled trial. Bhoi, SK; Kalita, J; Misra, UK; Prasad, S, 2014)	0.4
" Meanwhile, adherence to recommendations on standardized methodologies for registration and report of glucocorticoid adverse events is essential for improving our knowledge and competence in the best management of these important medications."	( Safety of low- to medium-dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years. da Silva, JA; Santiago, T, 2014)	0.4
" Adverse events (AEs) possibly related to cabazitaxel occurred in 143 (93."	( Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program. Antón Aparicio, LM; Batista, N; Castellano, D; Esteban, E; Germà, JR; Luque, R; Maroto, P; Méndez-Vidal, MJ; Pérez-Valderrama, B; Sánchez-Hernández, A, 2014)	0.4
" Pregnancy with SLE is associated with an increase risk of adverse maternal and fetal outcomes."	( Safety of tacrolimus treatment during pregnancy and lactation in systemic lupus erythematosus: a report of two patients. Izumi, Y; Migita, K; Miyashita, T, 2014)	0.4
" In the present study, we have integrated this blood glucose kinetic model in the CIA model to enable quantification of both efficacy and adverse effects in one animal model."	( Glucose kinetics in the collagen-induced arthritis model: an all-in-one model to assess both efficacy and metabolic side effects of glucocorticoids. Ballak, DB; Bastiaanssen, EA; Bleeker, A; Dokter, WH; Grefhorst, A; Groen, AK; Koenders, MI; Laskewitz, AJ; Schouten, AE; Toonen, EJ; van der Vleuten, MA; van Dijk, TH; van Doorn, C; van Lierop, MJ, 2014)	0.4
" We analyzed their biochemistries, immune parameters, liver synthetic function, and noninvasive assessments of liver fibrosis, as well as treatment efficacy and adverse effects at baseline and at 1, 3, 6, 12, 24, and 36 months."	( Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis. Deng, YQ; Fang, YQ; Jia, W; Li, J; Lv, DX; Wang, GQ; Wang, Y; Yu, M, 2014)	0.72
"The primary outcomes are: (i) effectiveness (assessor-blinded blister count at 6 weeks) and (ii) safety [proportion of patients experiencing ≥ grade 3 adverse events (i."	( A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mg kg(-1) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines Bratton, DJ; Chalmers, JR; Foster, KA; Kirtschig, G; Mason, J; Nunn, AJ; Whitham, D; Williams, HC; Wojnarowska, F, 2015)	0.63
"4%) treatment-related deaths due to adverse events, which were interstitial lung disease, and febrile neutropenia and bacterial pneumonia."	( Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan. Adachi, H; Fukuta, F; Hirose, T; Itoh, N; Kitamura, H; Kunishima, Y; Masumori, N; Matsukawa, M; Miyake, M; Miyao, N; Shigyo, M; Taguchi, K; Takagi, S; Takahashi, A; Yanase, M, 2015)	0.69
" Although most patients safely received docetaxel and prednisolone, we must always keep interstitial lung disease in mind as a possible lethal adverse event."	( Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan. Adachi, H; Fukuta, F; Hirose, T; Itoh, N; Kitamura, H; Kunishima, Y; Masumori, N; Matsukawa, M; Miyake, M; Miyao, N; Shigyo, M; Taguchi, K; Takagi, S; Takahashi, A; Yanase, M, 2015)	0.94
"SC MTX is a safe and effective treatment option for patients with RA."	( Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. Haile, SR; Müller, RB; Schiff, MH; von Kempis, J, 2015)	0.42
" Herein, we assessed the safety of rituximab treatment and its effect in ameliorating the adverse effects of prednisolone (PRED) in a larger study sample."	( Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome. Iwabuchi, Y; Miyabe, Y; Moriyama, T; Nitta, K; Takei, T, 2016)	0.92
" We compared the adverse effects of PRED (osteoporosis, hypertension, and diabetes mellitus) between the first rituximab infusion (baseline) and the end of the 24-month observation period."	( Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome. Iwabuchi, Y; Miyabe, Y; Moriyama, T; Nitta, K; Takei, T, 2016)	0.7
" There were no severe adverse effects of rituximab."	( Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome. Iwabuchi, Y; Miyabe, Y; Moriyama, T; Nitta, K; Takei, T, 2016)	0.7
"Rituximab treatment was effective and safe in patients with steroid-dependent nephrotic syndrome, allowed reduction of the PRED dose, and ameliorated the adverse effects of PRED."	( Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome. Iwabuchi, Y; Miyabe, Y; Moriyama, T; Nitta, K; Takei, T, 2016)	0.7
"Long-term adverse effects of oral glucocorticoids are frequent and serious."	( Exploratory study of total and free prednisolone plasma exposure and cushingoid appearance, quality of life and biochemical toxicity in adult male kidney transplant recipients. Barraclough, KA; Bergmann, TK; Campbell, SB; Inder, WJ; Isbel, NM; McWhinney, BC; Ostini, R; Russell, A; Staatz, CE, 2015)	0.69
"Male kidney transplant recipients were recruited for serial blood sampling and assessment of glucocorticoid-related adverse effects including dyslipidaemia, abnormal body fat distribution, Cushingoid appearance and impaired quality of life."	( Exploratory study of total and free prednisolone plasma exposure and cushingoid appearance, quality of life and biochemical toxicity in adult male kidney transplant recipients. Barraclough, KA; Bergmann, TK; Campbell, SB; Inder, WJ; Isbel, NM; McWhinney, BC; Ostini, R; Russell, A; Staatz, CE, 2015)	0.69
" In this work, the effectiveness, toxic side effects (5 mg prednisolone (PD) eq/kg × 3 d, 10 mg PD eq/kg × 3 d), and pharmacokinetic characteristics (5 mg PD eq/kg) were examined using rats with colitis induced through 2,4,6-trinitrobenzenesulfonic acid."	( Comparison of Simple Eudragit Microparticles Loaded with Prednisolone and Eudragit-Coated Chitosan-Succinyl-Prednisolone Conjugate Microparticles: Part II. In Vivo Evaluation of Efficacy, Toxicity, and Biodisposition Characteristics. Kikuchi, H; Onishi, H, 2015)	0.91
"Short term prednisolone use was generally safe and did not prevent reaccumulation of ascites in this study population."	( The safety and efficacy of prednisolone in preventing reaccumulation of ascites among endomyocardial fibrosis patients in Uganda: a randomized clinical trial. Freers, J; Josephson, RA; Kayima, J; Longenecker, CT; Nabunnya, YB, 2015)	1.1
" None of the nine patients had local or systemic adverse events related to the vector during the 9-month follow-up period."	( Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy. Chen, C; Dong, XY; He, H; Hu, WK; Li, B; Ma, SQ; Pei, H; Wan, X; Wang, DW; Yang, S; Zhang, G; Zhao, MJ, 2016)	0.43
" These two pilot studies compare the efficacy and side effect profile of ciclosporin plus prednisolone against prednisolone alone in the treatment of patients with either new ENL or chronic and recurrent ENL."	( Comparison of Efficacy and Safety of Ciclosporin to Prednisolone in the Treatment of Erythema Nodosum Leprosum: Two Randomised, Double Blind, Controlled Pilot Studies in Ethiopia. Alembo, DT; Idriss, MH; Lambert, SM; Lockwood, DN; Nicholls, PG; Nigusse, SD; Walker, SL; Yamuah, LK, 2016)	0.91
" Adverse events attributable to prednisolone were more common that those attributable to ciclosporin."	( Comparison of Efficacy and Safety of Ciclosporin to Prednisolone in the Treatment of Erythema Nodosum Leprosum: Two Randomised, Double Blind, Controlled Pilot Studies in Ethiopia. Alembo, DT; Idriss, MH; Lambert, SM; Lockwood, DN; Nicholls, PG; Nigusse, SD; Walker, SL; Yamuah, LK, 2016)	0.97
"In this study, it was aimed to investigate the toxic and teratogenic effects of cyclosporine A and tacrolimus and their combinations with prednisolone using an in vitro rat embryo culture technique."	( Investigation of developmental toxicity and teratogenicity of cyclosporine A, tacrolimus and their combinations with prednisolone. Acar, H; Fazliogullari, Z; Karabulut, AK; Unver Dogan, N; Uysal, II, 2016)	0.85
"Intrapolyp steroid injection appears to be an effective and safe method for treatment of nasal polyps, with comparable results to oral short-term steroid treatment."	( Intrapolyp steroid injection for nasal polyposis: Randomized trial of safety and efficacy. Bercin, S; Gul, F; Kırıs, M; Muderris, T; Sevil, E; Yalçıner, G, 2016)	0.43
" The symptoms of COPD, forced expiratory volume in one second (FEV1) and other spirometric indicators, peripheral blood oxygen saturation (SpO2), and adverse events were studied."	( [Nebulized budesonide in the treatment of exacerbations of chronic obstructive pulmonary disease: Efficacy, safety, and effects on the serum levels of soluble differentiation molecules]. Czapaeva, MY; Karaulov, AV; Kazatskaya, ZA; Lazareva, ES; Makarova, EV; Menkov, NV; Novikov, VV; Varvarina, GN, 2016)	0.43
"Nebulized budesonide is an effective and safe alternative to SGCS in treating an exacerbation of COPD."	( [Nebulized budesonide in the treatment of exacerbations of chronic obstructive pulmonary disease: Efficacy, safety, and effects on the serum levels of soluble differentiation molecules]. Czapaeva, MY; Karaulov, AV; Kazatskaya, ZA; Lazareva, ES; Makarova, EV; Menkov, NV; Novikov, VV; Varvarina, GN, 2016)	0.43
"After LT, an immunosuppressive regimen without steroids could be a safe and feasible treatment for HBVrelated HCC patients, thus resulting in the reduction of HBV recurrence."	( Efficacy and Safety of a Steroid-Free Immunosuppressive Regimen after Liver Transplantation for Hepatocellular Carcinoma. Shen, Y; Wang, C; Wang, W; Wei, Q; Wu, J; Xie, H; Xu, X; Zhang, M; Zheng, S; Zhou, L; Zhuang, L; Zhuang, R, 2016)	0.43
" In comparison with few minor adverse events in other two cohorts, several serious adverse events were documented in the tacrolimus group."	( Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children. Babu, BG; Basu, B; Mahapatra, TK, 2017)	0.46
" Taking together the long-term efficacy and safety data observed, MMF appears as a safe and effective alternative to tacrolimus in managing pediatric FRNS/SDNS."	( Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children. Babu, BG; Basu, B; Mahapatra, TK, 2017)	0.46
"Rituximab (RTX) is regarded as a relatively safe and effective treatment for children with steroid-dependent nephrotic syndrome (SDNS)."	( Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. Fujinaga, S; Ozawa, K; Sakuraya, K; Shimizu, T; Yamada, A, 2016)	0.43
"This was a single-center retrospective analysis of adverse events during B-cell depletion periods after a single dose of RTX (375 mg/m2) in 60 patients with complicated SDNS (total 126 doses)."	( Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. Fujinaga, S; Ozawa, K; Sakuraya, K; Shimizu, T; Yamada, A, 2016)	0.43
"Although neutropenia and hypogammaglobulinemia should be kept in mind as late-onset adverse events of RTX therapy in patients with complicated SDNS, severe infections during B-cell depletion periods are infrequent when our treatment strategies are implemented."	( Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. Fujinaga, S; Ozawa, K; Sakuraya, K; Shimizu, T; Yamada, A, 2016)	0.43
" We investigated whether high-dose MZR is effective and safe for renal transplant patients in conjunction with cyclosporine (CsA), basiliximab, and corticosteroids."	( Efficacy and Safety of High-Dose Mizoribine Combined With Cyclosporine, Basiliximab, and Corticosteroids in Renal Transplantation: A Japanese Multicenter Study. Akioka, K; Fujisawa, M; Fukuda, Y; Horimi, T; Ito, SI; Nakatani, T; Nishimura, K; Sugitani, A; Uchida, K; Ushigome, H; Yoshimura, N; Yuzawa, K, 2016)	0.43
" Safety included evaluation of adverse events."	( Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. Gedif, K; Lambert, SR; Markwardt, K; O'Halloran, H; Plager, DA; Roarty, J; VanderVeen, D; Wilson, ME, 2016)	0.75
" Compared to placebo, RTX combined with prednisone may be effective and safe for treating newly-diagnosed wAIHA in adults."	( A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). Audia, S; Ebbo, M; Frenzel, L; Galicier, L; Godeau, B; Hamidou, M; Jaccard, A; Khellaf, M; Le Guenno, G; Marie Michot, J; Michel, M; Morin, AS; Roudot-Thoraval, F; Royer, B; Terriou, L, 2017)	0.46
" The adverse events during TAS were generally tolerable, but 39 (10."	( Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. Choi, YS; Eom, HS; Han, JJ; Kang, HJ; Kim, HJ; Kim, K; Kim, MK; Kim, SH; Kwon, J; Lee, JH; Lee, JJ; Lee, JO; Lee, WS; Min, CK; Moon, JH; Yoon, DH; Yoon, SS, 2017)	0.46
" Using data from the UK Clinical Practice Research Datalink (CPRD), we examined the risk of oral GC-related serious adverse events (SAEs) in a UK population of patients with giant cell arteritis (GCA)."	( Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis. Collinson, N; Jick, SS; Klearman, M; Meier, CR; Musselman, D; Napalkov, P; Sarsour, K; Stone, JH; Tuckwell, K; Wilson, JC, 2017)	0.46
"Compared to lower average daily prednisolone doses, high average daily doses were associated with an increased risk of serious adverse effects."	( Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis. Collinson, N; Jick, SS; Klearman, M; Meier, CR; Musselman, D; Napalkov, P; Sarsour, K; Stone, JH; Tuckwell, K; Wilson, JC, 2017)	0.74
" Cyclosporine-associated nephrotoxicity (CAN) is a potential side effect of long-term cyclosporine treatment."	( Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment. Ando, T; Hamada, R; Hamasaki, Y; Hataya, H; Honda, M; Ishikura, K; Komaki, F; Ogata, K; Sakai, T, 2017)	0.46
" Secondary outcomes included the effectiveness of blister control after 6 weeks, relapses, related adverse events and quality of life."	( A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracycl Chalmers, JR; Chapman, A; Childs, M; Godec, TR; Harman, K; Kirtschig, G; Mason, J; Nunn, AJ; Schmidt, E; Walton, S; Whitham, D; Williams, HC; Wojnarowska, F, 2017)	0.66
" The limitations of the trial were the wide non-inferiority margin, the moderate dropout rate and that serious adverse event collection was unblinded."	( A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracycl Chalmers, JR; Chapman, A; Childs, M; Godec, TR; Harman, K; Kirtschig, G; Mason, J; Nunn, AJ; Schmidt, E; Walton, S; Whitham, D; Williams, HC; Wojnarowska, F, 2017)	0.66
" In the propranolol group, the patients were admitted, observed for adverse effects for 3 days after treatment initiation, and then released and treated as outpatients for 16 weeks (2 mg/kg/d)."	( Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial. Cheon, JE; Choe, YS; Choi, TH; Choi, Y; Hong, KY; Jeong, JH; Kang, HJ; Kim, DY; Kim, KH; Lee, H; Park, JB; Park, KD; Park, YW; Shin, HY, 2017)	0.46
" While comparing the effect of medication between the groups, we monitored the adverse effects of both drugs."	( Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial. Cheon, JE; Choe, YS; Choi, TH; Choi, Y; Hong, KY; Jeong, JH; Kang, HJ; Kim, DY; Kim, KH; Lee, H; Park, JB; Park, KD; Park, YW; Shin, HY, 2017)	0.46
" Haemocytopenia was the predominant adverse effect, and acute toxicity was moderate, tolerable and well managed in both arms."	( The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. Chang, Y; Duan, W; Fu, X; Li, L; Li, X; Li, Z; Nan, F; Sun, Z; Wang, X; Wu, J; Yan, J; Young, KH; Zhang, L; Zhang, M; Zhang, X, 2017)	0.46
" And the adverse drug reactions (ADRs) of tacrolimus were monitored in each patient from the beginning of tacrolimus treatment to the end of the follow-up period."	( A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis. Ahn, SW; Cho, EB; Hong, YH; Joo, IS; Kang, SY; Kim, BJ; Min, JH; Minn, YK; Nam, TS; Oh, J; Oh, SY; Park, JS; Park, YE; Seok, HY; Seok, JI; Seok, JM; Shin, HY; Shin, JY; Suh, BC; Sung, JJ, 2017)	0.46
"This trial shows that MR prednisone appears to be a safe and effective treatment for GCA with a similar outcome profile to standard IR prednisolone."	( A 26-week feasibility study comparing the efficacy and safety of modified-release prednisone with immediate-release prednisolone in newly diagnosed cases of giant cell arteritis. Achilleos, K; Dasgupta, B; Gayford, D; Mackerness, C; Mapplebeck, S; Maw, WW; Merinopoulos, D; Raine, C; Schofield, P; Stapleton, PP, 2018)	0.89
" Outcome measures evaluated were subsidence of patient-perceived pruritus, improvement in rash quantified by a specific score, adverse effects and relapse at 12 weeks."	( Double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of short-course low-dose oral prednisolone in pityriasis rosea. Gupta, A; Kumar, A; Priya, A; Sonthalia, S; Srivastava, S; Yadav, P; Zawar, V, 2018)	0.69
" No adverse effects reported in either group."	( Double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of short-course low-dose oral prednisolone in pityriasis rosea. Gupta, A; Kumar, A; Priya, A; Sonthalia, S; Srivastava, S; Yadav, P; Zawar, V, 2018)	0.69
"Corticosteroids (CSs), used to treat rheumatoid arthritis (RA), confer a risk of adverse events (AEs)."	( Safety and efficacy of alternate-day corticosteroid treatment as adjunctive therapy for rheumatoid arthritis: a comparative study. Kishimoto, M; Ohde, S; Okada, M; Suda, M; Tsuda, T, 2018)	0.48
"To evaluate the adverse events profile of oral prednisolone among adult asthma patients in the UK."	( Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis. Bloechliger, M; Chang, SC; Heaney, LG; Jick, SS; Kuhlbusch, K; Meier, CR; Reinau, D; Spoendlin, J, 2018)	0.74
"Using data from the UK-based Clinical Practice Research Datalink, we conducted a series of cohort studies to quantify incidence rates and incidence rate ratios, and a series of nested case-control analyses to estimate crude and adjusted odds ratios, of 11 different potential corticosteroid-related adverse events (bone-related conditions, hypertension, peptic ulcer, severe infections, herpes zoster, diabetes mellitus type 2, cataract, glaucoma, chronic kidney disease, affective disorders, and cardiovascular events)."	( Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis. Bloechliger, M; Chang, SC; Heaney, LG; Jick, SS; Kuhlbusch, K; Meier, CR; Reinau, D; Spoendlin, J, 2018)	0.48
"Uveitis due to brimonidine is a rare adverse effect, but it must be known."	( Hypertensive acute granulomatous anterior uveitis as a side effect of topical brimonidine. Arciniegas-Perasso, CA; Clemente-Tomás, R; Duch-Samper, AM; García-Ibor, F; Hervás-Hernandis, JM; Ruiz-Del Río, N, 2018)	0.48
" The toxic action of the drug may be connected with the extent and routes of its biotransformation."	( Cytotoxicity of anticancer candidate salinomycin and identification of its metabolites in rat cell cultures. Olejnik, M; Radko, L, 2018)	0.48
" The primary outcome was safety, evaluated by the incidence and severity of adverse events."	( Safety of IBI-10090 for inflammation associated with cataract surgery: Phase 3 multicenter study. Donnenfeld, ED; Matossian, C; Solomon, KD, 2018)	0.48
" Two serious adverse events unrelated to treatment were reported."	( Safety of IBI-10090 for inflammation associated with cataract surgery: Phase 3 multicenter study. Donnenfeld, ED; Matossian, C; Solomon, KD, 2018)	0.48
"Intralesional steroid injection plus oral steroid administration is safe and effective in preventing stricture following esophageal ESD for esophageal epithelial neoplasms with a mucosal defect extending no less than two-thirds of the circumference in a long-term follow-up."	( Long-term efficacy and safety of intralesional steroid injection plus oral steroid administration in preventing stricture after endoscopic submucosal dissection for esophageal epithelial neoplasms. Chen, T; Chen, W; Chu, Y; Li, H; Xu, M; Yao, L; Zhang, Y; Zhong, Y; Zhou, P, 2019)	0.51
" Although their conventional adverse effects including hyperglycemia, hypertension, hyperlipidemia, and osteoporosis are well-recognized and managed, steroid-induced cardiac arrhythmias are known to a lesser extent."	( Dose-dependent bradycardia as a rare side effect of corticosteroids: a case report and review of the literature. Bodakçi, E; Korkmaz, C; Üsküdar Cansu, D, 2018)	0.48
" Serious adverse events were reported in 12 (1·7%) of 724 patients treated with primary IVIG plus prednisolone; two of these patients had hypertension and bacteraemia that was probably related to prednisolone."	( Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study. Chiga, M; Hori, N; Kaneko, T; Komiyama, O; Matsushima, T; Misawa, M; Miura, M; Miyata, K; Morikawa, Y; Nakazawa, M; Obonai, T; Sakakibara, H; Takahashi, T; Tamame, T; Tsuchihashi, T; Yamagishi, H; Yamashita, Y, 2018)	0.95
"Overall, adjunctive systemic corticosteroids therapy was effective and safe for patients with severe CAP."	( Efficacy and safety of adjunctive corticosteroids therapy for patients with severe community-acquired pneumonia: A systematic review and meta-analysis. Guo, J; Huang, J; Huang, W; Li, H; Zhang, T, 2019)	0.51
" In case 2, the only adverse event was hypokalemia, which was treated using potassium preparations."	( Safety of Abiraterone Acetate Administration in Elderly Patients Receiving Peritoneal Dialysis with Castration-Resistant Prostate Cancer: Two Case Reports. Kimata, R; Kondo, Y; Tomita, Y, 2019)	0.51
" However, different liposomal drugs have different levels of reactogenicity, which means that the optimal protocol for each liposomal drug may differ and should be identified and evaluated to make the treatment as safe and convenient as possible."	( Liposome-induced hypersensitivity reactions: Risk reduction by design of safe infusion protocols in pigs. Fülöp, T; Kozma, GT; Mészáros, T; Metselaar, JM; Rosivall, L; Storm, G; Szebeni, J; Urbanics, R; Vashegyi, I, 2019)	0.51
" Efficacy and rate of adverse events (AEs) were evaluated during a 24-month period after tocilizumab commencement."	( Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis. Aalto, K; Backström, M; Grönlund, MM; Kröger, L; Markula-Patjas, K; Putto-Laurila, A; Remes-Pakarinen, T; Vähäsalo, P, 2020)	0.56
"To compare the early biochemical response and rate of adverse effects in patients who received prednisolone (PRED)/azathioprine (AZA) and those who received budesonide (BUD)/AZA as the first-line treatment for autoimmune hepatitis."	( The efficacy and adverse effects of budesonide in remission induction treatment of autoimmune hepatitis: a retrospective study. Binicier, OB; Günay, S, 2019)	0.73
" Biochemical and hemogram data at baseline and after 6 months of treatment, and adverse effects observed in the follow-up, were compared."	( The efficacy and adverse effects of budesonide in remission induction treatment of autoimmune hepatitis: a retrospective study. Binicier, OB; Günay, S, 2019)	0.51
"There was no difference between the groups in biochemical response (17 patients receiving PRED/AZA and 18 receiving BUD/AZA) and the rate of adverse effects (9 patients receiving PRED/AZA and 5 receiving BUD/AZA)."	( The efficacy and adverse effects of budesonide in remission induction treatment of autoimmune hepatitis: a retrospective study. Binicier, OB; Günay, S, 2019)	0.51
" Lower, although not significantly, rate of adverse effects and lower total number of adverse effects indicate that BUD/AZA may potentially be used as the first-line treatment of choice, especially in patients with obesity, diabetes, resistant hypertension, glaucoma, or osteoporosis."	( The efficacy and adverse effects of budesonide in remission induction treatment of autoimmune hepatitis: a retrospective study. Binicier, OB; Günay, S, 2019)	0.51
" Several immune-mediated neurological adverse events associated with ICIs have been reported to date, such as Guillain-Barré syndrome."	( Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report. Kakumoto, T; Kanzaki, M; Kishi, K; Miyamoto, A; Mochizuki, S; Sakoh, T; Sato, K; Uesaka, Y, 2019)	0.51
"Metronomic chemotherapy could prolong survival time of unfit AML patients, especially in the first 12 months after diagnosis without increasing treatment-associated adverse events."	( Efficacy and Safety of Metronomic Chemotherapy Versus Palliative Hydroxyurea in Unfit Acute Myeloid Leukemia Patients: A Multicenter, Open-Label Randomized Controlled Trial. Charoenprasert, K; Chinthammitr, Y; Kasyanan, H; Panoi, N; Phinyo, P; Pongudom, S; Purattanamal, J; Surawong, A; Wongyai, K, 2020)	0.56
" There are many reports of its toxicity to animals but little is known about the potential adverse effects in humans."	( Primary Human Hepatocytes, but Not HepG2 or Balb/c 3T3 Cells, Efficiently Metabolize Salinomycin and Are Resistant to Its Cytotoxicity. Olejnik, M; Posyniak, A; Radko, L, 2020)	0.56
" Eight serious adverse events were recorded, four events in three (16%) patients assigned rituximab (lumbar compression fracture and infection around nail of right foot [n=1], diplopia [n=1], and uterine cancer [n=1]) and four events in two (11%) people allocated to placebo (exacerbation of glaucoma and bleeding in the right eye chamber after surgery [n=1], and visual impairment and asymptomatic white matter brain lesion on MRI [n=1]); all patients recovered."	( Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Fukaura, H; Kiriyama, T; Maruyama, H; Misu, T; Mori, M; Nakashima, I; Nomura, K; Ochi, K; Oeda, T; Okada, K; Sawada, H; Shimizu, Y; Tahara, M; Umemura, A; Yamamoto, K, 2020)	0.56
" SjS is a relatively rare immune-related adverse event that might sometimes be overlooked."	( Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer. Furuta, Y; Higashi, T; Miyamoto, H; Nagaoka, K; Naito, H; Nakayama, H; Naoe, H; Tanaka, M; Yoshida, R, 2020)	0.56
"In this population, with thorough screening and careful post-gene transfer management, replacement therapy with onasemnogene abeparvovec-xioi is safe and shows promise for early efficacy."	( Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes. Alfano, LN; Bass, N; Broomall, E; Connolly, AM; Ginsberg, M; Goldstein, J; Iammarino, MA; Karingada, C; Lowes, LP; Mendell, JR; Miller, NF; Mosher, KA; Noritz, G; Powers, B; Rossman, I; Storey, MA; Tsao, CY; Waldrop, MA, 2020)	0.56
" RAI is associated with troublesome early, intermediate and late adverse effects."	( Prophylactic prednisolone for the prevention of early and intermediate adverse effects of radioactive iodine therapy in patients with thyroid cancer: study protocol for a single-centre, phase II/III, randomized, double-blinded, placebo-controlled clinical Jayarajah, U; Seneviratne, SA; Wijekoon, M, 2020)	0.93
" Clinically significant adverse effects assessed as related to RAI as well as prednisolone therapy and the quality of life parameters will be compared between the two groups."	( Prophylactic prednisolone for the prevention of early and intermediate adverse effects of radioactive iodine therapy in patients with thyroid cancer: study protocol for a single-centre, phase II/III, randomized, double-blinded, placebo-controlled clinical Jayarajah, U; Seneviratne, SA; Wijekoon, M, 2020)	1.16
"If proven beneficial, this intervention can be incorporated into the standard practice to reduce early and intermediate adverse effects of RAI for thyroid cancer with a potential improvement of quality of life."	( Prophylactic prednisolone for the prevention of early and intermediate adverse effects of radioactive iodine therapy in patients with thyroid cancer: study protocol for a single-centre, phase II/III, randomized, double-blinded, placebo-controlled clinical Jayarajah, U; Seneviratne, SA; Wijekoon, M, 2020)	0.93
" The disease phenotypes, laboratory data, concomitant medication use, and adverse events were also investigated."	( Efficacy and safety of apremilast for 3 months in Behçet's disease: A prospective observational study. Hirahara, L; Kirino, Y; Mizuki, N; Nakajima, H; Soejima, Y; Takase-Minegishi, K; Takeno, M; Takeuchi, M; Yoshimi, R, 2021)	0.62
" Rituximab (RTX) might be an effective and safe choice."	( Efficacy and safety of rituximab for childhood refractory nephrotic syndrome: A meta-analysis of randomized controlled trials. Chang, D; Gong, M; Hu, Z; Li, Z; Liu, C; Zhang, Q, 2021)	0.62
" No significant differences between the RTX and the control group were found in total adverse events (AEs) or serious AEs."	( Efficacy and safety of rituximab for childhood refractory nephrotic syndrome: A meta-analysis of randomized controlled trials. Chang, D; Gong, M; Hu, Z; Li, Z; Liu, C; Zhang, Q, 2021)	0.62
" Other adverse reactions such as fever, debilitation, and alopecia were also observed."	( Efficacy and safety of docetaxel and prednisolone chemotherapy in very elderly men with metastatic castration-resistant prostate cancer (mCRPC) in real world: a single institute experience. Hu, YC; Jiang, JH; Ma, L; Ma, Q; Wang, KY; Zhang, LL, 2021)	0.89
" Liver-related adverse events, laboratory data, concomitant medications, and prednisolone use were analyzed."	( Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. Chand, D; Kaufmann, P; Kleyn, A; Kullak-Ublick, G; McMillan, H; Mohr, F; Montgomery, K; Sun, R; Tauscher-Wisniewski, S; Tukov, FF, 2021)	0.85
"Based on adverse events and laboratory data, 90 of 100 patients had elevated liver function test results (alanine aminotransferase, and/or aspartate aminotransferase, and/or bilirubin concentrations)."	( Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. Chand, D; Kaufmann, P; Kleyn, A; Kullak-Ublick, G; McMillan, H; Mohr, F; Montgomery, K; Sun, R; Tauscher-Wisniewski, S; Tukov, FF, 2021)	0.62
" Most common adverse event was nasopharyngitis (15/50 patients, 30."	( Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study. Arai, G; Furukawa, J; Iinuma, M; Kamiya, N; Kikukawa, H; Kobayashi, H; Kobayashi, K; Maniwa, A; Mikami, K; Nakashima, T; Nakatsu, H; Nasu, Y; Okuno, N; Satoh, T; Tanabe, K; Uemura, H, 2021)	0.88
" In the future, more selectively acting substances could achieve an uncoupling of desired and adverse effects."	( [Safety aspects of the treatment with glucocorticoids for rheumatoid arthritis]. Keyßer, G, 2021)	0.62
" Disease exacerbation, GC dose, IgG-IgG4 titre and adverse events were evaluated using univariate analyses, including the Kaplan-Meier method."	( Effectiveness and safety of mizoribine for the treatment of IgG4-related disease: a retrospective cohort study. Fukui, S; Ikeda, Y; Kawaai, S; Kishimoto, M; Nakai, T; Nomura, A; Ohde, S; Okada, M; Suda, M; Tamaki, H, 2021)	0.62
" Adverse events and adverse drug reactions were evaluated for safety."	( Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study. Fujino, A; Harada, S; Imanaka, K; Koroki, Y; Yasuda, Y, 2021)	0.88
" Adverse events were observed in 225/492 patients (45."	( Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study. Fujino, A; Harada, S; Imanaka, K; Koroki, Y; Yasuda, Y, 2021)	0.88
"Immune checkpoint inhibitors (ICIs), particularly anti-PD-1 antibody, have dramatically changed cancer treatment; however, fatal immune-related adverse events (irAEs) can develop."	( A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. Arai, J; Ariizumi, H; Hamada, K; Hirasawa, Y; Horiike, A; Imamura, CK; Ishida, H; Ishiguro, T; Iwamoto, S; Kiuchi, Y; Kobayashi, S; Kubota, Y; Matsui, H; Oguro, N; Ohkuma, R; Sakaki, M; Sambe, T; Shida, M; Shiozawa, E; Taniguchi, M; Tate, G; Tsunoda, T; Tsurutani, J; Uchida, N; Wada, S; Yoshimura, K, 2021)	0.62
" Data presented are from a composite of preclinical studies, seven clinical trials, and postmarketing sources (clinical trials, n = 102 patients; postmarketing surveillance, n = 665 reported adverse event [AE] cases)."	( Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy. Chand, DH; Day, JW; Finkel, RS; Kleyn, A; Mendell, JR; Mercuri, E; Reyna, SP; Strauss, KA; Tauscher-Wisniewski, S; Tukov, FF, 2021)	0.62
" The benefits of glucocorticoids in terms of symptoms and structural damage were confirmed, but the proportion of patients with at least one adverse event of special interest (serious or glucocorticoids-related) was increased by 24%, mostly due to nonsevere infections."	( The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence. Boers, M; Buttgereit, F; da Silva, JAP; Luís, M; Saag, K, 2022)	0.72
"2 in DAS28-ESR for ≥ 6 months) and discontinuations due to treatment failure in the low dose group, and we compared the incidence of serious adverse events (SAEs) between LD and SD groups."	( Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study. Avgoustidis, N; Bertsias, A; Bertsias, G; Flouri, I; Kalogiannaki, E; Kougkas, N; Papalopoulos, I; Repa, A; Sidiropoulos, P, 2022)	0.72
" Since adverse effects of a short course of high-dose systemic corticosteroids have not been documented with good evidence, the trial will improve knowledge on possible side effects in the different treatment arms with a focus on hyperglycemia and hypertension."	( Efficacy and safety of systemic, high-dose glucocorticoid therapy for idiopathic sudden sensorineural hearing loss : Study protocol for a three-armed, randomized, triple-blind, multicenter trial (HODOKORT). Böselt, I; Girndt, M; Ludwig-Kraus, B; Meisner, C; Plontke, SK; Rahne, T; Richter, M, 2022)	0.72
" Secondary endpoints were time to relapse, mean cumulative dose of prednisolone after rituximab infusion, mean duration of follow up, and adverse events to rituximab if any."	( Long-term efficacy and safety analysis of single cycle of biosimilar rituximab in pemphigus: A retrospective study of 76 patients from India. Mistry, D; Shah, BJ; Shah, SR, 2022)	0.96
" The purpose of this study was to clarify the frequency of adverse events caused by drugs used in JIA treatment and characterize their safety profiles using a spontaneous reporting system database."	( Adverse event profiles of drugs used for treatment of juvenile idiopathic arthritis according to spontaneous reporting system database. Hirai, T; Hosohata, K; Iida, T; Inada, A; Kambara, H; Niinomi, I; Oyama, S; Sano, Y; Uchida, M; Wakabayashi, T, 2022)	0.72
" The safety endpoint was the frequency of adverse events over 1 year before and after switching."	( Safety and efficacy of switching immunosuppressive drugs for maintenance treatment in patients with systemic lupus erythematosus: A retrospective cohort study. Akahoshi, M; Akashi, K; Arinobu, Y; Ayano, M; Horiuchi, T; Kimoto, Y; Mitoma, H; Niiro, H; Ono, N, 2023)	0.91
" The frequency of adverse events was similar in the year before and after switching the drug."	( Safety and efficacy of switching immunosuppressive drugs for maintenance treatment in patients with systemic lupus erythematosus: A retrospective cohort study. Akahoshi, M; Akashi, K; Arinobu, Y; Ayano, M; Horiuchi, T; Kimoto, Y; Mitoma, H; Niiro, H; Ono, N, 2023)	0.91
"Immunosuppressive drug switching led to reduced disease activity and decreased glucocorticoid dose without disease exacerbations and severe adverse events."	( Safety and efficacy of switching immunosuppressive drugs for maintenance treatment in patients with systemic lupus erythematosus: A retrospective cohort study. Akahoshi, M; Akashi, K; Arinobu, Y; Ayano, M; Horiuchi, T; Kimoto, Y; Mitoma, H; Niiro, H; Ono, N, 2023)	0.91
" Any adverse events that required dose reduction or cessation of hydroxychloroquine, indicating intolerance to the drug, were recorded for up to 26 weeks after initiation of hydroxychloroquine."	( Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus. Araki, K; Hirata, S; Ishitoku, M; Kohno, H; Masuda, S; Mokuda, S; Oka, N; Sugimoto, T; Watanabe, H; Yorishima, A; Yoshida, Y, 2023)	0.91
" Secondary outcomes include safety and tolerability of MMF and azathioprine, time to remission, changes in Model For End-Stage Liver Disease (MELD)-score, adverse events, and aspects of quality of life."	( Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial. Bakker, SF; Bartelink, M; Beuers, UHW; Biewenga, M; de Boer, YS; de Jonge, HJM; Drenth, JPH; Gevers, TJG; Gisbertz, IAM; Guichelaar, MMJ; Levens, AD; Pape, S; Pronk, MAMCB; Sebib Korkmaz, K; Sijtsma, MGM; Snijders, RJALM; Soufidi, K; Stoelinga, AEC; van den Berg, AP; van den Brand, FF; van der Meer, AJ; van Gerven, NMF; van Hoek, B; Vanwolleghem, T; Verdonk, RC; Verwer, BJ; Vrolijk, JM, 2022)	0.72
" Here we characterise the safety of these agents in subpopulations and assess manageability of key adverse events (AEs)."	( Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. Bracarda, S; Chen, G; Chi, KN; de Bono, J; Garcia, J; Harris, A; Hinton, H; Massard, C; Matsubara, N; Olmos, D; Sandhu, S; Sane, R; Schenkel, F; Sternberg, CN; Sweeney, C, 2023)	0.91
"Glucocorticoids prescribed to limit inflammation, have significant adverse effects."	( 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial. Agbaje, O; Arvaniti, A; Bateman, E; Bonaventura, I; Coleman, RL; Cornfield, T; Duffy, J; Eastell, R; Gossiel, F; Hodson, L; Holman, RR; Isidori, AM; Jane Escott, K; Karpe, F; Kirik, U; Marjot, T; Milton, JE; Moolla, A; Nikolaou, N; Othonos, N; Pofi, R; Sadler, R; Scott, CAB; Stewart, PM; Stimson, RH; Tomlinson, JW; van Beek, AP; van Faassen, M; Webster, C; White, S; Whittaker, A, 2023)	1.18
" Although he was previously treated with prednisolone (1 mg/kg/day) for immune-related adverse event (irAE) hepatitis by a previous doctor, he still had worsening liver function and was transferred to our hospital."	( Immune-related adverse events in hepatitis treated with thiopurine-based immunosuppressants: A case report. Hamaguchi, M; Horie, M; Isobe, T; Kawakado, K; Nagase, M; Nakashima, K; Okimoto, T; Tobita, H; Tsubata, Y; Yoshihara, K, 2023)	1.18
" This suggests that withdrawal of low-dose prednisolone is feasible and safe after 2 years of administration."	( Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial. Allaart, CF; Almayali, AAH; Baudoin, P; Boers, M; Bos, R; Buttgereit, F; Cutolo, M; Da Silva, JA; Griep, E; Hartman, L; Klaasen, R; Kok, MR; Lems, W; Masaryk, P; Opris, D; Raterman, HG; Smulders, Y; Szekanecz, Z; Ter Wee, MM, 2023)	1.17

Pharmacokinetics

The pharmacokinetic profile of a single 10 mg oral dose of prednisolone was studied in three groups of six patients with rheumatoid arthritis (RA), polymyalgia rheumatica (PMR) and bronchial asthma (BA) who were already receiving steroid therapy. Clinical factors tested for influence on pharmacokinetics parameters were weight, haemoglobin, duration and duration.

Excerpt	Reference	Relevance
" With increasing dose there is prolongation of the plasma half-life and increase in the volume of distribution and plasma clearance of prednisolone."	( Dose dependent pharmacokinetics of prednisolone. Downie, WW; Leatham, PA; Lowe, JR; Pickup, ME; Rhind, VM; Wright, V, 1977)	0.74
" Suppression of plasma cortisol and alterations in blood basophil and helper-T cell trafficking were used as pharmacodynamic indices."	( Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man. Jusko, WJ; Law, RM; Ludwig, EA; Middleton, E; Sloan, RR; Wald, JA, 1992)	0.52
" Furthermore, the results of the present study confirm the presence of pharmacodynamic corticosteroid effects on blood cell count and blood glucose."	( Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration. Barth, J; Brandis, KH; Damoiseaux, M; Derendorf, H; Hochhaus, G; Möllmann, H, 1992)	0.55
" Indeed, test doses of cyclosporin followed by series of blood samples and the calculation of individual pharmacokinetic parameters are needed to assure successful immunosuppression right from the start."	( Optimisation of immunosuppressive therapy using pharmacokinetic principles. Grevel, J, 1992)	0.28
" To estimate HC production after DEX administration a pharmacokinetic model was developed and applied to the time course of plasma HC."	( Time-dependent effects of dexamethasone administration on the suppression of plasma hydrocortisone, assessed with a pharmacokinetic model. Braat, MC; Koopmans, RP; Oosterhuis, B; van Boxtel, CJ, 1992)	0.28
" Blood and urine samples were collected, and the pharmacokinetic parameters of prednisone and prednisolone were determined in each treatment period."	( Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. Blum, R; Garg, V; Jusko, WJ; Wilner, KD, 1992)	0.72
" The prednisolone pharmacokinetic parameters derived demonstrated an increased total clearance (by 60%), an increased volume of distribution (by 46%), a lower peak concentration (by 35%), and no difference in elimination half-life in patients with CF compared with those with asthma."	( Altered prednisolone pharmacokinetics in patients with cystic fibrosis. Accurso, FJ; Dove, AM; Hill, MR; Jusko, WJ; Larsen, GL; Szefler, SJ, 1992)	1.23
" The pharmacokinetic parameters of PSL were determined by non-compartment analysis."	( Effect of oral administration of glycyrrhizin on the pharmacokinetics of prednisolone. Chen, MF; Kanaoka, M; Kato, H; Shimada, F; Yano, S, 1991)	0.51
" Since the pharmacokinetics of prednisolone are little altered in renal transplantation, it is concluded that lymphocyte sensitivity specific to prednisolone may be a pharmacodynamic marker characteristic of successful graft survival in patients with histo-incompatibility and/or drug resistance."	( Role of altered prednisolone-specific lymphocyte sensitivity in chronic renal failure as a pharmacodynamic marker of acute allograft rejection after kidney transplantation. Hirano, T; Kang, XX; Kozaki, M; Oka, K; Sakurai, E; Tamaki, T, 1991)	0.91
" The 50% inhibitory concentration values derived from pharmacodynamic models developed to describe the direct suppressive effects of corticosteroids indicated no alteration in intrinsic sensitivity in the presence of ketoconazole."	( Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. Jusko, WJ; Ludwig, EA; Middleton, E; Yamashita, SK, 1991)	0.51
"The pharmacokinetic characteristics of prednisolone and of chlorambucil and its beta-oxidized metabolite, phenylacetic mustard (PAM) were studied in plasma after the oral administration of 200 mg prednimustine (Sterecyt) and a regimen consisting of 20 mg prednisolone plus 20 mg chlorambucil, respectively."	( A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients. Bastholt, L; Gunnarsson, PO; Johansson, CJ; Johansson, SA; Mouridsen, H; Pfeiffer, P; Svensson, L, 1991)	0.79
" To ascertain which pharmacokinetic properties of these drugs explain this difference, we gave methylprednisolone and prednisolone, 5 mg/kg intravenous bolus, to 23 adult rabbits."	( Methylprednisolone achieves greater concentrations in the lung than prednisolone. A pharmacokinetic analysis. Bloedow, DC; Greos, LS; Hill, MR; Irvin, CG; Larsen, GL; Szefler, SJ; Vichyanond, P, 1991)	0.98
" Eleven blood samples were collected over 24 h for the pharmacokinetic studies on day 1 (first day of treatment) and on day Y (after the clinical evaluation)."	( Pharmacokinetics of prednisone and prednisolone in bullous pemphigoid patients. Chosidow, O; Diquet, B; Etienne, SD; Herson, S; Puech, AJ; Vandermeersch, V; Vu-Thi-My-Le, C, 1991)	0.56
" The absorption of each of the three compounds was rapid, as the peak concentration was attained within 20 min after injection."	( Pharmacokinetics of prednisolone and its local anti-inflammatory steroid-21-oate ester derivatives. In vitro and in vivo comparative study. al-Habet, SM; Lee, HJ; Taraporewala, IB, )	0.45
"To determine the pharmacokinetic changes of prednisolone associated with an alternate-day regimen, 12 patients with various diseases were studied longitudinally."	( The pharmacokinetics of plasma total and free prednisolone during an alternate-day regimen. Adachi, K; Fuwa, Y; Goshima, E; Miura, K; Yamakita, N; Yasuda, K, 1991)	0.8
" Thirdly, due to the short half-life of prednisolone no steady-state is achieved, and therefore area under the concentration-time curve needed to be determined in all studies."	( Clinical pharmacokinetics of prednisone and prednisolone. Frey, BM; Frey, FJ, 1990)	0.81
" After the development of a data base of pharmacokinetic parameters, we examined glucocorticoid pharmacokinetics in 54 patients between 2 and 70 years of age using 70 pharmacokinetic studies after administration of intravenous methylprednisolone (n = 25), oral methylprednisolone (n = 15), intravenous prednisolone (n = 18), and oral prednisone (n = 12)."	( Monitoring glucocorticoid therapy: a pharmacokinetic approach. Ball, BD; Bartoszek, M; Brenner, AM; Hill, MR; Szefler, SJ, 1990)	0.46
" All the pharmacokinetic parameters, including the conversion of prednisone to prednisolone were similar to the data already published in children with INS."	( Pharmacokinetics of prednisolone in children with the nephrotic syndrome. Alvinerie, M; Barthe, P; Bouissou, F; Houin, G; Rostin, M, 1990)	0.83
" The pharmacokinetic parameters of PSL were determined, using noncompartmental analysis."	( Effect of glycyrrhizin on the pharmacokinetics of prednisolone following low dosage of prednisolone hemisuccinate. Chen, MF; Kanaoka, M; Kato, H; Shimada, F; Yano, S, 1990)	0.53
"3 h and 1160 micrograms/l, respectively), the initial and terminal elimination half-life (3."	( Effects of low-dose prednisolone on cyclosporine pharmacokinetics in liver transplant recipients: radioimmunoassay with specific and non-specific monoclonal antibodies. Arnold, JC; O'Grady, JG; Tredger, JM; Williams, R, 1990)	0.6
" These findings suggest a decreased systemic availability of prednisolone after prednisolone sodium metasulfobenzoate (Solupred) administration and show, from a strictly pharmacokinetic point of view, that equimolar doses of prednisone and prednisolone sodium metasulfobenzoate are not equivalent therapies."	( [Pharmacokinetic parameters of prednisone and prednisolone in healthy volunteers]. Chosidow, O; Diquet, B; Etienne, SD; Godeau, P; Herson, S; Vandermeersch, V; Vu-Thi-My-Le, C, 1990)	0.78
"To determine the pharmacokinetic changes of prednisolone associated with differing therapy regimens, we studied 15 patients with various diseases who were treated with daily doses of prednisolone and were then placed on an intermittent regimen, [administration for 4 consecutive days (on-day period), followed by 3 days cessation (off-day period)]."	( Changes in the pharmacokinetics of plasma total and free prednisolone during daily and intermittent regimens. Adachi, K; Fuwa, Y; Goshima, E; Miura, K; Yamakita, N; Yasuda, K, 1990)	0.79
" The presented methods are simple, rapid, specific, sensitive, reproducible, and economical for the pharmacokinetic study of these steroids."	( Two chromatographic methods for the determination of corticosteroids in human biological fluids: pharmacokinetic applications. al-Habet, SM; Rogers, HJ, 1989)	0.28
" For total prednisolone, the mean elimination half-life was relatively short (1."	( Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia. Blackburn, M; Choonara, I; Lewis, I; Rayner, P; Wheeldon, J, 1989)	0.99
" The described method involves a simple organic extraction procedure and separation of steroids using a C18 reversed-phase column for pharmacokinetic study."	( High-performance liquid chromatographic determination of prednisolone and its steroid 21-oate ester derivatives in rat plasma: pharmacokinetic applications. Al-Habet, SM; Lee, HJ, 1989)	0.52
"The pharmacokinetics and pharmacodynamic response to prednisolone were examined in dietary-induced obese rats and matched controls."	( Pharmacokinetics and pharmacodynamics of prednisolone in obese rats. D'Ambrosio, R; Jusko, WJ; Nichols, AI; Pyszczynski, NA, 1989)	0.79
" Sulphasalazine itself is poorly absorbed (3 to 12%) and its elimination half-life of about 5 to 10 hours is probably affected by the absorption process."	( Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Klotz, U, )	0.13
" This different pharmacokinetic behavior might offer an explanation for the superior therapeutic effects of prednimustine demonstrated by clinical studies."	( Studies on the pharmacokinetics of chlorambucil and prednimustine in patients using a new high-performance liquid chromatographic assay. Loos, U; Malek, M; Mühlenbruch, B; Musch, E; Oppitz, MM; Rüb, HP; von Unruh, GE, 1989)	0.28
" The purpose of this study was to investigate possible correlations between the pharmacokinetic values of prednisolone and the main clinical criteria of effectiveness and safety."	( [Pharmacokinetics of prednisolone in children. Study of a correlation with tolerability and therapeutic effect in nephrosis]. Baron, S; Bensman, A; Raux Demay, MC; Vasmant, D, 1988)	0.81
" The use of prednisolone in patients with sarcoidosis can be safely based upon pharmacokinetic data obtained from normal volunteers."	( Angiotensin-converting enzyme. Investigation of diurnal variation, the effect of a large dose of prednisolone, and prednisolone pharmacokinetics in patients with sarcoidosis. Al Habet, SM; Kemp, MW; McAllister, WA; Thompson, PJ; Turner-Warwick, ME, 1986)	0.87
" The results of the three experiments support the use of a non-linear reversible metabolism model to describe the pharmacokinetic relationship between prednisone and prednisolone."	( The non-linear pharmacokinetics of prednisone and prednisolone. III. Experiments using the rabbit as an animal model. Ferry, JJ; Wagner, JG, )	0.58
" To compare clinical and pharmacokinetic variables of methylprednisolone and oral prednisolone in patients with RA, a controlled crossover study was carried out."	( Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. Boutagy, J; Brooks, PM; Cosh, D; Donovan, S; McCredie, M; Needs, CJ; Smith, M, 1988)	0.84
"The effects of beta- and gamma-cyclodextrins (CyDs) on the pharmacokinetic behavior of prednisolone after intravenous or intramuscular administration in rabbits were investigated."	( Effects of beta- and gamma-cyclodextrins on the pharmacokinetic behavior of prednisolone after intravenous and intramuscular administrations to rabbits. Arimori, K; Uekama, K, 1987)	0.73
" Cmax, Tmax and AUCp."	( [Pharmacokinetics of prednisolone (PSL) during PSL treatment. I. PSL pharmacokinetics during daily PSL treatment]. Adachi, K; Fuwa, Y; Goshima, E; Minamori, Y; Miura, K; Murase, H; Murayama, M; Yamakita, N; Yasuda, K, 1986)	0.59
"The pharmacokinetic profile of a single 10 mg oral dose of prednisolone was studied in three groups of six patients with rheumatoid arthritis (RA), polymyalgia rheumatica (PMR) and bronchial asthma (BA) who were already receiving steroid therapy."	( Prednisolone pharmacokinetics in patients with rheumatoid arthritis, polymyalgia rheumatica and asthma. Astbury, C; Bird, HA; Dixon, JS; Taggart, AJ, 1986)	1.96
" Half-life (0."	( Dose-dependent pharmacokinetics of prednisolone in normal and adrenalectomized rats. Boudinot, FD; Jusko, WJ, 1986)	0.55
"Three simple linear and three simple non-linear pharmacokinetic models are presented which incorporate the reversible metabolism that occurs between prednisone and prednisolone."	( The non-linear pharmacokinetics of prednisone and prednisolone. I. Theoretical. Ferry, JJ; Wagner, JG, )	0.58
" Plasma levels of the ester and prednisolone were measured and pharmacokinetic parameters were calculated."	( Pharmacokinetics of prednisolone after high doses of prednisolone hemisuccinate. Barth, J; Derendorf, H; Möllmann, H; Neveling, D; Rehder, J; Rohdewald, P, )	0.74
" It is suggested that prednisolone pharmacodynamics may be influenced by pharmacokinetic differences, and that differences in renal function may be an important contributing factor."	( Different prednisolone pharmacokinetics in Cushingoid and non-Cushingoid kidney transplant patients. Bergrem, H; Flatmark, A; Jervell, J, 1983)	0.98
" The results showed no significant differences between the two groups in estimates of prednisolone plasma protein binding parameters and peak time, peak concentration, mean input time, clearance/F, volume of distribution/F, or half-life (t 1/2), using total or unbound prednisolone concentrations."	( The absence of effect of azathioprine on prednisolone pharmacokinetics following maintenance prednisone doses in kidney transplant patients. Amend, WJ; Birnbaum, JL; Gambertoglio, JG; Holford, HG; Lizak, PS; Salvatierra, O, 1984)	0.76
" After dexamethasone alcohol (IV) or dexamethasone 21-isonicotinate (IV), the half-life of elimination was similar (53 minutes) for both formulations."	( Dexamethasone and prednisolone in the horse: pharmacokinetics and action on the adrenal gland. Alvinerie, M; Baggot, JD; Brandon, RA; de Pomyers, H; Toutain, PL, 1984)	0.6
" Along with the partial and total AUC and moment, the program generates model-independent pharmacokinetic parameters such as plasma clearance, terminal slope, half-life, volume of distribution at steady-state, mean residence time, and variance of the residence time."	( LAGRAN program for area and moments in pharmacokinetic analysis. Jusko, WJ; Rocci, ML, 1983)	0.27
" The pharmacodynamic component of the model was a hyperbolic function in which a threshold concentration parameter had to be incorporated."	( Pharmacokinetic-pharmacodynamic modeling of prednisolone-induced lymphocytopenia in man. Endert, E; Oosterhuis, B; Sauerwein, HP; Schellekens, PT; ten Berge, RJ; van Boxtel, CJ, 1984)	0.53
" Half-life values were similar on both occasions."	( Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. Barberis, L; Frigo, GM; Gatti, G; Martini, A; Notarangelo, LD; Perucca, E, 1984)	0.52
" The reduction in area under the time concentration curve of free, non-protein bound prednisolone was 56."	( Changes in prednisolone pharmacokinetics and protein binding during treatment with rifampicin. Bergrem, H; Refvem, OK, 1983)	0.88
"Clinical and pharmacokinetic observations suggest that azathioprine may diminish the plasma level of prednisolone."	( A single dose of azathioprine does not affect the pharmacokinetics of prednisolone following oral prednisone. Frey, BM; Frey, FJ; Guentert, T; Lozada, F, 1981)	0.71
"The simplest three pharmacokinetic models which apply in cases of reversible metabolism are described."	( Reversible metabolism and pharmacokinetics: application to prednisone-prednisolone. Albert, KS; DiSanto, AR; Gillespie, WR; Wagner, JG, 1981)	0.5
" Changes in prednisone half-life were insignificant, but increases in the half-life of its metabolite were dose-dependent."	( Dose dependent pharmacokinetics of prednisone and prednisolone in man. Jusko, WJ; Rose, JQ; Yurchak, AM, 1981)	0.52
" 7 It was concluded that over the dose range investigated, non-linear pharmacokinetic behaviour had not been demonstrated in this group of normal volunteers."	( Pharmacokinetics of intravenous and oral prednisolone. Al-Habet, S; Rogers, HJ, 1980)	0.53
"A problem in the evaluation of pharmacokinetic interactions between prednisolone and cortisol is that both steroids bind to cortisol binding globulin (CBG) and albumin."	( Pharmacokinetic interaction between endogenous cortisol and exogenous corticosteroids. Barth, J; Derendorf, H; Hochhaus, G; Möllmann, H; Rohatagi, S, 1995)	0.53
"Due to the short pharmacokinetic half-life of its active metabolite, pharmacodynamic effects of deflazacort are of shorter duration than those of methylprednisolone and prednisolone."	( Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Barth, J; Derendorf, H; Hochhaus, G; Möllmann, H; Rohatagi, S, 1995)	0.72
" Estrogen replacement therapy (ERT) did not restore POM pharmacokinetic parameters to PRM values."	( Menopause: pharmacodynamics and pharmacokinetics. Benet, LZ; Gustavson, LE, )	0.13
" This prospect was investigated using pharmacodynamic cell trafficking models."	( Prednisolone pharmacodynamics: leukocyte trafficking in the rat. Jusko, WJ; Wald, JA, 1994)	1.73
" The mean values of half-life and apparent volume of distribution at steady-state in each group were similar."	( Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats. Garg, V; Hon, YY; Jusko, WJ, 1994)	0.52
"Stable isotopically labeled steroids can, without radiation hazards, be safely used as biological internal standards to perform pharmacokinetic studies of steroids in man."	( [Stable isotope methodology in the pharmacokinetic study of steroids]. Kasuya, Y, 1994)	0.29
" Serial IV pharmacokinetic studies of prednisolone (1 mg/kg) in groups of 3 patients over a 1 month period of rifampin co-treatment or after its withdrawal, revealed significant changes in the area under the curve, the total clearance, the non-renal clearance and the half-life."	( Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. Chong, WS; Jang, IJ; Kim, S; Lee, JS; Lee, KH; Shin, JG; Shin, SG, 1993)	0.85
"95) giving a mean elimination half-life (t0."	( The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Bevan, DJ; Bunn, D; Hendry, BM; Higgins, RM; Lea, CK, 1996)	0.29
"The pharmacokinetic interaction of multiple oral doses of sirolimus (rapamycin) and prednisone were evaluated in 40 stable patients with renal transplants receiving concomitant multiple doses of cyclosporine."	( Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. Ferron, GM; Jusko, WJ; Kahan, BD; Mis, SM; Zimmerman, JJ, 1996)	0.62
" Peak concentration was significantly higher with liquid prednisolone (mean +/- SD 430."	( A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. Kamada, AK; LaVallee, NM; Scott, MB; Selner, JC; Szefler, SJ; Wiener, MB, )	0.38
" Samples from the arterial and venous blood catheters and from the ultradiafiltrate were collected over the next 12 hrs to calculate pharmacokinetic parameters and clearance of hemodiafiltration."	( Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. Gando, S; Hayakawa, T; Kameue, T; Nakanishi, Y; Nanzaki, S, 1998)	0.3
" Synopsis of pharmacokinetic and pharmacodynamic studies, possibly explaining the improved benefit-risk ratio of prednicarbate."	( Prednicarbate versus conventional topical glucocorticoids: pharmacodynamic characterization in vitro. Bader, M; Gysler, A; Kleuser, B; Korting, HC; Lange, K; Schäfer-Korting, M, 1997)	0.3
" Due to the complicated pharmacokinetic properties of prednisolone, it is extremely difficult to determine the dose needed to obtain a desired target concentration."	( Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration. Barth, J; Derendorf, H; Hochhaus, G; Möllmann, C; Möllmann, H; Rohatagi, S; Soldner, A, 1997)	0.85
" The presence of multicompartment response variables and/or polyexponential loss complicates the response patterns and resolution of pharmacologic parameters of indirect response models and requires careful experimental and data analysis approaches in order to properly evaluate such pharmacodynamic responses."	( Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition. Jusko, WJ; Krzyzanski, W, 2001)	0.31
" Plasma cortisol concentrations were determined as a pharmacodynamic index."	( Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Archer, VC; Chosidow, O; Diquet, B; Lebrun-Vignes, B; Levron, JC; Puech, AJ; Warot, D, 2001)	0.56
" The pharmacokinetic interaction between methylprednisolone and itraconazole is probably related to inhibition of hepatic CYP3A4 activity by itraconazole."	( Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Archer, VC; Chosidow, O; Diquet, B; Lebrun-Vignes, B; Levron, JC; Puech, AJ; Warot, D, 2001)	0.82
" Total and free plasma prednisolone concentrations were assayed by HPLC and ultrafiltration, and pharmacokinetic data were analyzed by compartmental fitting using WinNonlin."	( Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. Blum, RA; Jusko, WJ; Lates, CD; Magee, MH, 2001)	2.06
" Pharmacokinetic parameters of prednisolone as assessed by Cmax, t 1/2, AUC, or serum protein binding were not affected by prasterone."	( Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women. Blum, RA; Jusko, WJ; Meno-Tetang, GM; Schwartz, KE, 2001)	0.6
"3% for Cmax and 98."	( Pharmacokinetics of two oral prednisolone tablet formulations in healthy volunteers. Benöhr, P; Luippold, G; Marto, M; Mühlbauer, B; Schneider, S, 2001)	0.6
" Their pharmacodynamic interactions were examined in blood from healthy adult male and female volunteers using an in vitro phytohemagglutinin (PHA)-stimulated whole-blood lymphocyte proliferation technique."	( Pharmacodynamic interaction of recombinant human interleukin-10 and prednisolone using in vitro whole blood lymphocyte proliferation. Chakraborty, A; Jusko, WJ, 2002)	0.55
" Pharmacokinetic parameters were estimated in one-chamber model with absorption."	( [Pharmacokinetic of prednisolone in patients with rheumatoid arthritis]. Chekalin, AF; Nesterov, SL; Rossokhin, VF; Shishkanov, SF, 2002)	0.64
"In spite of the same dose of prednisolone, its serum concentration as well as pharmacokinetic parameters were individual in each patient."	( [Pharmacokinetic of prednisolone in patients with rheumatoid arthritis]. Chekalin, AF; Nesterov, SL; Rossokhin, VF; Shishkanov, SF, 2002)	0.93
" However, the potential bilateral pharmacokinetic interaction between atorvastatin and CsA in renal transplant recipients has not previously been examined."	( Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Asberg, A; Bergan, S; Fjeldså, E; Hartmann, A; Holdaas, H, 2001)	0.31
" Model simulations well captured the pharmacodynamic data once initial conditions were corrected for observed baseline values."	( Integrated QSPR--pharmacodynamic model of genomic effects of several corticosteroids. Jusko, WJ; Mager, DE; Pyszczynski, NA, 2003)	0.32
"A two-compartment pharmacokinetic model was used to describe data from 23 children with ALL (aged 2-15 years)."	( Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. Jusko, WJ; Petersen, KB; Rasmussen, M; Schmiegelow, K, 2003)	0.6
" The median unbound clearance (32 l/h per m(2)) was lower, and the half-life (3."	( Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. Jusko, WJ; Petersen, KB; Rasmussen, M; Schmiegelow, K, 2003)	0.6
"The study showed complete oral bioavailability, a lower unbound clearance and a longer half-life for prednisolone than previously reported in childhood ALL."	( Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. Jusko, WJ; Petersen, KB; Rasmussen, M; Schmiegelow, K, 2003)	0.82
"97, mean bias < 1%; mean precision < 10%) these pharmacokinetic parameters."	( Prednisolone: limited sampling strategies for estimating pharmacokinetic parameters. Estrela, Rde C; Salvadori, MC; Suarez-Kurtz, G, 2004)	1.77
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."	( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004)	0.32
" We compared three groups of children according to the growth kinetics during the study year (catch-up, stable, or decline) for clinical and pharmacokinetic parameters."	( Glucocorticoid pharmacokinetics and growth retardation in children with renal transplants. Bresson, JL; Broyer, M; Chavatte, C; Gimenez, F; Guest, G; Hankard, R; Le Bihan, C; Loirat, C; Maisin, A; Mogenet, A; Niaudet, P; Proust, V; Singlas, E, 2004)	0.32
"The pharmacodynamic interactions between recombinant mouse interleukin-10 (IL-10) and prednisolone were examined in lipopolysaccharide (LPS)-induced experimental endotoxemia in Balb/c mice."	( Pharmacodynamic interactions between recombinant mouse interleukin-10 and prednisolone using a mouse endotoxemia model. Chakraborty, A; Jusko, WJ; Pyszczynski, NA; Yeung, S, 2005)	0.78
"There were no statistically significant differences in the pharmacokinetic parameters calculated from plasma data in the three situations studied."	( Pharmacokinetics of prednisolone in man during acute and chronic exposure to high altitude. Arancibia, A; Chávez, J; Gai, MN; González, C; Paulos, C; Pinilla, E; Ritschel, WA; Villanueva, S, 2005)	0.65
"A population pharmacokinetic analysis of cyclosporine (CsA) was performed, and the influence of covariates on CsA oral clearance and relative bioavailability was investigated."	( Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Akhlaghi, F; Baheti, G; Rosenbaum, SE; Trull, AK, 2005)	0.33
"), respectively, showed significant change of the pharmacokinetic parameters of Dx compared with the control rats."	( Pharmacokinetic interaction with digoxin and glucocorticoids in rats detected by radio-immunoassay using a novel specific antiserum. Fujii, Y; Higashi, Y; Ikeda, Y; Yamamoto, R; Yamashiro, M, 2005)	0.33
"Corticosteroid therapy has been associated with bone toxicities (eg, osteonecrosis) and Cushing syndrome in HIV-infected patients; this may be partially attributable to a pharmacokinetic drug interaction between HIV protease inhibitors and corticosteroids."	( Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers. Alfaro, RM; Formentini, E; Kovacs, J; Long, M; Natarajan, V; Penzak, SR, 2005)	1.77
" This study compared the pharmacokinetic profiles of MPA and its major metabolite MPA glucuronide (MPAG) in combination with tacrolimus (TAC) or cyclosporine (CyA) during the maintenance period (>6 months) following renal transplantation."	( Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Hashimoto, H; Kagawa, Y; Maeda, T; Naito, T; Otsuka, A; Ozono, S; Shinno, K; Suzuki, K; Takayama, T; Ushiyama, T, 2006)	0.33
" The pharmacokinetic properties of CyA vary widely and lipoproteins are the major complexing constituents for CyA in the plasma."	( Effect of plasma lipid on pharmacokinetics of ciclosporin and its relationship with plasma prednisolone level in renal transplant patients. Ito, Y; Kokuhu, T; Okamoto, M; Shibata, N; Sugioka, N; Takada, K; Yoshimura, N, 2006)	0.55
" Finally, theoretical assumptions about the potential pharmacokinetic changes of glucocorticoids in pregnancy and their application to clinical settings are discussed."	( Pharmacokinetics of corticosteroids during pregnancy. Ghulmiyyah, LM; Hankins, GD; Pacheco, LD; Snodgrass, WR, 2007)	0.34
" Based on literature datasets, a linear two-compartment pharmacokinetic model was developed to adequately describe the reversible metabolism between free prednisone and prednisolone."	( A pharmacokinetic/pharmacodynamic approach to predict total prednisolone concentrations in human plasma. Derendorf, H; Winkler, J; Xu, J, 2007)	0.78
" We aimed at investigating the effect of high-doses of MZ on prevention of anti-donor antibody (Ab) production and acute Ab-mediated rejection (AMR) on the basis of the pharmacokinetic profile in a pig kidney transplantation model."	( Prophylactic treatment of antibody-mediated rejection with high-dose mizoribine and pharmacokinetic study. Kobayashi, T; Kuzuya, T; Liu, D; Ma, Y; Miwa, Y; Morozumi, K; Nagasaka, T; Nakao, A; Oikawa, T; Uchida, K; Yokoyama, I, 2007)	0.34
" However, this sensitivity was not satisfactory for corticosterone during pharmacokinetic studies involving dexamethasone due to its strong adrenosuppressive effect."	( Quantification of dexamethasone and corticosterone in rat biofluids and fetal tissue using highly sensitive analytical methods: assay validation and application to a pharmacokinetic study. Jusko, WJ; Samtani, MN, 2007)	0.34
"We investigated the pharmacokinetic equivalency of oral and intravenous etoposide in ten patients (male, n=7; female, n=3; median age 56 years) with aggressive lymphomas."	( Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. Ehninger, G; Friedrichsen, K; Haenel, M; Kroschinsky, FP; Mueller, J; Prondzinsky, R; Pursche, S; Schleyer, E, 2008)	0.35
"Twenty-eight days of SJW treatment resulted in no significant alterations in the pharmacokinetic parameters for prednisone or prednisolone."	( Lack of pharmacokinetic interaction between St. John's wort and prednisone. Bell, EC; Chan, HM; Lin, YJ; Ravis, WR, 2007)	0.55
" The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11."	( Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Habuchi, T; Inoue, K; Kagaya, H; Miura, M; Saito, M; Satoh, S; Suzuki, T, 2008)	0.35
" AUCs of OP and IVMP were determined by the trapezoid method; pharmacokinetic parameters were obtained using noncompartmental and compartmental analysis."	( Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Daru, JA; Gursahaney, A; Ngai, KL; Pachman, LM; Rouster-Stevens, KA, 2008)	0.63
" Mean peak concentration was higher for IVMP (34."	( Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Daru, JA; Gursahaney, A; Ngai, KL; Pachman, LM; Rouster-Stevens, KA, 2008)	0.63
"Twenty-four patients who were enrolled in a large randomized trial of thalidomide vs no thalidomide maintenance therapy for myeloma, in which all patients also received zoledronic acid, were recruited to a pharmacokinetic and renal safety sub-study, and followed for up to 16 months."	( Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. Bilic, S; Copeman, M; Cremers, S; Kennedy, N; Lynch, K; Neeman, T; Ravera, C; Roberts, A; Schran, H; Spencer, A, 2008)	0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" Even at comparable weight-adjusted doses, prednisolone side effects vary considerably between individuals, suggesting between-patient pharmacokinetic differences."	( Role of prednisolone pharmacokinetics in postchallenge glycemia after renal transplantation. Bergrem, H; Bergrem, HA; Hartmann, A; Hjelmesaeth, J; Jenssen, T, 2008)	1.04
" The purpose of this study was to evaluate the presystemic extraction and pharmacodynamic action of buccal budesonide."	( Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. Bertz, H; Dilger, K; Finke, J; Gratwohl, A; Halter, J; Lopez-Lazaro, L, 2009)	0.35
" A population pharmacokinetic analysis was performed to estimate the effects of demographic factors, hematocrit, serum albumin concentration, prednisolone dose, TRL dose interval, polymorphisms in genes coding for ABCB1, CYP3A5, CYP3A4, and the pregnane X receptor on TRL pharmacokinetics."	( Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Danhof, M; de Fijter, JW; den Hartigh, J; Guchelaar, HJ; Ploeger, BA; Press, RR; van der Straaten, T; van Pelt, J, 2009)	0.55
"African green monkeys (vervets) have been proposed as an alternate species that might allow improved access and provide high-quality pharmacokinetic results comparable with other primates."	( Exploration of the African green monkey as a preclinical pharmacokinetic model: oral pharmacokinetic parameters and drug-drug interactions. Bhadresa, S; Coon, DJ; Lawrence, MS; Magiera, D; Struharik, M; Ward, KW, 2009)	0.35
" This validated method has been used successfully in clinical pharmacokinetic studies of CRx-102 in healthy volunteers."	( Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantitation of prednisolone and dipyridamole in human plasma and its application in a pharmacokinetic study. Chen, M; Granvil, C; Ji, QC; Kansra, VV; Padval, MV; Zhang, ZY, 2009)	0.56
" Pharmacodynamic (PD) assay for evaluating the inhibition of interleukin-2 (IL-2) production for each patient could provide a more appropriate dosing regimen."	( Evaluation of interleukin-2 mRNA in whole blood as a parameter for monitoring cyclosporine pharmacodynamics. Katayama, A; Kobayashi, T; Kuzuya, T; Miwa, Y; Nagasaka, T; Nakao, A; Uchida, K; Yamada, K, 2009)	0.35
" The large pharmacokinetic (PK) and pharmacodynamic (PD) variability and narrow therapeutic range of MPA provide a potential for therapeutic drug monitoring."	( Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study. Bergan, S; Bremer, S; Holdaas, H; Jørgensen, PF; Midtvedt, K; Rootwelt, H; Stenstrøm, J; Vethe, NT, 2009)	0.35
"There were no differences in dose (D) and body weight (BW)-adjusted pharmacokinetic parameters of tacrolimus among the three groups."	( No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation. Habuchi, T; Inoue, T; Kagaya, H; Miura, M; Saito, M; Satoh, S; Suzuki, T; Tsuchiya, N, 2009)	0.57
"021, respectively), but there were no significant differences in the half-life and T(max) of prednisolone between the two groups."	( Inter-individual difference determinant of prednisolone pharmacokinetics for Japanese renal transplant recipients in the maintenance stage. Habuchi, T; Inoue, K; Kagaya, H; Miura, M; Saito, M; Satoh, S, 2009)	0.84
"Detailed pharmacokinetic (PK) studies in rats were performed (i)to compare the PK of prednisolone (PRN) and loteprednol etabonate (LE, a soft corticosteroid) as well as their common inactive metabolite delta1-cortienic acid (delta1-CA), (ii) to investigate the excretion of delta1-CA after PRN and LE administration, and (iii) to investigate the effect of delta1-unsaturation on the excretion of delta1-CA versus CA."	( Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats. Bodor, N; Buchwald, P; Tang, Y; Wu, WM, 2010)	0.81
" The favorable pharmacokinetic profile of mapracorat supports further clinical investigation and suggests that a convenient daily dosing regimen may be efficacious for this novel ophthalmic anti-inflammatory therapy."	( Ocular pharmacokinetics of mapracorat, a novel, selective glucocorticoid receptor agonist, in rabbits and monkeys. Lowe, ER; Proksch, JW; Ward, KW, 2011)	0.37
"To estimate the population pharmacokinetic parameters of cyclosporine in Korean adults undergoing living-donor kidney transplantation, and to identify clinical factors affecting cyclosporine pharmacokinetics."	( Population pharmacokinetics of cyclosporine in Korean adults undergoing living-donor kidney transplantation. Ji, E; Kang, W; Kim, IW; Kim, KI; Kim, MY; Kwon, KI; Lee, HS; Oh, JM; Shin, WG; Yun, HY, 2011)	0.37
" The effects of several clinical covariates on cyclosporine pharmacokinetic parameters were evaluated over 12 months after transplantation."	( Population pharmacokinetics of cyclosporine in Korean adults undergoing living-donor kidney transplantation. Ji, E; Kang, W; Kim, IW; Kim, KI; Kim, MY; Kwon, KI; Lee, HS; Oh, JM; Shin, WG; Yun, HY, 2011)	0.37
"This population pharmacokinetic model identified important sources of variability in cyclosporine pharmacokinetics."	( Population pharmacokinetics of cyclosporine in Korean adults undergoing living-donor kidney transplantation. Ji, E; Kang, W; Kim, IW; Kim, KI; Kim, MY; Kwon, KI; Lee, HS; Oh, JM; Shin, WG; Yun, HY, 2011)	0.37
"The purpose of this study was to characterize the pharmacokinetic (PK) properties of prednisolone, the metabolite of the prodrug prednisone, in cSLE patients and explore the relationship between PK properties and cSLE disease activity."	( Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. Brunner, HI; Rieder, MJ; Sagcal-Gironella, AC; Sherwin, CM; Tirona, RG; Vinks, AA, 2011)	0.92
" Dose-response data and pharmacokinetic data were used to calculate effective and safe clinical doses of paquinimod."	( Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in Axelsson, B; Bengtsson, AA; Leanderson, T; Lood, C; Ohman, MW; Rönnblom, L; Sparre, B; Sturfelt, G; Tuvesson, H; van Vollenhoven, RF, 2012)	0.38
" In patients with SLE, the pharmacokinetic properties of paquinimod were linear and well suitable for once-daily oral treatment."	( Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in Axelsson, B; Bengtsson, AA; Leanderson, T; Lood, C; Ohman, MW; Rönnblom, L; Sparre, B; Sturfelt, G; Tuvesson, H; van Vollenhoven, RF, 2012)	0.38
" Altered organ function, changing biochemistry and use of a number of concomitant medicines in transplantation appear to lead to pharmacokinetic differences in transplant recipients compared with other patient groups."	( Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. Barraclough, KA; Bergmann, TK; Lee, KJ; Staatz, CE, 2012)	0.63
" However, there is little information about the pharmacokinetic interaction of sorafenib."	( Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. Fujiyama, Y; Hira, D; Morita, SY; Noda, S; Shioya, M; Terada, T, 2013)	0.64
" The aims of this study were to evaluate the correlation between free serum and salivary PLN levels and to quantify this relationship within a population pharmacokinetic model."	( Monitoring prednisolone and prednisone in saliva: a population pharmacokinetic approach in healthy volunteers. Ackermans, MT; Freijer, J; Guan, Z; Kist-van Holthe, JE; Nauta, J; Ruiter, AF; Teeninga, N; van Gelder, T, 2013)	0.78
" Population pharmacokinetic analysis was performed with nonlinear mixed effect modeling using NONMEM."	( Monitoring prednisolone and prednisone in saliva: a population pharmacokinetic approach in healthy volunteers. Ackermans, MT; Freijer, J; Guan, Z; Kist-van Holthe, JE; Nauta, J; Ruiter, AF; Teeninga, N; van Gelder, T, 2013)	0.78
"This study is the first to describe the relationship between salivary and (free) serum PLN using a population pharmacokinetic model."	( Monitoring prednisolone and prednisone in saliva: a population pharmacokinetic approach in healthy volunteers. Ackermans, MT; Freijer, J; Guan, Z; Kist-van Holthe, JE; Nauta, J; Ruiter, AF; Teeninga, N; van Gelder, T, 2013)	0.78
" Some pharmacokinetic studies have demonstrated increased prednisolone exposure in patients on cyclosporine therapy compared with azathioprine, whereas other studies have found no difference."	( Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. Barraclough, KA; Bergmann, TK; Campbell, SB; Isbel, NM; McWhinney, BC; Staatz, CE, 2014)	0.87
"Adult male kidney transplant recipients treated with prednisolone and either cyclosporine or tacrolimus were recruited for pharmacokinetic blood sampling at the outpatient clinic at the Princess Alexandra Hospital, Brisbane, Australia."	( Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. Barraclough, KA; Bergmann, TK; Campbell, SB; Isbel, NM; McWhinney, BC; Staatz, CE, 2014)	0.88
" Pharmacokinetic parameters of prednisone or its pharmacologically active metabolite, prednisolone, are not well characterized in transplant recipients."	( Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitus. Akhlaghi, F; Gohh, RY; Ionita, IA; Ogasawara, K, 2014)	0.88
" PDC showed similar pharmacokinetic profile to PRED, but exhibited higher efficiency (1."	( L-Carnitine ester of prednisolone: pharmacokinetic and pharmacodynamic evaluation of a type I prodrug. Lim, LY; Mo, J; Zhang, ZR, 2014)	0.72
"The aim was to develop a theory-based population pharmacokinetic model of tacrolimus in adult kidney transplant recipients and to externally evaluate this model and two previous empirical models."	( Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Åsberg, A; Bergan, S; Bergmann, TK; Bremer, S; Hennig, S; Holford, N; Midtvedt, K; Staatz, CE; Størset, E, 2014)	0.4
"A theory-based population pharmacokinetic model was superior to two empirical models for prediction of tacrolimus concentrations and seemed suitable for Bayesian prediction of tacrolimus doses early after kidney transplantation."	( Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Åsberg, A; Bergan, S; Bergmann, TK; Bremer, S; Hennig, S; Holford, N; Midtvedt, K; Staatz, CE; Størset, E, 2014)	0.4
" Comparing pharmacokinetic data with MRI data it was observed that maximal blood levels occurred before the solvent and the dispersion agent were removed from the muscle tissue."	( Simultaneous magnetic resonance imaging and pharmacokinetic analysis of intramuscular depots. Evert, K; Hadlich, S; Kühn, JP; Oswald, S; Probst, M; Scheuch, E; Seidlitz, A; Siegmund, W; Weitschies, W, 2016)	0.43
" Pharmacokinetic parameters were analyzed in relation to relapse patterns and side effects."	( Population Pharmacokinetics of Prednisolone in Relation to Clinical Outcome in Children With Nephrotic Syndrome. Ackermans, MT; Guan, Z; Kist-van Holthe, JE; Nauta, J; Stevens, J; Teeninga, N; van der Heijden, AJ; van Gelder, T; van Schaik, RH, 2016)	0.72
" The purpose of this study was to develop a population pharmacokinetic model and investigate the influence of clinical factors on the pharmacokinetics of tacrolimus in adult Thai kidney transplant patients from routine data monitoring."	( Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. Avihingsanon, Y; Praisuwan, S; Techawathanawanna, N; Treyaprasert, W; Vadcharavivad, S, 2016)	0.43
" Clinical factors tested for influence on pharmacokinetic parameters were weight, haemoglobin, duration of tacrolimus therapy, prednisolone dose, serum albumin and estimated glomerular filtration rate."	( Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. Avihingsanon, Y; Praisuwan, S; Techawathanawanna, N; Treyaprasert, W; Vadcharavivad, S, 2016)	0.64
" The population pharmacokinetic equation that predicted CL/F of tacrolimus was CL/F = 21·5 × exp((-0·05 () (HB) ( - 11·8)))  × (DOT/125)(-0·06) , where CL/F was tacrolimus apparent oral clearance (L/h), HB was haemoglobin levels (g/dL), and DOT was duration of tacrolimus therapy (days)."	( Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. Avihingsanon, Y; Praisuwan, S; Techawathanawanna, N; Treyaprasert, W; Vadcharavivad, S, 2016)	0.43
"The first population pharmacokinetic model of tacrolimus in Thai adult kidney transplant patients was developed and validated."	( Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. Avihingsanon, Y; Praisuwan, S; Techawathanawanna, N; Treyaprasert, W; Vadcharavivad, S, 2016)	0.43
"This report summarizes phase 1 studies that evaluated pharmacokinetic interactions between the novel triazole antifungal agent isavuconazole and the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults."	( Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults. Akhtar, S; Desai, A; Groll, AH; Han, D; Howieson, C; Kato, K; Kowalski, D; Lademacher, C; Lewis, W; Mandarino, D; Pearlman, H; Townsend, R; Yamazaki, T, 2017)	0.85
" Conventional pharmacokinetic methods for immunosuppressive drug monitoring are not cell type-specific."	( Pharmacodynamic Monitoring of Tacrolimus-Based Immunosuppression in CD14+ Monocytes After Kidney Transplantation. Baan, CC; de Graav, GN; Dieterich, M; Hesselink, DA; Kannegieter, NM; Kraaijeveld, R; Leenen, PJM; Rowshani, AT, 2017)	0.46
" This inhibition can be determined by phospho-specific flow cytometry, which enables the assessment of the pharmacodynamic effects of immunosuppressive drugs in a cell type-specific manner."	( Pharmacodynamic Monitoring of Tacrolimus-Based Immunosuppression in CD14+ Monocytes After Kidney Transplantation. Baan, CC; de Graav, GN; Dieterich, M; Hesselink, DA; Kannegieter, NM; Kraaijeveld, R; Leenen, PJM; Rowshani, AT, 2017)	0.46
" In this study, the validity of these strategies was verified by investigating the plasma pharmacokinetic and urinary excretion profiles of relevant glucocorticoids in bovines, subjected to exogenous prednisolone treatment or tetracosactide hexaacetate administration to induce endogenous prednisolone formation."	( Pharmacokinetic and urinary profiling reveals the prednisolone/cortisol ratio as a valid biomarker for prednisolone administration. Croubels, S; De Clercq, N; Delahaut, P; Devreese, M; Fichant, E; Van Meulebroek, L; Vanden Bussche, J; Vanhaecke, L, 2017)	0.9
"To develop an objective, readily measurable pharmacodynamic biomarker of glucocorticoid (GC) activity."	( Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids. Bandyopadhyay, S; Carman, JA; Connolly, S; Fan, L; Furie, R; Goldstine, C; Holloway, D; Hu, Y; Johnsen, A; Kansal, S; Latek, R; Lee, D; Nadler, SG; Shadick, N; Somerville, JE; Townsend, R; Weinblatt, ME, 2018)	0.48
"The GC gene signature identified in this study represents a pharmacodynamic marker of GC exposure."	( Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids. Bandyopadhyay, S; Carman, JA; Connolly, S; Fan, L; Furie, R; Goldstine, C; Holloway, D; Hu, Y; Johnsen, A; Kansal, S; Latek, R; Lee, D; Nadler, SG; Shadick, N; Somerville, JE; Townsend, R; Weinblatt, ME, 2018)	0.48
" To take advantage of the predictive power of machine learning and the explanatory power of pharmacokinetics, we propose a latent variable mixture model for learning clusters of pharmacokinetic models demonstrated on a clinical data set investigating 11β-hydroxysteroid dehydrogenase enzymes (11β-HSD) activity in healthy adults."	( Learning pharmacokinetic models for in vivo glucocorticoid activation. Arlt, W; Bunte, K; Chappell, MJ; Hassan-Smith, ZK; Smith, DJ; Tiňo, P; Tomlinson, JW, 2018)	0.48
" The influence of hyperhydration on the plasma and urinary pharmacokinetic (PK) profiles of BDS and metabolites was also examined."	( Effect of hyperhydration on the pharmacokinetics and detection of orally administered budesonide in doping control analysis. Al-Maadheed, M; Athanasiadou, I; Dokoumetzidis, A; Georgakopoulos, C; Mbeloug, M; Saleh, A; Valsami, G; Vonaparti, A, 2019)	0.51
" The method was successfully applied to a preclinical pharmacokinetic (PK) study of the six GCs on female nude mice after a single oral dose of 1 mg/kg."	( Development and validation of a LC-MS/MS method for simultaneous determination of six glucocorticoids and its application to a pharmacokinetic study in nude mice. Guo, Y; Hao, C; Kong, D; Li, J; Tian, X; Xue, J; Yao, Q; Zhou, T, 2020)	0.56
" A population pharmacokinetic model was developed and post hoc area under the curve (AUC) was tested against treatment outcome parameters."	( Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response. Bierings, MB; de Haas, V; Kaspers, GJL; Mathôt, RAA; Pieters, R; Sassen, SDT; Te Loo, DMWW; Tissing, WJE; van den Bos, C; van der Sluis, IM; Zwaan, CM, 2021)	0.89
" This study was undertaken to characterize pharmacokinetic profiles of ipatasertib and its metabolite M1 (G-037720) and to understand the sources of variability."	( Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients. Chanu, P; Kotani, N; Sane, R; Wade, JR; Wang, N; Wilkins, J; Winkler, J; Yoshida, K, 2021)	0.62
" Despite various review articles having suggested the presence of pharmacokinetic interactions between MPA and steroids, definitive data have not yet been demonstrated."	( Clinical Evidence on the Purported Pharmacokinetic Interactions between Corticosteroids and Mycophenolic Acid. Kiang, T; Rong, Y, 2023)	0.91

Compound-Compound Interactions

JKB-122 as monotherapy or in combination with prednisolone may offer a viable approach to the treatment of AIH.

Excerpt	Reference	Relevance
"Twenty-one patients with myasthenia gravis underwent a course of plasma exchange combined with immunosuppressive therapy."	( Plasma-exchange combined with immunosuppressive therapy in myasthenia gravis. Allan, TL; Behan, PO; Burnett, AK; Haase, G; Shakir, RA; Simpson, JA, 1979)	0.26
"The dynamics of penicillin concentrations in the blood and lung tissue of animals with chronic experimental pneumonia after its repeated administration in combination with prednisolone was studied."	( [Penicillin distribution in the body of animals with experimental chronic pneumonia when administered repeatedly in combination with prednisolone]. Sazonov, VF, 1976)	0.65
" Using a rabbit model, the effects of trifluridine (F3TdR) on corneal edema and stromal disease were examined when combined with each of three immunosuppressive agents."	( Therapeutic response of herpes simplex virus-induced corneal edema to trifluridine in combination with immunosuppressive agents. O'Brien, WJ; Taylor, JL, 1991)	0.28
" We have characterized PCN or macrolides induced cytochromes P-450 by their specific ability to interact with macrolide derivatives and, using the cytochrome P-450 spectral binding assays, we have shown that some compounds, implicated in drug interaction with macrolides, interact preferentially with the same cytochromes."	( Specific drug binding to rat liver cytochrome P-450 isozymes induced by pregnenolone-16 alpha-carbonitrile and macrolide antibiotics. Implications for drug interactions. Delaforge, M; Sartori, E, 1990)	0.28
" The low toxicity combined with worthwhile remissions make this an attractive first-line option for elderly patients."	( Phase 2 study of mitozantrone in combination with chlorambucil and prednisolone for relapsed and refractory non-Hodgkins lymphoma. Cotter, FE; Jones, L; Lord, D; Newland, AC, )	0.37
" The best use of FK at low doses was in combination with CyA and Pred."	( Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Casavilla, A; Cemaj, S; Demetris, AJ; Ghalab, A; Imventarza, O; Mazzaferro, V; Okuda, K; Rhoe, BS; Todo, S; Ueda, Y, 1987)	0.27
"The dynamics of the immunological parameters was studied in 17 patients with multiple sclerosis (MS) who received prednisolone therapy in combination with plasmacytapheresis."	( [The dynamics of immunological indicators in the treatment of patients with multiple sclerosis with prednisolone combined with plasmapheresis]. Gannushkina, IV; Kir'iakov, VA; Neretin, VIa; Sapfirova, VA; Zhirnova, IG, 1988)	0.7
"A study of pirprofen (rengasil) combined with small doses of corticosteroids in 93 patients with rheumatoid arthritis during a double blind multicentre testing showed good and satisfactory therapeutic results in 60%."	( [Study of pirprofen (rengasil) combined with maintenance doses of corticosteroids in rheumatoid arthritis in a double-blind multicenter trial]. Alekberova, ZS; Kobaladze, SG; Pokryshkin, VI; Taletene, IP; Trofimova, TM, 1986)	0.27
"Fifty RA patients receiving prednisolone and prednisolone combined with retabolil were examined."	( [Experimental substantiation of the treatment of patients with rheumatoid arthritis with prednisolone and its combination with retabolil (clinico-experimental study)]. Bagirova, VV; Iaglinskiĭ, VA; Kriukov, AP, 1986)	0.79
" Hoe S 2922) in combination with the steroid prednicarbate (prednisolone 17-(ethylcarbonate)-21-propionate, Hoe 777) were used."	( [Treatment of impetiginized eczema with prednicarbate in combination with a quarternary ammonium salt]. Schäfer, V; Wölbling, RH, 1987)	0.52
" Our policy is to carry out an extended thymectomy combined with pre- and post-operative administration of prednisolone on alternate days."	( Favorable results of thymectomy combined with prednisolone alternate-day administration in myasthenia gravis. Baba, M; Obata, S; Saito, Y; Yamaguchi, Y, 1987)	0.74
"SA96 in combination with indomethacin or prednisolone was investigated for their effects on the adjuvant arthritis in Lewis rats."	( [Pharmacological studies of N-(2-mercapto-2-methylpropanoyl)-L-cysteine (SA96). V. Effects of SA96 in combination with indomethacin or prednisolone on adjuvant arthritis in rats]. Hayashi, M; Iso, T; Kasamatsu, S; Mibu, H; Nakata, K; Yamauchi, H, 1985)	0.74
" These effects, combined with the common use of cimetidine in clinical practice, make the risk of adverse drug interactions a relatively frequent risk in the clinical setting."	( Drug interactions involving cimetidine--mechanisms, documentation, implications. Greene, W, 1984)	0.27
" Prednisolone in combination with asathioprin (imuran) administered to CBA mice inhibited the GVHR."	( [Effect of prodigiosin and its combination with immunodepressants on the graft versus host reaction in mice]. Alekhin, EK; Shigaev, NI, 1983)	1.18
" The clinical picture was markedly mitigated by the early initiation of silybin therapy, in combination with penicillin and cortisone."	( [Treatment of Amanita phalloides poisoning with silybin in combination with penicillin and cortisone]. Egermann, G; Hofer, JF; Mach, K; Sommer, K, 1983)	0.27
"Anti-acetylcholine receptor antibody titres have been monitored in the sera of 19 myasthenic patients treated with plasma exchange combined with a three month period of immunosuppressive therapy."	( Anti-acetylcholine receptor antibody titres in the sera of myasthenia patients treated with plasma exchange combined with immunosuppressive therapy. Behan, PO; Carter, B; Harrison, R; Lunt, GG; Simpson, JA, 1980)	0.26
"In treatment of GO, 24 Gy of radiation is a more effective dose than 10 Gy when combined with systemic corticosteroids."	( Graves ophthalmopathy: MR evaluation of 10-Gy versus 24-Gy irradiation combined with systemic corticosteroids. Futami, S; Hoshi, H; Jinnouchi, S; Morita, M; Murakami, N; Nagamachi, S; Nakahara, H; Noguchi, S; Ohnishi, T; Tamaru, M, 1995)	0.29
"VCAP chemotherapy combined with natural interferon-alpha (HBLI) was performed on elderly patients over 65 year with multiple myeloma (MM), and its clinical effects were compared with those of VCAP chemotherapy without HLBI on elderly MM and also with those of HLBI-VCAP and VCAP combination therapy on non-elderly MM."	( [VCAP chemotherapy combined with interferon-alpha (HLBI) for elderly multiple myeloma]. Katoh, M; Niitsu, N; Shikoshi, K; Takata, M; Umeda, M, 1994)	0.29
" The type of interaction was different between patients, and depends on the drug combination and concentrations."	( Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Hählen, K; Kaspers, GJ; Pieters, R; Van Wering, ER; Van Zantwijk, I; Veerman, AJ, 1995)	0.29
" This pilot study examines the effect of donor bone marrow (DBM) infusion and antithymocyte serum (ATS) in combination with immunosuppressive drug therapy in prolonging renal allograft survival in dogs."	( Renal allograft survival in outbred mongrel dogs using rabbit anti-dog thymocyte serum in combination with immunosuppressive drug therapy with or without donor bone marrow. Atilola, M; Binnington, AG; Holmberg, DL; Johnston, K; Mathews, KA; Maxie, G; Miller, CM; Smith, G, )	0.13
", twice a day for 5 days) alone or in combination with prednisolone (2 mg."	( Suppression of renal scarring by prednisolone combined with ciprofloxacin in ascending pyelonephritis in rats. Haraoka, M; Kubo, S; Kumazawa, J; Matsumoto, T; Takahashi, K; Tanaka, M, 1994)	0.82
" This study examined whether AZA combined with standard prednisolone therapy improved the therapeutic outcome compared with monotherapy with prednisolone."	( Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Ewe, K; Hommel, G; Meyer zum Büschenfelde, KH; Press, AG; Singe, CC; Stufler, M; Ueberschaer, B, 1993)	0.83
" These results suggest that either salt of prednisolone, when combined with ciprofloxacin, reduces ocular inflammation without affecting the antimicrobial efficacy of the antibiotic."	( Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis. Callegan, MC; Engel, LS; Hill, JM; Hobden, JA; O'Callaghan, RJ, 1993)	1.99
"We carried out lymphocytapheresis (LCP) in combination with the administration of immunosuppressive drugs in patients with myasthenia gravis (MG), who were resistant to conventional immunosuppressive therapy, and examined its efficacy and effects on peripheral blood lymphocyte subsets."	( Lymphocytapheresis in combination with immunosuppressive drugs for refractory myasthenia gravis: two-color flow cytometric analysis of changes in peripheral blood lymphocyte subsets. Furutama, D; Makino, S; Nakajima, H; Ohsawa, N; Shinoda, K, 1995)	0.29
" In the present study, mature female rats were treated with prednisolone (Pred) or vehicle, in combination with ovariectomy (ovx), dietary calcium deficiency (LoCa), or right hind limb immobilization (IM)."	( Prednisolone alone, or in combination with estrogen or dietary calcium deficiency or immobilization, inhibits bone formation but does not induce bone loss in mature rats. Birchman, R; Dempster, DW; Liang, XG; Lindsay, R; Shen, V; Wu, DD, 1997)	1.98
" We conclude that the treatment with CPM combined with PSL may be useful, when neurological manifestations of MCTD are serious and resistant to conventional therapy."	( [A case of mixed connective tissue disease with lupus-like manifestations of the central nervous system, successfully treated with cyclophosphamide combined with prednisolone]. Iga, M; Kai, Y; Kuroki, M; Kuwata, G; Matsuyama, M; Murai, K; Okamoto, M; Okayama, A; Tanaka, G; Tsubouchi, H, 2000)	0.5
" Eighty-six patients were treated in combination with high-dose or pulsed corticosteroids and irradiation."	( Clinical outcomes of orbital irradiation combined with or without systemic high-dose or pulsed corticosteroids for Graves' ophthalmopathy. Abe, M; Fukada, S; Hagiwara, M; Hirota, S; Hishikawa, Y; Kono, M; Takada, Y; Tsujino, K, 2000)	0.31
"Orbital irradiation combined with high-dose or pulsed corticosteroids is an effective treatment for moderate to severe GO, especially in cases with major manifestations of soft-tissue signs, extraocular muscle impairment, or sight loss."	( Clinical outcomes of orbital irradiation combined with or without systemic high-dose or pulsed corticosteroids for Graves' ophthalmopathy. Abe, M; Fukada, S; Hagiwara, M; Hirota, S; Hishikawa, Y; Kono, M; Takada, Y; Tsujino, K, 2000)	0.31
"This study evaluated the effects of azathioprine in combination with low-dose prednisolone in the management of patients with intractable autoimmune hepatitis."	( Therapeutic effects of azathioprine in combination with low-dose prednisolone in patients with intractable autoimmune hepatitis type 1. Fujiwara, A; Miyake, Y; Miyashita, M; Nishimura, M; Sakaguchi, K; Takenami, T; Terao, M; Tsuji, T, 2001)	0.78
"Rituximab, a chimeric monoclonal antibody, produces response rates of up to 73% in patients with previously untreated indolent non-Hodgkin's lymphoma (NHL), and has high activity when combined with chemotherapy."	( Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. Christodoulou, C; Dimopoulos, M; Economopoulos, T; Fountzilas, G; Hamilos, G; Kalantzis, D; Nicolaides, C; Papageorgiou, E; Pavlidis, N, 2003)	0.32
" Considering these mechanisms of the reproductive failure generation by APLs, the application of immune suppressive therapy in combination with anti-coagulation therapy should be reconsidered as a treatment option."	( Effect of sairei-to combined with aspirin and prednisolone on four recurrent reproductive failure women who are positive for anti-phospholipid antibodies. Adachi, H; Ishii, K; Kurabayasi, T; Kurata, H; Natsume, N; Takaki, Y; Takakuwa, K; Tamura, M; Tanaka, K, 2003)	0.58
"To compare potency and efficacy of dexamethasone (DEXA) and prednisolone (PRED) in assumed equipotent doses in combination with endogenous cortisol, using lymphocyte counts, plasma osteocalcin (OC), and eosinophilic cationic protein (ECP) as effect variables and to evaluate potential differences between healthy subjects and asthmatic patients."	( Pharmacokinetic/pharmacodynamic modelling of effects of dexamethasone and prednisolone in combination with endogenous cortisol on lymphocyte counts and systemic markers of bone turn over and inflammation in healthy and asthmatic men. Dekhuijzen, PN; Derks, MG; Dubois, EF; Schweitzer, DH; van Boxtel, CJ; Zwinderman, AH, 2004)	0.8
"5 mg, respectively, on separate occasions, in combination with subcutaneously injected granulocyte-colony-stimulating factor (G-CSF) as a stimulant for ECP production."	( Pharmacokinetic/pharmacodynamic modelling of effects of dexamethasone and prednisolone in combination with endogenous cortisol on lymphocyte counts and systemic markers of bone turn over and inflammation in healthy and asthmatic men. Dekhuijzen, PN; Derks, MG; Dubois, EF; Schweitzer, DH; van Boxtel, CJ; Zwinderman, AH, 2004)	0.55
"In a double-blind manner, 149 patients were randomized to a 12-week treatment with FK778 in combination with tacrolimus (Tac) and corticosteroids (S)."	( The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Chang, R; Charpentier, B; Grinyó, JM; Jurewicz, A; Klinger, M; Kreis, H; Mourad, G; Neuhaus, P; Paczek, L; Paul, LC; Rostaing, L; Short, C; Squifflet, JP; van Hooff, JP; Vanrenterghem, Y; Wlodarczyk, Z, 2004)	0.32
" We present an asthmatic patient who developed primary bacterial peritonitis while receiving a leukotriene modulator in combination with prednisolone therapy."	( Leukotriene inhibitors in combination with steroids: potential role in the development of primary bacterial peritonitis. Ammori, BJ; Farooq, A, 2005)	0.53
"We report a case of IgA nephropathy with tuberculous pleurisy that was treated with steroid pulse therapy combined with tonsillectomy."	( [Steroid pulse therapy combined with tonsillectomy in a patient with IgA nephropathy complicated with tuberculous pleurisy]. Koike, K; Okuda, S; Sugawara, K; Takeda, K; Tamaki, K; Wakasugi, D, 2005)	0.33
"To report on visual acuity (VA) and angiographic outcomes in patients presenting with subfoveal choroidal neovascular membranes (CNV) secondary to punctate inner choroidopathy (PIC), treated with photodynamic therapy (PDT) with verteporfin combined with systemic corticosteroids."	( Photodynamic therapy combined with systemic corticosteroids for choroidal neovascularisation secondary to punctate inner choroidopathy. Amin, K; Fong, KC; Horgan, SE; Inzerillo, D; Thomas, D, 2008)	0.35
" All patients were treated with PDT combined with oral prednisolone (1 mg/kg body weight/day) which was started 5 days before PDT."	( Photodynamic therapy combined with systemic corticosteroids for choroidal neovascularisation secondary to punctate inner choroidopathy. Amin, K; Fong, KC; Horgan, SE; Inzerillo, D; Thomas, D, 2008)	0.59
"The vaso-occlusive effect of PDT combined with the vasostatic and anti-inflammatory effect of systemic oral prednisolone appears to be a safe and effective option in the primary treatment of subfoveal CNV in patients with PIC."	( Photodynamic therapy combined with systemic corticosteroids for choroidal neovascularisation secondary to punctate inner choroidopathy. Amin, K; Fong, KC; Horgan, SE; Inzerillo, D; Thomas, D, 2008)	0.56
" We report a case of primary MALT lymphoma of the bladder regressed after rituximab in combination with CHOP chemotherapy (R-CHOP)."	( [A case of primary mucosa-associated lymphoid tissue lymphoma of the bladder regressed after rituximab in combination with CHOP chemotherapy]. Hosomi, M; Itoh, K; Kakuta, Y; Katoh, T; Saitoh, J; Yazawa, K, 2006)	0.33
"3HCL, a potent inhibitor of P-glycoprotein (P-gp), when administered orally alone and in combination with the CHOP regimen in patients with untreated non-Hodgkin's lymphoma and to determine whether zosuquidar."	( Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Bouafia, F; Burgess, M; Dumontet, C; Morschhauser, F; Sloots, L; Zinzani, PL, 2007)	0.34
"To investigate the effects of short-term prednisolone ingestion combined with intense training on exercise performance, hormonal (adrenocorticotrophic hormone (ACTH), prolactin, luteinising hormone (LH), growth hormone (GH), thyroid-stimulating hormone (TSH), dehydroepiandrosterone (DHEA), testosterone, insulin) and metabolic parameters (blood glucose, lactate, bicarbonate, pH)."	( Short-term glucocorticoid intake combined with intense training on performance and hormonal responses. Arlettaz, A; Collomp, K; De Ceaurriz, J; Le Panse, B; Lecoq, AM; Portier, H; Rieth, N, 2008)	0.61
"To investigate the effects of vitamin K2 (Vit K2) alone or in combination with etidronate and risedronate on bone loss, osteoclast induction, and inflammation in patients with rheumatoid arthritis (RA)."	( Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K, 2008)	0.35
"Vit K2 alone or in combination with bisphosphonates for treatment of osteoporosis in patients with RA may inhibit osteoclast induction via decreases in levels of RANKL."	( Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K, 2008)	0.35
" MMF combined with prednisolone is an effective and well-tolerated induction treatment for patients with active lupus nephritis and for controlling SLE systemic activity."	( A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. F, L; H, W; H, Z; L, W; X, P; Y, T; Z, H; Z, S, 2008)	0.91
" Patients were randomly assigned to receive either 12 courses of the chemotherapy regimen CHVP (cyclophosphamide, adriamycin, etoposide, and prednisolone) plus interferon-alpha2a (CHVP+I arm) over 18 months or 6 courses of the same chemotherapy regimen combined with 6 infusions of 375 mg/m(2) rituximab and interferon for the same time period (R-CHVP+I arm)."	( Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Audhuy, B; Bouabdallah, R; Brice, P; Dartigeas, C; de Guibert, S; Doyen, C; Ferme, C; Feugier, P; Foussard, C; Haioun, C; Mahé, B; Morschhauser, F; Mounier, N; Rossi, JF; Salles, G; Sebban, C; Xerri, L, 2008)	0.55
" To assess drug-drug interactions, co-administration experiments were conducted with ketoconazole and either propranolol or erythromycin."	( Exploration of the African green monkey as a preclinical pharmacokinetic model: oral pharmacokinetic parameters and drug-drug interactions. Bhadresa, S; Coon, DJ; Lawrence, MS; Magiera, D; Struharik, M; Ward, KW, 2009)	0.35
" Here we delineate the in vitro metabolism and explore the potential for a drug-drug interaction between the active agents in CRx-102."	( Biotransformation and in vitro assessment of metabolism-associated drug-drug interaction for CRx-102, a novel combination drug candidate. Chen, J; Chen, M; Kansra, VV; Padval, MV; Zhang, ZY, 2009)	0.35
" We report a case of the patient with autoimmune pancreatitis combined with extensive involvement of extrahepatic and intrahepatic bile duct, which had a favorable response to steroid therapy."	( [A case of autoimmune pancreatitis combined with extensive involvement of biliary tract]. Baek, YH; Cho, JH; Choi, SR; Jung, CK; Lee, CM; Lee, SW; Roh, MH; Won, JJ, 2009)	0.35
" However, it is unknown if higher RDI in chemotherapy when combined with rituximab leads to a better outcome in aggressive B-cell lymphoma."	( Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. Aimoto, M; Aimoto, R; Hino, M; Inoue, E; Kanashima, H; Koh, H; Koh, KR; Mugitani, A; Nakamae, H; Nakane, T; Nakao, Y; Ohsawa, M; Ohta, K; Sakamoto, E; Takeoka, Y; Terada, Y; Teshima, H; Yamane, T, 2009)	0.35
"The objective of this study was to evaluate the efficacy and toxicity of docetaxel in combination with prednisolone in Japanese patients with hormone refractory prostate cancer."	( Docetaxel in combination with prednisolone for hormone refractory prostate cancer. Ide, H; Kikuchi, E; Kono, H; Miyajima, A; Nagata, H; Nakagawa, K; Nakashima, J; Ohigashi, T; Oya, M, 2010)	0.86
"To investigate the feasibility and efficacy of rituximab combined with high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation (ASCT) in patients with aggressive B-cell non-Hodgkin lymphoma (NHL)."	( [A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma]. Cen, XN; Chen, H; Han, MZ; Han, XH; He, XH; Huang, H; Huang, HQ; Jiang, WQ; Liu, P; Ma, J; Ren, HY; Shen, XM; Shi, YK; Wang, C; Wang, JM; Yang, S; Zhou, SY; Zhu, J, 2009)	0.35
" Here we report a similar case of SLE combined with CD in a 23-year-old girl who displayed systemic symptoms, including systemic lymphadenopathy and abnormal laboratory findings indicating the active phase of SLE."	( A case report of systemic lupus erythematosus combined with Castleman's disease and literature review. Chen, XY; Wang, HY; Xia, JY; Xu, F; Xue, J; Yang, Y, 2012)	0.38
"The effectiveness of steroid pulse therapy combined with tonsillectomy (ST) has been shown in immunoglobulin A nephropathy (IgAN) patients with moderate or severe urinary abnormalities."	( Clinical effectiveness of steroid pulse therapy combined with tonsillectomy in patients with immunoglobulin A nephropathy presenting glomerular haematuria and minimal proteinuria. Fukuhara, S; Gillespie, B; Hayashino, Y; Hotta, O; Ieiri, N; Kawaguchi, T; Miyazaki, M; Taguma, Y; Yamazaki, S, 2010)	0.36
" Imatinib mesylate, a recently introduced specific tyrosine kinase inhibitor of BCR-ABL, in combination with chemotherapy, resulted in more than 90% hematologic CR in adult Ph-positive ALL, including molecular CR in more than 50% of patients."	( Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy. Ohno, R, 2006)	0.33
"We compared the preventive effects of cyclosporine A combined with prednisolone and melatonin (Sigma-Aldrich) on damage to the contralateral testis after ipsilateral testicular torsion-detorsion between pubertal and adult rats."	( Preventive effects of cyclosporine a combined with prednisolone and melatonin on contralateral testicular damage after ipsilateral torsion-detorsion in pubertal and adult rats. Baek, M; Choi, H; Choi, WS; Chung, JS; Hong, SK; Jeong, SJ, 2010)	0.85
"The preventive effects of cyclosporine A combined with prednisolone on contralateral testicular damage were noted only in pubertal rats while the preventive effects of melatonin were noted in pubertal and adult rats."	( Preventive effects of cyclosporine a combined with prednisolone and melatonin on contralateral testicular damage after ipsilateral torsion-detorsion in pubertal and adult rats. Baek, M; Choi, H; Choi, WS; Chung, JS; Hong, SK; Jeong, SJ, 2010)	0.86
" We concluded that orbital MR imaging combined with CAS could improve the sensitivity of detection of active disease and the prediction of the response to ivGC."	( Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves' ophthalmopathy. Murakami, T; Nakashima, A; Noguchi, H; Noguchi, S; Noguchi, Y; Ohyabu, Y; Tachibana, S, 2010)	0.36
" Patients with previously untreated aggressive NHL were randomized to receive either eight cycles of (R)CHOP given every 3 wk or (R)CHOP combined with gemcitabine [Gem-(R)CHOP]."	( Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma--EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54). Aurer, I; Baila, L; Eghbali, H; Fortpied, C; Khaled, HM; Raemaekers, J; van der Maazen, RW, 2011)	0.37
" Here we report a phase II study of the THP-COP regimen combined with R (R-THP-COP) every 3 weeks."	( Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. Fukuno, K; Goto, H; Goto, N; Hara, T; Kanemura, N; Kasahara, S; Kitagawa, J; Moriwaki, H; Sawada, M; Takahashi, T; Takami, T; Tsurumi, H; Yamada, T; Yoshikawa, T, 2011)	0.59
"Evaluate costs and benefits of rituximab in combination with cyclophosphamide/vincristine/prednisolone chemotherapy regimen (R-CVP), in previously untreated patients with indolent non-Hodgkin lymphoma (NHL), compared to CVP alone from a Portuguese National Health System (NHS) perspective."	( [Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal]. Braga, P; Carvalho, S; Gomes, M; Guerra, L; Lúcio, P; Marques, H; Negreiro, F; Pereira, C; Silva, C; Teixeira, A, )	0.58
" In this cross-sectional study we show that MS patients treated with IFN-β alone or in combination with low-dose prednisolone displayed increased proportion of all NK cell subsets in the active phase of the cell cycle (Ki-67+)."	( Increase of Ki-67+ natural killer cells in multiple sclerosis patients treated with interferon-β and interferon-β combined with low-dose oral steroids. Aranami, T; Chihara, N; Gran, B; Lin, Y; Ogawa, M; Okamoto, T; Sanvito, L; Tomita, A; Yamamura, T, 2011)	0.58
" Some immunosuppressive drugs also interact with one another: cyclosporine raises the level of mTOR inhibitors and lowers the level of mycophenolate."	( [Drug interactions and immunosuppression in organ transplant recipients]. Amundsen, R; Asberg, A; Bergan, S; Midtvedt, K; Vethe, NT, 2011)	0.37
" Consequently, she was diagnosed with liver cirrhosis due to autoimmune hepatitis (AIH) combined with SSc."	( Liver cirrhosis due to autoimmune hepatitis combined with systemic sclerosis. Goo, SM; Jang, JY; Jeen, YM; Jeon, CH; Jeong, SW; Kim, SG; Kim, YS; You, BC, 2012)	0.38
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."	( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012)	0.38
" Drug-drug interactions (DDIs) involving OAAs pose a major concern in oncology practice due to these drugs' narrow therapeutic indices and potential for compromised efficacy and fatal adverse events."	( Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study. Chan, A; Ko, Y; Lim, SW; Ng, RC; Salim, A; Tan, SL; Wong, YP; Yong, WP, 2012)	0.38
" This report presents the case of a large PCL that was successfully treated by emergency surgical resection combined with postoperative chemotherapy."	( Successful treatment of a large primary cardiac lymphoma by surgical resection combined with chemotherapy: report of a case. Fukushima, S; Kawamura, T; Miyagawa, S; Nishi, H; Saito, S; Sakaguchi, T; Sawa, Y; Yamauchi, T; Yoshikawa, Y, 2013)	0.39
" Elevated serum tumor necrosis factor-α, interferon-γ, and IL-12 levels returned to normal 10 days after initiating plasma exchange combined with leukocytapheresis, with a reduction in white blood cell count."	( Successful remission induced by plasma exchange combined with leukocytapheresis against refractory systemic juvenile idiopathic arthritis. Abe, J; Fujimaru, T; Ito, S; Kamei, K; Miyazono, A; Ogura, M; Sato, M, 2014)	0.4
" Our study suggests that the MTD of idarubicin in combination with HD-MTX, VDS, and PRED, should be 16 mg/m(2) ."	( A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial. Brion, A; Chabin, M; Clavert, A; Colombat, P; Cumin, I; Delwail, V; Escoffre-Barbe, M; Gardembas, M; Ingrand, P; Lacotte-Thierry, L; Legouffe, E; Olivier, G; Solal-Celigny, P, 2014)	0.62
"The aim of this study was to evaluate the effect of treatment with methotrexate (MTX), by itself or combined with other non-biological disease-modifying antirheumatic drugs (DMARDs) (methotrexate, MTX with prednisolone, MTX with leflunomide, MTX with chloroquine, and MTX with sulfasalazine) on clinimetric outcomes in a retrospective cohort with a 6-month follow-up and under a Treat to Target (T2T) approach."	( Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study. Castro, C; de la Hoz-Valle, J; Palomino, A; Sánchez, G; Santos-Moreno, PI; Villarreal, L, 2015)	0.6
"The purpose of this study is to compare the efficacy and safety of Gefitinib versus VMP in combination with three-dimensional conformal radiotherapy (3D-CRT) for multiple brain metastases from non-small cell lung cancer (NSCLC)."	( Comparison of Gefitinib versus VMP in the combination with radiotherapy for multiple brain metastases from non-small cell lung cancer. Chen, S; Hao, Y; Li, B; Li, L; Liu, C; Ning, F; Wang, F; Yu, Z, 2015)	0.42
" Prednisolone combined with UDCA and azathioprine showed a higher efficacy based on our new criteria."	( Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis. Deng, YQ; Fang, YQ; Jia, W; Li, J; Lv, DX; Wang, GQ; Wang, Y; Yu, M, 2014)	1.63
" Although the patient declined surgery using an external approach, treatment with systemic corticosteroids combined with antibiotics resulted in tumor regression and an endoscopic en bloc resection was possible."	( Pre-operative effects of the administration of systemic corticosteroids combined with antibiotics on a lobular capillary hemangioma in the nasal cavity. Fujikawa, A; Hanazawa, T; Nakamura, H; Okamoto, Y; Yonekura, S, 2016)	0.43
"To investigate the clinical efficacy of L-asparginasum, ASP) combined with CHOP for treating patients with extranodal natural killer/T-cell lymphoma."	( [Clinical Efficacy of L-Asparaginasum Combined with CHOP for Treating Patients with Extranodal Natural Killer/T Cell Lymphoma]. Fang, RY; Ma, DL; Zhang, DF, 2015)	0.42
"A total of 68 patients with extranodal natural killer/T-cell lymphoma in our hospital from August 2007 to May 2009 were enrolled in this study, out of them 34 patients received CHOP regimen (CHOP group) and other 34 patients received CHOP regimen combined with L-Asparaginasum (ASP+CHOP group)."	( [Clinical Efficacy of L-Asparaginasum Combined with CHOP for Treating Patients with Extranodal Natural Killer/T Cell Lymphoma]. Fang, RY; Ma, DL; Zhang, DF, 2015)	0.42
"L-Asparaginasum combined with CHOP for treating patients with extranodal natural killer/T-cell lymphoma is effective, and may be used in clinic."	( [Clinical Efficacy of L-Asparaginasum Combined with CHOP for Treating Patients with Extranodal Natural Killer/T Cell Lymphoma]. Fang, RY; Ma, DL; Zhang, DF, 2015)	0.42
" This study aimed to assess the efficacy and toxicity of dose-adjusted CHOP alone or in combination with rituximab (R-CHOP) by examining the stem cell mobilization in NHL patients."	( Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma. Gui, L; Han, X; He, X; Liu, P; Qin, Y; Shi, Y; Yang, J; Yang, S; Yao, J; Zhang, C; Zhang, S; Zhao, L; Zhou, P; Zhou, S, 2015)	0.62
" Treatment protocols were a single-course steroid pulse combined with mizoribine during a period from August 2006 to June 2010 (Group A; n = 34) and a three-course steroid pulse during a period from July 2010 to March 2013 (Group B; n = 32)."	( Comparison of immunosuppressive therapies for IgA nephropathy after tonsillectomy: three-course versus one-course steroid pulse combined with mizoribine. Arai, M; Hirama, A; Ikeda, M; Kaneko, T; Morita, M; Shimizu, A; Tsuruoka, S; Watanabe, Y, 2015)	0.42
"Single-course steroid pulse therapy combined with mizoribine was considered to have a protective effect on the renal function in IgA nephropathy, especially accompanying renal dysfunction."	( Comparison of immunosuppressive therapies for IgA nephropathy after tonsillectomy: three-course versus one-course steroid pulse combined with mizoribine. Arai, M; Hirama, A; Ikeda, M; Kaneko, T; Morita, M; Shimizu, A; Tsuruoka, S; Watanabe, Y, 2015)	0.42
" We compared these findings with others obtained using cyclophosphamide (CPA) combined with low-dose CS: the current standard therapy for IPF."	( Cyclosporine A combined with low-dose corticosteroid treatment in patients with idiopathic pulmonary fibrosis. Azuma, A; Inase, N; Inoue, E; Kudoh, S; Miyazaki, Y; Ogura, T; Sugiyama, Y; Takeuchi, M; Taniguchi, H; Yoshizawa, Y, 2015)	0.42
"To analyze the effect of intensified topical steroid therapy after Descemet membrane endothelial keratoplasty combined with cataract surgery (triple-DMEK) on the incidence of postoperative cystoid macular edema (CME)."	( Intensified Topical Steroids as Prophylaxis for Macular Edema After Posterior Lamellar Keratoplasty Combined With Cataract Surgery. Bachmann, BO; Cursiefen, C; Felsch, M; Hoerster, R; Siebelmann, S; Stanzel, TP, 2016)	0.43
"To investigate the effect of intensified postoperative topical steroid therapy after Descemet membrane endothelial keratoplasty combined with cataract surgery (Triple-DMEK) on postoperative endothelial cell density (ECD)."	( Intensified Early Postoperative Topical Steroids Do Not Influence Endothelial Cell Density After Descemet Membrane Endothelial Keratoplasty Combined With Cataract Surgery (Triple-DMEK). Bachmann, BO; Cursiefen, C; Hoerster, R; Siebelmann, S; Stanzel, TP, 2016)	0.43
" We randomly assigned participants (1:1) to receive either oral prednisone alone, 1·0 or 1·5 mg/kg per day tapered over 12 or 18 months (prednisone alone group), or 1000 mg of intravenous rituximab on days 0 and 14, and 500 mg at months 12 and 18, combined with a short-term prednisone regimen, 0·5 or 1·0 mg/kg per day tapered over 3 or 6 months (rituximab plus short-term prednisone group)."	( First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Alexandre, M; Avenel-Audran, M; Bedane, C; Bénéton, N; Benichou, J; Bernard, P; Beylot-Barry, M; Bouaziz, JD; Caillot, F; Calbo, S; Caux, F; D'Incan, M; Debarbieux, S; Delaporte, E; Dereure, O; Dupin, N; Dupuy, A; Duvert-Lehembre, S; Golinski, ML; Hebert, V; Houivet, E; Ingen-Housz-Oro, S; Joly, P; Jullien, D; Labeille, B; Machet, L; Maho-Vaillant, M; Misery, L; Musette, P; Paul, C; Picard-Dahan, C; Prost-Squarcioni, C; Quereux, G; Richard, MA; Sassolas, B; Vabres, P; Vermeulin, T, 2017)	0.46
"The aim of this study was to compare asparaginase-related toxicities in two asparaginase preparations, namely native Escherichia coli L-asparaginase (L-ASP) and pegylated asparaginase (PEG-ASP) in combination with ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) in natural killer (NK)/T-cell lymphoma (NTCL)."	( Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type. Cho, YS; Heo, DS; Jung, SH; Keam, B; Kim, DW; Kim, HJ; Kim, IH; Kim, M; Kim, TM; Lee, JY; Lee, SH; Ock, CY, 2018)	0.86
" The results suggest that JKB-122 as monotherapy or in combination with prednisolone may offer a viable approach to the treatment of AIH."	( JKB-122 is effective, alone or in combination with prednisolone in Con A-induced hepatitis. Chiu, PJS; Hsu, MC; Hu, NY; Liu, SH; Shih, YC; Wang, CW; Wu, ESC, 2017)	0.94
" To investigate the effects of these compounds on bortezomib's anti-proliferative potency and its intracellular accumulation and potency to inhibit the chymotrypsin-like proteasomal subunit, seven myeloma cell lines were investigated after exposure to bortezomib alone or either combined with adriamycin plus dexamethasone (PAD regimen) or melphalan plus prednisolone (VMP regimen), respectively."	( Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro. Burhenne, J; Schäfer, J; Theile, D; Weiss, J, 2019)	0.68
"In this study we compared the anatomic and functional outcomes of two steroid treatments on rhegmatogenous retinal detachment (RRD) combined with choroidal detachment (CD), namely treatment with oral prednisolone (1 mg/kg daily) for 3-7 days before vitrectomy or a single periocular injection of methylprednisolone (40 mg) 1-3 days before vitrectomy."	( The effect of single periocular injection of methylprednisolone and drainage of suprachoroidal fluid in the treatment of rhegmatogenous retinal detachment combined with choroidal detachment. Chen, H; Chen, X; Wang, X; Wei, Y; Zhou, R, 2019)	0.95
" Seventy five eyes with RRD combined with CD were divided into 2 groups based on the two different treatment regimens as above."	( The effect of single periocular injection of methylprednisolone and drainage of suprachoroidal fluid in the treatment of rhegmatogenous retinal detachment combined with choroidal detachment. Chen, H; Chen, X; Wang, X; Wei, Y; Zhou, R, 2019)	0.77
"For RRD combined with CD, eyes treated with a single periocular injection of methylprednisolone (40 mg, 1-3 days before pars plana vitrectomy) combined with the drainage of suprachoroidal fluids during the surgery had similar anatomic and functional outcomes compared to the eyes treated with oral prednisolone for 3-7 days before vitrectomy."	( The effect of single periocular injection of methylprednisolone and drainage of suprachoroidal fluid in the treatment of rhegmatogenous retinal detachment combined with choroidal detachment. Chen, H; Chen, X; Wang, X; Wei, Y; Zhou, R, 2019)	0.99
" This study was designed to find out whether there is an augmentation of the therapeutic effectiveness of the antiinflammatory drugs like diclofenac sodium (NSAID), prednisolone (steroid) and atorvastatin (statin) when used in combination with ascorbic acid (antioxidant)."	( Evaluation of the Anti-Inflammatory Activities of Diclofenac Sodium, Prednisolone and Atorvastatin in Combination with Ascorbic Acid. Ahmed, T; Ahsan, CR; Al Shoyaib, A; Archie, SR; Chowdhury, FA; Faruk, A, 2020)	0.99
" The inhibitions of such responses were measured after administering a drug alone and in combination with ascorbic acid."	( Evaluation of the Anti-Inflammatory Activities of Diclofenac Sodium, Prednisolone and Atorvastatin in Combination with Ascorbic Acid. Ahmed, T; Ahsan, CR; Al Shoyaib, A; Archie, SR; Chowdhury, FA; Faruk, A, 2020)	0.79
" In stage II, Japanese patients with castration-resistant prostate cancer were administered ipatasertib 200 or 400 mg/day in combination with abiraterone and prednisolone in 28-day cycles."	( Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors. Doi, T; Endo-Tsukude, C; Fujiwara, Y; Iwasa, S; Matsubara, N; Nakagawa, S; Takahashi, S; Tanaka, A; Tomomatsu, J, 2019)	0.93
" The ipatasertib MTD was 600 mg as monotherapy and MAD was 400 mg in combination with abiraterone and prednisolone."	( Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors. Doi, T; Endo-Tsukude, C; Fujiwara, Y; Iwasa, S; Matsubara, N; Nakagawa, S; Takahashi, S; Tanaka, A; Tomomatsu, J, 2019)	0.95
"Ipatasertib, at the monotherapy MTD of 600 mg/day and MAD of 400 mg/day in combination with abiraterone and prednisolone, was safe and tolerable in Japanese patients with solid tumors."	( Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors. Doi, T; Endo-Tsukude, C; Fujiwara, Y; Iwasa, S; Matsubara, N; Nakagawa, S; Takahashi, S; Tanaka, A; Tomomatsu, J, 2019)	0.95
"To investigate the incidence and outcomes of cystoid macular edema (CME) after Descemet membrane endothelial keratoplasty (DMEK) alone and DMEK combined with cataract surgery (DMEK triple)."	( Incidence and Outcomes of Cystoid Macular Edema after Descemet Membrane Endothelial Keratoplasty (DMEK) and DMEK Combined with Cataract Surgery. Bae, SS; Ching, G; Covello, AT; Holland, S; Iovieno, A; McCarthy, M; Ritenour, R; Yeung, SN, 2021)	0.62
"From a total of 1,174 IgAN patients in a multicenter retrospective cohort analysis in Japan, 195 patients were treated by tonsillectomy combined with corticosteroid."	( Impact of the number of steroid pulses in tonsillectomy combined with steroid pulse therapy: a nationwide retrospective study in Japan. Hirano, K; Kataoka, H; Kawamura, T; Koike, K; Maruyama, S; Matsuo, S; Matsuzaki, K; Moriyama, T; Nitta, K; Suzuki, Y; Yasuda, T; Yasuda, Y; Yokoo, T, 2021)	0.62
" Prednisolone was tested alone and in combination with other drugs."	( Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice. Barkhouse, M; Dang, UJ; Giri, M; Gordish-Dressman, H; Hathout, Y; Hoffman, EP; Nagaraju, K; Uaesoontrachoon, K; Ziemba, M, 2021)	1.53
"A case of intractable IgG4-related orbital disease (IgG4-ROD) was successfully treated by debulking surgery combined with low-dose prednisolone and azathioprine as maintenance therapy."	( Debulking Surgery Combined with Low-Dose Oral Prednisolone and Azathioprine for Intractable IgG4-Related Orbital Disease: A Case Report. Chen, CH; Kuo, HH; Wu, SY, 2021)	1.08
" However, data regarding the therapeutic outcomes of oral steroid combined with oral NAC for ISSNHL are still limited."	( Effects of oral N-acetylcysteine combined with oral prednisolone on idiopathic sudden sensorineural hearing loss. Chen, SL; Chin, SC; Ho, CY, 2022)	0.97
"This study demonstrated the effect of oral steroid combined with oral NAC for ISSNHL."	( Effects of oral N-acetylcysteine combined with oral prednisolone on idiopathic sudden sensorineural hearing loss. Chen, SL; Chin, SC; Ho, CY, 2022)	0.97
" Seventy adults with severe SLE including lupus nephritis will be randomized 1:1 to receive either standard of care consisting of prednisolone and mycophenolate as induction and maintenance treatment, or belimumab and rituximab combined with standard of care as induction treatment, followed by prednisolone and belimumab as maintenance treatment."	( Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial. Arends, EJ; de Leeuw, K; Huizinga, TWJ; Limper, M; Rabelink, TJ; Rotmans, JI; Soonawala, D; Teng, YKO; Toes, REM; van Kooten, C; van Ommen, E; van Paassen, P; van Schaik, M, 2022)	0.93
" At present, the treatment norm for ELP has not well defined, and so the aim of this study is to evaluate the effect of bronchoalveolar lavage in combination with glucocorticoids on children with ELP."	( The effect of therapeutic bronchoalveolar lavage in combination with glucocorticoids on children with acute exogenous lipoid pneumonia. Chen, D; Chen, X; Huang, Z; Lin, Y; Lu, C; Wu, S; Xu, J; Xu, Q; Yang, S, 2023)	0.91
" Multiple bronchoalveolar lavages in combination with oral prednisolone for children who had a confirmed history of exogenous oily substances ingestion were an efficient and safe for the clearance of oily materials from the lung and the prevention of fibrosis."	( The effect of therapeutic bronchoalveolar lavage in combination with glucocorticoids on children with acute exogenous lipoid pneumonia. Chen, D; Chen, X; Huang, Z; Lin, Y; Lu, C; Wu, S; Xu, J; Xu, Q; Yang, S, 2023)	1.15
"Management of drug-drug interactions (DDIs) for ensitrelvir, a novel 3-chymotrypsin-like protease inhibitor of SARS-CoV-2 infection is crucial."	( Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults. Fukuhara, T; Kubota, R; Kuwata, A; Matsuo, Y; Matsuzaki, T; Shimizu, R; Sonoyama, T, 2023)	0.91
" Either dexamethasone, prednisolone, or midazolam was administered alone (Day - 2) or in combination with ensitrelvir (Day 5) in each of the cohorts."	( Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults. Fukuhara, T; Kubota, R; Kuwata, A; Matsuo, Y; Matsuzaki, T; Shimizu, R; Sonoyama, T, 2023)	1.22

Bioavailability

The results are consistent with the hypothesis that CsA increases the bioavailability of prednisolone. The plasma levels of the drug were determined by radioimmunoassay in six children receiving corticosteroids for nephrotic syndrome.

Excerpt	Reference	Relevance
" The decrease in ocular steroid bioavailability could not be directly equated with differences in antinflammatory effectiveness, so that the therapeutic relevance of the demonstrated drug interaction is not known."	( Drug interaction in the eye. Concurrent corticosteroid-antibiotic therapy for inflammatory keratitis. Kupferman, A; Leibowitz, HM, 1977)	0.26
" Butanol reduced the rate of absorption of sulfapyridine but did not significantly affect the absorption rates of prednisolone or salicylic acid."	( Effects of normal alcohols on intestinal absorption of salicylic acid, sulfapyridine, and prednisolone in rats. Hayton, WL, 1975)	0.69
" Breakfast given before prednisolone tended to reduce the rate of absorption of the drug, the effect being quantitatively most pronounced with large doses."	( Variation in plasma prednisolone concentrations in renal transplant recipients given enteric-coated prednisolone. Chakraborty, J; English, J; Henderson, RG; Marks, V; Wheatley, T, 1979)	0.89
" Prednisone is effectively absorbed and converted to its active therapeutic derivative, prednisolone, in healthy volunteers and in patients with liver disease; the bioavailability of oral prednisone approximates 100% of an intravenous dose and is comparable after administration of either prednisone or prednisolone."	( Corticosteroid pharmacokinetics in liver disease. Go, VL; Uribe, M, )	0.35
" The median value of bioavailability (relative to oral dose) of methylprednisolone acetate based on unchanged methylprednisolone plasma levels was 14."	( Rectal and oral absorption of methylprednisolone acetate. Albert, KS; Garg, DC; Sakmar, E; Wagner, JG; Weidler, DJ, 1979)	0.77
" The bioavailability of the CAP based preparation is similar to that of plain prednisolone."	( The effect of food and tablet formulation on plasma prednisolone levels following administration of enteric-coated tablets. James, VH; Lee, DA; Taylor, GM; Walker, JG, 1979)	0.74
" Dissolution parameters were correlated with results obtained in three human bioavailability trials which were previously reported."	( Comparison of two dissolution apparatuses with correlation of in vitro-in vivo data for prednisone and prednisolone tablets. Ayres, JW; Mackichan, JJ; Milsap, RL; Wagner, JG, )	0.35
" In patients, variability was similarly wide after both preparations, but overall bioavailability after both prednisone and prednisolone was similar to that found in controls, although three patients showed subnormal values after both preparations, possibly as a result of impaired intestinal absorption."	( Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability. Chakraborty, J; Davis, M; English, J; Ideo, G; Marks, V; Tempini, S; Williams, R, 1978)	0.83
" When premicellar concentrations of butyric, octanoic, or dodecanoic acid were present in the perfusate, the griseofulvin absorption rate decreased while that of prednisolone increased."	( Effects of short and medium chain fatty acids on absorption of lipophilic drugs from perfused rat intestine. Grisafe, JA; Hayton, WL, 1978)	0.45
"In order to assess the bioavailability of steroids from a high-viscosity gel, rabbit cornea and aqueous humor levels were measured over 12 hr following topical instillation of a gel and reference preparation."	( A bioavailability comparison in rabbits of two steroids formulated as high-viscosity gels and reference aqueous preparations. Boltralik, JJ; Schoenwald, RD, 1979)	0.26
" Factors that affect bioavailability among drugs of the same type (especially oral drugs) include not only disintegration and absorption rates but also the amount of food taken before or with the dose, interactions with other drugs, the physical state of the patient, and the "first-pass effect" upon drug with high liver clearance."	( Drug bioavailability studies. Wagner, JG, 1977)	0.26
" The area under the drug concentration in aqueous humor-vs-time curve (a measure of the drug's bioavailability in aqueous humor) was 88 mug min/ml, and its half-life in human aqueous humor was 28 minutes."	( Penetration of topically administered prednisolone acetate into the human aqueous humor. Alvarez, JA; Berrospi, AR; Galvis, V; Kupferman, A; Leibowitz, HM; Restropo, GV, 1977)	0.53
" Thus, no influence of cholestyramine on the bioavailability of orally administered prednisolone could be demonstrated."	( [Does cholestyramine impair the bioavailability of prednisolone?]. Audétat, V; Bircher, J; Paumgartner, G, 1977)	0.73
" It was shown that the CPB method has considerably greater precision than the RIA method and could be employed in bioavailability and pharmacokinetic studies of both prednisolone and prednisone."	( Plasma prednisolone concentrations: comparison of radioimmunoassay and competitive protein binding assay. Ayres, JW; Hallmark, MR; Sakmar, E; Tembo, AV; Wagner, JG, 1977)	0.91
" The bioavailability of the two preparations was similar."	( Plasma prednisolone levels in man following administration in plain and enteric-coated forms. May, CS; Paterson, JW; Wilson, CG, 1977)	0.71
" Intersubject variability in bioavailability was noted."	( Plasma prednisolone levels from enteric and non-enteric coated tablets estimated by an original technique. Bradbrook, ID; Morrison, PJ; Rogers, HJ, 1977)	0.71
"With a fasted dog as an animal model, the bioavailability and pharmacokinetics of prednisolone were studied following rapid intravenous injection and oral dosing of a prednisolone sodium phosphate solution and also following oral doses of prednisolone as tablets and a slurry."	( Prednisolone bioavailability in the dog. Tse, FL; Welling, PG, 1977)	1.93
"A three-way crossover bioavailability study was performed using nine adult male volunteers with three different commercial prednisone tablets."	( In vitro and in vivo availability of commercial prednisone tablets. Albert, KS; Blair, DC; Sakmar, E; Sullivan, TJ; Wagner, JG, 1975)	0.25
" A comparison of each drug's corneal bioavailability with its anti-inflammatory effectiveness shows the acetate derivative of prednisolone to be a more potent anti-inflammatory agent than the phosphate derivative."	( Anti-inflammatory effectiveness of topically administered corticosteroids in the cornea without epithelium. Kupferman, A; Leibowitz, HM, 1975)	0.46
" A considerable inter-patient variation in bioavailability after a standard dose of prednisolone (20 mg) was noted."	( Measurement of plasma prednisolone in man. May, CS; Paterson, JW; Ssendagire, R; Wilson, CG, 1975)	0.79
" Bioavailability averaged 88."	( Altered prednisolone pharmacokinetics in patients with cystic fibrosis. Accurso, FJ; Dove, AM; Hill, MR; Jusko, WJ; Larsen, GL; Szefler, SJ, 1992)	0.72
"The superior bioavailability and therapeutic effect of prednisolone acetate over prednisolone sodium phosphate was described about 15 years ago."	( The bioavailability and therapeutic effectiveness of prednisolone acetate vs. prednisolone sodium phosphate: a 20-year review. Sousa, FJ, 1991)	0.78
" The mean bioavailability was 14% for chlorambucil, 21% for phenylacetic acid mustard, and 22% for prednisolone, when given as prednimustine, compared to the administration of free compounds in stoichiometrically equivalent doses."	( Comparative pharmacokinetics of chlorambucil and prednimustine after oral administration. Loos, U; Malek, M; Musch, E; Riedel, E, 1991)	0.5
"Comparative corneal penetration studies in the literature with prednisolone sodium phosphate solution and prednisolone acetate suspension administered to rabbit eyes give conflicting results concerning the greater bioavailability of prednisolone acetate."	( Comparative corneal penetration of prednisolone sodium phosphate and prednisolone acetate in NZW rabbits. Bidgood, AM; Musson, DG; Olejnik, O, 1991)	0.8
"Prednisolone absorption and bioavailability of 10 mg enteric-coated (EC) and plain (uncoated) tablets were investigated after fasting and heavy meals (EC only) consumed to satiety in normal healthy volunteers."	( Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets. Al-Habet, SM; Rogers, HJ, 1989)	1.96
" Sulphasalazine itself is poorly absorbed (3 to 12%) and its elimination half-life of about 5 to 10 hours is probably affected by the absorption process."	( Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Klotz, U, )	0.13
"A randomized, four-way cross-over study was conducted in eight healthy male volunteers to determine the relative and absolute bioavailability of prednisone (PN) and prednisolone (PL)."	( Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. Bekersky, I; Colburn, WA; Ferry, JJ; Heath, EC; Horvath, AM; Ryan, CF, 1988)	0.72
" Such a process of absorption was different of that described for prednisolone acetate suspension for which rate of absorption was slower."	( [Pharmacokinetics of prednisolone administered to cows in the form of a prednisolone acetate solution in dimethyl sulfoxide in association with antibiotics]. Alvinerie, M; Oukessou, M; Toutain, PL, 1987)	0.83
"The absolute bioavailability of prednisolone was assessed in ten asthmatic patients who responded poorly to ordinary doses of corticosteroids so-called "steroid-resistant" bronchial asthma."	( Bioavailability of prednisolone in asthmatic patients with a poor response to steroid treatment. Grettve, L; Lindström, B; Lönnerholm, G; Mortimer, O; Zetterström, O, 1987)	0.88
", prolongation of half-life, and decreases in MCR and bioavailability on on-day of intermittent period were observed in comparison with those before treatment, respectively."	( [Pharmacokinetics of prednisolone (PSL) during PSL treatment. II. PSL pharmacokinetics during intermittent treatment with PSL administration 4 consecutive days a week]. Adachi, K; Fuwa, Y; Goshima, E; Minamori, Y; Miura, K; Murase, H; Murayama, M; Yamakita, N; Yasuda, K, 1987)	0.59
" Bioavailability of prednisolone after the oral administration of prednisone and methylprednisolone ranged from 86% to 104% during anticonvulsant therapy."	( Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. Bartoszek, M; Brenner, AM; Szefler, SJ, 1987)	2.04
" The enhanced rate of bioavailability of prednisolone after intramuscular administration in the form of a suspension may be due to the rapid dissolution of CyD complexes."	( Effects of beta- and gamma-cyclodextrins on the pharmacokinetic behavior of prednisolone after intravenous and intramuscular administrations to rabbits. Arimori, K; Uekama, K, 1987)	0.77
" Bioavailability was calculated by the ratio of AUCp."	( [Pharmacokinetics of prednisolone (PSL) during PSL treatment. I. PSL pharmacokinetics during daily PSL treatment]. Adachi, K; Fuwa, Y; Goshima, E; Minamori, Y; Miura, K; Murase, H; Murayama, M; Yamakita, N; Yasuda, K, 1986)	0.59
" While the parent steroids are well absorbed over the entire length of the intestinal tract, variability in plasma levels is observed at higher doses."	( Oral absorption of 21-corticosteroid esters: a function of aqueous stability and intestinal enzyme activity and distribution. Amidon, GL; Fleisher, D; Johnson, KC; Stewart, BH, 1986)	0.27
" The freely soluble succinate and phosphate esters were well absorbed in the jejunum."	( Uptake of prodrugs by rat intestinal mucosal cells: mechanism and pharmaceutical implications. Amidon, GL; Brabec, RK; Stewart, BH, 1986)	0.27
"The relative bioavailability of single oral doses of prednisone with and without sucralfate administration was determined in 12 healthy male volunteers."	( Lack of effect of sucralfate on prednisone bioavailability. Amend, WJ; Birnbaum, J; Gambertoglio, JG; Lizak, P; Romac, DR; Yong, CL, 1987)	0.27
" This indicates that in vitro data can be useful in predicting oral bioavailability of GCS."	( Effect of structural alterations on the biotransformation rate of glucocorticosteroids in rat and human liver. Andersson, P; Lihné, M; Ryrfeldt, A; Thalén, A, 1987)	0.27
" In view of the low plasma prednisolone concentrations obtained, there are theoretical advantages in using a poorly absorbed enema to avoid the possibility of systemic steroid effects in patients requiring long term steroid treatment."	( Therapeutic benefits from a poorly absorbed prednisolone enema in distal colitis. Berghouse, L; English, J; Lennard-Jones, JE; Macrae, FA; McIntyre, PB, 1985)	0.83
" Thus, the concomitant administration of azathioprine does not appear to alter the bioavailability or elimination of prednisolone at these doses."	( The absence of effect of azathioprine on prednisolone pharmacokinetics following maintenance prednisone doses in kidney transplant patients. Amend, WJ; Birnbaum, JL; Gambertoglio, JG; Holford, HG; Lizak, PS; Salvatierra, O, 1984)	0.74
" After prednisolone 21-sodium succinate (IM), absorption was rapid and bioavailability was high."	( Dexamethasone and prednisolone in the horse: pharmacokinetics and action on the adrenal gland. Alvinerie, M; Baggot, JD; Brandon, RA; de Pomyers, H; Toutain, PL, 1984)	1.06
" The bioavailability of prednisone in these patients exhibited a low intersubject variability, while the metabolic clearance rate of total and of unbound prednisolone varied considerably from patient to patient."	( Prednisolone clearance: a possible determinant for glucocorticoid efficacy in patients with oral vesiculo-erosive diseases. Benet, LZ; Frey, FJ; Lozada, F, 1983)	1.91
"The effect of intestinal malabsorption on the oral bioavailability of prednisolone has been studied in six patients with celiac disease and in six patients with malabsorption of various etiologies, five of whom had undergone gut resections."	( Bioavailability of prednisolone in patients with intestinal malabsorption: the importance of measuring serum protein-binding. Bergrem, H; Opedal, I, 1983)	0.83
" The elimination half-time and the extent of bioavailability of total prednisolone tended to be lower in the patients, and the extent of free, unbound prednisolone higher, but the differences were not statistically significant."	( Prednisolone pharmacokinetics and protein-binding in patients with portosystemic shunt. Bergan, A; Bergrem, H; Opedal, I; Ritland, S, 1983)	1.94
" There were marked differences in plasma prednisolone concentrations, clearance rates, and bioavailability of both free and total fractions at different times of the day."	( Diurnal variation in prednisolone kinetics. Dunne, M; English, J; Marks, V, 1983)	0.85
" This may be attributable to differences in steroid bioavailability to cells."	( Prednisolone levels in plasma and leukemia cells during therapy of chronic lymphocytic leukemia. Bird, CC; Child, JA; Panesar, NS; Roberts, BE, 1984)	1.71
" The absolute bioavailability of both corticosteroids was higher than 80% and independent of both dose levels investigated."	( The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. Haack, D; Kloss, G; Nieuweboer, B; Täuber, U; Vecsei, P; Wendt, H, 1984)	0.53
" Drug glycosides are hydrophilic and, thus, poorly absorbed from the small intestine."	( A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. Chang, GW; Friend, DR, 1984)	0.27
" The mean prednisolone bioavailability from oral prednisone was not different between nephrotic patients and controls."	( Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. Frey, BM; Frey, FJ, 1984)	0.95
" The results indicate that aluminium phosphate does not reduce the bioavailability of cimetidine and prednisolone."	( Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone. Albin, H; Bedjaoui, A; Begaud, B; Demotes-Mainard, F; Vincon, G, 1984)	0.72
" The bioavailability of prednisone, the interconversion of prednisone into prednisolone, the total and unbound prednisolone clearances, the prednisolone binding capacity of albumin and transcortin, and the affinity of albumin for prednisolone were not different when the 14 patients without cushingoid side effects were compared with the 13 cushingoid patients."	( Endogenous and exogenous glucocorticoids in cushingoid patients. Amend, WJ; Benet, LZ; Frey, BM; Frey, FJ; Lozada, F, 1982)	0.49
" These results suggest variable bioavailability of prednisolone, but do not indicate the reason."	( Variation in 17 oxogenic steroid excretion following oral prednisolone in children with lymphoblastic leukaemia. French, AJ; Lilleyman, JS; Young, IP, 1981)	0.76
"The pharmacokinetics and bioavailability of prednisolone after doses of oral prednisone and intravenous prednisolone were determined in seven patients receiving corticosteroids for treatment of inflammatory bowel disease in active disease and remission."	( Effect of inflammatory bowel disease on absorption and disposition of prednisolone. George, DE; Jusko, WJ; Lebenthal, E; Milsap, RL; Murray, KA; Szefler, SJ, 1983)	0.76
" The bioavailability after oral administration was 84."	( Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration. Bergrem, H; Grøttum, P; Rugstad, HE, 1983)	0.53
" A crossover bioavailability study was performed using human subjects with lower doses of prednisolone tablets, where the plasma levels of the drug were determined by radioimmunoassay."	( Improvement of oral bioavailability of prednisolone by beta-cyclodextrin complexation in humans. Arimori, K; Fujinaga, T; Matsuo, N; Otagiri, M; Sugii, A; Tasaki, K; Uekama, K; Uemura, Y, 1983)	0.76
" Because of the marked reduction in the extent of bioavailability of total, and especially free, prednisolone, dosage adjustments should be made accordingly if prednisolone and rifampicin are prescribed concomitantly."	( Changes in prednisolone pharmacokinetics and protein binding during treatment with rifampicin. Bergrem, H; Refvem, OK, 1983)	0.87
" The maximum serum concentration of prednisolone was higher, (mean Cmax; fasting: 597 +/- 101 ng/ml, non-fasting: Cmax 489 +/- 56 ng/ml) and the rate of absorption more rapid in the fasting than in the non-fasting subjects (absorption t1/2 fasting: 15."	( Immunosuppressive treatment policies. A) Glucocorticoids: absorption of prednisolone. I. The effect of fasting, food, and food combined with antacids. Bergrem, H; Djøseland, O; Jervell, J; Rugstad, HE, 1981)	0.77
"Limited information is available on the pharmacokinetics and bioavailability of prednisone and prednisolone in patients with different disease states."	( Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review. Amend, WJ; Benet, LZ; Gambertoglio, JG, 1980)	0.73
"Prednisone and prednisolone are drugs with the potential for therapeutic inequivalence due to bioavailability problems."	( Prednisone and prednisolone bioavailability in renal transplant patients. Amend, WJ; Birnbaum, JL; Feduska, NJ; Frey, FJ; Gambertoglio, JG; Holford, NH; Lizak, PS; Salvatierra, O; Vincenti, F, 1982)	0.97
"To assess the relative bioavailability of a recently developed liquid prednisone preparation, prednisolone pharmacokinetics were evaluated after the administration of three separate steroid preparations."	( Bioavailability assessment of a liquid prednisone preparation. Flesher, KA; Georgitis, JW; Szefler, SJ, 1982)	0.48
" Distribution, elimination and other bioavailability parameters were calculated from the obtained data."	( [Pharmacokinetics of prednisolone in adrenal insufficiency ]. Benker, G; Hackenberg, K; Reinwein, D; von Papen, C, 1982)	0.58
"The pharmacokinetics and bioavailability of prednisolone and prednisone after doses of 60 mg/m2 oral prednisone and 50 mg/m2 intravenous prednisolone were determined in six children receiving corticosteroids for treatment of nephrotic syndrome during active disease and in remission."	( Effect on nephrotic syndrome on absorption and disposition of prednisolone in children. Appiani, AC; Assael, BM; Edefonti, A; Jusko, WJ; Rocci, ML, 1982)	0.77
" Three poorly controlled patients were studied on a high-dose alternate-day steroid regimen, and a marked decrease in pyridostigmine bioavailability on the same dose of drug was observed in all three."	( Plasma pyridostigmine levels in myasthenia gravis. De Silva, P; Havard, CW; White, MC, 1981)	0.26
" It is suggested that prednisolone plasma levels are as good a parameter of Prednimustine absorption and bioavailability as chlorambucil levels, Prednimustine itself having never been detected in plasma."	( Prednisolone plasma levels after oral administration of Prednimustine. Comparison with levels obtained after administration of an equimolar dose of prednisolone. Hove, WV; Sayed, A; Vermeulen, A, 1981)	2.02
" Sodium cromoglycate and nedocromil sodium, which are poorly absorbed from the gastrointestinal tract, were tested by intraperitoneal administration."	( LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity. Bonhomme, Y; Brown, T; Murray, N; Zoerkler, N, 1994)	0.29
"The pharmacokinetics of prednisone and prednisolone was examined in 12 healthy male subjects to assess the bioavailability and the parameters of reversible metabolism between the two steroids."	( Bioavailability and reversible metabolism of prednisone and prednisolone in man. Garg, V; Jusko, WJ, 1994)	0.8
" Budesonide is a potent, well-absorbed corticosteroid, but because of a high rate of first-pass metabolism in the liver, its systemic bioavailability is low."	( A comparison of budesonide with prednisolone for active Crohn's disease. Danielsson, A; Goebell, H; Jewell, D; Lamers, C; Löfberg, R; Lorenz-Meyer, H; Malchow, H; Olaison, G; Rutgeerts, P; Thomsen, OO, 1994)	0.57
" The low systemic bioavailability after dermal application was also reflected in an unchanged cortisol secretion pattern."	( Studies on the pharmacokinetics and metabolism of prednicarbate after cutaneous and oral administration. Barth, J; Derendorf, H; Hochhaus, G; Höhler, T; Lehr, KH; Möllmann, HW, 1993)	0.29
"), the bioavailability (0."	( Metabolism of prednisone in kidney transplanted patients with necrosis of the femoral head. Egfjord, M; Lausten, GS; Olgaard, K, 1993)	0.29
" The bioavailability and volume of distribution of prednisolone were unaffected by menopausal status."	( The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Benet, LZ; Harris, RZ; Mroczkowski, P; Tsunoda, SM; Wong, H, 1996)	0.79
"01), and the relative bioavailability of the prednisolone liquid using prednisone liquid as the reference standard was 116 +/- 14%."	( A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. Kamada, AK; LaVallee, NM; Scott, MB; Selner, JC; Szefler, SJ; Wiener, MB, )	0.39
"The freeze-dried ternary formulations of meclizine (MZ, an anti-motion sickness drug), prednisolone (PRED, an anti-inflammatory drug) and norfloxacin (NFLX, an anti-microbial drug) which are poorly water-soluble and are low bioavailability drugs, were prepared using egg albumin and olive oil."	( Pharmaceutical properties of freeze-dried formulations of egg albumin, several drugs and olive oil. Kakegawa, H; Matsumoto, H; Miyataka, H; Nishiki, M; Satoh, T; Tsuji, Y, 1996)	0.52
" Budesonide is a topically acting corticosteroid with low systemic bioavailability and is efficacious in the treatment of inflammatory bowel disease."	( Suppression of intestinal mucosal natural killer cells by corticosteroids. Griffioen, G; Lamers, CB; Mieremet-Ooms, MA; Van der Zon, JM; Van Hogezand, RA; Van Ierssel, AJ; Verspaget, HW, 1997)	0.3
" The lower variability of trough levels and the higher L/D ratio in the CyE group, which are related ti improved bioavailability of CyE, may explain the lower rejection rate among these patients."	( Comparison of Neoral and Sandimmun for induction and maintenance immunosuppression after kidney transplantation. Haberal, M; Karakayali, H; Moray, G; Senel, FM; Yildirim, S, 1997)	0.3
" Budesonide is a potent corticosteroid with low systemic bioavailability due to an extensive first pass liver metabolism."	( Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Campieri, M; Doe, W; Ferguson, A; Nilsson, LG; Persson, T, 1997)	0.56
" In April 1995, the microemulsion-based formulation of cyclosporin (Neoral) was introduced based on its increased bioavailability at 'no extra cost'."	( Neoral--new cyclosporin for old? Scott, DG; Somerville, MF, 1997)	0.3
" Our previous study on paediatric patients showed that Neoral (a new microemulsion formulation) had better bioavailability than CsA capsules."	( Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Chen, WP; Fu, LW; Lin, CY; Yang, LY, 1998)	0.3
"4) were prepared by the enzymatic hydrolysis of casein, and their effects on in vitro dissolution rates and oral bioavailability of drugs were evaluated."	( Casein hydrolysate as a rapid and/or enteric dissolving additive for oral drugs. Imai, T; Nishiyama, T; Otagiri, M; Shameem, M, 1998)	0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
"The relative bioavailability of different prednisolone (CAS 50-24-8) tablet formulations (Prednisolon Ferring 2, 5, and 20 mg) was investigated in comparison to a reference formulation."	( Bioequivalence of different prednisolone tablet formulations. Benöhr, P; Luippold, G; Marto, M; Mühlbauer, B; Schneider, S, 2001)	0.87
" The results of these studies indicate that prednisone has poor efficacy for the treatment of heaves because it is poorly absorbed and the active metabolite prednisolone is rarely produced."	( Prednisone per os is likely to have limited efficacy in horses. Kollias-Baker, C; Peroni, DL; Robinson, NE; Stanley, S, 2002)	0.51
"When topical controlled delivery of ophthalmic drugs is realised via erodible inserts, drug bioavailability is maximised, if release is controlled exclusively by insert erosion, since parallel mechanisms which increase the release rate, also increases the dose fraction cleared from the precorneal area by tear fluid draining."	( A study of release mechanisms of different ophthalmic drugs from erodible ocular inserts based on poly(ethylene oxide). Di Colo, G; Zambito, Y, 2002)	0.31
" Transdermal delivery provided equivalent to or higher bioavailability (drug distribution) to the eyeball of topical administration."	( Drug delivery to the eye with a transdermal therapeutic system. Isowaki, A; Matsuo, Y; Ohtori, A; Tojo, K, 2003)	0.32
"Predocol is an oral preparation of a poorly absorbed salt of prednisolone that is effective in reducing inflammation over short treatment periods in patients with active ulcerative colitis."	( Oral prednisolone metasulphobenzoate in the treatment of active ulcerative colitis. Balan, K; Binnie, JA; Cameron, EA; Middleton, SJ; Skerratt, SA; Solanki, C; Swift, A, 2003)	1.07
"Budesonide is a corticosteroid with low systemic bioavailability because of its high first-pass metabolism in the liver."	( Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Escher, JC, 2004)	0.66
" The bioavailability is nearly 100% after oral application, and the main metabolites are 4-hydroxytrofosfamide, and 4-hydroxyifosfamide."	( Hypersensitivity pneumonitis associated with the use of trofosfamide. Hartmann, JT; Kanz, L; Kopp, HG, 2004)	0.32
"Cyclosporine A (CsA) is characterized by high interindividual variations in oral bioavailability and a narrow therapeutic index."	( MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Bonhomme-Faivre, L; Chatled, S; Devocelle, A; Farinotti, R; Maccario, J; Picard, V; Saliba, F, 2004)	0.32
" Prednisolone bioavailability was measured using a limited 6-hour area under the curve (AUC), with prednisolone measured using specific HPLC assay."	( Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population. Hickman, PE; McWhinney, BC; Potter, JM; Sampson, L, 2004)	1.51
"The results are consistent with the hypothesis that CsA increases the bioavailability of prednisolone, most likely through inhibition of P-glycoprotein."	( Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population. Hickman, PE; McWhinney, BC; Potter, JM; Sampson, L, 2004)	0.82
"A population pharmacokinetic analysis of cyclosporine (CsA) was performed, and the influence of covariates on CsA oral clearance and relative bioavailability was investigated."	( Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Akhlaghi, F; Baheti, G; Rosenbaum, SE; Trull, AK, 2005)	0.33
" The area under the concentration-time course of Dx was significantly lower than that using Antiserum-II and the total body clearance values were significantly higher, while an obvious change of bioavailability was not observed."	( Pharmacokinetic interaction with digoxin and glucocorticoids in rats detected by radio-immunoassay using a novel specific antiserum. Fujii, Y; Higashi, Y; Ikeda, Y; Yamamoto, R; Yamashiro, M, 2005)	0.33
" In this study, we assessed the cutaneous bioavailability of topically applied maxacalcitol ointment in vivo by tape stripping."	( In vivo assessment of the cutaneous bioavailability of topically applied maxacalcitol. Hirata, K; Ikeda, Y; Kano, S; Kondo, K; Takahara, J; Umemura, K; Yanagihara, H, 2005)	0.33
" The mean bioavailability of oral etoposide was 58+/-15% with an interpatient variability of 26%."	( Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. Ehninger, G; Friedrichsen, K; Haenel, M; Kroschinsky, FP; Mueller, J; Prondzinsky, R; Pursche, S; Schleyer, E, 2008)	0.35
" The effect of particle size in the micron and nano-size ranges as well as the effect of viscosity of the nanosuspension on the ocular bioavailability was studied by measuring the intraocular pressure of normotensive Albino rabbits using shiØetz tonometer."	( Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Abdel Rahman, AA; Ahmed, MB; Ghorab, MM; Kassem, MA; Khalil, RM, 2007)	0.34
"Patients with juvenile DM and ERL loss may have decreased bioavailability of OP compared with IVMP."	( Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Daru, JA; Gursahaney, A; Ngai, KL; Pachman, LM; Rouster-Stevens, KA, 2008)	0.63
" Whereas systemic exposure to budesonide was markedly lower in healthy subjects after the mouthwash compared to oral dosing (mean relative bioavailability 18%-36%), the systemic concentrations thereafter in patients were as high as those after the identical dose of oral budesonide."	( Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. Bertz, H; Dilger, K; Finke, J; Gratwohl, A; Halter, J; Lopez-Lazaro, L, 2009)	0.35
" Selected compounds were further evaluated for their oral anti-histaminic activity in mice and bioavailability in rats."	( Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Isobe, Y; Kubota, K; Kurebayashi, H; Miyachi, H; Onishi, M; Tobe, M, 2009)	0.35
"The results support our hypothesis that CD improves bioavailability of drugs to the synovial joints."	( "ChilDrive": a technique of combining regional cutaneous hypothermia with iontophoresis for the delivery of drugs to synovial fluid. Murthy, SN; Sammeta, SM, 2009)	0.35
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" Gatifloxacin showed better bioavailability and sustained action in aqueous humor and corneal tissue from the nanoparticles compared to the commercial eye drops."	( Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. El-Leithy, IS; Ibrahim, HK; Makky, AA, 2010)	0.58
" To show the importance of physicochemical properties, the classic QSAR and CoMFA of neonicotinoids and prediction of bioavailability of pesticides in terms of membrane permeability in comparison with drugs are described."	( Importance of physicochemical properties for the design of new pesticides. Akamatsu, M, 2011)	0.37
" In addition to their drug targeting application and their ability to improve bioavailability of drugs, nanoparticles can be designed to allow their detection with a variety of imaging methodologies."	( Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. Calcagno, C; Dijk, WJ; Fayad, ZA; Gianella, A; Griffioen, AW; Jarzyna, PA; Kann, B; Mani, V; Mulder, WJ; Ramachandran, S; Storm, G; Tang, J; Thijssen, VL, 2011)	0.37
" It is used frequently in children with croup and bacterial meningitis, and is well absorbed orally."	( Single dose oral dexamethasone versus multi-dose prednisolone in the treatment of acute exacerbations of asthma in children who attend the emergency department: study protocol for a randomized controlled trial. An Fhailí, SN; Crispino-O'Connell, G; Cronin, J; Hayden, J; Kennedy, U; McCoy, S; O'Sullivan, R; Wakai, A; Walsh, S, 2012)	0.63
" Findings suggest low comparative bioavailability of oral prednisone compared to prednisolone in cats and consideration of lean body mass or ideal body weight for dosing practices."	( Influence of body condition on plasma prednisolone and prednisone concentrations in clinically healthy cats after single oral dose administration. Center, SA; Randolph, JF; Rishniw, M; Simpson, KW; Warner, KL, 2013)	0.89
"42 h (dogs), and bioavailability of 74."	( VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Damsker, JM; Hoffman, EP; McCall, JM; Nagaraju, K; Reeves, EKM, 2013)	0.39
" Ocular irritation, bioavailability and anti-inflammatory effects were evaluated and compared with the conventional suspension and solution eye drops."	( Preparation, characterization and evaluation of novel elastic nano-sized niosomes (ethoniosomes) for ocular delivery of prednisolone. Abdallah, OY; Abdelkader, H; Farid, RM; Gaafar, PM, 2014)	0.61
" In vivo data of buccal film show greater bioavailability (AUC0-α: 24."	( Buccal films of prednisolone with enhanced bioavailability. Goomber, G; Gupta, S; Kumria, R; Nair, AB, 2016)	0.78
" Tacrolimus clearance was 30% higher (95% CI 13, 46%) and bioavailability 18% lower (95% CI 2, 29%) in CYP3A5 expressers compared with non-expressers."	( Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Åsberg, A; Bergan, S; Bergmann, TK; Bremer, S; Hennig, S; Holford, N; Midtvedt, K; Staatz, CE; Størset, E, 2014)	0.4
" Compound 13d, having good in vitro ADME profile and moderate oral bioavailability in mice, showed potent anti-inflammatory activity against hapten-induced contact hypersensitivity reaction in mice following topical and oral administration."	( Synthesis and biological evaluation of novel orally available 1-phenyl-6-aminouracils containing dimethyldihydrobenzofuranol structure for the treatment of allergic skin diseases. Fujiwara, N; Hasegawa, F; Inoue, Y; Isobe, M; Isobe, Y; Tobe, M; Tsuboi, K, 2016)	0.43
"The developed SMEDDS are a feasible option to conventional eye drops for its capability to improve bioavailability via its longer precorneal residence time and its capacity to sustain the release of the drug."	( Ocular Self-Microemulsifying Drug Delivery System of Prednisolone Improves Therapeutic Effectiveness in the Treatment of Experimental Uveitis. Dubey, V; Kesavan, K; Tiwari, R, 2019)	0.76
"We found that formulation did not influence bioavailability and that use of >20 mg prednisolone daily increased everolimus clearance."	( A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. Burger, DM; de Fijter, JW; Guchelaar, HJ; Moes, DJAR; Reinders, MEJ; Ter Heine, R; van Erp, NP; van Herpen, CM, 2018)	0.71
"Budesonide with multi-matrix technology (MMX) is an oral corticosteroid, shown to have high topical activity against ulcerative colitis (UC) while maintaining low systemic bioavailability with few adverse events."	( Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands. Ghatnekar, O; Gherardi, A; Kuijvenhoven, J; Roze, S; Yip Sonderegger, YL, 2018)	0.48
"It can be stated that the innovative PR-containing compositions are suitable for producing mucoadhesive, properly preserved aqueous ophthalmic solutions with increased bioavailability attributes."	( Development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer. Aigner, Z; Bíró, T; Budai-Szűcs, M; Csányi, E; Csóka, I; Facskó, A; Horvát, G; Szabó-Révész, P; Urbán, E, 2018)	0.83
" Thus, IGFBP-4 may modulate IGF bioavailability in IBD."	( The IGF system in patients with inflammatory bowel disease treated with prednisolone or infliximab: potential role of the stanniocalcin-2 / PAPP-A / IGFBP-4 axis. Agnholt, J; Frystyk, J; Hjortebjerg, R; Thomsen, KL, 2019)	0.75
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"We combined PD with curcumin (CU), an effective monomer from traditional Chinese medicine, and human serum albumin (HSA) in a nanoparticulate system (N-PD/CU) to compensate for the poor bioavailability of PD and CU."	( Co-Delivery of Prednisolone and Curcumin in Human Serum Albumin Nanoparticles for Effective Treatment of Rheumatoid Arthritis. Li, C; Li, H; Lin, Y; Tang, C; Yan, F; Zhong, Z; Zhou, M, 2019)	0.87
" Oral dexamethasone demonstrates bioavailability similar to that of oral prednisolone but has a longer half-life."	( Two regimens of dexamethasone versus prednisolone for acute exacerbations in asthmatic Egyptian children. Elazab, GA; Elkharwili, DA; Elrifaey, SM; Ibrahim, OM, 2020)	1.06
" To overcome limitations in the bioavailability of Curcumin, the therapeutic effect of oral Nano-Curcumin was evaluated for the first time."	( Comparison of oral Nano-Curcumin with oral prednisolone on oral lichen planus: a randomized double-blinded clinical trial. Basirat, M; Kia, SJ; Moosavi, MS; Mortezaie, T, 2020)	0.82
" In comparison with previous studies, current results clarify the importance of Nano-Curcumin bioavailability in therapeutic effects."	( Comparison of oral Nano-Curcumin with oral prednisolone on oral lichen planus: a randomized double-blinded clinical trial. Basirat, M; Kia, SJ; Moosavi, MS; Mortezaie, T, 2020)	0.82
"The results of this work indicate a good strategy for the selection of mucoadhesive polymers for SLP-based tablets in improving the bioavailability of poorly water-soluble drugs."	( Effects of Mucoadhesive Polymers on Released Particles and Drug Release in Solid Lipid Particle-Based Buccal Tablets. Phan, TTH; Tran, PHL; Tran, TTD, 2021)	0.62
" Ipatasertib bioavailability and M1 formation increased after multiple dosing, resulting in an increase in exposure beyond that expected from accumulation alone."	( Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients. Chanu, P; Kotani, N; Sane, R; Wade, JR; Wang, N; Wilkins, J; Winkler, J; Yoshida, K, 2021)	0.62
" Predictably, the excretion trend of the analytes of interest were generally comparable with those obtained after oral administration, even if the excretion profile showed a broad interindividual variability, with the absorption rate and the systemic bioavailability after rectal administration being strongly influenced by the type of formulations (suppository or rectal cream, in our case) as well as the physiological conditions of the absorption area."	( Urinary excretion profile of prednisolone and prednisone after rectal administration: Significance in antidoping analysis. Botrè, F; Colamonici, C; Comunità, F; Curcio, D; de la Torre, X; Iannella, L; Mazzarino, M, 2022)	1.01
"001), with increases in poorly bioavailable oral corticosteroids in Crohn's (pandemic 15."	( Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study. Bhala, N; Brookes, MJ; Conley, TE; Gonzalez, HA; Hicks, LC; Kennedy, NA; Kent, AJ; Lamb, CA; Mehta, SJ; Patel, KV; Saifuddin, A; Sebastian, S; Segal, JP; Subramanian, S; Walker, GJ, 2022)	0.72
" However, low water solubility and bioavailability have hindered its application."	( Preparation of Pinocembrin-Loaded F127/MPEG-PDLLA Polymer Micelles and Anti-Osteoporotic Activity. Adu-Frimpong, M; Cao, X; He, Q; Ji, H; Li, X; Rong, W; Shen, X; Shi, F; Toreniyazov, E; Wang, Q; Xia, X; Xu, X; Yu, J; Zhang, J, 2022)	0.72

Dosage Studied

There was an increased risk of IFI in the lupus patients receiving high daily dosage of prednisolone therapy. No correlation was observed between the daily prednislone dosage (mg/d or mg kg d) and glucose AUC.

Excerpt	Relevance	Reference
" The common liquid dosage preservatives methylparaben, propylparaben, and sodium benzoate do not interfere with quantitative prednisolone, prednisone, and hydrocortisone determinations."	( High-pressure liquid chromatographic evaluation of aqueous vehicles for preparation of prednisolone and prednisone liquid dosage forms. Gupta, VD, 1979)	0.69
" The impact of the duration of the disease, of sex, age, and the dosage of corticosteroids on the postoperative development of the disease is demonstrated."	( [Results of splenectomy in patients with hypoplastic and aplastic anemia]. Grosdow, DM; Sliskow, SS, 1975)	0.25
" In fact, when the optimum dosage of 75 (mumol/kg)/day x 5 was used, the administration of ara-C alone was followed by an increased life span (ILS) of 45%."	( Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of prednisolone and prednisone. Hong, CI; Nechaev, A; West, CR, 1979)	0.46
" The substances are mesenchymosuppressive as well as immunosuppressive, but the present results show that the effective dosage is higher for mesenchymal suppression than for immunosuppression."	( Experimental results to immunomesenchymal suppression. Hauss, GM; Hauss, WH; Kramer, H; Müller, U; Wirth, W, 1975)	0.25
"5 months of synthetic ACTH-Z medication at either of these dosage levels, the response of urinary 17-KGS was found to have decreased to about 1/2 of its level at the beginning of medication."	( [A clinical study on the effect of extrinsic corticotropin on the pituitary-adrenocortical function (author's transl)]. Mori, M, 1978)	0.26
" Dosage is initially high (60--100 mg daily, secondarily on alternate days), and should be reduced very slowly, once a definite improvement is achieved."	( [Long term administration of oral prednisone or prednisolone in treatment of myasthenia gravis. Report of five cases (author's transl)]. Contamin, F; Ecoffet, M; Mignot, B; Offenstadt, G; Singer, B, )	0.39
" Eleven patients with advanced carcinoma of the lung (5 adenocarcinoma, 3 squamous cell carcinoma, 2 small cell carcinoma and 1 large cell carcinoma) were treated at a dosage of 40 mg."	( Preliminary clinical study of prednimustine in lung cancer. Catane, H; Catane, R; Kaufman, JH; Mittelman, A; Murphy, GP; Takita, H, 1977)	0.26
" Drug combinations incorporating niridazole at a lower dosage or for a shorter period were less effective, and azathioprine and prednisolone on their own or used together prolonged graft survival only marginally in this model."	( Prolonged allograft survival with niridazole, azathioprine, and prednisolone. Bird, M; Godfrey, AM; Jones, B; Millar, D; Miller, J; Salaman, JR, 1977)	0.7
" To prevent recurrent pulmonary infiltrates it is probably necessary to give prednisolone in a daily dosage of at least 10 mg for an indefinite period."	( Asthmatic pulmonary eosinophilia: a review of 65 cases. Douglas, AC; Grant, IW; Middleton, WG; Paterson, IC, 1977)	0.49
" CEA levels did not correlate with prednisolone dosage nor with number of rejection episodes, after allowing for time after transplantation and smoking habit."	( Carcinoembryonic antigen in renal allograft recipients and immunosuppressed renal patients. Coates, AS; Frost, M; Kincaid-Smith, P; Mathews, JD; Myers, JB, 1977)	0.53
" Emphases of the description are general principles of treatment, indications and dosage in systemic and local treatment, side effects, problems of long-term treatment, application of ACTH, the cortisonoid withdrawal syndrome, prophylaxis of therapy complications and references to the reduction of the dose or to the withdrawal of the treatment with cortisonoids."	( [Cortisonoids in the therapy of rheumatic diseases]. Reinicke, C, 1977)	0.26
"Forty mg has been shown to be the optimal daily dosage of prednisone for outpatients requiring oral steroids for active proctocolitis."	( A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Bown, RL; Lennard-Jones, JE; Powell-Tuck, J, 1978)	0.58
" In agreement with current literature, immunosuppression with ALG in high dosage seems to be justified."	( [Evaluation of the effectiveness of ALG in clinical kidney transplantation in alternating studies]. Bunzendahl, H; Pichlmayr, R; Tidow, G; Wonigeit, K, 1979)	0.26
" This gross day-to-day variation occurred irrespective of the dosage used."	( Variation in plasma prednisolone concentrations in renal transplant recipients given enteric-coated prednisolone. Chakraborty, J; English, J; Henderson, RG; Marks, V; Wheatley, T, 1979)	0.58
" Dosage in such patients should be reduced in accordance with serum albumin concentration."	( Corticosteroid pharmacokinetics in liver disease. Go, VL; Uribe, M, )	0.13
" This change coincided with the attainment of maintenance steroid dosage (usually prednisolone 10 mg."	( Hyperlipidaemia following renal transplantation. A study of the prevalence, 'natural history' and dietary treatment. Gokal, R; Mann, JI; Moore, RA; Morris, PJ, 1979)	0.49
" Whether similar improvement could have been achieved by a different dosage regimen of corticosteroid tablets or whether it might have ocurred spontaneously was not tested."	( Triamcinolone in corticosteroid-resistant asthma. Cayton, RM; Howard, P; Peake, MD, 1979)	0.26
" Corticosteroids reduced spleen size but reduction or withdrawal of the relatively high dosage required resulted in rebound splenomegaly within a period of three months to three years."	( Splenomegaly and splenectomy in sarcoidosis. Bradstreet, CM; Mitchell, DN; Salsbury, AJ; Webb, AK, 1979)	0.26
" Administration of a standard premedication dosage to patients sedated for other reasons occasionally led to worsened respiratory status; pre-medication should be reduced or eliminated in sedated patients."	( Bronchofiberscopy in the postoperative management of lung surgery patients. Nakhosteen, JA, 1979)	0.26
" These results suggest that Y-8004 may make feasible a reduction in dosage or a withdrawal of the steroid prescription."	( [Pharmacological studies of 2-(5H-(1)benzopyrano[2,3-b]pyridin-7-yl)propionic acid (Y-8004). (3) Its interaction with anti-inflammatory agents]. Foto, K; Imayoshi, T; Kadobe, Y; Maruyama, Y, 1977)	0.26
" It was concluded that the proper dosage of the prednisolone given to these children should be 1 mg/kg per day."	( The effect of different doses of prednisolone in the treatment of childhood ITP. Hathirat, P; Isarangkura, P; Uthai, K, 1979)	0.8
"The parenteral use of triamcinolone acetonide (Kenacort A) is said to have the following advantages: to keep the effect for two weeks by one injection, to be able to reduce the total treatment dosage and to secure the dosage regardless of patients cooperation."	( Parenteral treatment of sarcoidosis with triamcinolone. Hiraga, Y; Mikami, R; Osada, H; Yotsumoto, H, 1977)	0.26
" Sixty patients who were on corticosteroids (hereinafter their dosage is expressed as the equivalent of prednisolone) given at 10 to 40 mg initially and then on a gradually decreasing basis down to below 10 mg currently or who had already been withdrawn from such a drug regimen were involved in the study and analysed for baseline values for plasma cortisol."	( [Study on suppression of the pituitary-adrenocortical function by the therapeutic use of corticosteroids and its spontaneous recovery (author's transl)]. Mori, M, 1978)	0.47
" Monitoring prednisolone levels may be of value in identifying those children who accumulate excessively high levels on moderate dosage regimens."	( Plasma levels, half-life values, and correlation with physiologic assays for growth and immunity. Green, OC; Hart, RL; Kawahara, FS; Lewy, PR; Pachman, LM; Phillips, LS; Winter, RJ, 1978)	0.64
"Thirty-nine patients with gynecological malignancies who had failed on conventional chemotherapeutic agents were treated with Leo 1031 to study the effective dosage and toxicity of the compound in gynecological malignancies."	( Leo 1031 (NSC-134087) in gynecologic malignancies. Barlow, JJ; Lele, SB; Murphy, GP; Piver, MS, 1978)	0.26
" The patients were divided into three groups according to dosage and previous treatment."	( Continuous treatment of non-Hodgkin's malignant lymphoma with prednimustine (Leo 1031). Håkansson, L; Könyves, I; Lindberg, LG; Möller, T, 1978)	0.26
" The study revealed no correlation between steroid dosage and postoperative morbidity or mortality."	( Factors which influenced postoperative complications in patients with ulcerative colitis or Crohn's disease of the colon on corticosteroids. Allsop, JR; Lee, EC, 1978)	0.26
" Allergic nasal symptoms were disabling in many patients when the oral dosage of corticosteroids was tapered."	( Beclomethasone dipropionate aerosol in the treatment of steroid-dependent asthma. A 12-week double-blind study comparing beclomethasone dipropionate and a vehicle aerosol. Harvey, LL; Kass, I; Nair, SV, 1976)	0.26
" A significant relation between steroid dosage and blood pressure was found in only a quarter of the hypertensive patients, and in another quarter no cause could be found."	( Hypertension after renal transplantation. Alexandre, GP; Bachy, C; van Ypersele de Strihou, C, 1976)	0.26
" We, therefore, consider a preventive administration of biguanides to be effective in long term or high dosage administration of glucocorticoides."	( [Antagonistic action of prednisolone and buformin in the carbohydrate metabolism of healthy persons (author's transl)]. Bottermann, P; Ermler, R; Schweigart, U, 1976)	0.56
" Although under the given dosage the intensity of the immune reaction in the fluid remains uninfluenced with regard to plasma cells and an increase in gammaglobulin--a causal therapeutic effect cannot be shown--however, because of the results with regard to the condition of the fluid after the glucocorticoid it is useful for the control of therapy."	( [Changes in cerebrospinal fluid findings with glucocorticoid therapy]. Olischer, RM, 1975)	0.25
" Collaborators were supplied with 4 composites of tablets of different dosage levels, 2 containing prednisolone and 2 containing prednisone."	( Collaborative study of a semiautomated method for the analysis of prednisolone and prednisone tablets. Brower, JF, 1977)	0.71
" Thus, at the dosage used, beclomethasone dipropionate might have minor systemic endocrinometabolic effects."	( The endocrinometabolic effects of beclomethasone dipropionate in asthmatic patients. Copinschi, G; De Coster, A; Leclercq, R; Schandevyl, W; Virasoro, E; Yernault, JC, 1977)	0.26
" Prednisolone and indomethacin also reduced the periosteal reaction when administered from one day before injection with FCA, but they were inactive in this respect when dosing was started on day 21 when the periosteal reaction was well established."	( An X-ray analysis of adjuvant arthritis in the rat. The effect of prednisolone and indomethacin. Blackham, A; Burns, JW; Farmer, JB; Radziwonik, H; Westwick, J, 1977)	1.4
"With a fasted dog as an animal model, the bioavailability and pharmacokinetics of prednisolone were studied following rapid intravenous injection and oral dosing of a prednisolone sodium phosphate solution and also following oral doses of prednisolone as tablets and a slurry."	( Prednisolone bioavailability in the dog. Tse, FL; Welling, PG, 1977)	1.93
"The addition of phenobarbitone in therapeutic dosage to the drug regimen of prednisolone-treated subjects with rheumatoid arthritis produced measurable deterioration in the clinical status of the patients associated with a more rapid clearance of prednisolone from plasma."	( Effects of enzyme induction on metabolism of prednisolone. Clinical and laboratory study. Brooks, PM; Buchanan, WW; Downie, WW; Grove, M, 1976)	0.74
" The glucocorticoid effect on motoneuron outlasts the dosing period, suggesting an underlying alteration in the neuron."	( Glucocorticoids and mammalian motor nerve excitability. Baker, T; Okamoto, M; Riker, WF, 1975)	0.25
" Steroid therapy should not only be introduced rapidly at appropriate dosage levels as soon as the diagnosis is made but should not be reduced or discontinued prematurely."	( Visual complications of polymyalgia rheumatica (polymyalgia arteritica). Hart, FD, 1975)	0.25
" For avoiding irreparable and dangerous defects of the cartilage a sufficiency dosed treatment with corticoids is necessary."	( [Clinical-biochemical study of systemic panchondritis]. Bussler, H; Ehrig, J; Neupert, G; Rössner, B; Schramm, G, 1975)	0.25
" Addition of pg quantities of [3H]-prednisolone following oral dosage with prednisone or prednisolone."	( Measurement of plasma prednisolone in man. May, CS; Paterson, JW; Ssendagire, R; Wilson, CG, 1975)	0.85
"Infection of human foreskin cells (D-550) by the Snyder-Theilen strain of feline sarcoma virus produced small but countable foci and demonstrated "single-hit" dose-response kinetics."	( Influence of glucocorticoid, estrogen, and androgen hormones on transformation of human cells in vitro by feline sarcoma virus. Blakeslee, JR; Milo, GE; Olsen, RG; Schaller, JP; Yohn, DS, 1976)	0.26
" Steroid was also effective but reduction of the dosage resulted in worsening of symptoms."	( [A steroid-effective case with "prolonged" cerebellar ataxia]. Aso, K; Haga, Y; Kito, M; Maeda, N; Negoro, T; Okumura, A; Watanabe, K, 1992)	0.28
"7) cyclosporin-A treatment was associated with a marked decrease in the dosage of prednisolone, from a mean of 12."	( "Catch-up" growth in steroid dependent dermatomyositis treated with cyclosporin-A. Dubowitz, V; Hamill, G; Heckmatt, J; Saunders, C; Stanhope, R, 1992)	0.51
" This study shows that avascular necrosis occurs even when low dose steroids regimes are used and demonstrates no significant correlation between steroid dosage and the development of avn."	( Avascular necrosis of the femoral head post heart-transplantation and steroid dosage. Barry, C; Coughlan, RJ; Daly, C; Foley-Nolan, D; Neligan, M; Woods, A, 1992)	0.28
" In order to determine the ideal form of induction regimen, combination drugs with CYA, the initial dosage of CYA and its blood trough level were retrospectively analyzed with particular reference to the possible factors relevant to the occurrence of acute rejection episode in the first three post-transplant months and graft survival."	( [Study of 54 renal allograft recipients in the cyclosporin A era. What influences acute rejection episode and long-term graft survival?]. Chikaraishi, T; Hirano, T; Kanagawa, K; Koyanagi, T; Seki, T; Takeuchi, I; Tanda, K; Togashi, M; Tsubo, S, 1992)	0.28
"Due to good therapeutic results and few side-effects so-called "low-dose glucocorticoid therapy" (ldgc) with daily glucosteroid dosage below 10 mg prednisolone-equivalent has recently been recommended in managing polymyalgia rheumatica and giant cell arteritis."	( [Polymyalgia rheumatica and giant cell arteritis; diagnosis and side effects of low-dose long-term glucocorticoid therapy]. Hatz, HJ; Helmke, K, )	0.33
" Among the many pharmacological agents presently in use, only prednisone (or methylprednisolone) and cyclosporin require dosage individualisation."	( Optimisation of immunosuppressive therapy using pharmacokinetic principles. Grevel, J, 1992)	0.51
" Twelve potential risk factors were evaluated as covariates: recipient age, body weight after 6 months, body weight gain over 6 months, body mass index after 6 months, body mass index gain over 6 months, current cyclosporine dosage, trough level of cyclosporine in whole blood according to high-performance liquid chromatography after 6 months, cumulative cyclosporine dosage over 6 months, serum bilirubin, type of original cardiac disease, maintenance steroids, and steroid bolus treatment."	( The determinants of elevated total plasma cholesterol levels in cardiac transplant recipients administered low dose cyclosporine for immunosuppression. Grablowitz, V; Heinz, G; Laczkovics, A; Laufer, G; Miholic, J; Schreiner, W; Wolfram, J; Wollenek, G; Wolner, E, 1992)	0.28
" CsA dosage remained unchanged in the range of 200 mg/m2/day; CsA whole blood trough level was 120 to 130 ng/mL throughout the years."	( Long-term results of cyclosporin A therapy in children. Bökenkamp, A; Brodehl, J; Hoyer, PF; Offner, G, 1992)	0.28
" Cyclosporine A did not produce any side effects because the administered dosage was relatively low."	( Alopecia universalis treated with oral cyclosporine A and prednisolone: immunologic studies. Hori, Y; Irie, M; Nakagawa, T; Nakayama, J; Teshima, H; Urabe, A, 1992)	0.53
") on the suppression of plasma hydrocortisone (HC) was investigated in six healthy subjects, by comparing dosage times of 8 and 20 hr."	( Time-dependent effects of dexamethasone administration on the suppression of plasma hydrocortisone, assessed with a pharmacokinetic model. Braat, MC; Koopmans, RP; Oosterhuis, B; van Boxtel, CJ, 1992)	0.28
" The employment of a special diet favourably influenced the course of the disease and enabled the dosage of antirheumatic drugs to be reduced, thereby reducing the frequency of side-effects of the drugs."	( On the medicinal efficacy of dietetic therapy in patients with rheumatoid arthritis. Denissov, LN; Samsonov, MA; Sharafetdinov, Kh, 1992)	0.28
"5-50 mg/kg according to the same dosing protocol."	( Therapeutic activity of deoxyspergualin in comparison with cyclosporin A, and its combined use with cyclosporin A and prednisolone in highly allogeneic skin transplantation in the rat. Abe, F; Fujii, A; Hayashi, M; Mae, T; Nemoto, K; Sugawara, Y; Takeuchi, T, 1992)	0.49
"day-1; 136 achieved clinical remission, but 96 of them still had active endoscopic lesions and were randomized either to immediate start of steroid tapering (group A; n = 46) or to continued prednisolone treatment at the same dosage for 5 more weeks before steroid tapering was begun (group B; n = 50)."	( Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Anh, TN; Bories, P; Cortot, A; Florent, C; Gendre, JP; Landi, B; Metman, EH; Rene, E; See, A; Soule, JC, 1992)	0.47
" Measurement of plasma peak PE or AUC could be valuable for individualizing steroid dosing in children with RD."	( Use of a radioreceptor assay in the assessment of cushingoid features in patients with juvenile rheumatic diseases. Getson, PR; Lipnick, RN; Morales, A; Soldin, SJ; White, PH, 1992)	0.28
" Antirheumatic therapy therefore requires strict adherence to the prescribed indications and careful selection of the specific drug type and dosage regimen."	( [Glucocorticoids]. Hayashi, T, 1992)	0.28
" The addition of azathioprine therapy resulted in no appreciable reduction of steroid dosage nor improvement of yearly growth rate, although the frequency of relapse for that year was diminished."	( [Growth retardation in children with frequent relapsing nephrotic syndrome on steroid--improvement of height velocity after administration of immunosuppressive agent]. Kitamura, M, 1992)	0.28
" Through data of these cases, it is recommended that the maximum dosage is to be continued for as long as 2 to 19 weeks with average 7 weeks."	( [Myasthenia gravis and steroid therapy]. Araki, Y; Kinoshita, M; Nemoto, H; Niizuma, M; Wakata, N, 1992)	0.28
" They were compared with the dosage and trough blood levels of cyclosporin A, and, in 15 patients receiving prednisolone in addition to cyclosporin A, with steroid dosage."	( Renal haemodynamics of cyclosporin A nephrotoxicity in children with juvenile dermatomyositis. Dubowitz, V; el-Meleigy, D; Hasson, N; Heckmatt, JZ; Henderson, BL; Peters, AM; Rose, ML, 1991)	0.49
" After 25 days in the hospital, treatment with high dosage of methylprednisolone was started for presumed ulcerative colitis."	( Fatal cytomegalovirus (CMV) colitis in a patient receiving low dose prednisolone therapy. Aukrust, P; Bjørneklett, A; Farstad, IN; Holter, E; Kremer, D; Moum, B, 1991)	0.75
" Because neutropenia persisted despite the administration of prednisolone for 30 days, daily subcutaneous injection of human recombinant granulocyte colony-stimulating factor (rhG-CSF) at a dosage of 100 micrograms was started."	( Human recombinant granulocyte colony-stimulating factor for the treatment of autoimmune neutropenia. Akashi, K; Fujimoto, K; Harada, M; Ishibashi, H; Niho, Y; Sibuya, T; Takahashi, K; Taniguchi, S, 1991)	0.52
" In 18/33 patients an oligoarthropathy of large joints could be observed after a significant reduction of prednisolon dosage over a period of 5 months."	( [Musculoskeletal manifestations in patients after bone marrow transplantation. Initial clinical rheumatologic observations]. Kirchner, H; Link, H; Poliwoda, H; Schulte, D; Stoll, M; Wagener, P, )	0.13
"Infarct healing delay by prednisolone is dosage dependent, and smaller infarcts may be more sensitive to its effect."	( Effect of prednisolone on myocardial infarct healing: characteristics and comparison with indomethacin. Iimura, O; Ishimoto, R; Itoya, M; Miura, T; Shizukuda, Y, 1991)	0.99
" The eruption responded quickly to systemic steroids, with recrudescence when steroid dosage was reduced."	( Sweet's panniculitis. Cullity, J; Gebauer, K; Maguire, B, 1991)	0.28
" Twelve healthy subjects (4 m, 8 f) were treated for 1 week at each dosage level, the graduated dosages being given in ascending order."	( The assessment of the systemic effects of inhaled glucocorticosteroids. The effects of inhaled budesonide vs oral prednisolone on calcium metabolism. Andersson, KE; Jennings, BH; Johansson, SA, 1991)	0.49
" Late intensification consisted of a 5-day course of ARA-C and one dose of ADR which was repeated until the cumulative dosage of ADR reached 465 mg/m2."	( Improved prognosis of acute nonlymphocytic leukemia in children: results of the 12th-ANLL protocol of Tokyo Children's Cancer Study Group. Bessho, F; Kigasawa, H; Nakazawa, S; Ohkawa, Y; Sugita, K; Tsuchida, M; Tsukimoto, I; Tsunematsu, Y; Yamada, K; Yamamoto, M, 1991)	0.28
" One study compares a tapering dosage of topical prednisolone or placebo eye drops for HSV stromal keratitis (HEDS-SKN)."	( Design and organization of the herpetic eye disease study (HEDS). Barron, BA; Dawson, CR; Hauck, WW; Jones, DB; Kaufman, HE; Wilhelmus, KR, 1991)	0.54
" Secondary effects were observed in both therapeutic alternatives, the most notable being alterations in serum creatinine concentration and hypertension with the dosage of cyclosporine used."	( Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Chan, CC; Green, SB; Mellow, SD; Nussenblatt, RB; Palestine, AG; Stevens, G, 1991)	0.52
" Steroids were found to be beneficial and safe, in the dosage that we prescribed."	( Treatment of recent facial nerve damage with lagophthalmos, using a semistandardized steroid regimen. Hogeweg, M; Kiran, KU; Suneetha, S, 1991)	0.28
" These observations suggest that most of the patients with pemphigus respond well to the treatment of relatively small or moderate dosage of corticosteroids."	( [Statistical observations of pemphigus at the Nara University Hospital from 1975 to 1989]. Matsuoka, A; Miyagawa, S; Muramatsu, T; Nakatani, C; Sakamoto, K; Shirai, T, 1991)	0.28
" Receptor and TAT profiles were essentially superimposable for both dosing groups."	( Receptor-mediated prednisolone pharmacodynamics in rats: model verification using a dose-sparing regimen. Jusko, WJ; Nichols, AI, 1990)	0.61
" Higher dosage of prednisolone or prednisone more than 120 mg/day has never been used."	( Treatment of pemphigus. Ophaswongse, S; Piamphongsant, T, 1991)	0.62
" But, as many of them are young, treatment may present problems if they require high doses of steroids to control the scleral inflammation and then relapse when the dosage is reduced."	( Use of cyclosporin in the management of steroid dependent non-necrotising scleritis. Hakin, KN; Ham, J; Lightman, SL, 1991)	0.28
" The muscle spasms worsened when the dosage of glucocorticoid was reduced, and they improved on the increased dosage."	( [A case of generalized komuragaeri disease (Satoyoshi disease) treated with glucocorticoid]. Matsumoto, S; Miyao, M; Momoi, M; Yamagata, T; Yanagisawa, M, 1991)	0.28
" But eight weeks later, after dose reduction to 10 mg daily, the nephrotic syndrome recurred so that the dosage had to be increased again to 20 mg prednisolone daily."	( [Kimura disease with minimally proliferative glomerulonephritis]. Baretton, G; Sack, K; Steinhoff, J; Uthgenannt, D, 1991)	0.48
" The incidence of thrombosis is similar to that previously found in a cohort of consecutive patients treated at our Department with a different schedule and dosage of L-ase administration, and similar to that reported in previous series."	( Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia. Castaman, G; Dini, E; Rodeghiero, F, )	0.13
" Patients who responded less well to treatment tended to be younger, and their disease was more severe in that a higher dosage was required for initial control."	( The use of chlorambucil in the treatment of bullous pemphigoid. Hutchinson, PE; Milligan, A, 1990)	0.28
"0 mg prednisolone daily given in divided dosage in the morning and evening."	( Short term linear growth in asthmatic children during treatment with prednisolone. Pedersen, S; Wolthers, OD, 1990)	1.03
" Standardised reductions in corticosteroid dosage were therefore undertaken every five weeks, unless clinically contraindicated."	( Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis. Cole, PJ; Currie, DC; Darbyshire, JH; Harvey, C; Longbottom, JL; Lueck, C; Milburn, HJ; Nunn, AJ, 1990)	0.28
" This technique can be used to individualize glucocorticoid dosing regimens."	( Monitoring glucocorticoid therapy: a pharmacokinetic approach. Ball, BD; Bartoszek, M; Brenner, AM; Hill, MR; Szefler, SJ, 1990)	0.28
"When we perform renal biopsy in patients with lupus nephritis (LN), we use the histopathological findings in glomerulus for the choice and dosage of steroid and immunosuppressive therapy."	( [Morphologic transformation of renal lesions by steroid treatment and its therapeutic implication in a patient with lupus nephritis]. Kitamoto, K; Maemura, C; Nagasawa, T; Nakabayashi, K; Saito, M, 1990)	0.28
" All patients had previously relapsed while the dosage was being reduced or within 14 days of discontinuing prednisolone in the six months before receiving cyclophosphamide treatment (steroid dependent), and had severe steroid toxicity."	( Eight and 12 week courses of cyclophosphamide in nephrotic syndrome. Ito, S; Kuno, K; Ueda, N, 1990)	0.49
" The results in three heart transplantation models--auricular free graft in mice, abdominal graft in rats and cervical graft in rabbits--suggested that RSM injection in an appropriate dosage prolonged the survival time of cardiac allograft."	( Effect of radix Salviae miltiorrhizae extract injection on survival of allogeneic heart transplantation. Li, J; Niu, X; Qin, Z; Zhu, H; Zhuang, H, 1990)	0.28
" We conclude that changes in the clearance of prednisolone and altered protein binding might account for some of the variability in both therapeutic responses and the incidence of toxicity in patients treated with standard dosage regimens."	( Pharmacokinetics of prednisolone in children with nephrosis. Bowmer, CJ; Brocklebank, JT; Miller, PF; Wheeldon, J, 1990)	0.86
" It was controlled by increasing the cyclophosphamide dosage for six months."	( [Buccal lymphomatoid granulomatosis]. Auriol, M; Cabane, J; Chomette, G; Godeau, P; Raphael, M; Szpirglass, H, )	0.13
"5 mg/kg) in descending dosage (n = 8)."	( Prednisolone therapy of experimental allergic neuritis in Lewis rats does not induce relapsing or chronic disease. Schabet, M; Schott, K; Stevens, A; Wiethölter, H, 1990)	1.72
" Combination of radiotherapy and chemotherapy can improve the survival rate, but the optimal dosage needs to be investigated further."	( Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristine-doxorubicin-cyclophosphamide-prednisolone chemotherapy. Abe, M; Dodo, Y; Shibamoto, Y; Shima, N; Tsutsui, K; Yamabe, H, 1990)	0.48
" The rare clinical picture of a fatal cardiac rupture in the later phase of acute myocardial infarction and the precise dosage of prednisolone for her SLE are described."	( Cardiac rupture following acute myocardial infarction in systemic lupus erythematosus: case report. Kishimoto, M; Nakamura, Y; Ouami, H; Shibata, S; Takayanagi, K, 1990)	0.48
" She went into hematological remission 6 weeks following 40 mg/day treatment with prednisolone, but the anemia relapsed frequently when the dosage was lessened."	( [Chronic T-cell lymphoproliferative disorder associated with pure red cell aplasia]. Akihama, T; Chubachi, A; Endo, Y; Kuwayama, A; Miura, A; Yoshida, K, 1989)	0.5
" A numerical technique to determine the efficiency of TAT induction based on area under the curve calculations is presented, which supports the hypothesis that nonlinear dose-response effects are due to dose and time-dependent receptor depletion in the cytosol."	( Second generation model for prednisolone pharmacodynamics in the rat. Boudinot, FD; Jusko, WJ; Nichols, AI, 1989)	0.57
" AZP was orally administered to 3 dogs daily at a dosage of 1-10 mg/kg for a period from 3 days before infection until the end of the experiment."	( Influence of immunosuppressants against Dirofilaria immitis infection in dogs. Hayasaki, M; Ohishi, I, 1989)	0.28
" This decreased response in obese animals may indicate a need for joint pharmacokinetic/dynamic considerations in dosing obese individuals with corticosteroids."	( Pharmacokinetics and pharmacodynamics of prednisolone in obese rats. D'Ambrosio, R; Jusko, WJ; Nichols, AI; Pyszczynski, NA, 1989)	0.54
" Dosage reductions of CsA mitigate its nephrotoxic effect."	( Amplification of the nephrotoxic effect of cyclosporine by preexistent chronic histological lesions in the kidney. Bosman, FT; Kootstra, G; Leunissen, KM; Nieman, FH; Noordzij, TC; van Hooff, JP; Vromen, MA, 1989)	0.28
" To ensure the human therapeutic dose, each drug was given twice a day per os in 3 different dosage regimes."	( Impact of NSAIDS on murine antigen induced arthritis. I. Investigation of antiinflammatory and chondroprotective effects. de Vries, BJ; van den Berg, WB, 1989)	0.28
" Prednisolone was given in a dosage averaging 25 mg at 12 h intervals orally for up to 2 weeks to adult volunteers."	( Recovery from glucocorticoid inhibition of the responses to corticotrophin-releasing hormone. Fang, VS; Rosenfield, RL; Watson, AC, 1988)	1.19
" For rational dosage of these xenobiotics, their pharmacokinetics should be characterized."	( Marked interspecies differences between humans and pigs in cyclosporine and prednisolone disposition. Frey, BM; Frey, FJ; Gänger, H; Mettler, D; Sieber, M, )	0.36
" Permanent complete relief or pronounced improvement of the dyskinesias was observed at a dosage of 5 mg prednisolone/day."	( Successful treatment of tardive and spontaneous dyskinesias with corticosteroids. Benecke, R; Conrad, B; Klingelhöfer, J, 1988)	0.49
" In patients with nephrotic syndrome no correlation was found between pharmacokinetic values and criteria of clinical effectiveness, such as the time and dosage required to obtain remissions and the duration of these remissions."	( [Pharmacokinetics of prednisolone in children. Study of a correlation with tolerability and therapeutic effect in nephrosis]. Baron, S; Bensman, A; Raux Demay, MC; Vasmant, D, 1988)	0.59
" Prednisolone therapy in 22 patients (mean dosage 8 mg/day) was associated with reductions in estrone and testosterone levels; however, DHEAS and femoral BMD were also decreased in RA patients who were not receiving corticosteroids."	( Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis. Champion, GD; Eisman, JA; Pocock, NA; Sambrook, PN, 1988)	1.19
"0) at high prednisolone dosage compared to the lower incidence (CMV 54."	( Cytomegalo and herpes simplex virus infections in renal transplant recipients. Geelen, JL; Slaterus, KW; van der Noordaa, J; Wertheim, P; Wilmink, JM, 1985)	0.66
" An analysis with dose-response curves revealed that the glucocorticoids decreased the sensitivity of the GABAA receptor in a non-competitive manner."	( Glucocorticoid modulates the sensitivity of the GABAA receptor on primary afferent neurons of bullfrogs. Akasu, T; Ariyoshi, M, 1986)	0.27
" During gradual reduction of the steroid dosage osteocalcin returned to pretreatment values."	( Serum osteocalcin in rheumatoid arthritis and other inflammatory arthritides: relation between inflammatory activity and the effect of glucocorticoids and remission inducing drugs. Ekenstam, EA; Hällgren, R; Ljunghall, S, 1986)	0.27
"The best systemic treatment of dysthyroid ophthalmopathy remains high dosage Prednisolone."	( Systemic management of dysthyroid ophthalmopathy. Fells, P, 1988)	0.5
" In these 7 children prednisolone dosage could be decreased significantly or discontinued altogether (44."	( Immunoregulation with levamisole in children with frequently relapsing steroid responsive nephrotic syndrome. Alon, U; Drachman, R; Drukker, A; Etzioni, A; Mor, J; Ohali, M; Schlesinger, M; Shapira, H, 1988)	0.59
" Long term prophylactic inhalation of beclomethasone dipropionate in 26 children in a dosage up to 600 mcg/day before puberty and 400 mcg/day during puberty was shown not to affect growth."	( Growth and childhood asthma. Balfour-Lynn, L, 1986)	0.27
"The immunosuppressive treatment with cyclosporin A plus low-dose prednisolone in 33 children after kidney transplantation was compared with conventional treatment with azathioprine plus regular prednisolone dosage in 34 children."	( Cyclosporine in pediatric kidney transplantation. Brodehl, J; Hoyer, PF; Offner, G, 1987)	0.51
" Buserelin (d-Ser-[TBU]6 LHRH ethylamide) was prescribed in two different dosage schedules to twenty men, and in a single dosage schedule to eight women."	( Failure to preserve fertility in patients with Hodgkin's disease. Ahmed, R; Besser, GM; Crowther, D; Gregory, W; Malpas, JS; Rees, LH; Shalet, S; Smith, D; Waxman, JH; Wrigley, PF, 1987)	0.27
"Polylactic acid-polylipoic acid nanospheres (PLA-PLIA-NS) were prepared, and their properties as drug targeting dosage forms were evaluated."	( Preparation of polylactic acid-polylipoic acid nanospheres as drug targeting carriers. Arai, K; Machida, Y; Nagai, T; Nambu, N; Nambu, Y; Takayama, K; Ueda, H, 1987)	0.27
" During progressive decrease of steroid dosage 5 of these 8 patients remained well (mean follow-up 7 months), 2 relapsed and one died of marasmus."	( [Treatment of bullous pemphigoid by plasma exchange and prednisolone]. Guillaume, JC; Revuz, J; Roujeau, JC; Touraine, R; Touzet, C, 1985)	0.52
" All patients received oral prednisolone in the same initial dosage (0."	( Controlled study of plasma exchange in pemphigus. Doutre, MS; Guillaume, JC; Guillot, B; Lambert, D; Lauret, P; Lorette, G; Morel, P; Prigent, F; Roujeau, JC; Triller, R, 1988)	0.57
" To assess the influence on the course of these diseases of the clinical symptoms at initial presentation and of the starting dosage of corticosteroid (CS) treatment the data for 210 patients, who were diagnosed as having PMR or TA from 1976 to 1986 and were followed up closely, were reviewed."	( Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Cohen de Lara, A; Delecoeuillerie, G; Joly, P; Paolaggi, JB, 1988)	0.27
" By the fifth hospital day the patient's skin lesions and conjunctivitis had improved to the point that the prednisone dosage was tapered to 120 mg, then to 80 mg, and then to nothing over the following three days."	( Sulindac-induced toxic epidermal necrolysis. Garnett, WR; Small, RE, 1988)	0.27
" Neither dosage nor duration of treatment influenced severity, onset or duration of this mental disorders."	( [Cortisone-induced psychoses]. Bleistein, J; Bräunig, P, 1988)	0.27
" A dose-response study, at the range of 2-40 mg/kg, showed that a significant decrease was noted at 6 mg/kg and it was maximal (45% inhibition) at 20 and 40 mg/kg."	( Inhibition of prostaglandin synthesis in brain of rat by dexamethasone: lack of effect of dexamethasone phosphate ester and various hormonal steroids. Abu-Amer, Y; Shohami, E; Weidenfeld, J, 1988)	0.27
" This quantity appears minimal and supplemental dosing of prednisone or modification of administration time would seem to be unnecessary."	( [Removal of prednisone and prednisolone during plasma exchange]. Assogba, U; Baumelou, A; Durande, JP; Lenoir, G; Pecquinot, MA; Raymond, F; Rottembourg, J, 1988)	0.57
" Two patients in the azathioprine group required dosage reduction because of myelosuppression and both subsequently relapsed."	( Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Johnson, PJ; Keating, JJ; McFarlane, IG; Stellon, AJ; Williams, R, )	0.13
" Toxicity, particularly alopecia, was appreciably lower in the VMP treated patients, but subclinical cardiotoxicity was seen within the scheduled dosage for both combinations."	( Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast. Cornbleet, MA; Hutcheon, AW; Kaye, SB; Kerr, ME; Leonard, RC; Robinson, S; Smyth, JF; Soukop, M; White, G, 1987)	0.27
" Azathioprine dosage correlated negatively with post-transplantation polycythaemia regardless of the original cause of renal failure."	( Polycythaemia following renal transplantation: an association with azathioprine dosage? Hutton, RD; Newcombe, RG; Orchard, J; Price, KA; Salaman, JR; Webb, DB, 1987)	0.27
"8%) the oral prednisolone dosage was increased, from a mean of 10."	( [Management of rejection following heart transplantation using oral steroid medication]. Fieguth, HJ; Frimpong, K; Haverich, A; Herrmann, G; Jurmann, M; Kemnitz, J; Schäfers, HJ; Wahlers, T, 1987)	0.64
" Its implication for the dosage of steroids is opposite that in steroid-induced peptic ulcers."	( Oesophageal pemphigus vulgaris. Al Karawi, M; Coode, P; Mobacken, H; Mohamed, A, 1988)	0.27
" The treatment with ciclosporin has been continued in all 6 patients, but the dosage has been reduced to 5 mg/kg/day."	( Myasthenia gravis treated with ciclosporin. Gjerstad, L; Nyberg-Hansen, R, 1988)	0.27
" Prednisolone shifted the dose-response curve of the GABA current downward."	( Voltage-clamp studies of the inhibition of gamma-aminobutyric acid response by glucocorticoids in bullfrog primary afferent neurons. Akasu, T; Ariyoshi, M, 1987)	1.18
" Such chitosan/CMC-Na mixtures are a promising basis in the design of sustained release dosage forms of water-insoluble drugs."	( Sustained release tablets based on chitosan and carboxymethylcellulose sodium. Inouye, K; Machida, Y; Nagai, T, 1987)	0.27
"Rat recipients of renal allografts and unilaterally nephrectomized control rats were studied to evaluate the response in blood pressure to prednisolone in diverse doses, and to determine the dosage required to achieve adequate immunosuppression without undue complication of hypertension."	( Prednisolone and posttransplantation hypertension in rat renal allograft recipients. de Keijzer, MH; Molenaar, JC; Provoost, AP; Van Aken, M; Wolff, ED, 1987)	1.92
" In vitro, the dose-response curves to MP were examined in pretransplant PHA cultures."	( The impact of high lymphocyte sensitivity to glucocorticoids on kidney graft survival in patients treated with azathioprine and cyclosporine. Ladefoged, J; Langhoff, E, 1987)	0.27
" Although their initial dosage is subject to some controversy, corticosteroids (CS) provide currently the basis of therapy."	( [Immediate treatment of bullous pemphigus with a corticosteroid-cyclophosphamide combination]. Klene, C; Maleville, J; Taïeb, A, 1986)	0.27
" Treatment with prednisolone should be given for at least two years, with adjustment of dosage according to the serum levels of aspartate transaminase; maintenance does should be 8-12 mg a day."	( Treatment of chronic active hepatitis and other liver diseases with corticosteroid agents. Mackay, IR, 1987)	0.62
" Prednisolone (mean dosage 8 mg/day) was not associated with significantly increased bone loss in women, whereas higher dosages in men (mean 10."	( Determinants of axial bone loss in rheumatoid arthritis. Champion, GD; Eberl, S; Eisman, JA; Pocock, NA; Sambrook, PN; Yeates, MG, 1987)	1.18
" The initial dosage was maintained for 1 or 2 weeks in each group, tailing off with a period of several weeks of oral prednisolone."	( High-dose intravenous corticosteroids in the treatment of multiple sclerosis. Hamaguchi, K; Ohno, R; Sowa, K; Tanaka, H; Watanabe, Y, 1987)	0.48
" Patients with CAH received a four-week regimen of prednisolone with daily dosage tapering from 40 to 10 mg (total 700 mg)."	( Short-term prednisolone for inducing seroconversion from hepatitis B e antigen to antibody along with clinical improvement in patients with chronic active hepatitis type B. Ikeda, K; Kojima, M; Kumada, H; Mayumi, M; Seto, S; Suzuki, H; Tsukada, T; Yoshida, A, 1987)	0.91
" In view of the prominent cerebral edema associated with the intracranial lymphoma, dexamethasone was initiated at a daily dosage of 8 mg by intravenous administration."	( Steroid-induced regression of primary malignant lymphoma of the brain. Kikuchi, K; Kowada, M; Miura, S; Watanabe, K, 1986)	0.27
" In order to better understand the effects and mechanism of action of these treatments, we treated ducks chronically infected with duck hepatitis B virus (DHBV) with different dosage regimens of the two therapies."	( Effects of adenine arabinoside and corticosteroid on replication of duck hepatitis B virus DNA in the liver. Hirota, K; Okuda, K; Omata, M; Sherker, AH; Yokosuka, O, 1986)	0.27
" However, oral dosage of the drug is difficult and regular determinations of the trough blood concentration are indispensable."	( [Cyclosporin A in acute Crohn disease: initial findings]. Gyr, K; Marbet, UA; Stalder, GA, 1986)	0.27
" Extents of absorption are compared over a 10-fold dose range of parent steroid and with the steroid derivatives by measuring plasma levels from solid oral dosage in dogs."	( Oral absorption of 21-corticosteroid esters: a function of aqueous stability and intestinal enzyme activity and distribution. Amidon, GL; Fleisher, D; Johnson, KC; Stewart, BH, 1986)	0.27
" Blood samples were taken over a period of 12 hr after dosing for determination of corticosteroid levels and OKT4 positive lymphocyte counts."	( Prednisolone concentration-effect relations in humans and the influence of plasma hydrocortisone. Koopmans, RP; Oosterhuis, B; Schellekens, PT; ten Berge, IJ; van Boxtel, CJ, 1986)	1.71
" The use of these two drugs in combination does not result in an interaction requiring dosage regimen alteration."	( Lack of effect of sucralfate on prednisone bioavailability. Amend, WJ; Birnbaum, J; Gambertoglio, JG; Lizak, P; Romac, DR; Yong, CL, 1987)	0.27
" There were negative correlations between the receptor numbers (both whole cell and nucleus) of patients and daily dosage of prednisolone."	( [Studies on the glucocorticoid receptor in human peripheral lymphocytes. II. Regulation by glucocorticoid]. Oshima, H, 1986)	0.48
" The relative receptor number was expressed as a percentage of the receptor number to the mean of the receptor number in the group of patients stratified by every 10mg/day of the dosage of prednisolone."	( [Studies on the glucocorticoid receptor in human peripheral lymphocytes. III. Correlation between receptor number and clinical response to glucocorticoid]. Oshima, H, 1986)	0.46
" Most of the flare-ups occurred during the first year of therapy and in 55% of the patients on a prednisolone dosage of 5 mg or less."	( Long-term corticosteroid treatment in giant cell arteritis. Andersson, R; Bengtsson, BA; Malmvall, BE, 1986)	0.49
" As a decreased degradation of prednisolone during Cys treatment may lead to increased steroid activity, we recommend that a reduction of the prednisone dosage during Cys treatment is safe."	( Clinical results and cyclosporine effect on prednisolone metabolism of cadaver kidney transplanted patients. Ladefoged, J; Langhoff, E; Madsen, S; Olgaard, K, 1985)	0.82
" Nephrotoxicity, hepatotoxicity and other side-effects of cyclosporin A could usually be dealt with by dosage adjustments, making feasible the chronic ingestion of this agent."	( Cyclosporin A effective therapy for fifty-two cadaver kidney recipients. Asano, H; Fujita, T; Kano, T; Ohshima, S; Ono, Y; Takagi, H; Uchida, K, 1985)	0.27
" This lack of effect can be due to an inappropriate dosage of the steroid or failure of steroid treatment to alleviate endotoxin-mediated effects."	( Endotoxic shock in the awake young pig: absence of beneficial effect of prednisolone sodium succinate treatment. Houvenaghel, AM; Schrauwen, EM, 1985)	0.5
" These results suggested that prednisolone treatment with a smaller dosage as well as with the higher dosage resulted in a carbohydrate intolerance, the main cause of which is located in a postreceptor step (or steps) of insulin action."	( Erythrocyte insulin receptor and glucose tolerance test in children treated with prednisolone. Fujimoto, S; Kan, H; Matsuda, I, 1985)	0.78
" Renal calcification were more pronounced after dosing with 1 alpha OHD3 than after treatment with 1 alpha OHD2."	( Effects of vitamin D. A comparison of 1 alpha OHD2 and 1 alpha OHD3 in rats. Sjödén, G, 1985)	0.27
"5 mg/day of prednisolone on the amount of calcium deposited in the kidney of rats dosed with either 500 ng/d or 2000 ng/day of 1-alpha OHD2 or 1-alpha OHD3."	( The effect of prednisolone on kidney calcification in vitamin D-treated rats. Lindgren, U; Sjöden, G, 1985)	1.01
" The minor alterations in prednisolone kinetics during concomitant cimetidine dosing are not likely to induce clinically significant alterations in steroid effect."	( Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. Eshelman, FN; Ferguson, RK; Rocci, ML; Sirgo, MA; Vlasses, PH, 1985)	0.8
"Of nineteen patients with RPCGN who responded promptly to initial treatment with PMP or PX, and who were subsequently maintained on oral immunosuppression with prednisolone (reducing dosage from 30mg/day) and azathioprine/cyclophosphamide (1-3 mg/kg/day), five showed progressive loss of renal function within one year of responding to treatment."	( Follow-up prednisolone dosage in rapidly progressive crescentic glomerulonephritis successfully treated with pulse methylprednisolone or plasma exchange. Bone, JM; Stevens, ME, 1985)	0.87
" In 9 cases, prednisolone (40 mg/day) was given at a constant dosage for 4 wk before Ara-A treatment."	( Combination of short-term prednisolone and adenine arabinoside in the treatment of chronic hepatitis B. A controlled study. Hirota, K; Imazeki, F; Ito, Y; Mori, J; Okuda, K; Omata, M; Uchiumi, K; Yokosuka, O, 1985)	0.94
"3 years) with intrinsic asthma requiring corticosteroids were treated for an average of 36 days with budesonid (Pulmicort dosage aerosol, Astra Sweden) in a dose of 3 X 400 micrograms per day."	( [Results of treatment with budesonide (Pulmicort) in corticosteroid-dependent intrinsic asthma]. Petri, E, 1985)	0.27
" No detectable change in T(4) deiodination rate was observed with these agents in the dosage ranges employed in this study."	( A new method for the measurement of acute alterations in thyroxine deiodination rate in man. Nicoloff, JT, 1970)	0.25
" DDAVP in equivalent intravenous dosage has been found to be at least as potent and to have a more prolonged action, lasting 13-22 hours instead of 1-2 hours."	( DDAVP in treatment of vasopressin-sensitive diabetes insipidus. Fraser, TR; Ward, MK, 1974)	0.25
"A controlled trial in 20 adult patients with the nephrotic syndrome due to proliferative glomerulonephritis compared the effects of consecutive eight-week courses of treatment with prednisolone in conventional dosage and a low-dose azathioprine-prednisolone combination."	( Nephrotic syndrome due to primary renal disease in adults: II. A controlled trial of prednisolone and azathioprine. Cameron, JS; Ogg, CS; Sharpstone, P, 1969)	0.66
"One hundred and ninety-one cases of acute lymphoblastic leukaemia were entered in a trial in which, for five months, all received cytotoxic therapy with prednisolone, vincristine, mercaptopurine, L-asparaginase, and methotrexate (the latter in high dosage followed by folinic acid)."	( Treatment of acute lymphoblastic leukaemia. Comparison of immunotherapy (B.C.G.), intermittent methotrexate, and no therapy after a five-month intensive cytotoxic regimen ((Concord trial). Preliminary report to the Medical Research Council by the Leukaemi , 1971)	0.45
" Five glucocorticoids, when administered daily to rats for 5-7 days at a dosage of 5mg/kg, were in the following order of effectiveness with respect to their ability to decrease the weight gain of whole animals and the vastus lateralis, vastus medialis and gluteus medius muscles: corticosterone	( Relative changes in the function of muscle ribosomes and mitochondria during the early phase of steroid-induced catabolism. Bullock, GR; Carter, EE; Elliott, P; Peters, RF; Simpson, P; White, AM, 1972)	0.43
" In the fulminant form of the disease the highly dosed application of prednisolone with ease the highly dosed application of prednisolone with parenteral hypercaloric nutrition and the substitution of mineral, protein and blood losses are therapeutically in the first place."	( [Ulcerative and granulomatous colitis]. Bosseckert, H, 1981)	0.5
"Miniaturised methods have been used to construct dose-response curves for the effects of inhibitory drugs on prostaglandin synthesis using individual rectal biopsies obtained from patients with ulcerative colitis."	( Inhibition of prostaglandin synthetase in human rectal mucosa. Hawkey, CJ; Lo Casto, M, 1983)	0.27
" Feed was infused continuously via a nasoduodenal tube in a dosage of 2600-3200 kcal/day."	( Is tube feeding with elemental diets a primary therapy of Crohn's disease? Egger-Schödl, M; Lochs, H; Meryn, S; Pötzi, R; Schuh, R; Westphal, G, 1984)	0.27
" dosing was 66."	( Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction. Benet, LZ; Frey, BM; Frey, FJ; Holford, NH; Lozada, F, 1982)	1.71
" Immunosuppression was generally reduced in the second trimester and was temporarily increased above the maintenance dosage after delivery."	( [Pregnancy after kidney transplantation. Report of 6 successful cases with multiple risk factors]. Hengst, P; May, G; Mebel, M; Schilling, H; Schmitt, E; Scholz, D, 1983)	0.27
" Age, sex, type of original nephropathy, graft source or prednisolone dosage are not related to hypertension; body weight is greater in hypertensive patients."	( Prevalence and causes of hypertension late after renal transplantation. Alexandre, GP; Kinnaert, P; Pirson, Y; Toussaint, C; Van Geertruyden, H; van Ypersele de Strihou, C; Vereerstraeten, P; Wauthier, M, 1983)	0.51
" Reduction of the oral prednisone dosage provoked a severe exacerbation, with erythroderma associated with massive pustule formation."	( Subcorneal pustular dermatosis with vesiculo-bullous eruption. Demonstration of subcorneal IgA deposits and a leukocyte chemotactic factor. Iwase, Y; Iwatsuki, K; Tagami, H; Yamada, M, 1983)	0.27
" We conclude from these results (1) that previously the dosage of CyA administered at this centre was probably too high, and (2) early adjustment of dose levels on the basis of blood concentrations and with low-dose prednisone cover appears to be safe and effective, but requires further verification."	( Cyclosporin A used alone or in combination with low-dose steroids in cadaveric renal transplantation. Brünisholz, M; Brunner, F; Follath, F; Harder, F; Landmann, J; Lörtscher, R; Mihatsch, M; Thiel, G; Wenk, M, 1983)	0.27
" The dosage of CyA was related to body surface area, starting with 500 mg/m2 daily and was reduced weekly by 50 mg/m2 until the maintenance dose of 300 mg/m2 was reached at the end of the fifth week."	( Dosage of Cyclosporin A in children with renal transplants. Brodehl, J; Hoyer, PF; Offner, G; Pichlmayr, R; Wonigeit, K, 1984)	0.27
" Nevertheless, the best initial dosage is still unknown."	( [Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study]. Guillaume, JC; Morel, P, 1984)	0.54
"8 mg) participated in a double-blind cross-over study to determine the effect of timing (morning or night) of prednisolone dosage on morning stiffness."	( The timing of prednisolone dosage and its effect on morning stiffness in rheumatoid arthritis. Binder, A; De Silva, M; Hazleman, BL, 1984)	0.84
" The mean silybin dosage was 33 mg/kg body weight/day; the mean duration of silybin therapy was 81."	( [Pharmacotherapy of Amanita phalloides poisoning using silybin]. Csomos, G; Fuhrmann, M; Hruby, K; Thaler, H, 1983)	0.27
" Supplemental dosing of prednisone following plasma exchange appears unnecessary."	( Removal of prednisone and prednisolone by plasma exchange. Henry, DH; Stigelman, WH; Talbert, RL; Townsend, RJ, )	0.43
" The IV injection of prednisolone sodium succinate, 10 mg/kg at 25 minutes before dosing the pigs with endotoxin resulted in a significant increase in survival time."	( Endotoxin shock in the pig: beneficial effects of pretreatment with prednisolone sodium succinate. Houvenaghel, AM; Schrauwen, EM, 1984)	0.82
" The dosage level of treatment was low enough to avoid major hematologic changes."	( Effect of ophthalmic prednisolone acetate on the canine adrenal gland and hepatic function. Lavach, JD; Macy, DW; Roberts, SM; Severin, GA, 1984)	0.59
"Obesity is accompanied by altered secretion and disposition of sex and glucocorticoid hormones, including cortisol, and also confounds parameter normalization and drug dosage selection relative to body weight."	( Prednisolone disposition in obese men. Jusko, WJ; Milsap, RL; Plaisance, KI, 1984)	1.71
" Treatment with steroid enemas resulted in symptomatic and sigmoidoscopic evidence of improvement more frequently than treatment with a dosage of oral steroid calculated to achieve similar plasma prednisolone levels."	( A comparison of prednisolone enemas with low-dose oral prednisolone in the treatment of acute distal ulcerative colitis. Axon, AT; Dickinson, RJ; Dixon, MF; Hamilton, I; Pinder, IF; Ruddell, WS, 1984)	0.8
" The data showed no statistical difference in any of the pharmacokinetic parameters among tableted products, subjects, or dosing periods in the study."	( In vitro and in vivo bioequivalence of commercial prednisone tablets. Brown, WJ; Francisco, GE; Honigberg, IL; Kotzan, JA; Pelsor, FR; Schary, WL; Shah, VP; Stewart, JT, )	0.13
" Although a dosage of 400 mg/kg/day was suitable for most patients, the wide range of individual responses suggested the desirability of determining an optimal dose for each patients."	( A cooperative clinical trial of high-dose immunoglobulin therapy in 177 cases of idiopathic thrombocytopenic purpura. Akatsuka, J; Uchino, H; Yasunaga, K, 1984)	0.27
" Less neurotoxic and sufficiently effective dosage of VDS is considered to be 2 mg/m2, once weekly."	( [A randomized controlled study on vindesine and vincristine in combination with prednisolone in the treatment of adult acute lymphocytic leukemia and blastic crisis of chronic myeloid leukemia]. , 1983)	0.49
" No difference in nucleoid sedimentation was seen at a dosage of 5 mg of prednisolone, but after administration of 10, 25 and 40 mg a decrease in sedimentation velocity was observed and this effect might be explained by the DNA destabilizing effect of a steroid receptor complex followed by DNA strand breaks which had migrated into the nucleus."	( [Molecular biology studies of synovial fluid cells of patients with chronic polyarthritis after intra-articular prednisolone medication]. Bröll, H, 1984)	0.71
" Initial symptomatic response followed high dosage corticosteroid and immunosuppressant treatment, but reduction in the dosage of corticosteroids was achieved only by successive plasma exchange with concomitant reduction in plasma concentrations of both amiodarone and immune complexes."	( Amiodarone associated alveolitis and polyarthropathy. Treatment by plasma exchange. Douglas, AC; Paton, L; Russell, DC, 1983)	0.27
" It is recommended that for maximum efficacy and minimum toxicity prednisolone therapy be confined to once-daily dosing in the morning."	( Diurnal variation in prednisolone kinetics. Dunne, M; English, J; Marks, V, 1983)	0.82
" Oral prednisolone in the dosage described is as effective as about 10 times that dose of intravenous methylprednisolone; it is much cheaper and is viewed as less unpleasant by patients."	( Comparison of high-dose intravenous methylprednisolone with low-dose oral prednisolone in acute renal allograft rejection in children. Bewick, M; Chantler, C; Haycock, G; Orta-Sibu, N, 1982)	1.01
"A series of 29 children with dermatomyositis has been reviewed and the outcome compared between cases treated by us initially with a low dosage short duration course of corticosteroids, and those referred late and having had various different therapeutic regimens and usually more active and higher dosage drug schedules."	( Drug treatment of juvenile dermatomyositis. Dubowitz, V; Heckmatt, JZ; Miller, G, 1983)	0.27
" Because of the marked reduction in the extent of bioavailability of total, and especially free, prednisolone, dosage adjustments should be made accordingly if prednisolone and rifampicin are prescribed concomitantly."	( Changes in prednisolone pharmacokinetics and protein binding during treatment with rifampicin. Bergrem, H; Refvem, OK, 1983)	0.87
" Because of the marked reduction in total and especially free prednisolone, the dosage should be adjusted accordingly if prednisolone and rifampicin are prescribed concomitantly."	( Altered prednisolone pharmacokinetics in patients treated with rifampicin. Bergrem, H; Refvem, OK, 1983)	0.94
" All manifestations of the disease responded to the administration of prednisolone with rapid reduction of dosage to less than 10 mg daily."	( Hyaline-vascular variant of angiofollicular lymph node hyperplasia with systemic manifestations and response to corticosteroids. Bellingham, AJ; Goldsmith, HJ; Summerfield, GP; Taylor, W, 1983)	0.5
" The planned dosage intensity had to be significantly reduced in over half of the patients because of marrow toxicity."	( Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease. Dawson, AA; Fell, LF; Green, JA; Murray, S, 1980)	0.26
" After initial remission, the maintenance dosage of prednisolone was 10 mg per day, and the patients were prospectively followed for up to 3 1/2 years."	( Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. Lai, CL; Lam, KC; Trepo, C; Wu, PC, 1981)	0.83
" The daily dosage was such as to maintain the rosette-forming cell (RFC) level at 10% of baseline values."	( Antithymocyte globulin in cadaver kidney transplantation: a randomized trial based on T-cell monitoring. Bach, JF; Crosnier, J; Dandavino, R; Descamps, JM; Kreis, H; Mansouri, R; N'Guyen, AT, 1981)	0.26
"We undertook two randomised studies in an effort to decrease the dosage of steroids in transplanted patients and to replace harmful steroid therapy by nonsteroid anti-inflammatory (NSAI) drugs."	( Are there non-steroid-dependent rejection episodes? Crosnier, J; Descamps, JM; Kreis, H; Mansouri, R, 1980)	0.26
" It seems that a rather moderate dosage of methylprednisolone allows us to prolong and repeat the courses according to individual needs, and this may be the main reason for the significantly improved graft function at one year."	( Steroids and rejection treatment in the Gothenburg transplant programme. Brynger, H; Gelin, LE, 1980)	0.52
" A relationship between mortality from a urological complication and steroid dosage was found."	( The urological complications of 1000 renal transplants. Bewick, M; Ellis, FG; Mundy, AR; Podesta, ML; Rudge, CJ, 1981)	0.26
" It is suggested that the dosage of corticosteroid should be adjusted according to the severity of uveomeningitis."	( Systemic corticosteroid treatment in Vogt-Koyanagi-Harada disease. Hayasaka, S; Okabe, H; Takahashi, J, 1982)	0.26
" The dose-response curve for prednisolone plateaued at high doses."	( Influence of prednisolone on ethanol-induced gastric injury in the rat. Derelanko, MJ; Long, JF, 1982)	0.92
" Two oral corticosteroids, prednisolone (8 mg/day) and betamethasone (1 mg/day) have been compared in terms of efficacy and adrenal suppressive activity when used in chronic oral dosage in rheumatoid arthritis."	( A pharmacological and clinical comparison of prednisolone and betamethasone in rheumatoid arthritis. Al-Shakarchi, H; Bird, HA; Dixon, JS; Lowe, JR; Marwah, RJ; Pickup, ME; Wright, V, 1982)	0.82
" dosage range."	( Dose dependent pharmacokinetics of prednisone and prednisolone in man. Jusko, WJ; Rose, JQ; Yurchak, AM, 1981)	0.52
" Animals born of mothers given the highest dosage of the drug (400 microgram) weighed less than controls in adulthood."	( Deleterious effects of prenatal prednisolone exposure upon morphological and behavioral development of mice. Gandelman, R; Rosenthal, C, 1981)	0.55
" Peak prednisolone levels were reached at between 2 and 4 hours after the intra-articular injection at both dosage levels, though the peak was higher with the larger dose."	( Plasma steroid levels after intra-articular injection of prednisolone acetate in patients with rheumatoid arthritis. Chakraborty, J; English, J; Gibson, T; Marks, V; Reeback, JS, 1980)	0.99
"Changes in the level of neutrophil alkaline phosphatase (NAP) in a population of peripheral blood neutrophils were determined in healthy subjects dosed with either aetiocholanolone (Aetio, 4 mg/m2 im) or prednisolone sodium succinate (Pred, 30 mg/m2 iv)."	( Alkaline phosphatase as a marker of maturity in human neutrophils. Studies in normals dosed with aetiocholanolone and prednisolone. Mishler, JM; Williams, DM, 1980)	0.66
" Saliva prednisolone levels were measurable for at least 3 h after dosing but showed no consistent relationship to either total or free plasma prednisolone concentrations."	( Prednisolone concentrations in plasma, saliva and urine. Baylis, M; Chakraborty, J; English, J; Hayes, M; Marks, V, 1981)	2.14
" In the acute croton oil-induced ear edema dose-response bioassay, the topical anti-inflammatory potencies of these esters relative to prednisolone, 1, were: 8a:1."	( Steroidal anti-inflammatory antedrugs: synthesis and pharmacological evaluation of 16 alpha-alkoxycarbonyl-17-deoxyprednisolone derivatives. Choi, SJ; Khalil, MA; Kwon, T; Lee, HJ; Yoon, KJ, 1995)	0.7
" Height SD score for age (HtSDS(ca)), HtSDS for bone age (HtSDS(ba)), BMI and steroid dosage in early childhood (3."	( Adult height in women with early-treated congenital adrenal hyperplasia (21-hydroxylase type): relation to body mass index in earlier childhood. Grant, DB; Yu, AC, 1995)	0.29
" The initial heavy proteinuria promptly decreased after the prednisolone dosage was increased and disappeared 4 weeks later."	( Minimal-change nephrotic syndrome associated with systemic lupus erythematosus. Haramoto, T; Makino, H; Ogura, T; Ota, Z; Shikata, K, 1995)	0.53
" Dose escalation was required in order to control carcinoid symptoms, and the final dosage was 5,950 micrograms/day."	( Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide. Deguchi, H; Deguchi, K; Iwasaki, E; Kobayashi, T; Murashima, S; Shirakawa, S; Tsuda, M; Tsukada, T, 1994)	0.29
" Over the next 6 months the prednisolone dosage was decreased to 10 mg daily."	( [Collagenous sprue]. Fuhrmann, K; Hafkemeyer, P; Herbst, E; Köhler, G; Kreisel, W, 1995)	0.59
" At a dosage of 20 mg/day, however, multiple nodular shadows were present on the X-ray film of the chest, but they disappeared after the dosage was increased."	( [A case of idiopathic pulmonary arteritis with positive anti-myeloperoxidase antibodies]. Katou, K; Kimura, H; Kuriyama, T; Nagao, K; Okada, O; Shishihara, K; Tanabe, N; Tatsumi, K; Uchiyama, T, 1995)	0.29
" During the last 6 months prior to the study the patients had a median Crohn's disease activity index (CDAI) of 193 (interquartile range: 122-230) (monthly controls) with a median prednisolone dosage of 14 mg per day (9-20)."	( Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study. Kleinberger, M; Lochs, H; Moser, G; Novacek, G; Vogelsang, H, 1995)	0.48
" When the glucocorticoid dosage was reduced or the drug discontinued, the nephrotic syndrome recurred."	( [T-cell lymphoma under immunosuppressive treatment in minimal change glomerulopathy with nephrotic syndrome]. Schollmeyer, P; Späth, M, 1995)	0.29
" Corticosteroid dosage was then reduced according to clinical improvement."	( Long-term corticosteroid and dipyridamole treatment of membranoproliferative glomerulonephritis type I in children. Matsutani, H; Niimura, F; Takeda, A, 1995)	0.29
"A dose of CBG to yield 95% binding with 1000 ng/ml of prednisolone in vitro in rat plasma or saline was administered before dosing 2 mg/kg of prednisolone hemisuccinate or methylprednisolone intravenously."	( Effect of corticosteroid binding globulin on the pharmacokinetics of prednisolone in rats. Almon, RR; Jusko, WJ; Ko, HC, 1995)	0.77
" Dose-response profiles of the croton oil-induced ear edema bioassay in rats were used to calculate the following ID50 values (nmol/ear resulting in a 50% reduction of edema): prednisolone (P), 540 nmol; 2b, 135 nmol; and 3b, 101 nmol."	( New steroidal antiinflammatory antedrugs: steroidal [16 alpha,17 alpha-d]-3'-carbethoxyisoxazolines. Heiman, AS; Kwon, T; Lee, HJ; Oriaku, ET; Yoon, K, 1995)	0.48
"In the dosage used, diclofenac was as effective an anti-inflammatory agent for uncomplicated post-cataract inflammation as prednisolone."	( A comparison of topical diclofenac with prednisolone for postcataract inflammation. Brennan, KM; Roberts, CW, 1995)	0.77
" After an initial loading dose of 120 mg prednisolone per day for 6 weeks (11/1986), the steroid dosage was reduced to 40 mg (12/1986) and diminished to 15 mg/day in 1988 to 1989."	( [Löffler endocarditis fibroplastica with simultaneous infectious endocarditis]. Bethge, C; Drude, L; Herzum, M; Maisch, B; Menz, V; Schönian, U, 1994)	0.55
" Clinical response and outcome, as well as prednisone dosage and adverse effects, were recorded throughout the followup period."	( Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. Friedlander, Y; Nesher, G; Sonnenblick, M, 1994)	0.29
" The dosage of methylprednisolone (30 mg/kg/6 hours) which was successful in the National Acute Spinal Cord Injury Study 2 (NASCIS 2) evolved from the unique pharmacology of corticosteroids as antioxidants."	( Traumatic optic neuropathy. Goldberg, RA; Steinsapir, KD, )	0.45
" On increasing the dosage of CCA to 320 mg/day because of unsatisfactory symptomatic responses elicited at the initial dose level, the patient became free from an asthmatic attack with a return to normal of his eosinophilic count."	( [Successful treatment with lobenzarit disodium in case of Churg-Strauss syndrome]. Akiyama, Y; Dohi, Y; Imai, F; Katagiri, T; Ohno, S; Suzuki, T; Tanaka, M, 1993)	0.29
" The patient has been in full remission for 25 months (prednisolone dosage reduced to 12."	( [Angioimmunoblastic lymphadenopathy with dysproteinemia and sclerosing cholangitis]. Garbrecht, M; Nerl, C; Schmitt, W; Wegerle, W, 1994)	0.54
" In this trial, the combination therapy was effective for the decrease of urinary protein in one case, and for the reduction of a dosage of oral PSL in one case."	( [Effects of combined administration of prednisolone and mizoribine in the course of remission for SLE children with nephritis]. Aihara, Y; Ibe, M; Kuriyama, T; Mitsuda, T; Mori, M; Shimizu, C; Takahashi, Y; Yokota, S, 1994)	0.56
" All three glucocorticoids were found to cause a modest induction of NAT activity towards procainamide after dosing for 10 days."	( Glucocorticoid induction of hepatic acetyl CoA:arylamine N-acetyltransferase activity in the rat. Svensson, CK; Zaher, H, 1994)	0.29
" The three laboratory investigations were, therefore, of limited value in confirming relapses of PMR/GCA during prednisolone treatment, but alpha 1-ACT may be useful as an indicator of underlying disease activity and hence as a guide to the speed that the prednisolone dosage should be reduced."	( Alpha 1-antichymotrypsin, C-reactive protein and erythrocyte sedimentation rate in polymyalgia rheumatica and giant cell arteritis. Calvin, J; Hazleman, BL; Pountain, GD, 1994)	0.5
" Slope differences in the dose-response curves suggest that prednisolone-induced muscle atrophy in the plantaris was more severe than that in the diaphragm."	( Exercise and glucocorticoid-induced diaphragmatic myopathy. Chen, CL; Criswell, D; Herb, RA; Lieu, FK; Martin, D; Powers, SK; Stainsby, W; Wood, C, 1993)	0.53
"Twelve patients with chronic severe asthma, taking a mean daily dosage of 8 mg of prednisolone for a mean (SD) of 16."	( Sternomastoid muscle fatigue and twitch maximum relaxation rate in patients with steroid dependent asthma. Bugler, JR; Mak, VH; Spiro, SG, 1993)	0.51
" For the dosage tested, we found no depression of adrenal function, neither in circadian cortisol secretion nor in hCRH-stimulation-test."	( [Adrenal cortex function in children with bronchial asthma in fluticasone therapy]. Büttner, P; Hoffmann-Streb, A; L'Allemand, D; Niggemann, B; Wahn, U, 1993)	0.29
" Prednisolone dosage at start of therapy depended on initial inflammatory activity (CDAI)."	( [Alpha-interferon therapy in Crohn's disease: initial clinical results]. Ammann, R; Jost, R; Meyenberger, C; Münch, R; Wirth, HP; Zala, G, 1993)	1.2
" A recurrence occurred after 5 months, while on a prednisolone dosage of 10 mg daily, together for the first time with arthralgias, suggesting systemic involvement."	( [Glucocorticoid monotherapy for Cogan syndrome?]. Helmchen, C; Samtleben, W; Terjung, B, 1993)	0.54
" The dosage was 20 mg qid via a special inhaler."	( [Efficacy of disodium cromolyn in adult chronic asthma]. Ho, LI; Lien, TC; Wang, JH, 1993)	0.29
" The complete absence of suppression of the corticoadrenal axis by fluticasone propionate was encouraging, however, and a higher dosage schedule should be assessed."	( Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis. Burke, DA; Giaffer, MH; Hawkey, CJ; Hawthorne, AB; Holdsworth, CD; Keech, ML; Record, CO, 1993)	0.54
" Attempts to further decrease the dosage of steroids or to discontinue their use were met with immediate recurrences of manifestations of the disease."	( Usefulness of inhaled high-dose corticosteroids in allergic bronchopulmonary aspergillosis. Cormier, Y; Imbeault, B, 1993)	0.29
" The increasing dosage of steroid (60mg/day) improved general edema and decreased urinary protein, but abdominal pain and fullness occurred seven weeks after the admission."	( [Pneumatosis cystoides intestinalis following steroid treatment in a nephrotic syndrome patient: report of a case]. Iitsuka, T; Izumi, Y; Kobayashi, M; Koyama, A, 1993)	0.29
" The therapeutic protocol for ITP, proposed by the Japanese Idiopathic Disease of Hematopoietic Organ Research Committee, was modified for the elderly (group) as follows: the initial dosage of prednisolone was reduced by half and danazol therapy was selected in cases in which splenectomy was impossible."	( [Treatment of elderly patients with chronic idiopathic thrombocytopenic purpura]. Abe, T; Hasegawa, Y; Kojima, H; Nagasawa, T; Ninomiya, H; Shibuya, A, 1993)	0.48
" Increased TG levels were associated with increase in weight and higher daily prednisolone dosage at the time of evaluation."	( Dyslipoproteinemia in renal transplantation. Acharya, VN; Almeida, AF; Gunjotikar, RV; Taskar, SP, )	0.36
"The purpose of this study was to examine the relationship of cumulative steroid dosage and duration of therapy with osteoporosis."	( Osteoporosis in steroid-dependent asthma. Gordon, EH; Hahn, TJ; Klaustermeyer, WB; Villareal, MS, 1996)	0.29
" The dosage was reduced to 50 per cent after one week."	( [Pharmacokinetics and tolerance of an orally administered combination preparation containing phenylbutazone and prednisolone in the dog]. Engelke, A; Kietzmann, M; Meyer-Lindenberg, A; Nolte, I, 1996)	0.51
" This finding may serve to guide the selection of dexamethasone dosage in the treatment of ALL."	( Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Campana, D; Coustan-Smith, E; Evans, WE; Ito, C; Mahmoud, H; McNinch, L; Pui, CH, 1996)	0.55
"To compare the long term effects of low dosage prednisolone or deflazacort treatments on bone mass in patients with polymyalgia rheumatica."	( Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort. Krogsgaard, MR; Lund, B; Thamsborg, G, 1996)	0.75
" We emphasise that the accuracy especially of the CRP for early prediction of silent infection in preterm labour does not seem to be impaired by this corticosteroid in a dosage usually administered for prevention of respiratory distress syndrome."	( [Does lung maturation therapy with 16-methylene-prednisolone modify maternal infection parameters in threatened premature labor?]. Heyl, W; Rath, W; Reister, F; Winkler, M, 1996)	0.55
"The smaller dosage of tacrolimus led to a higher trough concentration of 14."	( Three-times-daily monotherapy with tacrolimus (FK 506) in kidney transplantation. Fukunishi, T; Hanafusa, T; Ichikawa, Y; Kyo, M; Nagano, S, 1996)	0.29
" The modal initial dosage of oral prednisolone was 40 mg for the adult and 30 mg for the child, and modal duration of oral steroid dosage was 5 days for both adult and child."	( Management of acute asthma attacks associated with respiratory tract infection: a postal survey of general practitioners in the U.K. Gruffydd-Jones, K; Jones, K, 1996)	0.57
" Forty-eight patients with acute optic neuritis were treated orally either with methylprednisolone (100 mg per day initially, dosage reduction every 3 days; n = 15) or with thiamine (100 mg per day; n = 33) in the control group, 36 of them in a double-blind procedure."	( The effect of oral prednisolone on visual evoked potential latencies in acute optic neuritis monitored in a prospective, randomized, controlled study. Diener, HC; Dietz, K; Trauzettel-Klosinski, S; Zrenner, E, )	0.68
" The aim of the present study was to evaluate if growth hormone administration would have an anabolic effect on rat bone when given to animals also receiving a high dosage of glucocorticoid."	( Growth hormone is not able to counteract osteopenia of rat cortical bone induced by glucocorticoid with protracted effect. Andreassen, TT; Brüel, A; Ortoft, G; Oxlund, H, 1995)	0.29
" After initial chemotherapy, he received intravenous methotrexate (total dosage 1,035 mg), intrathecal methotrexate (total dosage 221 mg), and whole brain irradiation (2,400 cGy)."	( Lenńox-Gastaut syndrome associated with leukoencephalopathy. Ikuta, H; Mitsufuji, N; Sawada, T; Yoshioka, H, 1996)	0.29
"Using standard lymphocyte culture techniques, the concentration of prednisolone (P) and methylprednisolone (MP) required to cause 50% inhibition (IC50) of the proliferative response to phytohemagglutinin (PHA) was determined from dose-response curves."	( Differential glucocorticoid responsiveness of dialysis patients' lymphocytes. Briggs, WA; Burdick, JF; Choi, MJ; Gao, ZH; Gimenez, LF; Scheel, PJ, )	0.37
" The steroid dosage could be significantly reduced in group 1 (-3."	( Association of methotrexate and corticosteroids in the treatment of patients with rheumatoid arthritis. Bologna, C; Jorgensen, C; Sany, J, )	0.13
" From the dose-response curves, the concentration of steroid required to cause 50% inhibition (IC50) of the PHA-induced proliferative response was determined."	( Lymphocyte responsiveness to glucocorticoids, cyclosporine, or both. Briggs, WA; Burdick, JF; Choi, MJ; Gao, ZH; Gimenez, LF; Scheel, PJ, 1996)	0.29
" We found three predictors of flares: renal disease, persistence of dsDNA antibodies for at least 1 year after the beginning of treatment and reduction in azathioprine dosage to below 2 mg/kg/d."	( Predictors of flares and long-term outcome of systemic lupus erythematosus during combined treatment with azathioprine and low-dose prednisolone. Abendroth, K; Hein, G; Oelzner, P; Stein, G, 1996)	0.5
" Follicular bronchiolitis was diagnosed from the results of an open-lung biopsy, and prednisolone therapy was started at a dosage of 40 mg/day."	( [Follicular bronchiolitis associated with rheumatoid arthritis]. Chida, K; Hayakawa, H; Imokawa, S; Iwata, M; Morita, S; Sato, A; Sato, J; Todate, A; Toyoshima, M; Tsukamoto, K, 1996)	0.52
" Dosage was reduced gradually to 10 mg daily over 4 weeks."	( Therapeutic responses to corticosteroids in Graves' ophthalmopathy. Chang, TC; Hsiao, YL; Huang, KM; Kao, SC; Lu, CP; Tzeng, SS, 1996)	0.29
" The requirement that suspension eyedrops and similar dosage forms should be redispersable after sedimentation upon storage is stated in the monographs on eyedrops of the German Pharmacopoeia and can be found in similar contexts in other pharmacopoeias."	( [Dosage problems in suspension eyedrops]. Diestelhorst, M; Kwon, KA; Süverkrüp, R, )	0.13
" A variable dosing pattern with acceptable mean was observed for Chibro-Amuno 3, while the results for Inflanefran-forte were fully satisfactory."	( [Dosage problems in suspension eyedrops]. Diestelhorst, M; Kwon, KA; Süverkrüp, R, )	0.13
" Nine sirolimus dosage levels from 1 mg/m2/day to 13 mg/m2/day were studied and compared with placebo."	( Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. Ferron, GM; Jusko, WJ; Kahan, BD; Mis, SM; Zimmerman, JJ, 1996)	0.62
" Reduction of the prednisolone dosage was associated with multiple erosions in the esophagus."	( Nonscarring inflammatory epidermolysis bullosa acquisita with esophageal involvement and linear IgG deposits. Inaoki, M; Mori, T; Nishimura, Y; Takehara, K; Taniuchi, K, 1997)	0.63
" As a consequence of improved delivery of enteral nutrition, in the year after the insertion of the gastrostomy there was a reduction in prednisolone dosage in all patients, with six patients being able to stop prednisolone completely."	( Experience of percutaneous endoscopic gastrostomy in children with Crohn's disease. Cosgrove, M; Jenkins, HR, 1997)	0.5
" The dosage schedule was governed by the clinical and echocardiographic findings."	( [Löffler's parietal fibroplastic endocarditis. Echocardiographic course over 5 years]. Braun, B; Günther, E; Hust, MH; Metzler, B; Perier, P, 1997)	0.3
"Four children, 4 to 10 years old, with chronic uveitis were treated with cyclosporin A (CsA; starting dosage 2 mg/kg per day) and prednisolone."	( [Cyclosporin A in therapy of chronic uveitis in childhood]. Dannecker, G; Schlote, T; Thiel, HJ; Zierhut, M, 1996)	0.5
" We also investigated the effect of glucocorticoid in 10 DMD patients taking a dosage of prednisolone 1 mg/kg on alternate day."	( [Glucocorticoid therapy in Duchenne muscular dystrophy]. Kang, J, 1996)	0.52
" Plasma collected at intervals over the 48 h from dosing also suppressed monocyte TNF-alpha release in relation to the prednisolone concentration therein."	( Suppression of human monocyte tumour necrosis factor-alpha release by glucocorticoid therapy: relationship to systemic monocytopaenia and cortisol suppression. Joyce, DA; Steer, JH; Vuong, Q, 1997)	0.51
" Both groups showed no statistical differences in number, kidney function, age, body weight, sex distribution, steroid dosage and follow-up time after transplantation."	( Effects of cyclosporin A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients. Arlt, M; Brückner, D; Dietl, KH; Hohage, H; Spieker, C; Zidek, W, 1997)	0.3
" However, in severely relapsed cases, corticosteroids are not always effective even when a high dosage is administered."	( A pilot study of centrifugal leukocyte apheresis for corticosteroid-resistant active ulcerative colitis. Ashida, T; Ayabe, T; Einami, K; Kohgo, Y; Nomura, M; Ono, M; Saitoh, Y; Santos, SB; Shibata, Y; Taniguchi, M; Taruishi, M, 1997)	0.3
"From each article, the following was abstracted: reference citation; type of control; whether study incorporated a run-in period in which the baseline level of prednisone was reduced to the lowest possible dose; dosage and length of methotrexate therapy; baseline dosage; and type of steroid."	( Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis. Marin, MG, 1997)	0.3
" The greatest effect was evident in patients in whom an effort was made to reduce baseline steroid dosage and in whom methotrexate was used for 24 weeks."	( Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis. Marin, MG, 1997)	0.3
"The aim of the study was to compare the long term effects of low dosage prednisolone or deflazacort treatment on bone mass in patients with polymyalgia rheumatica."	( [Bone loss during low dose glucocorticoid treatment in patients with polymyalgia rheumatica. A double-blind, prospective comparison between prednisolone and deflazacort]. Krogsgaard, MR; Lund, B; Thamsborg, G, 1997)	0.73
" His condition was dramatically improved within 1 week, and he is now well on an outpatient basis with the maintenance dosage of corticosteroid."	( A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Hotta, N; Kawahara, H; Matsuo, S; Mori, Y; Sutoh, H; Toriyama, T, 1997)	0.3
" The prednisolone dosage was then tapered to 5 mg/day."	( Subglottic stenosis in Wegener's granulomatosis limited to the head and neck region. Kadota, Y; Saeki, K; Yumoto, E, 1997)	0.81
" The occurrence of steroid side effects depends on dosage and duration of steroid treatment."	( [Steroid-induced myopathy in left-sided ulcerative colitis. Successful treatment and continued therapy with the topical steroid budesonide]. Andus, T; Caesar, I; Gross, V; Hohenberger, W; Roth, M; Schölmerich, J, 1997)	0.3
"To compare the efficacy and safety of two dosage regimens of budesonide and prednisolone in patients with active Crohn's disease affecting the ileum and/or the ascending colon."	( Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Campieri, M; Doe, W; Ferguson, A; Nilsson, LG; Persson, T, 1997)	0.79
"To probe into the pathogenesis of osteonecrosis of the femoral head, the authors obtained 37 asymptomatic human femoral heads at autopsy; of these, 13 were cases of high dosage corticosteroid therapy (steroid group) and 24 were cases without steroid therapy (nonsteroid group)."	( Histopathologic alterations of retinacular vessels and osteonecrosis. Hirano, K; Sueishi, K; Sugioka, Y; Tsutsui, H, 1997)	0.3
"We evaluated a 1-year course of a newly developed immunosuppressant, mizoribine (at a dosage of 3 mg/kg body weight per day), in nine children with steroid-dependent nephrotic syndrome."	( Mizoribine in steroid-dependent nephrotic syndrome of childhood. Hamasaki, T; Kinoshita, Y; Mori, M; Saeki, T; Sakano, T, 1997)	0.3
" As the steroid dosage was reduced, bone mass improved."	( Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Corrigall, V; Dasgupta, B; Dolan, AL; Li, F; Mackintosh, C; Moniz, C; Panayi, GS; Todd, P, 1997)	0.3
" No proteinuria was observed after total dosage of immunosuppressants was increased."	( [A case of recurrent IgA nephropathy following renal transplantation under tacrolimus (FK506)]. Hatori, M; Honda, M; Ichimaru, N; Imai, E; Kokado, Y; Kyo, M; Matsumiya, K; Miyamoto, M; Nonomura, N; Okuyama, A; Takahara, S; Takao, T; Yokoyama, K, 1997)	0.3
" Potency estimates were made by comparing the dose-response of natural and synthetic glucocorticoids to that of corticosterone, the major glucocorticoid in rats."	( Calcium-lowering action of glucocorticoids in adrenalectomized-parathyroidectomized rats. Specificity and relative potency of natural and synthetic glucocorticoids. Hirsch, PF; Mahgoub, A; Munson, PL, 1997)	0.3
"A 5-mg/kg dosage of ganciclovir was administered intravenously over a 60-min period under continuous venovenous hemodiafiltration."	( Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. Gando, S; Hayakawa, T; Kameue, T; Nakanishi, Y; Nanzaki, S, 1998)	0.3
" To address possible differences in steady-state time-course, the aim of this study was to determine if repeated dosing with inhaled fluticasone would have facilitatory effects on lymphocyte beta2-AR."	( Effects of oral and inhaled corticosteroid on lymphocyte beta2-adrenoceptor function in asthmatic patients. Lipworth, BJ; McFarlane, LC; Tan, KS, 1997)	0.3
"Repeated dosing with high-dose inhaled fluticasone did not up-regulate lymphocyte beta2-AR as compared with a single dose of oral prednisolone, despite having significantly suppressed early morning plasma cortisol."	( Effects of oral and inhaled corticosteroid on lymphocyte beta2-adrenoceptor function in asthmatic patients. Lipworth, BJ; McFarlane, LC; Tan, KS, 1997)	0.5
" A dose-response curve (DRC) for systemic beta2-responses to inhaled salbutamol (800 to 3,200 microg) was constructed before and after each treatment period (ie, FM + PL or FM + PRED)."	( Concomitant administration of low-dose prednisolone protects against in vivo beta2-adrenoceptor subsensitivity induced by regular formoterol. Lipworth, BJ; McFarlane, LC; Tan, KS, 1998)	0.57
" Its use as a second agent in combination with another immunosuppressant might enable reduction in the dosage or time of application."	( A low dose immunorestorative effect of aporphinoid alkaloid oxoglaucine on experimentally immunosuppressed and infected mice. Ivanovska, N; Philipov, S, 1997)	0.3
" Prednisolone dosage was reduced and cyclosporin (350 mg/d) substituted for azathioprine."	( [Late manifestation of a fatal Behçet's disease with cardiac involvement and lethal outcome]. Bocker, T; Görnig, M; Kaatz, M; Wollina, U; Zouboulis, CC, 1998)	1.21
"The influence of prednisolone on monocyte chemotactic activity in vitro at prednisolone concentrations comparable with those achieved in man following oral dosage has been investigated."	( Effect of long-term corticosteroid therapy on monocyte chemotaxis in man. Halliday, JW; Powell, LW; Tanner, AR, 1980)	0.6
"016) with the current glucocorticoid dosage (r=-0."	( Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Behre, HM; Castel, MA; Kamischke, A; Kemper, DE; Lüthke, M; Magnussen, H; Nieschlag, E; Rolf, C, 1998)	0.3
" We retrospectively evaluated 35 children with idiopathic NS, 24 with steroid-dependent NS (SDNS), and 11 with steroid-resistant NS (SRNS), who received CsA therapy for more than 12 months (median, 23 months) at the dosage maintaining 50 to 120 ng/mL in trough level."	( Follow-up study of children with nephrotic syndrome treated with a long-term moderate dose of cyclosporine. Fukushima, K; Hino, S; Murakami, K; Okada, M; Takemura, T; Yagi, K; Yoshioka, K, 1998)	0.3
" The dosage reductions are all significant but with no differences between the groups."	( Comparison of three treatment regimens of inhaled sodium cromoglycate in the management of adult patients with severe, steroid-dependent asthma. Asai, S; Edwards, A; Kohno, S; Matsuo, N; Matsuse, H; Obase, Y; Sakai, H; Shimoda, T, 1998)	0.3
" Duration of treatment, dosage of drugs per kg body weight and serum cyclosporin levels were recorded."	( Contribution of individual drugs to gingival overgrowth in adult and juvenile renal transplant patients treated with multiple therapy. Ashley, FP; Koffman, CG; Morel, A; Ogg, CS; Rigden, SP; Smith, D; Wilson, RF, 1998)	0.3
" The median total dosage of prednisolone at the time of diagnosis was 189 mg/kg (single manifestation 150 mg/kg; multiple manifestations 313 mg/kg) with a total range of 13-555 mg/kg."	( Avascular necrosis of bone following allogeneic stem cell transplantation: MR screening and therapeutic options. Böhm, P; Einsele, H; Faul, C; Kanz, L; Pereira, P; Wiesmann, A, 1998)	0.59
" The same symptoms subsequently recurred, and ESR and CRP levels increased proportionately to a decreased dosage of prednisolone."	( [Chronic thromboembolic pulmonary hypertension associated with initial pulmonary involvement in Takayasu arteritis]. Kashiwabara, K; Kiguchi, T; Kishi, K; Kobayashi, K; Kusama, H; Matsuoka, T; Nakamura, H; Sarashina, G; Yagyu, H, 1998)	0.51
" After tapering of the corticosteroid dosage to a low level the retinal detachment resolved without laser treatment."	( Fibrotic scar formation in central serous chorioretinopathy developed during systemic treatment with corticosteroids. Hooymans, JM, 1998)	0.3
"The colon-targeted delivery capsule (CTDC), a new capsule-type dosage form for colonic delivery of drugs, was investigated for the in vivo drug release behavior in dogs."	( In vivo drug release behavior in dogs from a new colon-targeted delivery system. Hatano, H; Ishibashi, T; Kobayashi, M; Mizobe, M; Yoshino, H, 1999)	0.3
" Whole blood T-cell trafficking was determined indirectly by using the glucocorticoid receptor antagonist RU-40555 (250 ng/mL) added to ex vivo cultures of whole blood from animals dosed with prednisolone."	( Influence of gender on prednisolone effects on whole blood T-cell deactivation and trafficking in rats. Gobburu, JV; Jusko, WJ; Meno-Tetang, GM, 1999)	0.8
" The interindividual variation was found to be mainly the time lag between dosage and maximum effect."	( The effects of the glucocorticoids prednisolone, deflazacort and beclomethasone-dipropionate on the RM 3/1 macrophage in human peripheral blood. Schmutzler, W; Zwadlo-Klarwasser, G, 1998)	0.58
" These values were sustained throughout dosing but declined rapidly to baseline upon cessation of treatment."	( Pharmacological validation of a feline model of steroid-induced ocular hypertension. Bhattacherjee, P; Graff, G; Paterson, CA; Spellman, JM; Yanni, JM, 1999)	0.3
" During pregnancy she was treated with a daily dosage of prednisolone 15 mg."	( Successful pregnancy and delivery in a case of systemic lupus erythematosus treated with immunoadsorption therapy and cyclosporin A. Kodama, N; Maeshima, E; Mune, M; Yamada, Y; Yukawa, S, 1999)	0.55
" The administration of G-CSF at a dosage of 5 micrograms/kg/day for 11 doses following CHOP resulted in an overall net cost of $Can1257."	( Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma. Altmayer, C; Dranitsaris, G; Quirt, I, 1997)	0.3
" Corticosteroid dosage was tapered according to a standard protocol."	( Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Krummenauer, F; Meyer zum Büschenfelde, KH; Neurath, MF; Peters, M; Schlaak, JF; Wanitschke, R, 1999)	0.3
" Except for the angiotensin-converting enzyme inhibitor, these medications were not effective in terms of allowing a reduction in the high dosage of steroid, which in turn threatened progressive osteoporosis and lumbar vertebrae fracture."	( Effect of pituitary microsurgery on acromegaly complicated nephrotic syndrome with focal segmental glomerulosclerosis: report of a rare clinical case. Akikusa, B; Hasegawa, S; Iesato, K; Murotani, N; Saeki, N; Shimada, T; Wakashin, M; Yamamoto, S; Yoshida, H, 1999)	0.3
" MMF was administered at a dosage of 2 gm/day whereas Aza was initiated at 2 mg/kg/day and adapted by leukocyte count."	( Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation. Artemiou, O; Birsan, T; Dekan, G; Klepetko, W; Taghavi, S; Wisser, W; Wolner, E; Zuckermann, A, 1999)	0.3
" After increased dosage of systemic prednisolone was prescribed, the retinal vascular changes resulting from CRVO (papillophlebitis) in the left eye gradually abated."	( Central retinal vein occlusion during remission of ulcerative colitis. Doi, M; Fujioka, C; Nakaseko, Y; Uji, Y, )	0.41
"3 mg/kg body weight) initially for 2 months; the dosage was then reduced to half of the initial dose for the third month and was halved again for the fourth and final month."	( The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients. Hann, SK; Kim, SM; Lee, HS, 1999)	0.3
" A moderate to high dosage of corticosteroids suppressed the development of new skin lesions, but relapses occurred when these systemic corticosteroids were tapered."	( Epstein-Barr virus-associated lymphoproliferative skin lesion with recurrent necrotic papulovesicles of the face. Jung, DY; Kim, JW; Lee, SK; Lee, WW, 1999)	0.3
" In this group, a trial of prednisone withdrawal was initiated when patients were 6 months or more post-OLT, with normal liver function, and receiving an average prednisone dosage of 10 mg/d."	( Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Everson, GT; Kam, I; Shrestha, R; Trouillot, TE; Wachs, M, 1999)	0.3
"The objective of the present study was to evaluate the dosing regimen of immunosuppressants necessary to avoid the formation of anti-hGH antibodies in a pig model."	( Plasma concentration of hGH and anti-hGH antibodies after subcutaneous administration of hGH for 3 weeks to immunosuppressed pigs. Agersø, H; Drustrup, J; Haahr, PM; Jørgensen, KD; Wilken, M, 1999)	0.3
" All groups were dosed subcutaneously (s."	( Plasma concentration of hGH and anti-hGH antibodies after subcutaneous administration of hGH for 3 weeks to immunosuppressed pigs. Agersø, H; Drustrup, J; Haahr, PM; Jørgensen, KD; Wilken, M, 1999)	0.3
"To determine the systemic dose-response relationships with oral prednisolone and inhaled fluticasone propionate administered in a putative 11:1 mg equivalent basis, in terms of effects on adrenal, bone and haematological markers."	( Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults. Lipworth, BJ; Wilson, AM, 1999)	0.77
"Systemic tissues exhibit different dose-response relationships for the effects of inhaled and oral corticosteroids with suppression of cortisol being greater than osteocalcin or eosinophils."	( Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults. Lipworth, BJ; Wilson, AM, 1999)	0.53
" No untoward effect from drugs sufficient to alter the dosage used was recorded."	( Clinical features and treatment outcome of idiopathic membranous nephropathy in Chinese patients. Chan, TM; Cheng, IK; Lai, KN; Tang, S, 1999)	0.3
"Initial dosage of prednisolone was 15."	( Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. Matoba, K; Miyawaki, S; Nishiyama, S, 1999)	0.96
"The prednisolone group received prednisolone at a dosage of 5 mg/kg, and the control group received sham saline injections for 5 days."	( Detrimental effects of short-term glucocorticoid use on the rat diaphragm. Dodd, SL; Eason, JM; Martin, AD; Powers, SK, 2000)	0.87
" From these dose-response profiles, the following ID(50) values (nmol/ear resulting in a 50% reduction of edema) were calculated: 540, 618, 454, and 346 nmol for prednisolone (P), methyl 21-desoxy-21-chloro-11beta,17alpha-dihydroxy-3,20-dioxo-1, 4-pregnadien-16alpha-carboxylate (PClCM), methyl 21-desoxy-21-chloro-11beta,17alpha-dihydroxy-9alpha-fl uoro-3, 20-dioxo-1,4-pregnadien-16alpha-carboxylate (FPClCM), and methyl 21-desoxy-21-chloro-9alpha-fluoro-11beta-hydroxy-3,20-dioxo- 1, 4-pregnadien-16alpha-carboxylate (FDPClCM), respectively."	( New steroidal anti-inflammatory antedrugs: methyl 21-desoxy-21-chloro-11beta,17alpha-dihydroxy-3,20-dioxo-1, 4-pregnadiene-16alpha-carboxylate, methyl 21-desoxy-21-chloro-11beta-hydroxy-3,20-dioxo-1, 4-pregnadiene-16alpha-carboxylate, and their 9alpha-flu Chen, M; Heiman, AS; Ko, D; Lee, HJ, 2000)	0.5
" He was hospitalized for severe exacerbation that worsen when steroid dosage was increase."	( [A rare cause of asthma exacerbation: systemic anguilluliasis]. Didier, A; Leophonte, P; Linas, MD; Recco, P; Rivals, A; Rouquet, RM, 2000)	0.31
" Information on the disease, initial DMARDs prescriptions and their side effects, prednisolone use, dosage and side effect(s) were focused and compared among three 5-year periods (1983-1987, 1988-1992 and 1993-1997)."	( Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study. Akkasilpa, S; Deesomchok, U; Osiri, M, 2000)	0.79
" The initial prednisolone dosage was 50 mg and was tapered according to a standard protocol."	( Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Galle, PR; Krummenauer, F; Mayet, WJ; Neurath, MF; Orth, T; Peters, M; Schlaak, JF; Wanitschke, R, 2000)	0.68
"Treatment consisted uniformly of prednisolone in a starting dosage of 250 mg tapering over 18 days and accompanying infusion of dextran and pentoxifylline."	( Bell's palsy: a 10-year experience with antiphlogistic-rheologic infusion therapy. Eckel, HE; Guntinas-Lichius, O; Sittel, A; Sittel, C; Stennert, E, 2000)	0.59
" Cyclophosphamide and anticoagulants along with increasing the dosage of corticosteroid were effective."	( Dermatomyositis with splenic and renal infarctions during corticosteroid therapy. Fukasawa, C; Hara, M; Harigai, M; Kamatani, N; Matsuda, Y; Nakajima, H; Takeuchi, M; Terajima, H; Yamada, T, 2000)	0.31
" On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs."	( Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression. Fink, H; Ibebunjo, C; Khiroya, R; Martyn, J; Shin, YS, 2000)	1.75
" Mycophenolate mofetil was used in combination with cyclosporine and prednisone and allowed for significant reductions in dosage of these immunosuppressants."	( Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Meriggioli, MN; Rowin, J, 2000)	0.31
" The dosage of levamisole given was 2 to 3 mg/kg daily or every other day, depending on the patients' response."	( Levamisole in steroid-sensitive nephrotic syndrome children with steroid-dependency and/or frequent relapses. Chi, CS; Fu, LS, )	0.13
" Although initiation of high-dose prednisolone therapy resulted in a gradual improvement in clinical symptoms, reducing the dosage of prednisolone caused a relapse."	( Interstitial cystitis and ileus in pediatric-onset systemic lupus erythematosus. Ito, T; Kakizaki, Y; Nakahata, T; Sugimoto, K; Tanaka, H; Tateyama, T; Tomimoto, K; Waga, S; Yokoyama, M, 2000)	0.59
" There has been no study on prednisolone dosage for the effective treatment of nephrotic syndrome."	( Older boys benefit from higher initial prednisolone therapy for nephrotic syndrome. The West Japan Cooperative Study of Kidney Disease in Children. Haruki, S; Hayashi, S; Hiraoka, M; Mayumi, M; Miyagawa, K; Ohshima, Y; Okuhara, K; Suehiro, F; Takeda, N; Tsukahara, H, 2000)	0.87
" After tapering the dosage of prednisolone in 5 mg increments per week, the pneumomediastinum disappeared without treatment."	( [Mixed connective tissue disease-associated interstitial pneumonia complicated by pneumomediastinum during prednisolone therapy]. Kashiwabara, K; Kishi, K; Kobayashi, K; Matsuoka, T; Nakamura, H; Narushima, K; Sarashina, G; Yagyu, H, 2000)	0.81
" These studies show that it is possible to detect the active ingredients in the intact dosage form, even where the substance comprises <1% of the total mass of the tablet."	( Evaluation of solid-state forms present in tablets by Raman spectroscopy. Langkilde, FW; Taylor, LS, 2000)	0.31
" In the light of our data and of other publications, early treatment with corticosteroids in sufficient dosage seems appropriate, while therapeutic nihilism in AIFP does not seem justified."	( [Antiphlogisitc-rheologic infusion therapy of acute idiopathic facial paralysis. Experiences and results of 344 cases]. Sittel, C; Stennert, E, 2000)	0.31
" The mean oral prednisolone dosage was significantly greater in RG than NG during the first (P=0."	( Randomized trial of blood eosinophil count monitoring as a guide to corticosteroid dosage adjustment after heart transplantation. Akhlaghi, F; Cary, N; Large, S; Parameshwar, J; Sharples, LD; Steel, LA; Trull, AK; Wallwork, J, 2000)	0.66
" Restriction of the EOS-guided steroid dosing protocol to periods of prolonged hospitalisation during the first 3 postoperative months should limit the requirement for higher prednisolone dosage without affecting immunosuppressive efficacy."	( Randomized trial of blood eosinophil count monitoring as a guide to corticosteroid dosage adjustment after heart transplantation. Akhlaghi, F; Cary, N; Large, S; Parameshwar, J; Sharples, LD; Steel, LA; Trull, AK; Wallwork, J, 2000)	0.5
" Initial dosage was 60 mg/day, and 1 week later, the dosage was gradually dropped since the patient responded favourably."	( Case of ulcerative colitis associated with oesophageal ulcer. Akahane, Y; Asakawa, A; Fujii, E; Fujino, MA; Kojima, Y; Morozumi, A; Nakamura, T; Ohtaka, M; Sato, T; Shimazaki, R, )	0.13
" However, it is important to monitor serum SRL levels to determine the optimal dosing regimen."	( A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Ascher, NL; Chang, GJ; Freise, CE; Hirose, R; Mahanty, HD; Roberts, JP; Stock, PG; Vincenti, F, 2000)	0.31
"A cross-sectional comparison of lumbar spine-bone mineral density (LS-BMD) was undertaken in 76 subjects after stratifying them according to dosage and administration route of corticosteroid."	( Bone mineral density in prepubertal asthmatics receiving corticosteroid treatment. Eisman, JA; Freezer, N; Harris, M; Hauser, S; Kelly, PJ; Morton, J; Nguyen, TV; Rodda, C; Strauss, BJ; Walker, JL, 2001)	0.31
"We investigated whether there was a dose-response relationship for the use of corticosteroids in childhood acute lymphoblastic leukemia (ALL)."	( Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. Chilton, D; Cohen, HJ; Gelber, RD; Sallan, SE; Schwartz, CL; Thompson, EB; Young, ML, 2001)	0.31
" Increase in dosage of prednisolone resolved the skin lesion, leaving depressed atrophic scars."	( Lupus erythematosus panniculitis in a patient with autoimmune hepatitis. Fujiwara, K; Ishii, M; Kono, T; Saito, S; Taniguchi, S, )	0.44
" In conclusion, the systemic corticosteroids are effective in 36% of patients, independent of dosage and pharmacological agents and duration of the therapy."	( Management of cutaneous hemangiomas: a retrospective analysis of 1109 cases and comparison of conventional dose prednisolone with high-dose methylprednisolone therapy. Akyüz, C; Büyükpamukçu, M; Kutluk, MT; Yariş, N, )	0.34
" If an underlying problem requires long-term immunosuppressive medication, it is wiser to choose cimetidine rather than increasing the steroid dosage to resolve atypical PFAPA."	( PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis). Chen, LC; Huang, JL; Lee, KF; Lee, WI; Lin, SJ; Yang, MH; Yeh, KW, 1999)	0.3
" In the first group, only prednicarbat cream was applied to affected places twice a day for a maximum of 10 days, while in the other group also cetirizin was administered once a day in a dosage according to the patient's age."	( [Prednicarbate and cetirizin dihydrochloride in the treatment of atopic eczema in the acute phase in children]. Bartosíková, L; Dzúrová, J; Frána, L; Frána, P; Kollár, P; Kotolová, H; Necas, J; Petrzelková, J, 2001)	0.31
" Development of this complication was associated with elevated intravenous FK 506 dosing schedules, with the mean cumulative dose 43% higher than treated patients with unaffected kidney function."	( Renal complications and development of hypertension in the European study of FK 506 and cyclosporin in primary liver transplant recipients. Bismuth, H; Calne, R; Devlin, J; Groth, C; McMaster, P; Neuhaus, P; Otto, G; Pichlmayr, R; Williams, R, 1994)	0.29
" Despite this, the pharmacokinetics of prednisolone have never been fully characterized in these patients, and consequently dosing remains empirical."	( Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. Akhlaghi, F; Holt, DW; Lee, T; Majid, O; Trull, A, 2001)	0.85
" Thereafter the dosage of prednisolone was gradually reduced."	( [Repeated deterioration of tuberculous meningitis due to a reduction in the corticosteroid dosage during chemotherapy]. Itoh, H; Miyoshi, Y; Murai, H; Noda, S, 2000)	0.61
" To further test this relationship between sodium transport and autoimmune hearing loss, dosage comparisons were made of prednisolone and aldosterone control of the auditory dysfunction in autoimmune MRL/MpJ-Fas(lpr) mice."	( Aldosterone and prednisolone control of cochlear function in MRL/MpJ-Fas(lpr) autoimmune mice. Kempton, JB; Trune, DR, 2001)	0.86
" Three patients with chronic and active ASD unresponsive to corticosteroids and methotrexate were given intravenous Infliximab infusions at a dosage of 3 mg/kg at weeks 0, 2, 6 and then once every 8 weeks."	( Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Bobbio-Pallavicini, F; Caporali, R; Cavagna, L; Epis, O; Montecucco, C, )	0.13
" Five patients who treated with steroids at the onset of neurological symptoms showed clinical improvement, regardless of their age, sex, the pathology and stage of breast cancer, or the total dosage of chemotherapeutic agents."	( 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. Cho, KH; Choi, SM; Kim, BC; Kim, MK; Lee, SH; Yang, YS, 2001)	0.31
"The extent and severity of hyperplasia was significantly correlated with the dosage and serum level of CsA at 3, 6 and 12 months post-transplantation; last recorded dosage, however (p<0."	( Cyclosporin A-induced gingival overgrowth is unrelated to allograft function in renal transplant recipients. Baboolal, K; Newcombe, RG; Subramanian, N; Thomas, DW, 2001)	0.31
" The steroid therapy was continued for 4 months with decreasing dosing schedule."	( [A case of retroperitoneal fibrosis responding to steroid therapy]. Habuchi, T; Horikawa, Y; Inoue, T; Kato, T; Satoh, S; Shimoda, N; Tachiki, Y, 2001)	0.31
" The dosage of the steroid, life style factors, menopausal status, low bone mineral density at baseline and previous osteoporotic fractures predispose for the manifestation of steroid-induced osteoporosis."	( [Risk of osteoporosis in steroid therapy. When and how to counter the risk]. Aschl, G; Hinterreiter, M; Kirchgatterer, A; Knoflach, P, 2001)	0.31
" Relapse treatment consisted of cessation of inhaled corticosteroids and start of oral corticosteroids at a dosage of 2 mg/kg/d and then a tapered dose."	( Inhaled corticosteroids for maintenance treatment in childhood pulmonary sarcoidosis. Anadol, D; Göçmen, A; Kiper, N; Ozçelik, U, 2001)	0.31
" Corticosteroid toxicity is a major problem, either because of inappropriate dosage or prolonged disease."	( Polymyalgia rheumatica and giant cell arteritis. Avoiding management traps. de Jager, JP, 2001)	0.31
" Reduction in the dosage of topical corticosteroid and medical treatment of the raised IOP resulted in resolution of the microcystic edema and interface fluid accumulation."	( Interface fluid after laser in situ keratomileusis. Fogla, R; Padmanabhan, P; Rao, SK, 2001)	0.31
" Gender, age at onset, duration of illness from onset, prednisolone dosage at the most-recent relapse, and regimens of initial steroid therapy at onset were not associated with risk."	( Prediction of subsequent relapse in children with steroid-sensitive nephrotic syndrome. Mizusawa, Y; Simoda, M; Takeda, A; Takimoto, H, 2001)	0.56
" However, these differences do not suggest the need for dosage adjustments, and additional experiments with repeat dosing are needed to fully evaluate the clinical implication of these findings."	( Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. Blum, RA; Jusko, WJ; Lates, CD; Magee, MH, 2001)	1.75
"This study sought to determine effects of multiple dosing of prasterone (DHEA, dehydroepiandrosterone) on the pharmacokinetics of prednisolone and endogenous cortisol secretion."	( Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women. Blum, RA; Jusko, WJ; Meno-Tetang, GM; Schwartz, KE, 2001)	0.52
" During steroid pulse therapy, the patients who were treated with insulin needed a higher dosage of insulin; after steroid pulse therapy, the dosage returned to baseline."	( Steroid pulse therapy combined with tonsillectomy in IgA nephropathy associated with diabetes mellitus. Chiba, S; Furuta, T; Honda, S; Horigome, I; Hotta, O; Miyazaki, M; Noshiro, H; Satoh, M; Taguma, Y, 2001)	0.31
" Plasmapheresis used in the treatment regimen substantially reduced the dosage of corticosteroids."	( [Extracorporeal methods in treating sarcoidosis patients]. Romanov, VV, 2001)	0.31
" CsA side effects can be eliminated by reducing the dosage of the drug."	( Cyclosporine nephrotoxicity: associated allograft dysfunction at low trough concentration. Druskis, V; Jankauskiene, A; Laurinavicius, A, 2001)	0.31
" Dosing of rats with NCX-1015 (0."	( Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Del Soldato, P; Flower, RJ; Mancini, L; Paul-Clark, MJ; Perretti, M, 2002)	0.31
" From these dose-response profiles, the following ID(50) values (nmol/ear resulting in a 50% reduction of edema) were calculated: prednisolone (Pred); 454, FP16CM; 255, 21-acetate (FP16CM-acetyl); 402, 21-propionate (FP16CM-propionyl); 474, 21-valerate (FP16CM-valeryl); 446 and 21-pivalate (FP16CM-pivalyl); 219 nmol."	( New steroidal antiinflammatory antedrugs: Methyl 3,20-dioxo-9 alpha-fluoro-11 beta,17 alpha,21-trihydroxy-1,4-pregnadiene-16 alpha-carboxylate and its 21-O-acyl derivatives. Heiman, AS; Hudson, CE; Ko, DH; Lee, HJ, 2002)	0.52
" Optimal sequencing of therapy and dosage still have to be examined."	( [Treatment of keratitis superficialis chronica of the dog with strontium 90]. Allgoewer, I; Brunnberg, L; Grüning, G; Hinkelbein, W; Höcht, S; Nausner, M, 2002)	0.31
" We propose that prednisolone at the 5-mg dosage (which gave partial HPA suppression), together with the assessment of salivary cortisol, can be used to investigate both impaired and enhanced glucocorticoid-mediated negative feedback in large samples of patients with psychiatric disorders."	( A novel prednisolone suppression test for the hypothalamic-pituitary-adrenal axis. Checkley, SA; English, J; Kerwin, RW; Lightman, S; Papadopoulos, AS; Pariante, CM; Poon, L, 2002)	1.09
" Complications due to treatment included: duodenal ulcer in one patient that responded to medical treatment, and transient elevation in serum creatinine levels in three patients, which returned to normal after decrease in dosage or cessation of oral CSA."	( Combined intravenous pulse methylprednisolone and oral cyclosporine A in the treatment of corneal graft rejection: 5-year experience. Cheng, LL; Lam, DS; Leung, AT; Rao, SK; Wong, AK; Young, AL, 2002)	0.6
" However, when the steroid dosage was reduced, signs of hyperthyroidism such as systolic hypertension and tachycardia were observed."	( Development of hyperthyroidism in a patient with idiopathic nephrotic syndrome. Harada, T; Hirai, H; Kondou, H; Kubota, T; Nakajima, S; Sawada, A; Shima, M; Shimizu, N, 2002)	0.31
" Older patients who require a higher dosage of oral glucocorticosteroids at hospital discharge and who have low serum albumin levels are at greater risk of death within the first year after hospitalization."	( Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Baima, B; Büchner, L; Büdinger, L; Hertl, M; Jung, M; Kaiser, HW; Kippes, W; Mecking, D; Messer, G; Messmer, EM; Meurer, M; Partscht, K; Pawelczyk, B; Pfeiffer, C; Prudlo, C; Rzany, B; Schuhmann, M; Sinkgraven, R; Sticherling, M; Zillikens, D, 2002)	0.31
" The chest radiographic findings were spontaneously resolved after three years with no increase in the dosage of oral corticosteroids."	( [Pulmonary sarcoidosis in a case of dermatomyositis under long-term steroid therapy]. Akiba, Y; Fujiuchi, S; Ide, H; Kikuchi, K; Nakano, H; Nishigaki, Y; Ohsaki, Y; Osanai, S; Yamamoto, Y, 2002)	0.31
" The dosage of steroids was tapered in 3 out of 4 CyA-responsive cases without re-exacerbation."	( Usefulness of cyclosporine A on rapidly progressive interstitial pneumonia in dermatomyositis. Inase, N; Miyake, S; Miyasaka, N; Miyazaki, Y; Ohtani, Y; Sawada, M; Takano, S; Yoshizawa, Y, 2002)	0.31
" albicans with fatal outcome was induced by a repeated dosing of prednisolone."	( Protection of mice from lethal endogenous Candida albicans infection by immunization with Candida membrane antigen. Ab, S; Mizutani, S; Ono, Y; Takesako, K; Tansho, S; Yamaguchi, H, 2002)	0.55
" Information on uveitis diagnosis, associated risk factors, steroid dosage and treatment duration, prophylaxis and management, was collected."	( Corticosteroid-induced osteoporosis in patients with uveitis. Anderton, LC; Cheong, FM; Jones, NP; Lesnik-Oberstein, S; Murray, PI; Pavesio, C; Stanford, MR; Whallett, A, 2002)	0.31
"The aim of this study was to evaluate the long-term effects in young children with Duchenne dystrophy of an intermittent low dosage regime of prednisolone (0."	( An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Dubowitz, V; Kinali, M; Main, M; Mercuri, E; Muntoni, F, 2002)	0.77
" Furthermore, the ability of MMF treatment to reduce the steroid dosage and/or substitute other immunosuppressive agents with unacceptable side-effects (cyclosporin A, tacrolimus, azathioprine) was evaluated."	( [Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis]. Forrester, JV; Greiner, K; Santiago, C; Varikkara, M, 2002)	0.31
"Systemic corticosteroids and inhaled beta(2) agonists are accepted first line treatments for acute severe asthma, but there is no consensus on their optimum dosage and frequency of administration."	( Randomised pragmatic comparison of UK and US treatment of acute asthma presenting to hospital. Daynes, TJ; Harrison, BD; Innes, NJ; Stocking, JA, 2002)	0.31
" Therefore, an alternative treatment is necessary in order to decrease steroid dosage and avoid the clinical problems associated with steroids."	( Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Asakura, H; Hibi, T; Hiwatashi, N; Muto, T; Nagawa, H; Satomi, M; Sawada, K; Sawada, T; Shimoyama, T, 2003)	0.32
" Due to the small inter- and intraindividual variations in the pharmacokinetic parameters, body surface area-based dosing is sufficient to obtain similar systemic exposure among patients."	( Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. Jusko, WJ; Petersen, KB; Rasmussen, M; Schmiegelow, K, 2003)	0.6
" Dosing of these agents was concentration-controlled and open-labeled."	( Bicêtre hospital experience with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study. Bäckman, L; Brattström, C; Calne, R; Campistol, JM; Charpentier, B; Claesson, K; Durand, D; Groth, CG; Kreis, H; Lang, P; Morales, JM; Touraine, JL; Wramner, L, 2003)	0.32
" When prednisolone alone proved ineffective, supplementary treatment with suplatast tosilate, an antiallergic selective Th2 cytokine inhibitor, improved the patient's inflammation, reduced the level of cardiac enzymes, and allowed for a reduction in corticosteroid dosage without any adverse effects."	( Effect of suplatast tosilate, an antiallergic selective Th2 cytokine inhibitor, on acute eosinophilic myocarditis: a case report. Haraguchi, M; Itagaki, K; Itoh, S; Kimura, M; Matsuzaki, M; Tanaka, M; Umemoto, S, 2003)	0.8
" However, the effects of a low maintenance dosage of corticosteroids on BW have not been studied longitudinally in RTx patients."	( Weight changes after renal transplantation: a comparison between patients on 5-mg maintenance steroid therapy and those on steroid-free immunosuppressive therapy. Christiaans, MH; Kooman, JP; Nieman, FH; van den Ham, EC; van Hooff, JP, 2003)	0.32
" High dosage steroid should be started before there is biopsy confirmation of the disease."	( [Excessive hyperferritinemia as an indication of a reactive hemophagocytosis syndrome]. Brunner, J; Dinser, R; Engel, A, 2003)	0.32
" The correlation of proximal muscle strength, but not HG strength, with steroid dosage further supports a cause-effect relationship."	( Corticosteroids and skeletal muscle function in cystic fibrosis. Barry, SC; Gallagher, CG, 2003)	0.32
"Both patients were treated with interferon-alpha in dosages of 3 million units of IFN-alpha 2b or an equivalent dosage of interferon-acon thrice weekly subcutaneously."	( [Interferon-alpha treatment of the Churg-Strauss syndrome]. Förster, M; Kroegel, C; Mock, B; Reissig, A; Schilder, C, 2003)	0.32
" No severe growth retardation was observed, but the duration and dosage of ALD prednisolone could be reduced further, since the patients with FSMPGN seemed to have an excellent prognosis."	( Focal segmental membranoproliferative glomerulonephritis in children. Iitaka, K; Moriya, S; Motoyama, O; Nakamura, S; Sakai, T, 2003)	0.55
"We found that MMF permitted a reduction in prednisolone dosage without disease relapse."	( An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Al Fares, S; Albert, S; Bhogal, B; Black, MM; Harman, KE; Powell, AM; Setterfield, J, 2003)	0.58
" This case suggests that combining ECCT with steroid therapy can maintain such poorly controlled and high-risk UC patients safely for the scheduled colectomy while improving the prognosis by reducing the dosage of steroid efficiently prior to operation."	( Poorly controlled ulcerative colitis treated by colectomy during remission induced by extracorporeal leukocyte removal therapy. Fukuda, Y; Fukui, S; Fukunaga, K; Hori, K; Matoba, Y; Ohnishi, K; Sagayama, K; Sawada, K; Shimoyama, T, 2003)	0.32
" In the dosage used, none of the compounds promoted discernible salt and water retention."	( 16a-Methyl corticosteroids; a new series of anti-inflammatory compounds; clinical appraisal of their antirheumatic potencies. BOLAND, EW, 1958)	0.24
" The size of dosage and individual susceptibility appeared to be important factors in the development of digestive disturbances from steroids."	( Effectiveness of antacids in reducing digestive disturbances in patients treated with prednisone and prednisolone. BOLAND, EW, 1958)	0.45
" In the first case, prednisolone in a dosage of 20 mg."	( HEMATOLOGICAL COMPLICATIONS OF PHENYLBUTAZONE THERAPY: REVIEW OF THE LITERATURE AND REPORT OF TWO CASES. CHALMERS, TM; MCCARTHY, DD, 1964)	0.57
" However, when the dosage was tapered, the BOOP recurred."	( [Successful treatment of bronchiolitis obliterans organizing pneumonia with cyclosporin and steroids]. Hamada, H; Higaki, J; Hiwada, K; Irita, J; Ito, R; Kadowaki, T; Katayama, H; Kukita, H; Mutsukado, Y; Onishi, H; Watanabe, A; Yokoyama, A, 2003)	0.32
" The daily dosage of prednisolone and beclomethasone was progressively decreased while the gain in nasal comfort was being preserved."	( [Sino-nasal polyposis. Evaluation of the efficacy of combined local and general corticotherapy in a series of 100 consecutive patients with a 3-year follow-up]. Avant, P; Bonfils, P; Norès, JM, 2002)	0.63
"To determine whether a topical ophthalmic diclofenac sodium formulation containing a proprietary polymeric drug delivery system (ISV-205), when dosed concomitantly with 1% prednisolone acetate, is effective in blocking the intraocular pressure (IOP) response in humans."	( Prevention of corticosteroid-induced intraocular pressure elevation using ISV-205. Stewart, WC, 2003)	0.51
" Initial dosage prednisolone was given for 1 month, and then tapered gradually in terms of dosage and interval."	( [Quadritherapy with cyclosporine for membranous lupus nephropathy]. Iwasawa, H; Matsumoto, H; Nagaoka, Y; Nakao, T; Okada, T; Tomaru, R; Wada, T, 2003)	0.66
" The daily oral steroid dosage (prednisolone 25."	( Risk factors for nontraumatic osteonecrosis of the femoral head after renal transplantation. Asano, T; Fujioka, M; Hirota, Y; Horii, M; Inoue, S; Kim, WC; Kubo, T; Nakagawa, M; Ogura, T; Shibatani, M; Tanaka, T, 2003)	0.6
" For the treatment of pemphigus, a course of the lowest possible corticosteroid dosage in combination with immunosuppressive agents appears to be effective and less toxic than a high corticosteroid dosage."	( Pemphigus in Korea: clinical manifestations and treatment protocol. Choi, WW; Chung, JH; Seo, PG, 2003)	0.32
" The average dosage of, respectively, procaine benzylpenicillin (I."	( Pharmacological and toxicological aspects of combination of beta-lactam and aminoglycoside antibiotic, prednisolone and procaine hydrochloride on the example of Vetramycin. Kania, BF; Kania, K, 2003)	0.53
" The aim of our study was to review our data to determine if the steroid dosage is associated with the incidence of early complications after bowel resection in patients with prolonged steroid therapy for Crohńs disease (CD)."	( Preoperative steroid administration: effect on morbidity among patients undergoing intestinal bowel resection for Crohńs disease. Anthoni, C; Bruewer, M; Kersting, S; Krieglstein, CF; Laukoetter, MG; Rijcken, EJ; Senninger, N; Utech, M, 2003)	0.32
" In children with a history of FSGS, caution is necessary when altering the dosing schedule of prednisone."	( Nephrotic syndrome after conversion to alternate day steroids in two children with a history of recurrent FSGS. Greenbaum, LA; Hanevold, CD, 2003)	0.32
" The optimal dosage appears to be 3 mg/day in terms of efficacy and safety."	( Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. Abe, T; Hara, M; Hashimoto, H; Irimajiri, S; Kondo, H; Sugawara, S; Uchida, S, 2004)	0.32
"Concurrently with the changes in prednisolone dosage serum OC levels increased significantly at 28 weeks (p<0."	( The effect of the steroid-sparing response to low-dose methotrexate on bone metabolism in glucocorticoid-dependent asthmatics. Girgis, SI; Ind, PW; Nwokeji, A; Shakur, BH; Shiner, RJ, 2004)	0.6
" There was a significant correlation between age at the onset of CSC and the daily dosage of corticosteroid."	( Seventeen cases of central serous chorioretinopathy associated with systemic corticosteroid therapy. Adachi-Usami, E; Igarashi, Y; Koyama, M; Mizota, A, )	0.13
" Prednisone, begun perioperatively, was reduced gradually from a mean initial dosage of 38."	( [Pneumocystis carinii pneumonia complicating brain tumor]. Gejyo, F; Nishibori, T; Takahashi, H; Tanaka, R; Tsukada, H; Uzuka, T, 2004)	0.32
" The daily dosage of prednisolone and beclometasone was progressively decreased, while the gain in nasal comfort was being preserved."	( Medical treatment of stage I nasal polyposis over a 3-year follow-up period. Avan, P; Bonfils, P; Halimi, P; Norès, JM, 2004)	0.64
"To evaluate the circadian variation in patients with renal transplant on twice daily dosing in order to evaluate if patients could need a dosage adjustment in diurnal or nocturnal dose."	( Circadian variation of cyclosporine A in renal transplanted patients. González López, EH; Jung Cook, H; Nava, A; Reyna Rodríguez, C, )	0.13
" Oral steroid dosage had slowly been tapered over 1 month."	( Pulmonary involvement in Crohn's disease report of a case and review of the literature. Asahi, H; Inoue, Y; Irinoda, T; Omori, H; Saito, K, 2004)	0.32
" Relapses did not occur with the tapering of PSL dosage when the ELISA values decreased to 40% of initial values, although they were still not within the normal range."	( Monitoring of ELISA for anti-BP180 antibodies: clinical and therapeutic analysis of steroid-treated patients with bullous pemphigoid. Esaki, C; Ichiki, Y; Izumi, T; Kitajima, Y, 2004)	0.32
" Owners of the dogs recorded pruritus daily using a 10 cm visual analog scale and the dosage of prednisolone was established based on the pruritus score, according to written instructions."	( A randomized, controlled study to evaluate the steroid sparing effect of essential fatty acid supplementation in the treatment of canine atopic dermatitis. Bergvall, K; Hedhammar, A; Holm, BR; Kristensen, F; Larsen, S; Saevik, BK; Saijonmaa-Koulumies, LE, 2004)	0.54
" Hence, a reduction in CsA dosage in kidney transplant recipients (KTR) may improve long-term outcomes."	( Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. Cardarelli, F; Cosimi, AB; Delmonico, FL; Farrell, ML; Pascual, M; Saidman, SL; Shih, V; Tolkoff-Rubin, N; Winkelmayer, WC; Wong, W, 2004)	0.32
" To fully benefit from this promising new drug, FK778 dosing will be optimized in subsequent studies."	( The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Chang, R; Charpentier, B; Grinyó, JM; Jurewicz, A; Klinger, M; Kreis, H; Mourad, G; Neuhaus, P; Paczek, L; Paul, LC; Rostaing, L; Short, C; Squifflet, JP; van Hooff, JP; Vanrenterghem, Y; Wlodarczyk, Z, 2004)	0.32
" Therapeutic studies were performed for up to 8 weeks of dosing with prednisolone, methotrexate, 3 nonsteroidal antiinflammatory drugs (celecoxib, diclofenac, and indomethacin), a p38 MAPK inhibitor, SB242235, and human soluble TNF receptor (sTNFR; etanercept) and murine sTNFR fusion proteins."	( Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology. Bush, K; Life, P; Morgan, R; Patten, C; Rioja, I; Trill, J; Wooley, P, 2004)	0.56
" The protocol calls for a 10-day pretransplantation conditioning period, starting with one dosage of rituximab and followed by full dose tacrolimus, mycophenolate mofetil and prednisolone."	( ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Fehrman, I; Genberg, H; Kumlien, G; Lundgren, T; Sandberg, J; Tydén, G, 2005)	0.52
" The intraperitoneal dosing of LPS produced large and transient elevations of plasma TNF-alpha, IFN-gamma, and NO concentrations."	( Pharmacodynamic interactions between recombinant mouse interleukin-10 and prednisolone using a mouse endotoxemia model. Chakraborty, A; Jusko, WJ; Pyszczynski, NA; Yeung, S, 2005)	0.56
" Placebo-controlled studies with varying dosage schedules are required to standardize the dose of prednisolone used in pulse therapy, optimize the therapeutic efficacy, and minimize side effects."	( Placebo-controlled oral pulse prednisolone therapy in alopecia areata. Dogra, S; Handa, S; Kar, BR; Kumar, B, 2005)	0.83
" As the prednisolone dosage could not be decreased to less than 2 mg/kg/48 h, the patient was re-challenged with Cs A 1 1/2 years later."	( The use of cyclosporine in a boy with a prior episode of posterior encephalopathy. Hasegawa, N; Iwasaki, N; Izumi, I; Kanemoto, K; Nakahara, C, 2005)	0.76
"The aims of the current study were to determine whether therapeutic drug monitoring (TDM) might benefit kidney transplant recipients receiving everolimus, and to establish dosage recommendations when everolimus is used in combination with cyclosporine and corticosteroids."	( Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Kovarik, J; Li, Y; Lorber, MI; Mayer, HW; Ponticelli, C; Schmidli, H; Whelchel, J, 2005)	0.33
"The aim of our study was to evaluate spontaneous fluctuations in serum PTH levels in six adult male patients (aged 31-64 years) receiving chronic (>6 months) therapy with glucocorticoids (daily dosage >7."	( Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Bilezikian, JP; Bonadonna, S; Bugari, G; Burattin, A; Giustina, A; Iori, N; Nuzzo, M; Rosei, EA; Valle, D; Veldhuis, JD, 2005)	0.33
"Univariate analysis identified the duration of transplant, papilla bleeding index, creatinine serum concentration, azathioprine and prednisolone dosage as risk factors for overgrowth severity."	( Risk factors for gingival overgrowth in patients medicated with ciclosporin in the absence of calcium channel blockers. Ellis, JS; Seymour, RA; Thomason, JM, 2005)	0.53
" Dosage of each of the three immunosuppressants was identified as a risk factor for the severity of gingival change."	( Risk factors for gingival overgrowth in patients medicated with ciclosporin in the absence of calcium channel blockers. Ellis, JS; Seymour, RA; Thomason, JM, 2005)	0.33
" The serum titer of anti-Ach-receptor antibodies decreased in parallel with clinical improvement due to tacrolimus, and we accordingly reduced the dosage of prednisolone."	( Low-dose tacrolimus for two cases of myasthenia gravis with invasive thymoma that relapsed shortly after thymectomy. Deguchi, K; Ikeda, K; Kuriyama, S; Sasaki, I; Shimamura, M; Takeuchi, H; Touge, T; Tsukaguchi, M; Urai, Y, 2005)	0.53
" The antitumor effects of the free drugs have only been observed using treatment schedules based on high and frequent dosing for prolonged periods of time."	( Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Fens, MH; Janssen, AP; Metselaar, JM; Molema, G; Schiffelers, RM; Storm, G, 2005)	0.64
" In this multicenter study, THP (pirarubicin)-COP (cyclophosphamide, vincristine, and prednisolone) was compared to two thirds dosage of full CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen with regard to both adverse events and efficacy."	( Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma. Harada, M; Hotta, T; Kitamura, K; Masaoka, T; Masuda, M; Matsuda, T; Miura, AB; Miyazaki, T; Mizoguchi, H; Mori, M; Niho, Y; Saito, H; Shibata, A; Takaku, F, 2005)	0.55
" Prednisolone in standard dosage schedule as recommended by WHO is now being widely used in control programmes."	( Reactions and their management. Ganapati, R; Pai, VV, 2004)	1.23
" Protocol biopsies may have therapeutic implications and may provide valuable information in the evaluation of start and dosing of ERT."	( Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabry's disease. Bostad, L; Houge, G; Iversen, BM; Kaarbøe, O; Lyngdal, PT; Svarstad, E; Tøndel, C, 2005)	0.33
" There is increasing evidence that, even in equipotent dosage for glucocorticoid effect, dexamethasone has enhanced lymphoblast cytotoxicity and penetration of the central nervous system (CNS) compared with prednisolone."	( Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Eden, TO; Kinsey, SE; Lilleyman, J; Mitchell, CD; Richards, SM; Vora, A, 2005)	0.78
" Records were reviewed for the dosage of immunosuppression, rate of relapse, steroid side effects, current status of liver function tests and evidence for cirrhosis and its complications."	( Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Boyer, JL; Seela, S; Sheela, H, 2005)	0.33
" Median taking compliance was 100% (range 60-105%), median dosing compliance was 99% (range 58-100%); median timing compliance (TIC) was 94% (42-100%)."	( Prevalence of prednisolone (non)compliance in adult liver transplant recipients. Drent, G; Geest, SD; Haagsma, EB; Kleibeuker, JH; Slooff, MJ; Ten Vergert, EM; van den Berg, AP; van den Bosch, HJ, 2005)	0.69
" Further trials are necessary to determine the optimal dosage and duration of therapy, and its efficacy in comparison to standard regimens."	( Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Au, TC; Mok, CC; Siu, YP; To, CH; Tong, KH, 2005)	0.33
" Both medications were dosed 4 times per day for 14 days and then BID until the container was empty."	( A clinical comparison of two different prednisolone acetate formulations in patients undergoing cataract surgery. Gayton, JL, 2005)	0.6
" The dosage of oral corticosteroids and/or second-line immunosuppressive medication was reduced or stopped altogether in 18 of 33 eyes (54."	( Outcome of intravitreal triamcinolone in uveitis. Kok, H; Lau, C; Lightman, S; Maycock, N; McCluskey, P, 2005)	0.33
" The PSL dosage was gradually tapered in accordance with improvement."	( Leukocytapheresis therapy for steroid-naïve patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. Abe, T; Aoyama, N; Fukagawa, M; Kasuga, M; Maekawa, S; Nakahara, T; Nishioka, C; Shirasaka, D; Tamura, T; Umezu, M, 2005)	0.33
" Type and dosage of immunosuppressive agents, pretransplant weight and human leukocyte antigen (HLA) phenotypes in PTDM patients were compared with 61 matched controls."	( Is HLA-DR6 a protective factor against posttransplantation diabetes mellitus? Amjadi, H; Amouzegar, A; Einollahi, B; Firouzan, A; Hemati, K; Nafar, M; Pour-Reza-Gholi, F, 2005)	0.33
" Intravenous prednisolone dosage was started with 4 mg/kg per day and tapered by a half dose every 2 days."	( Glucocorticoid receptor alpha expression in the intrahepatic biliary epithelium and adjuvant steroid therapy in infants with biliary atresia. Muraji, T; Tatekawa, Y; Tsugawa, C, 2005)	0.7
" During first 6 months of the trial, the patients also received prednisolone, which was started at a dosage of 15 mg daily and tapered to zero by the end of the sixth month."	( A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Davis, P; Fritzler, M; Kovalenko, W; Nadashkevich, O, 2006)	0.57
" In this context, we speculated that single-dose daily administration of low-dose CsA may be associated with a higher peak blood level without associated trough blood level elevation, and thereby yield better results and allow safer use of the drug than the conventional twice daily administration dosing used for the treatment of childhood idiopathic nephrotic syndrome (INS)."	( C1-C2 point monitoring of low-dose cyclosporin a given as a single daily dose in children with steroid-dependent relapsing nephrotic syndrome. Ito, E; Kudo, M; Nakahata, T; Suzuki, K; Tanaka, H; Tsugawa, K; Waga, S, 2005)	0.33
" Upon successive dose reduction to a maintenance dosage of 10 mg prednisolone, the patient's clinical status and peripheral blood count remained stable."	( Hypereosinophilic syndrome associated with acute necrotizing myocarditis and cardiomyopathy. Fries, JW; Hoppe, UC; Huntgeburth, M; Lindner, M, 2005)	0.57
" These results suggest a possible pharmacological action by PSL on the core circadian oscillation mechanism and indicate the possibility that the alteration of clock function induced by PSL can be avoided by optimizing the dosing schedule."	( Chronic treatment with prednisolone represses the circadian oscillation of clock gene expression in mouse peripheral tissues. Koyanagi, S; Kuramoto, Y; Ohdo, S; Okamura, H; Okazawa, S; Shimeno, H; Soeda, S; Ushijima, K, 2006)	0.64
" The daily steroid dosage can be tapered rapidly, and the SLE-associated hyperlipidemia resolved parallel to the resolution of the acute lupus nephritis."	( Sequential evaluation of clinical and laboratory changes amongst children suffering from lupus nephritis during intermittent intravenous cyclophosphamide therapy. Chiu, SJ; Huang, JL; Hung, IJ; Ou, LS; Tsai, TL, 2006)	0.33
" Patients received either two infusions of infliximab (5 mg/kg) alone (n=8) or in combination with long-term methotrexate at a dosage of 20 mg/week (n=11) over 48 weeks."	( Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. Blumenstein, I; Schröder, O; Stein, J, 2006)	0.33
" In this situation, administration of hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP), 400 microg/day, was started instead of BUD, and then improvement of the clinical symptoms, PEF and pulmonary function were observed promptly, followed by reduction in the dosage of PSL and a short-acting beta-stimulant."	( [A case of severe persistent bronchial asthma who showed significant improvement by switching to hfa-bdp, with reducing the dosage of oral steroids]. Ohbayashi, H, 2005)	0.33
" However, imatinib mesylate was effective independently of the dosing regime."	( Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Chaudhary, NI; Park, JE; Schnapp, A, 2006)	0.33
" The treatment duration was 5 days at usual recommended dosage regimens."	( [Efficacy of Derinox assessed with one PNIF (Peak Nasal Inspiratory Flow) in patients suffering from common cold]. Bruhwyler, J; Concas, V; Dessanges, JF; Peynegre, R, 2005)	0.33
" For experiment 2, prednisolone administration at either dosage and duration did not alter plasma leptin concentrations in any dogs."	( Effects of administration of glucocorticoids and feeding status on plasma leptin concentrations in dogs. Honjo, T; Kitagawa, H; Kitoh, K; Maeda, S; Nishii, N; Ohba, Y; Ohtsuka, Y; Saito, M; Takasu, M, 2006)	0.66
" Patients received a total steroid dosage between 100 and 500 mg of prednisolone."	( Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment. Bauer, K; Dunky, A; Feyertag, J; Haberhauer, G; Kittl, EM; Skoumal, M, 2006)	0.57
" Intramuscular injections of dexamethasone 5 mg were given for 10 days, followed by oral administration of prednisolone at a dosage of 15 mg for two weeks and 10 mg for two weeks."	( A case of complete ophthalmoplegia in herpes zoster ophthalmicus. Lew, H; Shin, HM; Yun, YS, 2005)	0.54
" These cases also had an increase in steroid dosage at the time of recurrence, but have been controlled medically so far."	( Indications for surgery in intestinal Behçet's disease. Katashi, F; Kurata, M; Murata, H; Nozue, M; Seino, K; Sumita, T, )	0.13
" Prednisolone was replaced to a lower dosage dexamethasone (2 mg/day)."	( Hepatocellular carcinoma with persistent hypoglycemia: successful treatment with corticosteroid and frequent high carbohydrate intake. Bubpha, P; Thipaporn, T; Varaphon, V, 2005)	1.24
" Later, pleural effusion waxed and waned depending on the dosage of PSL, but no other causative disorder was demonstrated by extensive examinations."	( [Case of dermatomyositis complicated with massive pleural effusion that preceded the myopathy]. Hagiyama, H; Iwai, H; Kohsaka, H; Koike, R; Kubota, T; Miyasaka, N; Nagasaka, K; Nanki, T; Nishio, J; Nonomura, Y; Ogawa, J; Sugihara, T; Tsubata, R, 2002)	0.31
" Takayasu arteritis had developed in a 24-year-old woman (March 2003) who had been treated with glucocorticoid including methylprednisolone pulse therapy and methotrexate; however, she relapsed during the tapering of the dosage of oral prednisolone."	( Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Aratake, K; Arima, K; Eguchi, K; Huang, M; Ida, H; Iwanaga, N; Izumi, Y; Kamachi, M; Kawakami, A; Nakamura, H; Origuchi, T; Tamai, M; Tanaka, F, 2006)	0.54
" All six patients received prophylactic cranial irradiation with a dosage of 18 or 24 Gy."	( Moyamoya syndrome following childhood acute lymphoblastic leukemia. Hanada, R; Ikuta, K; Ishimoto, K; Kaneko, T; Kikuchi, A; Maeda, M; Okimoto, Y; Tsuchida, M, 2007)	0.34
" She recovered completely by gradual dosage increase of short-acting corticosteroid after the discontinuation of prednisolone."	( Acute onset of steroid psychosis with very low dose of prednisolone in Sheehan's syndrome. Cho, DH; Chung, DJ; Chung, MY; Hong, SI; Kang, HC, 2006)	0.79
" We evaluated total Quantitative MG (Q-MG) score, anti-acetylcholine receptor (AChR) antibody titer in the blood, interleukin 2 (IL-2) production in peripheral blood mononuclear cells (PBMCs), administration dosage of prednisolone (PSL), and adverse effects of FK506."	( Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. Igarashi, S; Naruse, S; Nishizawa, M; Onodera, O; Oyake, M; Shimohata, T; Tada, M; Tanaka, K; Tsuji, S, 2006)	0.52
"A reduction in steroid dosage of 50% without worsening of the symptoms was observed 1 year after FK506 administration in three out of six steroid-dependent MG patients (50."	( Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. Igarashi, S; Naruse, S; Nishizawa, M; Onodera, O; Oyake, M; Shimohata, T; Tada, M; Tanaka, K; Tsuji, S, 2006)	0.33
" Side-effects of corticosteroid therapy remain a major clinical problem after transplantation, justifying the use of prednisolone TDM to optimize dosing and minimize morbidity."	( Therapeutic drug monitoring of prednisolone after lung transplantation. Glanville, AR; Kear, LM; McWhinney, BC; Morton, JM; Potter, J; Williamson, S, 2006)	0.83
" The introduction of infliximab has improved disease control, although a search for an optimum remittive dosing schedule is ongoing."	( Treatment of vulval Crohn's disease with infliximab. Hudson, N; Lewis, FM; Preston, PW, 2006)	0.33
" Previous reports suggested that modification of MZR therapy with a total dosage and administration schedule may improve the therapeutic effect."	( [Beneficial and adverse effects of high-dosage MZR therapy in the management of children with frequently relapsing nephrotic syndrome]. Goto, M; Hamasaki, Y; Hataya, H; Honda, M; Ikeda, M; Ishikura, K, 2006)	0.33
" A reduction in MPA dosage at the time of conversion may be necessary to prevent over-immunosuppression."	( Conversion to everolimus in maintenance patients--current clinical strategies. Pohanka, E, 2006)	0.33
" 36, 52, and 60 have anti-inflammatory activity in a mouse model of inflammation after topical dosing with 52 and 60, having an effect similar to that of dexamethasone."	( Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series. Barker, M; Clackers, M; Copley, R; Demaine, DA; Haase, MV; House, D; Humphreys, D; Inglis, GG; Johnston, MJ; Jones, HT; Loiseau, R; Macdonald, SJ; McLay, IM; Nisbet, L; Pacquet, F; Shanahan, SE; Skone, PA; Tape, D; Uings, I; Upton, R; Vinader, VM; Washington, M, 2006)	0.33
" dosage (10 AM & 10 PM) plus 6 placebo tablets in the morning (8 AM)."	( Comparison of a short course of prednisolone with sustained-release theophylline in the control of nocturnal asthma. Chhabra, SK, )	0.41
" Tacrolimus was employed for the maintenance therapy, and the oral prednisolone dosage could successfully be tapered without recurrence, along with the decrement of the titer of MPO-ANCA."	( Tacrolimus as a reinforcement therapy for a patient with MPO-ANCA-associated diffuse alveolar hemorrhage. Eguchi, K; Honda, E; Honda, S; Ida, H; Iwanaga, N; Kawakami, A; Kawasaki, S; Nakamura, H; Origuchi, T; Tsuchihashi, Y; Yoshimine, H, 2007)	0.58
" Although corticosteroid therapy has been reported to be effective in some CCE patients, the indications of steroid therapy, dosage of corticosteroids, duration of the treatment, or efficacy of prophylactic administration of antibiotics are not yet established."	( [Pulmonary infection of Pneumocystis carinii and Cytomegalo virus in the treatment of cholesterol crystal embolism]. Fujii, M; Fujita, Y; Kitamura, H; Matsui, I; Okuno, A; Yamamoto, R, 2006)	0.33
" Data about BNP dosage for cardiovascular monitoring of patients with ALA on renal replacement therapy are lacking."	( Role of B-type natriuretic peptide in cardiovascular state monitoring in a hemodialysis patient with primary amyloidosis. Cantelli, S; Catizone, L; Fabbian, F; Molino, C; Russo, G; Russo, M; Sartori, S; Stabellini, N, 2006)	0.33
" Those receiving a higher CsA dosage (<2."	( Bone mineral density in long-term Chinese heart transplant recipients: a cross-sectional study. Chen, YH; Chou, NK; Kuo, HL; Su, IC; Wang, SS; Yang, RS, 2006)	0.33
" The dosage of prednisolone was tapered, without a relapse, and then the corticosteroid therapy was stopped."	( Nephrotic syndrome associated with interferon-beta-1b therapy for multiple sclerosis. Fujita, T; Kumasaka, R; Murakami, R; Nakamura, M; Nakamura, N; Okumura, K; Osawa, H; Shimada, M; Shirato, K; Yamabe, H, 2006)	0.69
"Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing prednisolone are reviewed."	( Biowaiver monographs for immediate release solid oral dosage forms: prednisolone. Barends, DM; Derendorf, H; Dressman, JB; Junginger, HE; Krämer, J; Midha, KK; Shah, VP; Stavchansky, S; Vogt, M, 2007)	0.77
" The potential salt form would ideally decrease the rate of (SBE)7M-beta-CD release from osmotic pump formulations and result in an increase in the rate and extent of drug release in osmotic pump tablet and pellet dosage forms."	( Evaluation of various properties of alternative salt forms of sulfobutylether-beta-cyclodextrin, (SBE)7M-beta-CD. Haslam, JL; Sotthivirat, S; Stella, VJ, 2007)	0.34
" Information on dosage of prednisolone and immunosuppressive agents was also analyzed."	( Follow-up of linear growth of body height in children with nephrotic syndrome. Hung, YT; Yang, LY, 2006)	0.63
" Infliximab was administered by intravenous infusion at a dosage of 3 mg/kg."	( The effect of infliximab on chemokines in patients with rheumatoid arthritis. Ichikawa, T; Kageyama, Y; Nagano, A; Suzuki, M; Torikai, E, 2007)	0.34
" She subsequently received maintenance dosing in the outpatient clinic weekly for 4 weeks and bimonthly for 8 weeks, and she continues monthly maintenance VIT."	( Ultrarush venom desensitization after systemic reactions during conventional venom immunotherapy. Chegini, S; Hamilos, DL; Oren, E, 2006)	0.33
" Accordingly, we made the diagnosis of cryptococcal meningitis and immediately started multiple anti fungal drugs with dosage modification according to her impaired renal function."	( [A case of cryptococcal meningitis with nephrotic syndrome and renal insufficiency under immunosuppressive therapy]. Ichikawa, D; Kimura, K; Sato, T; Shima, Y; Tsuchida, H; Yasuda, T, 2007)	0.34
"Although mizoribine (MZ), which inhibits inosine monophosphate dehydrogenase in the same way as mycophenolate mofetil, recently proved more effective when higher doses were administered than previously approved, neither the optimal dosage nor blood concentration has yet been clarified."	( Prophylactic treatment of antibody-mediated rejection with high-dose mizoribine and pharmacokinetic study. Kobayashi, T; Kuzuya, T; Liu, D; Ma, Y; Miwa, Y; Morozumi, K; Nagasaka, T; Nakao, A; Oikawa, T; Uchida, K; Yokoyama, I, 2007)	0.34
" The aim of the present study was to compare the efficacy of two dosage regimens in this setting."	( Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation. Berlakovich, GA; Burghuber, C; Györi, G; Hetz, H; Mühlbacher, F; Silberhumer, G; Soliman, T; Steininger, R, 2007)	0.34
" We also evaluated the effectiveness and side effects of prednisolone using chitosan capsules compared with the conventional dosage form (gelatin capsules)."	( [Study on the colon specific delivery of prednisolone using chitosan capsules]. Yamamoto, A, 2007)	0.85
"5 mg/kg per day of CsA; the dosage was adjusted to reach a blood trough level of 80-150 ng/ml."	( Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. Amano, K; Kameda, H; Nagasawa, H; Ogawa, H; Sekiguchi, N; Takei, H; Takeuchi, T; Tsuzaka, K, 2007)	0.34
" By taking advantage of the heterogeneous methotrexate dosing that occurs among Japanese rheumatologists, we analyzed the efficacy and safety of different methotrexate doses."	( Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Hara, M; Inoue, E; Kamatani, N; Nakajima, A; Tanaka, E; Taniguchi, A; Terai, C; Tomatsu, T; Yamanaka, H, 2007)	0.34
" Dosage forms and the solid-state properties of drugs and excipients in a formulation may be influenced by the processing conditions used."	( Characterization of prednisolone in controlled porosity osmotic pump pellets using solid-state NMR spectroscopy. Haslam, JL; Lubach, JW; Munson, EJ; Sotthivirat, S; Stella, VJ, 2007)	0.66
" Secondary end points were time to first relapse, biomarkers, cumulative glucocorticosteroid dose, and the number of patients who remained relapse-free while the glucocorticosteroid dosage was tapered to 10 mg/d."	( Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Cid, MC; Hoffman, GS; Merkel, PA; Rahman, MU; Rendt-Zagar, KE; Salvarani, C; Stone, JH; Visvanathan, S; Weyand, CM; Xu, W, 2007)	0.34
"5 mg/kg) (MP group); and a group given a reduced dosage of ketoprofen (0."	( The interaction between orally administered non-steroidal anti-inflammatory drugs and prednisolone in healthy dogs. Hara, S; Motoishi, K; Naito, Y; Narita, T; Sato, R; Tani, K, 2007)	0.56
" Initial experiences with systemic administration of glucocorticoids after PCI failed to confirm the expected benefits of this treatment, probably as a result of inadequate dosage and pharmacokinetic calculations."	( Glucocorticoids in the prevention of restenosis after coronary angioplasty: therapeutic potential. Brunelleschi, S; Ferrero, V; Pesarini, G; Ribichini, F; Vassanelli, C, 2007)	0.34
" Clinicians must remain alert to detect amiodarone-related pneumonitis even under low dosage and short duration of amiodarone usage."	( Amiodarone-related pneumonitis. Chang, SN; Chiang, FT; Hsu, KL; Hwang, JJ; Lai, LP; Lin, JL; Tsai, CT; Tseng, CD, 2007)	0.34
" However, the symptoms were aggravated when the prednisolone dosage was reduced, and the titer of anti-MuSK antibody rose at the same time."	( [Titer of anti-muscle-specific receptor tyrosine kinase (MuSK) antibody correlated with symptomatic improvement in response to corticosteroid therapy in a patient with anti-MuSK antibody-positive myasthenia gravis: a case report]. Kawajiri, M; Kohara, K; Miki, T; Nakahama, Y; Ochi, M; Ohta, K, 2007)	0.6
" A young patient presenting with toxic maculopathy after 57 g of hydroxychloroquine and a daily dosage of 2 mg/kg body weight prompted us to retrospectively look at our patients examined in this respect over about 1 year."	( [Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses]. Berndt, S; Foerster, J; Rüther, K; Schroeter, J, 2007)	0.34
"In the treatment of tuberculosis with rifampicin in patients treated with prednisolone and cyclosporine, we have to increase the dosage of these drugs."	( [Examination of administrative dosage of cyclosporine during anti-tuberculosis chemotherapy including rifampicin]. Akagawa, S; Kawabe, Y; Kawashima, M; Kurashima, A; Machida, K; Masuda, K; Matsui, Y; Nagai, H; Nagayama, N; Suzuki, J; Tamura, A; Yotsumoto, H, 2007)	0.57
" Prednisolone had been also administrated in all patients and the dosage was doubled from the beginning of the treatment."	( [Examination of administrative dosage of cyclosporine during anti-tuberculosis chemotherapy including rifampicin]. Akagawa, S; Kawabe, Y; Kawashima, M; Kurashima, A; Machida, K; Masuda, K; Matsui, Y; Nagai, H; Nagayama, N; Suzuki, J; Tamura, A; Yotsumoto, H, 2007)	1.25
"The appropriate dosage of cyclosporine was found to be approximately 3 times that of the initial dosage in all patients, but it required a long-term and frequent measurements of trough levels before reaching this goal."	( [Examination of administrative dosage of cyclosporine during anti-tuberculosis chemotherapy including rifampicin]. Akagawa, S; Kawabe, Y; Kawashima, M; Kurashima, A; Machida, K; Masuda, K; Matsui, Y; Nagai, H; Nagayama, N; Suzuki, J; Tamura, A; Yotsumoto, H, 2007)	0.34
"The utility of thermal inkjet (TIJ) technology for preparing solid dosage forms of drugs was examined."	( Thermal inkjet application in the preparation of oral dosage forms: dispensing of prednisolone solutions and polymorphic characterization by solid-state spectroscopic techniques. Albrecht, M; Ashvar, CS; Kane, KM; Meléndez, PA; Smith, PA, 2008)	0.57
" Myocarditis should be screened systematically even when specific symptoms are missing; dosage of troponin serum is a simple and reliable mean for such screening."	( [Troponin dosage in a patient with asymptomatic myocarditis due to trichinellosis]. Abboud, P; Caron, F; Dupouy-Camet, J; Etienne, M; Favennec, L; Gargala, G; Gauliard, E; Gueit, I; Lachkar, S; Tron, C, 2008)	0.35
" More patients completed the first year without unplanned DMARD changes and without dosage adjustment and fewer had DMARD changes due to side effects or inefficacy in the step-down group compared with step-up, whereas the number of adverse events was comparable."	( Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Esselens, G; Verschueren, P; Westhovens, R, 2008)	0.35
" Steroid therapy was stopped or tapered at 50-100% of the baseline dosage in all long-term responders."	( Rituximab therapy for childhood Evans syndrome. Aladjidi, N; Armari-Alla, C; Bader-Meunier, B; Bellmann, F; Bertrand, Y; Chaussé, A; Ledeist, F; Leverger, G; Monpoux, F; Munzer, M; Nelken, B; Pariente, A; Perel, Y; Picard, C; Robert, A; Yacouben, K, 2007)	0.34
" In multivariate analysis, the effect of high dosage CYC on FVC persisted (OR 10."	( Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease. Karadimitrakis, SP; Plastiras, SC; Tzelepis, GE; Vlachoyiannopoulos, PG, )	0.13
" Thereafter, when tapering the dosage from 60 to 30 mg/day, the lupus nephritis flared up and he was re-hospitalized in February of 2001."	( A case of lupus nephritis improved after appropriately adjusting the dosage of mizoribine. Fukuda, W; Hamaguchi, M; Ishino, H; Kadoya, M; Kawahito, Y; Kohno, M; Niimi, M; Tsubouchi, Y; Wada, M; Yamamoto, A; Yoshikawa, T, 2008)	0.35
" This makes it possible to decrease the dosage and duration of topical prednisolone acetate."	( Intracameral triamcinolone acetonide to control postoperative inflammation following cataract surgery with phacoemulsification. Akova, YA; Borazan, M; Karalezli, A, 2008)	0.58
" Papillary bleeding index, time since transplant and azathioprine dosage were significant in the univariate and multivariate models (adjusted R=43."	( Gingival overgrowth in renal transplant subjects medicated with tacrolimus in the absence of calcium channel blockers. Cezário, ES; Costa, FO; Cota, LO; Ferreira, SD; Siqueira, FM; Soares, RV; Zenóbio, EG, 2008)	0.35
" In severe to critical asthma, differences between sites were common and related to recommendations for: ipratropium use; metered-dose inhaler versus nebulised delivery of salbutamol in severe asthma; use of intravenous aminophylline, intravenous magnesium and dosing of intravenous salbutamol in critical asthma."	( Paediatric acute asthma management in Australia and New Zealand: practice patterns in the context of clinical practice guidelines. Acworth, J; Babl, FE; Borland, M; Cotterell, E; Francis, P; Jamison, S; Krieser, D; Neutze, J; Ngo, P; Schutz, J; Sheriff, N; Thomson, F, 2008)	0.35
" Cox-regression analysis showed that the duration of oral corticosteroid treatment for less than 6 months was the only significant risk factor for recurrence of VKH after adjustment for age, gender, and the initial dosage of oral corticosteroid treatment (adjusted odds ratio=8."	( Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Chan, CK; Chan, RP; Lai, TY; Lam, DS, 2009)	0.35
" The therapeutic benefits of MZB pulse therapy were assessed based on a comparison of the incidence of relapse (times/year) and the required daily dosage of prednisolone (PSL) before and after therapy."	( Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome. Fujieda, M; Hayashi, A; Ishihara, M; Morita, T; Ohta, T; Sakano, T; Utsunomiya, Y; Wakiguchi, H, 2008)	0.54
"05), and the required daily dosage of PSL after therapy was lower than that before therapy (0."	( Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome. Fujieda, M; Hayashi, A; Ishihara, M; Morita, T; Ohta, T; Sakano, T; Utsunomiya, Y; Wakiguchi, H, 2008)	0.35
"Our results show that MZB pulse therapy is effective in decreasing the frequency of relapse and reducing the required PSL dosage in older pediatric patients with FR-SDNS."	( Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome. Fujieda, M; Hayashi, A; Ishihara, M; Morita, T; Ohta, T; Sakano, T; Utsunomiya, Y; Wakiguchi, H, 2008)	0.35
" The aim of this study is to evaluate the impact of dosing time on the PK/PD of prednisolone with a simulation approach using an interactive algorithm."	( Assessment of the impact of dosing time on the pharmacokinetics/pharmacodynamics of prednisolone. Derendorf, H; Sabarinath, SN; Winkler, J; Xu, J, 2008)	0.8
" On admission, he was administered intravenous immunoglobulins at a dosage of 400 mg/kg/day for 5 days yet continued to worsen."	( Corticosteroids can help distinguish between Guillain-Barré syndrome and first attack of chronic inflammatory demyelinating neuropathy: an illustrative case report. Alexander, KJ; Alshubaili, AF; Santhamoorthy, P; Sharafuddin, KM, 2008)	0.35
" No correlation was observed between the daily prednisolone dosage (mg/d or mg kg d) and glucose AUC."	( Role of prednisolone pharmacokinetics in postchallenge glycemia after renal transplantation. Bergrem, H; Bergrem, HA; Hartmann, A; Hjelmesaeth, J; Jenssen, T, 2008)	1.04
" We treated MCNS with PSL and cyclosporin (CyA) as an initial therapy to reduce PSL dosage and its side effects, and compared various clinical parameters in MCNS treated with the conventional PSL therapy."	( [Combined effect of cyclosporin and prednisolone for minimal change nephrotic syndrome: comparison with prednisolone therapy]. Fukatsu, A; Hayashi, M; Kimura, N, 2008)	0.62
" Total PSL dosage in Group A in hospital (386+/-173 mg) was smaller than in Group B (1,884+/-1,573 mg) (p=0."	( [Combined effect of cyclosporin and prednisolone for minimal change nephrotic syndrome: comparison with prednisolone therapy]. Fukatsu, A; Hayashi, M; Kimura, N, 2008)	0.62
" After exclusion of the unfulfilled criteria cases, 201 cases of Bell's palsy completed the study protocol and were followed for six months after a seven-day course of 60 mg/day followed by a five-day taper-off dosage of oral prednisolone."	( Clinical prognostic factors for treatment outcome in Bell's palsy: a prospective study. Sathirapanya, C; Sathirapanya, P, 2008)	0.53
" Conclusion Larger prospective studies are needed to determine the clinical relevance of TPMT activity and to determine accurate azathioprine dosing guidelines based on TPMT activity."	( Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris. Chams-Davatchi, C; Firooz, A; Ghandi, N; Hallaji, Z; Karbakhsh Davari, M; Valikhani, M, 2008)	0.35
" The mean maximum daily dosage of prednisolone was 32."	( Changes in body composition after glucocorticoid therapy in patients with systemic lupus erythematosus. Ma, KM; Mok, CC; To, CH, 2008)	0.63
" UC patients whose neutrophils were isolated were divided into two subgroups according to their total preoperative dosage of prednisolone: group H, > or =10,000 mg; group L, <10,000 mg."	( Neutrophil-related immunoinflammatory disturbance in steroid-overdosed ulcerative colitis patients. Araki, T; Kusunoki, M; Miki, C; Okita, Y; Uchida, K; Yoshiyama, S, 2008)	0.55
" In the present case, re-epithelization and healthy granulation were induced by the CDS without increasing the dosage of systemic prednisolone."	( Case report: a case of pyoderma gangrenosum with intractable leg ulcers treated by allogeneic cultured dermal substitutes. Furukawa, F; Kanazawa, N; Kishioka, A; Kuroyanagi, Y; Matsumoto, Y; Nishide, T; Toyozawa, S; Yamamoto, Y, 2008)	0.55
" Consensus may end there, as there is no clear-cut "best" route of administration or dosing schedule."	( Relapse management in multiple sclerosis. Thrower, BW, 2009)	0.35
" The immune-specific amplification of prednisolone anti-inflammatory activity by dipyridamole did not extend to glucocorticoid-mediated adverse effects, including corticosterone suppression or increased expression of tyrosine aminotransferase, in vivo after repeat dosing in rats."	( Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Avery, W; Borisy, AA; Farwell, M; Finelli, AL; Fraser, CC; Zimmermann, GR, 2009)	0.62
" Our findings suggested that the initial dosage of theophylline should be adjusted according to the gender of pediatric patients and particularly in the case of infants."	( Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. Igarashi, T; Iwakawa, S, 2009)	0.35
" Whereas systemic exposure to budesonide was markedly lower in healthy subjects after the mouthwash compared to oral dosing (mean relative bioavailability 18%-36%), the systemic concentrations thereafter in patients were as high as those after the identical dose of oral budesonide."	( Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. Bertz, H; Dilger, K; Finke, J; Gratwohl, A; Halter, J; Lopez-Lazaro, L, 2009)	0.35
" Because patients are typically dosed per kilogram body weight, this might result in underexposure and overexposure in patients, with a low and high body weight, respectively."	( Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Danhof, M; de Fijter, JW; den Hartigh, J; Guchelaar, HJ; Ploeger, BA; Press, RR; van der Straaten, T; van Pelt, J, 2009)	0.35
" Pharmacodynamic (PD) assay for evaluating the inhibition of interleukin-2 (IL-2) production for each patient could provide a more appropriate dosing regimen."	( Evaluation of interleukin-2 mRNA in whole blood as a parameter for monitoring cyclosporine pharmacodynamics. Katayama, A; Kobayashi, T; Kuzuya, T; Miwa, Y; Nagasaka, T; Nakao, A; Uchida, K; Yamada, K, 2009)	0.35
" To determine if administration of an immunosuppressive dosage of prednisolone to adult dogs latently infected with CHV-1 results in recurrent ocular disease, adult beagles with and without experimentally induced CHV-1 latent infection were divided into groups: group 1 latently infected and administered prednisolone, group 2 latently infected and administered placebo, and group 3 not latently infected and administered prednisolone."	( Experimental reactivation of latent canine herpesvirus-1 and induction of recurrent ocular disease in adult dogs. Bicalho, RC; Dubovi, EJ; Kim, SG; Ledbetter, EC, 2009)	0.59
" To perform the immediate effect analysis (GPi or zero time), of each mixture either at room or refrigerator temperature, the preparation procedure was similar, although GPR, iodoform, Rifocort and camphorated paramonochlorophenol were stored in the refrigerator and then taken out, dosed and manipulated, and had their immediate effect tested after a 1-week period at storage of 4 degrees C average temperature."	( Antimicrobial action of a filling paste used in pulp therapy in primary teeth under different storage conditions. Ferreira, FV; Friedrich, RS; Guedes-Pinto, AC; Praetzel, JR; Weiss, RN, 2008)	0.35
" It has been reported that treatment of the steroid-induced psychiatric symptoms involves dosage reduction or discontinuation of steroid, and concomitant administration of psychotropics."	( Can "steroid switching" improve steroid-induced psychosis in a patient with advanced cancer? Ito, N; Okishiro, N; Tanimukai, H; Tsuneto, S, 2009)	0.35
"Treatment with cyclophosphamide and steroids for idiopathic membranous nephropathy (IMN) is effective in Caucasian patients, but the cumulative cyclophosphamide dosage exceeds 10 g and includes steroid pulse therapy."	( Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone. Eriguchi, M; Harada, A; Kamimura, T; Mizobuchi, T; Oka, H; Sugawara, K, 2009)	0.56
" Patients were treated with cyclophosphamide (50 mg/day for the first 3 months and 25 mg/day for the next 3 months) and prednisolone (30 mg/day for the first week and the dosage was gradually tapered to withdraw by 2 years)."	( Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone. Eriguchi, M; Harada, A; Kamimura, T; Mizobuchi, T; Oka, H; Sugawara, K, 2009)	0.77
"5 mg/day), and appears to be as efficient but less diabetogenic compared to the standard once daily dosing (4."	( Twice daily fractionated dose administration of prednisolone compared to standard once daily administration to patients with glomerulonephritis or with kidney transplants. Decker, SO; Keller, F; Mayer, J; Stracke, S, 2009)	0.61
" In contrast to the postdose reductions of IMPDH activity observed early posttransplant, IMPDH activity within both treatment groups was elevated throughout the dosing interval at week 13."	( Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study. Bergan, S; Bremer, S; Holdaas, H; Jørgensen, PF; Midtvedt, K; Rootwelt, H; Stenstrøm, J; Vethe, NT, 2009)	0.35
"The significant influence of MPA on IMPDH1 expression, possibly mediated through reduced guanine nucleotide levels, could explain the elevations of IMPDH activity within dosing intervals at week 13."	( Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study. Bergan, S; Bremer, S; Holdaas, H; Jørgensen, PF; Midtvedt, K; Rootwelt, H; Stenstrøm, J; Vethe, NT, 2009)	0.35
" Retreatment with an augmented dosage of prednisolone, +/- another immunosuppressive agent, resulted in CR and PR in 15 (79%) and 4 (21%) of these flare episodes, respectively."	( Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Mok, CC; Ng, WL; Wong, WS; Yim, CW; Ying, KY, 2009)	0.62
" No relationship was observed between osteoporosis and age, sex, body mass index, duration of hemodialysis therapy, cumulative dosage of any drugs, or use of pulsed methylprednisolone therapy."	( Osteoporosis and related risk factors in renal transplant recipients. Ahmadpoor, P; Ghafari, A; Makhdoomi, K; Rahimi, E; Reisi, S; Sepehrvand, N, 2009)	0.55
" Maximum tacrolimus dosage administrated for patients over a 6-month period appeared not to be predictive for the DAS28-CRP remission at 6 months."	( Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables. Aoyagi, K; Aramaki, T; Arima, K; Eguchi, K; Fujikawa, K; Furuyama, M; Ida, H; Iwamoto, N; Kamachi, M; Kawakami, A; Kawashiri, SY; Matsuoka, N; Mizokami, A; Nakamura, H; Nakashima, M; Origuchi, T; Tamai, M; Ueki, Y; Yamasaki, S, 2009)	0.35
" 2 patients reduced the MMF dosage because of anemia or herpes labialis."	( Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. Fujinaga, S; Hirano, D; Kaneko, K; Nishizaki, N; Ohtomo, Y; Ohtsuka, Y; Shimizu, T; Someya, T, 2009)	0.35
" While tapering the dosage of prednisolone, we carefully observed the appearance of skin lesions and erythema nodosum appearing on her right lower leg."	( [Case of neuro-Behçet disease with HLA-B54, Cw1, which is difficult in clinical diagnosis from neuro-Sweet disease]. Kumakiri, M; Kuriyama, M; Sato, M; Yoneda, M, 2009)	0.64
"4), while the risk factor for OFH was a recent maximum GC dosage (>1."	( Notable difference between the development of vertebral fracture and osteonecrosis of the femoral head in patients treated with high-dose glucocorticoids for systemic rheumatic diseases. Amano, K; Kameda, H; Nagasawa, H; Ogawa, H; Sekiguchi, N; Suzuki, K; Takei, H; Takeuchi, T, 2009)	0.35
" He was effectively managed with methylprednisolone pulse therapy (500 mg/day x 3 days) followed by progressive dosage tapering."	( [Case of microscopic polyangiitis presenting initially as prostatic vasculitis]. Akizawa, T; Ashikaga, E; Iyoda, M; Nagai, H; Shibata, T; Suzuki, H, 2009)	0.62
" In the main dosing study, the mean RBC 6-TGN level in patients who remained in remission during the 1-year observation time (n = 151) was 322."	( Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide. Abe, J; Arai, O; Hanai, H; Hosoda, Y; Iida, T; Ikeya, K; Kageoka, M; Kubota, T; Maruyama, Y; Miwa, I; Oohata, A; Takeuchi, K; Watanabe, F; Yoshirou, S, 2010)	0.36
" Due to lack of evidence, inclusion criteria was revised during the process of the review to include studies comparing different dosage of corticosteroids."	( Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation. Banihosseini, S; Ferrara, JL; Rabbani-Anari, M; Rahimi Darabad, R; Rohanizadegan, M; Salmasian, H; Shakiba, A, 2010)	0.36
" Prednisolone dosage was increased from 10 to 60 mg/day."	( Type B insulin resistance syndrome with systemic lupus erythematosus. Gohda, T; Horikoshi, S; Ohsawa, I; Sato, N; Shirato, I; Takagi, M; Tomino, Y; Yamaguchi, Y, 2010)	1.27
" This study was designed to deduce a dosage of prednisolone compatible with normal growth."	( Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome. Grundy, N; Simmonds, J; Trompeter, R; Tullus, K, 2010)	0.62
" Primary ocular CHV-1 infection was experimentally induced in mature specific pathogen-free beagles by topical ocular inoculation and the presence of reactivatable latency was later confirmed by administration of an immunosuppressive dosage of systemic corticosteroid to the dogs."	( The effect of topical ocular corticosteroid administration in dogs with experimentally induced latent canine herpesvirus-1 infection. Dubovi, EJ; Kice, NC; Kim, SG; Ledbetter, EC; Matusow, RB, 2010)	0.36
" After two years, the choice and dosing of DMARDs and prednisolone were not restricted, but the treatment was still targeted to achieve or maintain remission."	( Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial. Hannonen, PJ; Kaipiainen-Seppänen, OA; Karjalainen, AH; Karstila, KL; Korpela, MM; Leirisalo-Repo, M; Möttönen, TT; Mustonen, JT; Rantalaiho, VM, )	0.38
" Moreover, concurrent prednisolone use at a dosage of 20 mg/day or higher was associated with a 22% higher clearance of CsA, hence lower CsA exposure."	( Explaining variability in ciclosporin exposure in adult kidney transplant recipients. Danhof, M; de Fijter, H; den Hartigh, J; Guchelaar, HJ; Ploeger, BA; Press, RR; van der Straaten, T; van Pelt, H, 2010)	0.68
" However, chronic use of topical corticosteroids dosed at < or = 3 drops daily seemed to be associated with a lower risk of cataract development relative to eyes receiving higher doses over follow-up in the setting of suppressed uveitis."	( Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Dunn, JP; Jabs, DA; Thorne, JE; Woreta, FA, 2010)	0.36
"In 53 patients, acute inflammation was suppressed with effective prednisolone dosage (1-2 mg/kg/day, tapered to 10 mg within 4-6 weeks)."	( Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments. Bayer, A; Bayraktar, MZ; Durukan, AH; Erdem, U; Erdurman, C; Karagul, S; Köksal, S; Sobaci, G, 2010)	0.6
" Withdrawal of the ciclosporin and reduction of the prednisolone dosage resulted in spontaneous resolution of the skin lesions within 40 days."	( Cutaneous Alternaria infectoria infection in a dog in association with therapeutic immunosuppression for the management of immune-mediated haemolytic anaemia. Choi, JS; de Hoog, GS; Dedola, C; Else, RW; Ridyard, AE; Stuart, AP; Thoday, KL; van den Broek, AH, 2010)	0.61
" Compared to those who didn't, there were significantly more LL/BL patients with positive BI among SID whose cumulative prednisolone dosage was nearly 9000 mg as compared to half the amount among others."	( A study of steroid-induced diabetes mellitus in leprosy. Abraham, S; John, AS; Papang, R; Rao, PS, )	0.34
" There was an increased risk of IFI in the lupus patients receiving high daily dosage of prednisolone therapy."	( A retrospective study of catastrophic invasive fungal infections in patients with systemic lupus erythematosus from southern Taiwan. Chang, HY; Chang, TW; Lee, NY; Lin, TS; Liu, MF; Wang, CR; Wang, JY; Weng, CT; Weng, MY; Wu, AB, 2010)	0.58
"Taken together, the MTG-containing ZnO can be a more effective and convenient delivery system for the treatment of hemorrhoid with a reduced dosage interval."	( Effect of zinc oxide on the rheological and mucoadhesive properties of poloxamer 407-based mucoadhesive thermosensitive gel. Choi, HG; Kim, CK; Kim, HT; Kim, ST; Park, JS; Park, TH, 2010)	0.36
"001), and a significant decrease in the mean oral prednisone dosage (55."	( Azathioprine in severe uveitis of Behçet's disease. Amoura, Z; Bodaghi, B; Cacoub, P; Cassoux, N; Hajage, D; Le Hoang, P; Le Thi Huong, D; Resche-Rigon, M; Saadoun, D; Terrada, C; Wechsler, B, 2010)	0.36
" Difluprednate provides effective treatment for anterior uveitis and requires less frequent dosing than prednisolone acetate."	( Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. Crockett, RS; Davanzo, R; Flynn, TE; Foster, CS; McLeod, K; Vogel, R, 2010)	0.58
"Randomized controlled trials comparing any corticosteroid with placebo, no treatment, or other drug; or comparing one corticosteroid with another corticosteroid or dosage in women with HELLP syndrome."	( Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Chandra, S; Dowswell, T; Hofmeyr, GJ; Woudstra, DM, 2010)	0.36
"Dissolution testing is an important test for judging the effectiveness of a pharmaceutical dosage form."	( Solid dispersion of prednisolone: solid state characterization and improvement of dissolution profile. Khanam, J; Palanisamy, M, 2011)	0.69
"5 mg prednisolone/kg)and Group 1B (1 mg prednisolone/kg) according to the dosage of prednisolone."	( Influence of systemic steroids on subretinal fluid after scleral buckle surgery for macula-off retinal detachment. Chen, SN; Hwang, JF; Lin, CJ; Wu, JS, 2011)	0.88
" Treatment continued without obvious side effects, and PDL dosage was tapered to 10 mg/day."	( [Complete response achieved in a case of gastric gastrointestinal stromal tumor by administration of imatinib mesilate with concurrent relatively high-dose steroid therapy to control side effects]. Kishimoto, H; Nakamura, M; Otagiri, N; Sasahara, K; Tauchi, K; Tsukada, Y; Yoshifuku, S, 2010)	0.36
" Four (10%) containers did not include any additional type of warnings related to the medication, beyond the dosage amount and administration frequency."	( Characteristics of container labeling in a sample of commonly prescribed children's oral medications. DeVoe, JE; Keenum, AJ; Wallace, LS, 2010)	0.36
" The two treatment groups were compared for blood concentrations of CsA, the extent of acceptable dosage reduction for the maintenance of immunotherapy, potential effects of kidney protection, and promotion of graft function."	( Combination therapy with diltiazem plus CsA/MMF/Pred or CsA/Aza/Pred triple immunosuppressive regimens for use in clinical kidney transplantation in Northwestern China. Ding, X; Fan, X; Feng, X; Hou, J; Pan, X; Qin, G; Song, Y; Tian, P; Tian, X; Xiang, H; Xue, W; Yan, H, 2011)	0.37
"In our cohort of renal transplantation patients, co-administration of CsA and diltiazem increased CsA blood concentration, thereby resulting in a reduction in its required dosage treatment, which lightened the patients' economic burden while improving primary and long-term kidney function by promoting the recovery of graft function and decreasing hepatic and renal toxicity."	( Combination therapy with diltiazem plus CsA/MMF/Pred or CsA/Aza/Pred triple immunosuppressive regimens for use in clinical kidney transplantation in Northwestern China. Ding, X; Fan, X; Feng, X; Hou, J; Pan, X; Qin, G; Song, Y; Tian, P; Tian, X; Xiang, H; Xue, W; Yan, H, 2011)	0.37
" In groups 1 and 3, mean lomustine dosage was 60."	( Comparison of oral administration of lomustine and prednisolone or prednisolone alone as treatment for granulomatous meningoencephalomyelitis or necrotizing encephalitis in dogs. Boettcher, IC; Doherr, MG; Flegel, T; Henke, D; Matiasek, K; Oechtering, G; Oevermann, A, 2011)	0.62
" The aim of this work is to investigate the effect of a low dosage and long term dexamethasone treatment on the levels of endogenous corticosteroids in cattle and to evaluate the possible presence of prednisolone residues in bovines bred under strictly controlled conditions."	( Studies on the presence of natural and synthetic corticosteroids in bovine urine. Bozzetta, E; Caramelli, M; Draisci, R; Ferranti, C; Marchiafava, C; Palleschi, L; Pezzolato, M; Quadri, FD, 2011)	0.56
" In a subsequent dose-response study, we found that a single dose of 1mg/kg liposomal prednisolone phosphate (PLP) was still equally effective in suppressing joint inflammation as 4 repeated once-daily injections of 10mg/kg free PLP."	( Safety of glucocorticoids can be improved by lower yet still effective dosages of liposomal steroid formulations in murine antigen-induced arthritis: comparison of prednisolone with budesonide. Hofkens, W; Nabbe, KC; Pesman, GJ; Storm, G; Sweep, FC; van den Berg, WB; van den Hoven, JM; van Lent, PL, 2011)	0.79
" Our results suggest that CMV reactivation occurs more frequently in DM patients than previously recognized; CMV reactivation occurs regardless of the dosage and duration of corticosteroid administration or the presence of underlying disease."	( Relationship between cytomegalovirus reactivation and dermatomyositis. Hirahara, K; Kanetaka, Y; Kano, Y; Kurata, M; Shiohara, T, )	0.13
" When treating rapidly progressive glomerulonephritis, immunosuppressive status should be carefully monitored regarding not only the dosage of therapeutic regimen but also the mental health status and nutrition of the patient."	( A case of Goodpasture syndrome positive for anti-GBM antibody and MPO-ANCA complicated by a variety of serious infections. Adachi, T; Hatta, T; Kimura, T; Kishimoto, N; Kusaba, T; Matsubara, H; Mori, Y; Nakagawa, H; Nakayama, M; Okigaki, M; Sakoda, C; Sonomura, K, 2011)	0.37
" The purpose of this investigation was to evaluate the ocular pharmacokinetics of mapracorat after topical dosing over a range of dose levels in rabbits and monkeys."	( Ocular pharmacokinetics of mapracorat, a novel, selective glucocorticoid receptor agonist, in rabbits and monkeys. Lowe, ER; Proksch, JW; Ward, KW, 2011)	0.37
" Given that repeat dosing of cells may be necessary to achieve a lasting therapeutic benefit, in this study, we examined approaches to avoid an immune response to multiple SC injections of UTC."	( Approaches to avoid immune responses induced by repeated subcutaneous injections of allogeneic umbilical cord tissue-derived cells. Chi, N; Cho, PS; Ferguson, KK; Goldman, SN; Hanekamp, JS; Hirsh, EL; Houser, S; Huang, CA; Lutton, BV; Messina, DJ; Popma, SH; Sachs, DH; Teague, AG; Yeap, BY, 2010)	0.36
" The prednisolone dosage was tapered over 3 - 8 weeks."	( [Juvenile sterile granulomatous dermatitis and lymphadenitis in the dog]. Eule, C; Kohn, B; Weingart, C; Welle, M, 2011)	0.88
" Correlation between daily corticosteroid dosage and remission time and factors relating to final visual acuity of <20/40 were studied."	( Central serous chorioretinopathy after renal transplantation. Byeon, SH; Kang, EC; Koh, HJ; Lee, CS; Lee, KS; Lee, SC, 2011)	0.37
"Thirty-one patients with SLE receiving a fixed dosage regimen of MMF (median and interquartile range, 1500 and 1000-2000mg/day) for at least 1month and who had not experienced any adverse drug reactions for more than 3months were enrolled."	( Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase. Kawakami, J; Mino, Y; Naito, T; Ogawa, N; Shimoyama, K, 2012)	0.38
"MMF improved clinical laboratory markers and reduced prednisolone dosage in SLE patients with predose plasma concentration of MPA and MPAG in the interquartile ranges of 0·94-2·96 and 18·6-53·7μg/mL, respectively."	( Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase. Kawakami, J; Mino, Y; Naito, T; Ogawa, N; Shimoyama, K, 2012)	0.63
"In a randomised placebo-controlled double-blind (participants and the investigators who performed the studies and assessed the outcomes were blinded) dose-response intervention study, 32 healthy men (age 22 ± 3 years; BMI 22."	( Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Ackermans, MT; Brands, M; Diamant, M; Muskiet, MH; Pouwels, PJ; Sauerwein, HP; Serlie, MJ; van der Zijl, NJ; van Raalte, DH, 2011)	0.37
" Therapy is safe because it is limited to several months and the dosage is continually weaned as the infant gains weight."	( Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. Couto, RA; Greene, AK, 2011)	0.88
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
" Methylprednisolone pulse therapy was performed in patients resistant to the high dosage of PSL."	( The short-term role of corticosteroid therapy for pulmonary arterial hypertension associated with connective tissue diseases: report of five cases and a literature review. Atsumi, T; Fujieda, Y; Horita, T; Kataoka, H; Kato, M; Koike, T; Nishimura, M; Odani, T; Ohira, H; Oku, K; Otomo, K; Tsujino, I; Yasuda, S, 2011)	0.82
"An analytical, pharmacokinetic and histopathologic investigation was conducted by two experimental trials on beef cattle in order to determine fate and effects of dexamethasone and prednisolone, administered to distinct cattle groups at low dosage for long periods of time."	( Effects of low-dose dexamethasone and prednisolone long term administration in beef calf: chemical and morphological investigation. Biolatti, B; Cannizzo, FT; Capra, P; Ciccotelli, V; Divari, S; Vincenti, M, 2011)	0.83
" Because of the variability in dose and dosing schedule, quantification of this risk is not possible."	( Official Positions for FRAX(®) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX(®) of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Cl Adachi, JD; Binkley, N; Geusens, PP; Hans, DB; Leib, ES; McCloskey, EV; Saag, KG, )	0.13
" Although these agents are dosed to directly target airway inflammation, adrenocortical suppression and other systematic effects are still seen."	( Synthesis, transport and mechanism of a type I prodrug: L-carnitine ester of prednisolone. Gong, T; Mo, JX; Shi, SJ; Sun, X; Zhang, Q; Zhang, ZR, 2011)	0.6
" Dose was raised until a final dosage of 30 mg/week."	( [Autoimmune pancreatitis associated with rheumatoid arthritis: successful combination therapy with steroids and methotrexate]. Boltuch-Sherif, J; Erlacher, L; Horvath-Mechtler, B; Kowalski-Bodzenta, J; Mustak, M, 2011)	0.37
" An ARB was given to all patients and the same dosage was used throughout the study."	( Triple therapy with single daily dose of cyclosporine in Japanese patients with idiopathic membranous nephropathy. Esaki, S; Gondo, A; Hayashi, A; Matsumoto, H; Miyaoka, Y; Nagaoka, Y; Nakao, T; Okada, T; Wada, T, 2011)	0.37
"There was a significant positive correlation between the levels of MIF and the total preoperative dosage of prednisolone."	( Neutrophil dysfunction in steroid-overdosed patients with ulcerative colitis: potential relevance of macrophage migration inhibitory factor to increased postoperative morbidity. Araki, T; Kusunoki, M; Miki, C; Okita, Y; Otake, K; Uchida, K; Yoshiyama, S, 2011)	0.58
"Current prednisone dosing in the treatment of young patients with childhood-onset systemic lupus erythematosus (cSLE) is largely based on achieving balance between therapeutic efficacy and toxicity, with weight-based dosing a common clinical practice."	( Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. Brunner, HI; Rieder, MJ; Sagcal-Gironella, AC; Sherwin, CM; Tirona, RG; Vinks, AA, 2011)	0.69
" Despite this very long experience, there remains considerable debate concerning the adequate dosing and timing of these medications, primarily because of frequent and sometimes serious side effects, particularly in high doses."	( A dose of only 5 mg prednisolone daily retards radiographic progression in early rheumatoid arthritis - the Low-Dose Prednisolone Trial. Rau, R; Wassenberg, S; Zeidler, H, )	0.45
" In both groups, the average UC clinical disease activity index, the endoscopic index, and the concomitant prednisolone dosage were significantly and equally reduced during the course of 10 LCAP."	( Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with Cellsorba in patients with active ulcerative colitis. Fukunaga, K; Hida, N; Iimuro, M; Kamikozuru, K; Kato, K; Kikuyama, R; Matsumoto, T; Miwa, H; Nagase, K; Nakamura, S; Ohda, Y; Takeda, N; Yokoyama, Y; Yoshida, K, 2011)	0.58
" Quetiapine treatment was initiated at an initial dosage of 300 mg/day."	( Report of a case of steroid-induced psychosis and inappropriate sexual behaviour in an adolescent. Demir, T; Dogangun, B; Karacetin, G; Kocabasoglu, N, 2012)	0.38
" Dose-response data and pharmacokinetic data were used to calculate effective and safe clinical doses of paquinimod."	( Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in Axelsson, B; Bengtsson, AA; Leanderson, T; Lood, C; Ohman, MW; Rönnblom, L; Sparre, B; Sturfelt, G; Tuvesson, H; van Vollenhoven, RF, 2012)	0.38
"Serum 25-hydroxyvitamin D [25(OH)D] concentrations were measured in 20 dogs with atopic dermatitis prior to treatment with a standard therapeutic dosage of prednisolone (0."	( Prednisolone therapy for atopic dermatitis is less effective in dogs with lower pretreatment serum 25-hydroxyvitamin D concentrations. Berry, J; Kovalik, M; Mellanby, RJ; Thoday, KL; van den Broek, AH, 2012)	2.02
"5 mg/kg/day (maximum 60 mg) tapered to 0 by 17 weeks (arm 1), or MTX (same dosage as arm 1), etanercept placebo, and prednisolone placebo (arm 2)."	( Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Brunner, HI; Chira, P; Giannini, EH; Gottlieb, BS; Hamilton, S; Hashkes, PJ; Higgins, GC; Huang, B; Ilowite, NT; Johnson, A; Kimura, Y; Lovell, DJ; Milojevic, D; O'Neil, KM; Punaro, MG; Ringold, S; Schanberg, LE; Spalding, SJ; Sundel, RP; Szer, IS; Wallace, CA; Zeft, AS, 2012)	0.59
" However, the most appropriate dosage regimen has not been determined and remains controversial."	( COPD exacerbations in general practice: variability in oral prednisolone courses. Berendsen, AJ; Bosveld, HE; de Vries, M; Kerstjens, HA; van der Molen, T, 2012)	0.62
" Serum ACE level was reduced in all cases, and daily steroid dosage was reduced."	( Refractory multisystem sarcoidosis responding to infliximab therapy. Carruthers, D; Croft, AP; Giovanni, G; Gordon, C; Khair, O; Situnayake, D; Sivaguru, A, 2012)	0.38
" Serum concentrations of calcium, phosphate, vitamin D metabolites and plasma concentrations of parathyroid hormone and ionised calcium together with urinary fractional excretion of calcium and phosphate, were measured in 16 dogs with atopic dermatitis before and 6 weeks after standard dosage prednisolone treatment (0."	( Short-term prednisolone therapy has minimal impact on calcium metabolism in dogs with atopic dermatitis. Berry, J; Evans, H; Kovalik, M; Mellanby, RJ; Thoday, KL; van den Broek, AH, 2012)	0.94
" Data was obtained relevant to demographic characteristics, anatomic classification, and laterality of uveitis, associated systemic disorder, dosage of cyclosporine and prednisolone, usage of other immunosuppressive drugs, visual acuity (VA), control of uveitic activity, and adverse effects during the cyclosporine use."	( Clinical outcomes of cyclosporine treatment for noninfectious uveitis. Chung, H; Lee, SH; Yu, HG, 2012)	0.57
" Prednisolone was administered in 10-, 20-, and 40-mg dosage to healthy volunteers to study detection of various metabolites."	( Simultaneous identification of prednisolone and its ten metabolites in human urine by high performance liquid chromatography-tandem mass spectrometry. Ahi, S; Beotra, A; Dubey, S; Jain, S; Upadhyay, A, 2012)	1.58
"Prednisolone in customary dosage does not seem to influence recovery of idiopathic sudden sensorineural hearing loss."	( Corticosteroid treatment of idiopathic sudden sensorineural hearing loss: randomized triple-blind placebo-controlled trial. Hultcrantz, E; Nosrati-Zarenoe, R, 2012)	1.82
" In the case example presented here the disease was due to an excessive dosage of prednisolone medication over a period of many years."	( [Esophagitis during immunosuppression]. Gross, WL; Moosig, F, 2012)	0.6
" Seven patients received a single topical dose of 30 mg and one special case subject received three doses with 4 weeks between dosing occasions."	( Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity. Admyre, C; Löfberg, R; Lutfi, T; Malek, M; Musch, E; von Stein, OD; von Stein, P; Zargari, A, 2013)	0.39
"Randomization within 72 hours in a factorial fashion to placebo plus placebo (n = 206); prednisolone, 60 mg/d for 5 days, with the dosage then tapered for 5 days, plus placebo (n = 210); valacyclovir hydrochloride, 1000 mg 3 times daily for 7 days, plus placebo (n = 207); or prednisolone plus valacyclovir (n = 206)."	( The effect of prednisolone on sequelae in Bell's palsy. Berg, T; Bylund, N; Engström, M; Hultcrantz, M; Jonsson, L; Kanerva, M; Marsk, E, 2012)	0.96
" The therapeutic benefits of MZB pulse therapy were assessed based on a comparison of the incidence of relapse and the required daily dosage of prednisolone (PSL) in the 12 months prior to and following therapy."	( Effect of single-dose oral mizoribine pulse therapy twice per week for frequently relapsing steroid-dependent nephrotic syndrome. Fujieda, M; Hayashi, A; Ishihara, M; Morita, T; Ohta, T; Okada, S; Sakano, T; Wakiguchi, H, 2012)	0.58
"01) and the required daily dosage of prednisolone (PSL) after therapy was lower than that before therapy (0."	( Effect of single-dose oral mizoribine pulse therapy twice per week for frequently relapsing steroid-dependent nephrotic syndrome. Fujieda, M; Hayashi, A; Ishihara, M; Morita, T; Ohta, T; Okada, S; Sakano, T; Wakiguchi, H, 2012)	0.65
" Blood samples were collected in four 12-hour dosing intervals during the first 3 weeks posttransplant, including samples drawn at 13 time points."	( The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. Bergan, S; Line, PD; Sæves, I, 2012)	0.69
" The results suggest that current prednisolone dosing early after liver transplantation might be too high, in particular when coadministered with methylprednisolone."	( The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. Bergan, S; Line, PD; Sæves, I, 2012)	0.96
"Although dosing and treatment protocol is still debatable, steroids and interferon are good options for hemangioma treatment."	( Infantile hemangiomas, complications and follow-up. Agaoglu, L; Akcay, A; Anak, S; Baykal, C; Devecioglu, O; Garipardic, M; Karakas, Z; Ozturk, G; Saribeyoglu, ET; Unuvar, A, 2012)	0.38
" He then was administered prednisolone at a dosage of 45 mg/d (0."	( De novo postallogeneic hematopoietic stem cell transplant membranous nephropathy. Ando, Y; Kusano, E; Mori, M; Morishita, Y; Muto, S; Numata, A; Saito, O; Takemoto, F; Yumura, W, 2013)	0.69
" BMI, weight, and height Z score trajectories were described according to GC starting dosage in prednisone equivalents: high (≥1."	( Glucocorticoid-related changes in body mass index among children and adolescents with rheumatic diseases. Alos, N; Atkinson, SA; Brant, R; Cabral, DA; Collet, JP; Couch, R; Cummings, EA; Dent, PB; Ellsworth, J; Guzman, J; Hay, J; Houghton, K; Huber, AM; Jurencak, R; Lang, B; Larche, M; Leblanc, C; Miettunen, P; Rauch, F; Rodd, C; Roth, J; Saint-Cyr, C; Scuccimarri, R; Shiff, NJ; Stein, R; Stephure, D; Taback, S; Ward, LM, 2013)	0.39
" This study highlights the importance of achieving early target exposure and suggests a potential role for individualized initial dosing or early therapeutic monitoring of all three immunosuppressive agents."	( Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week. Barraclough, KA; Campbell, SB; Hawley, CM; Isbel, NM; Johnson, DW; Leary, DR; Lee, KJ; McWhinney, BC; Staatz, CE; Ungerer, JP, 2012)	0.61
" The SLEDAI, BILAG, and urine protein levels and the prednisolone dosage were decreased after rituximab treatment, and the decreases in the BILAG, urine protein levels, and the prednisolone dose were found to be significant (P<0."	( Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis. Chen, JH; Han, F; Lan, L, 2012)	0.63
"In a randomized, placebo-controlled, double-blind, dose-response intervention study, 32 healthy males (age: 22 ± 3 years; BMI 22."	( Angiopoietin-like protein 4 is differentially regulated by glucocorticoids and insulin in vitro and in vivo in healthy humans. Brands, M; Diamant, M; Kersten, S; Mudde, K; Sauerwein, HP; Serlie, MJ; Stienstra, R; van Raalte, DH, 2012)	0.38
" Within the dosage range used in transplantation, prednisolone and prednisone exhibit concentration-dependent non-linear pharmacokinetics when parameters are measured with reference to total drug concentration."	( Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. Barraclough, KA; Bergmann, TK; Lee, KJ; Staatz, CE, 2012)	0.89
"To compare, for the first time, the in vitro antileukemic activity of prednisolone alone to that of a combination of prednisolone and dexamethasone using dexamethasone at a very low and presumably safe dosage (1/50 w/w)."	( Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia. Blazek, B; Bubanska, E; Burianova, R; Dzubak, P; Hajduch, M; Hak, J; Kaiserova, E; Konecny, P; Mihal, V; Novak, Z; Pospisilova, D; Radova, L; Salkova, S; Spenerova, M; Srovnal, J; Stary, J; Timr, P; Votava, T, 2014)	0.99
" Gene expression profiling of muscle tissue derived from arthritic mice showed a partial activity of Org 214007-0 at an equi-efficacious dosage of prednisolone, with an increased ratio in repression versus induction of genes."	( Org 214007-0: a novel non-steroidal selective glucocorticoid receptor modulator with full anti-inflammatory properties and improved therapeutic index. Alkema, W; Boots, AM; Conti, PG; de Vlieg, J; Dijkema, R; Dokter, WH; Grefhorst, A; Hofstra, CL; Ingelse, BA; Jans, CG; Kuipers, F; Laskewitz, AJ; Lusher, SJ; McGuire, R; Plate, R; Schoonen, WG; Smeets, RL; Smit, MJ; Timmers, CM; van Boeckel, CA; van der Maaden, HM; van Dijk, TH; van Duin, M; van Lierop, MJ; van Schaik, RC, 2012)	0.58
"A randomized, placebo-controlled, double-blind, dose-response intervention study was conducted in 32 healthy males (age: 21±2years; BMI: 21."	( Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance? Deacon, CF; Diamant, M; Heine, RJ; Holst, JJ; Karemaker, JM; Kwa, KA; Mari, A; Tushuizen, ME; van Genugten, RE; van Raalte, DH, 2013)	0.39
" The daily dosage of PSL could be significantly reduced in both PM and DM after starting TAC compared with before."	( Coadministration of tacrolimus with corticosteroid accelerates recovery in refractory patients with polymyositis/ dermatomyositis: a retrospective study. Ikeda, S; Ishii, W; Matsuda, M; Shimojima, Y; Tazawa, K, 2012)	0.38
" In this study, we used 15 mg/day of PSL as the initial dosage and tapered it by 5 mg every 2 weeks."	( Initial treatment with 15 mg of prednisolone daily is sufficient for most patients with subacute thyroiditis in Japan. Amino, N; Ito, M; Kubota, S; Kudo, T; Miyauchi, A; Nishihara, E, 2013)	0.67
"2%) needed increases in the dosage of PSL."	( Initial treatment with 15 mg of prednisolone daily is sufficient for most patients with subacute thyroiditis in Japan. Amino, N; Ito, M; Kubota, S; Kudo, T; Miyauchi, A; Nishihara, E, 2013)	0.67
"The treatment protocol that we employed had 15 mg/day of PSL as the initial dosage for the treatment of SAT, with tapering by 5 mg every 2 weeks, and was effective and safe for Japanese patients."	( Initial treatment with 15 mg of prednisolone daily is sufficient for most patients with subacute thyroiditis in Japan. Amino, N; Ito, M; Kubota, S; Kudo, T; Miyauchi, A; Nishihara, E, 2013)	0.67
" Combination therapy with prednisolone and low-dose cyclosporin A not only improved the clinical symptoms of the very elderly myasthenia gravis patients but also resulted in a rapid reduction in prednisolone dosage and prednisolone-related side effects."	( Prednisolone-sparing effect of cyclosporin A therapy for very elderly patients with myasthenia gravis. Fujita, K; Kaneko, S; Kusaka, H; Morita, J; Nakamura, S; Nakano, S; Shinde, A, 2013)	2.13
" There was a significant difference in the dosage of steroid per month just before colectomy between the two groups (P = 0."	( Characteristics of extremely early-onset pouchitis after proctocolectomy with ileal pouch-anal anastomosis. Araki, T; Fujikawa, H; Inoue, M; Inoue, Y; Kawamura, M; Kusunoki, M; Mohri, Y; Okita, Y; Shimura, T; Tanaka, K; Uchida, K, 2013)	0.39
" High-dose CEP was well tolerated, and in some patients single-agent CEP therapy resulted in a significant elevation of platelets, allowing a reduced dosage of PSL."	( [Clinical efficacy of high-dose cepharanthine for idiopathic thrombocytopenic purpura: retrospective multicenter analysis]. Endo, T; Fujimoto, K; Hashino, S; Imamura, M; Iwasaki, H; Kobayashi, N; Kohda, K; Kurosawa, M; Maekawa, I; Miyagishima, T; Miyake, T; Sasagawa, H; Takahata, M; Tanaka, J; Teshima, T; Tsustumi, Y, 2012)	0.38
"In a randomized, placebo-controlled, double-blind, dose-response intervention study, 32 healthy males (aged 22 ± 3 years; body mass index 22."	( No difference in glycosphingolipid metabolism and mitochondrial function in glucocorticoid-induced insulin resistance in healthy men. Aerts, JM; Brands, M; Diamant, M; João Ferraz, M; Sauerwein, HP; Serlie, MJ; van Raalte, DH; Verhoeven, AJ, 2013)	0.39
" Findings suggest low comparative bioavailability of oral prednisone compared to prednisolone in cats and consideration of lean body mass or ideal body weight for dosing practices."	( Influence of body condition on plasma prednisolone and prednisone concentrations in clinically healthy cats after single oral dose administration. Center, SA; Randolph, JF; Rishniw, M; Simpson, KW; Warner, KL, 2013)	0.89
" Consequently, sorafenib dosage was reduced to 200 mg daily, and the oral mucositis was attenuated."	( Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. Fujiyama, Y; Hira, D; Morita, SY; Noda, S; Shioya, M; Terada, T, 2013)	0.64
" If prednisolone or vigabatrin is used, high dosage is recommended."	( Treatment of infantile spasms. Edwards, SW; Hancock, EC; Osborne, JP, 2013)	0.95
" The patient initially received oral prednisolone at 30 mg/per day, followed by irradiation with a total dosage of 30 Gy to both eyes."	( IgG4-related inflammation of the orbit simulating malignant lymphoma. Hatanaka, K; Ishida, S; Ishijima, K; Kase, S; Noda, M; Yamamoto, T, 2013)	0.66
"The study enrolled 46 patients with PV who had absence of any lesion, and had a daily prednisolone dosage of ≤ 10 mg without adjuvant drug treatment in the preceding 6 months."	( Comparison of desmoglein 1 and 3 enzyme-linked immunosorbent assay and direct immunofluorescence for evaluation of immunological remission in pemphigus vulgaris. Balighi, K; Chams-Davatchi, C; Daneshpazhooh, M; Kalantari, MS; Kamyab, K; Mortazavizadeh, SM; Naraghi, ZS; Ramezani, A; Shamohammadi, S, 2014)	0.63
" However, there is still no consensus about its dosing regimens, efficacy, and side effects due to insufficient clinical trials."	( Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. Balighi, K; Chams-Davatchi, C; Cheyda, CD; Daneshpazhooh, M; Hajiseyed-javadi, M; Kamran, B; Khezri, S; Mahdavi-nia, M; Mahsa, HJ; Maryam, D; Mostafa, MN; Somayeh, K, 2013)	0.39
"In a randomised, placebo-controlled, dose-response intervention study, 32 healthy normoglycaemic men (age: 21 ± 2 years; BMI: 21."	( Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure: a randomised controlled trial. Diamant, M; Eringa, EC; Guigas, B; Ijzerman, RG; Linssen, MM; Ouwens, DM; Serné, EH; van Raalte, DH, 2013)	0.39
"A randomized, unmasked, multicenter study was conducted to evaluate the rate of pruritus reduction and improvement in clinical scoring by cyclosporine A (5 mg/kg orally, once daily for 28 days) either alone (n = 25 dogs) or with concurrent prednisolone (1 mg/kg once daily for 7 days, followed by alternate dosing for 14 days; n = 23 dogs) for the treatment of atopic dermatitis in dogs."	( Concurrent short-term use of prednisolone with cyclosporine A accelerates pruritus reduction and improvement in clinical scoring in dogs with atopic dermatitis. Bensignor, E; Carmichael, J; Dip, R; Letellier, I; Roberts, E; Rosenkrantz, W; Strehlau, G, 2013)	0.86
" Uncontrolled observational data suggest that divided dosing may reduce requirements for hypoglycaemic agents."	( Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation. Cohney, SJ; Colman, PG; Fourlanos, S; Yates, CJ, 2014)	0.71
"Split prednisolone dosing reduces glycaemic variability and hyperglycaemia early post-kidney transplant."	( Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation. Cohney, SJ; Colman, PG; Fourlanos, S; Yates, CJ, 2014)	1.19
" All patients were treated with 30mg/day of prednisone after device implantation, which was tapered to a maintenance dosage of 5-10mg/day."	( Recovery of atrioventricular block following steroid therapy in patients with cardiac sarcoidosis. Hayashi, H; Hayashi, M; Horie, T; Iwasaki, YK; Miyauchi, Y; Seino, Y; Shimizu, W; Shiomura, R; Takahashi, K; Tsuboi, I; Uetake, S; Yodogawa, K, 2013)	0.39
" Studies included were trials in which: (1) the participants were classified as having GCA by the 1990 ACR criteria or biopsy proven disease; (2) parallel-group randomised control of at least 16 weeks duration had been conducted with at least 20 participants; (3) the design included either alternative adjunct immunosuppressant regimens, alternative GCs dosing or routes of administration; and (4) outcome data was included on either relapse rates or rates of infection."	( Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. Loke, YK; MacGregor, AJ; Watts, RA; Yates, M, 2014)	1.85
"Differing study populations, lack of statistical power, method of data presentation (per couple or per cycle), the use of additional medications and differing dosage regimes contribute to data heterogeneity and suggest a cautious approach to data interpretation."	( Interventions to improve reproductive outcomes in women with elevated natural killer cells undergoing assisted reproduction techniques: a systematic review of literature. Barbosa, MA; Baumgarten, MN; Brosens, J; Campbell, B; Martins, WP; Polanski, LT; Quenby, S; Raine-Fenning, N, 2014)	0.4
"The aim of this study was to delineate the status of oral corticosteroid therapy in myasthenia gravis (MG), and to elucidate the effectiveness of oral corticosteroids according to dosing regimen."	( [Correlation between oral corticosteroid therapy and present disease status in myasthenia gravis]. Imai, T, 2013)	0.39
" However, we should adjust the dosage of CyA by therapeutic drug monitoring to avoid complications."	( Significance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial. Imai, E; Iwano, M; Kataoka, Y; Koyama, A; Maruyama, S; Matsumoto, K; Matsuo, S; Mitarai, T; Nangaku, M; Nishi, S; Ogahara, S; Saito, T; Sato, H; Shuto, H; Tomino, Y; Ueda, S; Yokoyama, H; Yorioka, N; Yoshimura, A, 2014)	0.67
" After adding MZR, we successfully tapered the orally dosed prednisolone without recurrent fever or complications."	( A case of microscopic polyangiitis in an elderly patient presenting predominantly with cholecystitis successfully treated with mizoribine. Ichinose, K; Iwanaga, N; Kawakami, A; Nakamura, H; Okada, A; Origuchi, T; Tamai, M; Yamasaki, S, 2014)	0.64
" Pemphigus activity scores, the time that new bulla formation stopped, the time corticosteroid was tapered, cumulative steroid dosage and medication side effects were analyzed."	( Assessment of the adjuvant effect of tacrolimus in the management of pemphigus vulgaris: A randomized controlled trial. Baghernejhad, M; Dastgheib, L; Sadati, MS, 2015)	0.42
"To estimate the burden of ocular complications like posterior subcapsular cataract (PSCC) and raised intra ocular pressure (IOP) in children with nephrotic syndrome on long term steroid therapy and to assess the correlation of cumulative dosage and duration of consumption of steroids with these ocular complications."	( Ocular complications in children with nephrotic syndrome on long term oral steroids. Gaur, S; Iyengar, A; Joseph, M; Koshy, AS; Nityanandam, S; Phadke, KD; Subramanian, S; Vasudevan, A, 2014)	0.4
"Rituximab is effective in inducing remission in ANCA-associated vasculitis (AAV), with randomized evidence to support its use as four infusions of 375 mg/m(2) (the conventional lymphoma dosing schedule)."	( Induction treatment of ANCA-associated vasculitis with a single dose of rituximab. Ashley, C; Burns, A; Dinneen, D; Howie, AJ; Little, MA; Pepper, RJ; Salama, AD; Sandhu, E; Stolagiewicz, NE; Turner-Stokes, T, 2014)	0.4
" Use of this single-dose protocol saved an estimated £4533/patient (US$7103; €5276) compared with a 4 × 375 mg/m(2) dosing schedule."	( Induction treatment of ANCA-associated vasculitis with a single dose of rituximab. Ashley, C; Burns, A; Dinneen, D; Howie, AJ; Little, MA; Pepper, RJ; Salama, AD; Sandhu, E; Stolagiewicz, NE; Turner-Stokes, T, 2014)	0.4
" The median initial dosage of corticosteroid (Prednisolone) was 30 mg/day (range: 15-60 mg/day), and the dosages were tapered according to improvement."	( Therapeutic strategy for granulomatous lobular mastitis: a clinicopathological study of 12 patients. Akahane, K; Ishigakis, S; Kato, M; Nagino, M; Nakamura, S; Noda, S; Satake, H; Shimoyama, Y; Tsunoda, N, 2013)	0.65
"To investigate the clinical efficacy of dietary fat restriction in dogs with IL that were unresponsive to prednisolone treatment or showed relapse of clinical signs and hypoalbuminemia when the prednisolone dosage was decreased."	( The clinical efficacy of dietary fat restriction in treatment of dogs with intestinal lymphangiectasia. Kagawa, Y; Okanishi, H; Watari, T; Yoshioka, R, )	0.34
"Nineteen of 24 (79%) dogs responded satisfactorily to dietary fat restriction, and the prednisolone dosage could be decreased."	( The clinical efficacy of dietary fat restriction in treatment of dogs with intestinal lymphangiectasia. Kagawa, Y; Okanishi, H; Watari, T; Yoshioka, R, )	0.35
"Dietary fat restriction appears to be an effective treatment in dogs with IL that are unresponsive to prednisolone treatment or that have recurrent clinical signs and hypoalbuminemia when the dosage of prednisolone is decreased."	( The clinical efficacy of dietary fat restriction in treatment of dogs with intestinal lymphangiectasia. Kagawa, Y; Okanishi, H; Watari, T; Yoshioka, R, )	0.35
"6 bicarbonate buffer system offers significant advantages during the development of dosage forms designed to release the drug in the upper small intestine."	( Accelerating the dissolution of enteric coatings in the upper small intestine: evolution of a novel pH 5.6 bicarbonate buffer system to assess drug release. Assi, P; Basit, AW; Goyanes, A; Merchant, HA; Varum, FJ; Zboranová, V, 2014)	0.4
" The risk of joint-related AVN as a side effect of adjunctive steroid therapy should be taken into consideration when evaluating the dosage and treatment duration in tuberculous encephalitis."	( Joint failure after steroid therapy in tuberculous encephalitis. Kircher, J; Krauspe, R; Patzer, T; Richter, J; Ziskoven, C, 2014)	0.4
" The dosage of MMF was initially 2,000 mg/day, but was reduced to 500 mg/day due to diarrhea 10 days before the operation."	( [Perioperative agranulocytosis induced by immunosuppressants in a renal graft recipient : a case report]. Inoue, T; Kamba, T; Kobayashi, T; Matsui, Y; Matsumoto, K; Murakami, K; Negoro, H; Ogawa, O; Okubo, K; Sugino, Y; Terada, N; Yamasaki, T; Yoshimura, K, 2014)	0.4
" Dosing was 4 times daily in months 1 to 3, thrice daily in month 4, twice daily in month 5, and once daily in months 6 to 12."	( Randomized comparison of topical prednisolone acetate 1% versus fluorometholone 0.1% in the first year after descemet membrane endothelial keratoplasty. Bachmann, BO; Kruse, FE; Price, FW; Price, MO; Tourtas, T, 2014)	0.68
"The aim of this study was to elucidate the effectiveness of oral prednisolone (PSL) according to dosing regimen in 472 patients with myasthenia gravis (MG)."	( Oral corticosteroid therapy and present disease status in myasthenia gravis. Fujihara, K; Imai, T; Konno, S; Masuda, M; Murai, H; Nagane, Y; Nakane, S; Suzuki, N; Suzuki, S; Suzuki, Y; Tsuda, E; Utsugisawa, K, 2015)	0.65
"Although glucocorticoids are widely used in the treatment of patients with early rheumatoid arthritis, the best dosage of glucocorticoids with regards to efficacy and safety is not known."	( Comparison of the efficacy and safety of two starting dosages of prednisolone in early active rheumatoid arthritis (CORRA): study protocol for a randomized controlled trial. Baraliakos, X; Braun, J; Klaassen-Mielke, R; Krause, D; Trampisch, HJ; Trampisch, US, 2014)	0.64
" In parallel, all patients will be treated with methotrexate (usual dosage 15 mg/week)."	( Comparison of the efficacy and safety of two starting dosages of prednisolone in early active rheumatoid arthritis (CORRA): study protocol for a randomized controlled trial. Baraliakos, X; Braun, J; Klaassen-Mielke, R; Krause, D; Trampisch, HJ; Trampisch, US, 2014)	0.64
"The CORRA trial will yield information concerning the optimal glucocorticoid dosage schedule in the treatment of patients with early rheumatoid arthritis."	( Comparison of the efficacy and safety of two starting dosages of prednisolone in early active rheumatoid arthritis (CORRA): study protocol for a randomized controlled trial. Baraliakos, X; Braun, J; Klaassen-Mielke, R; Krause, D; Trampisch, HJ; Trampisch, US, 2014)	0.64
"A randomized placebo-controlled study has demonstrated no effect of prednisolone in customary dosage on idiopathic sudden sensorineural hearing loss (ISSNHL)."	( Corticosteroid treatment of idiopathic sudden sensorineural hearing loss: analysis of an RCT and material drawn from the Swedish national database. Hultcrantz, E; Nosrati-Zarenoe, R, 2015)	0.65
" For initial remission induction, RTX was dosed at 1 g every 2 weeks or 375 mg/m(2) weekly for 4 consecutive weeks and for remission maintenance at 1 g every 6 months for 24 months."	( Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Alberici, F; Chaudhry, A; Jayne, DR; Jones, RB; Roberts, DM; Smith, KG; Smith, RM; Willcocks, LC, 2015)	0.42
" These results have suggested that a low dosage of prednisolone can be used with little concern for development of osteopenia in dogs."	( Quantitative computed tomographic assessment of bone mineral density changes associated with administration of prednisolone or prednisolone and alendronate sodium in dogs. Cho, KO; Choi, J; Oh, J; Park, S; Son, KY, 2015)	0.88
" However, the dosing and the duration of immunosuppressive therapy have not been systematically studied in the setting of treating ipilimumab-induced irAEs."	( Ipilimumab-induced toxicities and the gastroenterologist. Bye, W; Cheng, R; Cooper, A; Kench, J; McNeil, C; Shackel, N; Watson, G, 2015)	0.42
" The MG foundation of America (MGFA) classification, MGFA post-intervention status, dosage of prednisolone and pyridostigmine, and anti-acetylcholine receptor antibody titers were evaluated."	( Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis. Himuro, K; Kanai, T; Kawaguchi, N; Kuwabara, S; Oda, F; Uzawa, A; Yoshida, S; Yoshino, I, 2015)	0.64
" We believe close follow-up should be taken when CCS patients are making medicine dosage alteration and tumor marker such as CEA may be included in the surveillance examination."	( A case of recurrent Cronkhite-Canada syndrome containing colon cancer. Shi, H; Tian, Y; Wang, J; Xiao, J; Zhang, Y; Zhou, X; Zhu, X; Zong, Y, 2015)	0.42
"Orodispersible tablets (ODTs) and orodispersible films (ODFs) are solid oral dosage forms disintegrating or dissolving rapidly when placed in the mouth."	( Orodispersible films and tablets with prednisolone microparticles. Brniak, W; Jachowicz, R; Maślak, E, 2015)	0.69
" Dosing was 4 times daily for 2 months, thrice daily for 1 month, twice daily for 1 month, and once daily for 7 months."	( Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial. Feng, MT; Price, FW; Price, MO; Scanameo, A, 2015)	0.69
" Decreasing glucocorticoid dosage appears important for improving bone metabolism."	( Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis-results from the TOMORROW study. Inui, K; Koike, T; Mamoto, K; Nakamura, H; Okano, T; Sugioka, Y; Tada, M, 2016)	0.43
" Changes in prednisolone dosage correlated negatively with ΔOC (β = -0."	( Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis-results from the TOMORROW study. Inui, K; Koike, T; Mamoto, K; Nakamura, H; Okano, T; Sugioka, Y; Tada, M, 2016)	0.81
"Decreased glucocorticoid dosage improved bone metabolic markers in RA, but disease activity, bisphosphonate therapy, and period of biologics therapy did not influence levels of bone metabolic markers."	( Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis-results from the TOMORROW study. Inui, K; Koike, T; Mamoto, K; Nakamura, H; Okano, T; Sugioka, Y; Tada, M, 2016)	0.43
" Differences in standards of care and dosing complicate interpretation of this finding, but stratification by PRED/DFZ might be considered in clinical trials."	( Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Bello, L; Cnaan, A; Duong, T; Gordish-Dressman, H; Henricson, EK; Hoffman, EP; McDonald, CM; Morgenroth, LP, 2015)	0.81
" The aim of this study was to establish the optimal dosage and administration of immunosuppressants and antifungal agents."	( [Optimization of Immunosuppression and the Prevention of Fungal Infection in Autoimmune Diseases]. Mino, Y, 2015)	0.42
" Tacrolimus dosage was 2 mg/day (median)."	( Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. Adams, DH; Füssel, K; Hirschfield, GM; Hodson, J; Lohse, AW; Mann, J; Oo, YH; Schramm, C; Than, NN; Weiler-Normann, C; Wiegard, C, 2016)	0.43
" The patient interview revealed consumption to supra-therapeutic dosage of an association of naphazoline and prednisolone nasal sprays."	( [Malignant hypertension and cardiac decompensation after overuse of nasal decongestant: A case report and literature review]. Bontemps, H; Bourdelin, M; Le Vavasseur, O; Novais, T, 2016)	0.65
" Heterogeneity was related in part to the dosing strategy."	( Corticosteroids for treating sepsis. Annane, D; Bellissant, E; Bollaert, PE; Briegel, J; Keh, D; Kupfer, Y, 2015)	0.42
" Information on the dosage and timing of GC use was extracted."	( Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis. Abrahamowicz, M; Beauchamp, ME; Dixon, WG; Michaud, K; Movahedi, M; Pedro, S; Ray, DW, 2016)	0.43
" A range of conventional statistical models consistently confirmed increases in risk with the GC dosage and duration."	( Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis. Abrahamowicz, M; Beauchamp, ME; Dixon, WG; Michaud, K; Movahedi, M; Pedro, S; Ray, DW, 2016)	0.43
" Risk is influenced by the dosage and treatment duration, although only for GC use within the last 6 months."	( Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis. Abrahamowicz, M; Beauchamp, ME; Dixon, WG; Michaud, K; Movahedi, M; Pedro, S; Ray, DW, 2016)	0.43
" have published an open-labeled randomized clinical trial of 100 children with idiopathic nephrotic syndrome who were allocated either a body weight- or body surface area-based prednisolone dosing for a duration of 12 weeks."	( Should we stop dosing steroids per body surface area for nephrotics? Filler, G; Robinson, LA, 2016)	0.63
"Body surface area (BSA)-based prednisolone dosing for childhood nephrotic syndrome (NS) leads to higher cumulative prednisolone doses than body weight (BW)-based dosing."	( Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial. Harichandrakumar, KT; Krishnamurthy, S; Raman, V, 2016)	1.06
"This parallel-group open-label randomized clinical trial enrolled 100 children with idiopathic NS, to receive BW-based (n = 50) or BSA-based (n = 50) prednisolone dosing by block randomization in a 1:1 ratio."	( Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial. Harichandrakumar, KT; Krishnamurthy, S; Raman, V, 2016)	0.97
" The cumulative prednisolone dosage during the enrolment episode was higher in the BSA group."	( Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial. Harichandrakumar, KT; Krishnamurthy, S; Raman, V, 2016)	1.11
"Clinical outcomes with BW-based dosing are equivalent to BSA dosing-related outcomes, although cumulative prednisolone doses are lower in the former."	( Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial. Harichandrakumar, KT; Krishnamurthy, S; Raman, V, 2016)	0.98
" The dosage of imepitoin was increased from 20 mg/kg twice daily to 30 mg/kg twice daily, 3 days before the onset of skin lesions, due to uncontrolled seizures."	( Cutaneous adverse drug reaction in a dog associated with imepitoin. Bhatti, S; De Cock, H; Kitshoff, A; Royaux, E; Van Ham, L; Vandenabeele, S, 2016)	0.43
" Breed, age at diagnosis, weight, systemic disease status, eye affected, ophthalmic examination findings, systemic and topical therapy instituted, dosage and duration of therapy, visual outcome and histopathological analyses were recorded in cases meeting the inclusion criteria."	( An association between systemic cyclosporine administration and development of acute bullous keratopathy in cats. Bartoe, JT; Curran, PG; Gemensky-Metzler, AJ; Petersen-Jones, SM; Pierce, KE; Townsend, WM; Wilkie, DA, 2016)	0.43
" JLSG-02 has been revised from JLSG-96 in the following respects: prednisolone dosage during Induction A increased; duration of maintenance therapy extended from 24 to 48 weeks; cyclosporine introduced to Induction B for progressive disease."	( Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Bessho, F; Fujimoto, J; Horibe, K; Imamura, T; Imashuku, S; Ishii, E; Kawaguchi, H; Kobayashi, R; Koga, Y; Kudo, K; Morimoto, A; Sakashita, K; Shioda, Y; Tsunematsu, Y; Yasui, M, 2016)	0.9
" The majority of surveyed prescribers follow the British National Formulary for Children recommendations on dosage rather than those included in the British Thoracic Society and the Scottish Intercollegiate Guidelines Network."	( A review of prednisolone prescribing for children with acute asthma in the UK. Ahmad, AN; Batchelor, HK; Gilchrist, FJ; Lenney, W; Marriott, JF, 2016)	0.81
"We have extended the scope of this updated review to include comparisons of different corticosteroids and dosing regimens."	( Corticosteroids for the treatment of Duchenne muscular dystrophy. Brassington, R; Jichi, F; Kuntzer, T; Manzur, AY; Matthews, E, 2016)	0.43
" The most often prescribed oral steroids are prednisolone and dexamethasone, but current guidelines on dosing vary between countries, and often among different guideline producers within the same country."	( Different oral corticosteroid regimens for acute asthma. Kew, KM; Mansour, G; Normansell, R, 2016)	0.69
" Clinically feasible models that combine important factors may help guide individual tacrolimus dosage adjustment in kidney transplant patients."	( Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. Avihingsanon, Y; Praisuwan, S; Techawathanawanna, N; Treyaprasert, W; Vadcharavivad, S, 2016)	0.43
" Current GC dose of below 5 mg per day (prednisolone equivalent dose) was not associated with an increased risk of death, but a dose-response association was seen for higher dose categories."	( Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study. Costello, R; Dixon, WG; Lunt, M; Movahedi, M; Pye, SR; Sergeant, JC, 2016)	0.7
"The objective of this retrospective study was to examine factors that may have affected the stabilisation times of 50 dogs with spontaneous hypoadrenocorticism that were being treated with fludrocortisone acetate, with particular emphasis on dosing frequency and the concurrent use of prednisolone."	( Factors that affect stabilisation times of canine spontaneous hypoadrenocorticism. Boden, LA; Ramsey, IK; Roberts, E, 2016)	0.61
" This study evaluated the effectiveness and the proper dosage of omalizumab for Asian CSU patients in a real-life setting."	( Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population. Chularojanamontri, L; Kulthanan, K; Likitwattananurak, C; Tuchinda, P; Ungaksornpairote, C, 2017)	0.46
"Omalizumab at an initial dosage of 150 mg was effective in the treatment of recalcitrant CSU among Asians."	( Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population. Chularojanamontri, L; Kulthanan, K; Likitwattananurak, C; Tuchinda, P; Ungaksornpairote, C, 2017)	0.46
"Randomised trials and quasi-randomised trials comparing different routes of administration and dosage schemes of corticosteroid or adrenocorticotrophic hormone therapy versus a control group receiving no therapy considered effective for this condition, unless the same therapy was given in a similar way to the experimental group."	( Corticosteroids for Bell's palsy (idiopathic facial paralysis). Daly, F; Gagyor, I; Gammie, F; Madhok, VB; Somasundara, D; Sullivan, F; Sullivan, M, 2016)	0.43
" Finally, this efficacious formulation was used as core material for the development of a final dosage form: F6/Cps allowed to significantly reduce prednisolone release in simulated gastric fluid (12."	( Prednisolone Delivery Platforms: Capsules and Beads Combination for a Right Timing Therapy. Aquino, RP; Auriemma, G; Cerciello, A; Del Gaudio, P; Morello, S; Russo, P, 2016)	2.08
" Dosing regimens of oral steroids in EFT produced no differences in the time course."	( Early fast-acting treatment strategy against generalized myasthenia gravis. Akaishi, T; Aoki, M; Imai, T; Kawaguchi, N; Konno, S; Masuda, M; Minami, N; Murai, H; Nagane, Y; Suzuki, H; Suzuki, Y; Tsuda, E; Utsugisawa, K; Uzawa, A, 2017)	0.46
" By combining the advantages of thermally stable pharmaceutically approved polymers and fillers, this unique approach provides a low cost production method for on demand manufacturing of individualised dosage forms."	( Adaptation of pharmaceutical excipients to FDM 3D printing for the fabrication of patient-tailored immediate release tablets. Ahmed, W; Alhnan, MA; Arafat, B; Isreb, A; Kelarakis, A; Sadia, M; Sośnicka, A, 2016)	0.43
" If systemic corticosteroids are planned to be administrated in the prednisolone equivalent dosage of 5 mg/day or more for three months or longer, risk of bone fracture have to be assessed regardless of the primary pulmonary disease."	( [Steroids-induced osteoporosis due to the treatment for Pulmonary diseases.] Horita, N; Kaneko, T, )	0.37
" Compared to the dexchlorpheniramine plus betamethasone combination, it showed similar clinical action, but with a lower incidence of adverse events and higher dosing convenience."	( Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial. Amazonas, RB; Ensina, LF; Miranda, C; Sano, F; Silva, JMD; Solé, D; Wandalsen, GF, )	0.4
" The reintroduced imatinib dosage was stepped up every week starting from 10 mg/d and increasing to 25, 50, 75, 100, 150, 200, and 300 mg/d until the target dose of 400 mg/d was achieved."	( Slow desensitization of imatinib-induced nonimmediate reactions and dynamic changes of drug-specific CD4 Buranapraditkun, S; Klaewsongkram, J; Mongkolpathumrat, P; Sodsai, P; Thantiworasit, P, 2016)	0.43
" In spite of the temporary remission after re-initiation of oral steroid therapy, reduction of oral steroid dosage resulted in new lesion formation apart from the initial locations."	( An adult-onset multiphasic disseminated encephalomyelitis (MDEM) presenting favorable response to steroid therapy. Fujimura, H; Fukada, K; Hazama, T; Inoue, K; Kinoshita, M; Sugimura, Y, 2016)	0.43
" The current dosage of prednisolone correlated inversely with the levels of bioactive testosterone (r = -0."	( Effect of Corticosteroids and Cyclophosphamide on Sex Hormone Profiles in Male Patients With Systemic Lupus Erythematosus or Systemic Sclerosis. Arnaud, L; Gunnarsson, I; Hellbacher, E; Lundholm, H; Nordin, A; Svenungsson, E; Wikner, J; Zickert, A, 2017)	0.77
" Rituximab has proven effective for the treatment of steroid-refractory pemphigus, although there is controversy over the optimum dosing protocol."	( Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and single-centre long-term review of nine patients. Robinson, AJ; Scardamaglia, L; Unglik, GA; Varigos, GA; Vu, M, 2018)	0.48
" This was likely the result of low-frequency dosing and short duration of steroid use."	( Comparison of prednisolone acetate 1.0% and difluprednate ophthalmic emulsion 0.05% after cataract surgery: Incidence of postoperative steroid-induced ocular hypertension. Ernest, P; McBain, M; Mian, SI; Musch, DC; Niziol, LM; Person, E; Tijunelis, MA, 2017)	0.82
" Four different orodispersible dosage forms containing two poorly soluble drugs, levothyroxine and prednisolone, were produced on two different edible substrates by piezoelectric inkjet printing."	( Application of a handheld NIR spectrometer in prediction of drug content in inkjet printed orodispersible formulations containing prednisolone and levothyroxine. Desai, D; Preis, M; Sandler, N; Vakili, H; Wickström, H, 2017)	0.88
" Primary endpoints were remission induction, occurrence of relapses, prednisolone (PSL) dosage at time of remission, and adverse events."	( Interferon-α for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center Retrospective Observational Cohort Study. Forberg, T; Förster, M; Happe, J; Kroegel, C; Moeser, A; Neumann, T; Seeliger, B, 2017)	0.69
" In the treatment of CDS, it is recommended that a low dosage (15-30mg) of corticosteroids be used as first-line drugs rather than conventional NSAID therapy."	( Clinical and quantitative analysis of patients with crowned dens syndrome. Kamei, S; Takahashi, T; Takasu, T; Tamura, M, 2017)	0.46
" However, orally administered colchicine along with prednisolone effectively ameliorated her symptoms, and prednisolone dosage was reduced again."	( Serum cytokine profile in pediatric Sweet's syndrome: a case report. Fujino, H; Sumimoto, SI; Takano, Y; Yachie, A, 2017)	0.71
" However, after ME-CyA dosage reduction and discontinuation, the relapse rate increased."	( Combined cyclosporine and prednisolone therapy using cyclosporine blood concentration monitoring for adult patients with new-onset minimal change nephrotic syndrome: a single-center pilot randomized trial. Imai, N; Kimura, K; Matsui, K; Sakurada, T; Shibagaki, Y; Shirai, S; Sueki, S; Tominaga, N; Yasuda, T, 2018)	0.78
" They showed that the mean prednisolone dosage significantly decreased (6."	( A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis. Ahn, SW; Cho, EB; Hong, YH; Joo, IS; Kang, SY; Kim, BJ; Min, JH; Minn, YK; Nam, TS; Oh, J; Oh, SY; Park, JS; Park, YE; Seok, HY; Seok, JI; Seok, JM; Shin, HY; Shin, JY; Suh, BC; Sung, JJ, 2017)	0.75
"Five simple, sensitive, and eco-friendly LC and UV spectrophotometric methods have been developed for the simultaneous determination of phenylephrine hydrochloride (PHE) and prednisolone acetate (PRD) in their combined dosage form."	( Development and Validation of Eco-Friendly Liquid Chromatographic and Spectrophotometric Methods for Simultaneous Determination of Coformulated Drugs: Phenylephrine Hydrochloride and Prednisolone Acetate. El Mously, DA; Elsayed, GM; Hassan, NY; Mostafa, NM, 2017)	0.84
" Because muscle pain disappeared, the CAM dosage was halved."	( Successful treatment with clarithromycin and/or tacrolimus for two patients with polymyalgia rheumatica. Horita, T; Ohe, M; Oku, K; Shida, H, )	0.13
" Conclusion We confirmed that LI-CAP has therapeutic effects on reducing the dosage and discontinuing steroids in patients with steroid-dependent UC."	( Long-interval Cytapheresis as a Novel Therapeutic Strategy Leading to Dosage Reduction and Discontinuation of Steroids in Steroid-dependent Ulcerative Colitis. Etou, T; Iizuka, M; Kumagai, M; Matsuoka, A; Numata, Y; Sagara, S, 2017)	0.46
"The number of intramuscularly applied dosage forms has been continuously increasing during the last decades."	( In vitro dissolution testing of parenteral aqueous solutions and oily suspensions of paracetamol and prednisolone. Klein, S; Probst, M; Schmidt, M; Seidlitz, A; Tietz, K; Weitschies, W, 2017)	0.67
" The secondary outcomes are the number or relapses, progression to frequent relapsing or steroid dependent nephrotic syndrome and the cumulative dosage of prednisolone during the study period."	( REducing STEroids in Relapsing Nephrotic syndrome: the RESTERN study- protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study. Bouts, AHM; Dorresteijn, EM; Keijzer-Veen, MG; Roeleveld, N; Schijvens, AM; Schreuder, MF; Ter Heine, R; van de Kar, NCAJ; van den Heuvel, LPWJ; van Wijk, JAE, 2017)	0.65
" The suggested methods were validated in compliance with the ICH guidelines and were successfully applied to determine both drugs in their pure forms, laboratory prepared mixtures and dosage form."	( Validated Chromatographic Methods for the Simultaneous Determination of Sulfacetamide Sodium and Prednisolone Acetate in their Ophthalmic Suspension. AbdElHamid, G; El-Ragehy, NA; Hegazy, MA; Tawfik, SA, 2017)	0.67
" The eye and ear pain showed exacerbations and remissions on reducing the dosage of steroid drugs."	( Unique circumferential peripheral keratitis in relapsing polychondritis: A case report. Fujihara, M; Hirami, Y; Ishida, K; Kurimoto, Y; Motozawa, N; Nakamura, T; Sotozono, C; Takagi, S, 2017)	0.46
" The findings of this study indicate that cryptococcosis should be considered during the differential diagnosis of infection in patients receiving tocilizumab, especially in the presence of other risk factors for infections or a short tocilizumab dosing interval."	( Disseminated cryptococcosis in a patient taking tocilizumab for Castleman's disease. Kamei, H; Nishioka, H; Takegawa, H, 2018)	0.48
"This study compared the pharmacokinetics of Prednisolone (PDS) in small- and large breed dogs with a dosing format based on body surface area (BSA) or body weight (BW)."	( Comparison of body surface area-based and weight-based dosing format for oral prednisolone administration in small and large-breed dogs. Jeong, JW; Kim, SM; Koo, TS; Nam, A; Seo, KW; Song, KH, 2017)	0.94
"We examined the correlation between the dosing regimen of oral prednisolone (PSL) and the achievement of minimal manifestation status or better on PSL ≤5 mg/day lasting >6 months (the treatment target) in patients with generalised myasthenia gravis (MG)."	( Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan. Akaishi, T; Aoki, M; Imai, T; Kawaguchi, N; Konno, S; Masuda, M; Minami, N; Murai, H; Nagane, Y; Suzuki, H; Suzuki, Y; Tsuda, E; Utsugisawa, K; Uzawa, A, 2018)	0.72
"We classified 590 patients with generalised MG into high-dose (n=237), intermediate-dose (n=187) and low-dose (n=166) groups based on the oral PSL dosing regimen, and compared the clinical characteristics, previous treatments other than PSL and prognosis between three groups."	( Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan. Akaishi, T; Aoki, M; Imai, T; Kawaguchi, N; Konno, S; Masuda, M; Minami, N; Murai, H; Nagane, Y; Suzuki, H; Suzuki, Y; Tsuda, E; Utsugisawa, K; Uzawa, A, 2018)	0.48
" Hence maximum amount of drug could be released in the colon that may result in reduction in dose and dose frequency as well as side effects of drug as observed with the conventional dosage form of prednisolone."	( Eudragit S100 coated microsponges for Colon targeting of prednisolone. Hurkat, P; Jain, A; Jain, SK; Kumari, A; Tiwari, A, 2018)	0.91
"5 mg/d and standard immunosuppressant dosage tolerance) was assessed."	( Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: Berglind, A; Illei, GG; Morand, EF; Trasieva, T; Tummala, R, 2018)	0.48
" This led to the discovery of AZD9567 (15) with excellent in vivo efficacy when dosed orally in a rat model of joint inflammation."	( Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile. Berger, M; Bird, J; Chang, HF; Chapman, D; Dearman, M; Drmota, T; Edenro, G; Edman, K; Geschwindner, S; Harrison, R; Hegelund-Myrbäck, T; Hendrickx, R; Köhler, C; Lawitz, K; Lepistö, M; Llinas, A; Malmberg, J; Nikitidis, A; Olsson, RI; Ripa, L; Svanberg, P; Thorne, P; Ullah, V; Wissler, L, 2018)	0.48
" We postulate that there is room for improvement of dosing, as the optimal immunosuppressive dose in calcineurin-free regimens is unknown and since the once daily dosing regimen for oncological indications is often associated with treatment-limiting toxicity."	( A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. Burger, DM; de Fijter, JW; Guchelaar, HJ; Moes, DJAR; Reinders, MEJ; Ter Heine, R; van Erp, NP; van Herpen, CM, 2018)	0.48
"We developed a mechanistic population pharmacokinetic model for everolimus in cancer and transplant patients and explored alternative dosing regimens."	( A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. Burger, DM; de Fijter, JW; Guchelaar, HJ; Moes, DJAR; Reinders, MEJ; Ter Heine, R; van Erp, NP; van Herpen, CM, 2018)	0.48
" JLSG-02 was modified from JLSG-96 as follows: increased prednisolone dosage at the induction phase and extension of maintenance therapy duration from 24 to 48 weeks."	( Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group- Goto, H; Imamura, T; Imashuku, S; Kawaguchi, H; Kitoh, T; Kosaka, Y; Kudo, K; Morimoto, A; Shioda, Y; Tsunematsu, Y, 2018)	0.73
" Dogs were considered stable if they showed no signs of glucocorticoid deficiency or excess, sodium and potassium were within the laboratory reference limits and no change of prednisolone and/or fludrocortisone dosage was recommended by the clinician."	( Prednisolone dosages in Addisonian dogs after integration of ACTH measurement into treatment surveillance. Haninger, T; Zeugswetter, FK, 2018)	2.12
"We performed a post-hoc analysis of a randomised, placebo-controlled, double blind, dose-response intervention study involving 32 healthy males (age: 22 ± 3 years; BMI 22."	( The osteoblast: Linking glucocorticoid-induced osteoporosis and hyperglycaemia? A post-hoc analysis of a randomised clinical trial. Brands, M; de Jongh, RT; den Heijer, M; Heijboer, AC; Serlie, MJ; van Bommel, EJM; van Raalte, DH, 2018)	0.48
" oral dexamethasone versus oral prednisone), with consideration for dosing and pharmacokinetic properties, to better identify the optimal IM or oral corticosteroid regimens to improve patient outcomes."	( Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma. Campbell, S; Cross, E; Kirkland, SW; Rowe, BH; Villa-Roel, C, 2018)	0.48
" To assess the association between steroid dose used for relapse and subsequent outcomes, data of patients with tapered prednisolone (PSL) dosage to <10 mg/day before the first relapse in whom the dose was subsequently increased to ≥10 mg/day were extracted and assigned to the High-PSL or Low-PSL groups, based on the median dose of 20 mg/day."	( Treatment patterns and steroid dose for adult minimal change disease relapses: A retrospective cohort study. Ando, M; Kato, S; Katsuno, T; Maruyama, S; Ozeki, T; Tsuboi, N; Yamaguchi, M; Yasuda, Y, 2018)	0.69
"Although therapeutic drug monitoring of plasma mycophenolic acid (MPA) concentrations has been recommended to individualize dosage in transplant recipients, little is known regarding lymphocyte concentrations of MPA, where MPA inhibits inosine monophosphate dehydrogenase (IMPDH)."	( Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients. Carroll, RP; Coller, JK; McWhinney, BC; Md Dom, ZI; Sallustio, BC; Somogyi, AA; Tuke, J, 2018)	0.48
"This study first revealed that using higher dose steroids was an independent risk factor for rebleeding after endoscopic hemostasis for peptic ulcer bleeding, with a dose-response relation."	( The Use of Higher Dose Steroids Increases the Risk of Rebleeding After Endoscopic Hemostasis for Peptic Ulcer Bleeding. Asano, N; Asanuma, K; Hatta, W; Imatani, A; Kanno, T; Koike, T; Kondo, Y; Masamune, A; Saito, M; Takahashi, Y, 2018)	0.48
" Preventative measures are not usually required in patients who receive a short high-dosed treatment (30 mg PED in 7 days) or prednisolone at a dosage of < 15 mg/day."	( [Infections during glucocorticoid use]. den Hoed, CM; Minderhoud, TC; Schurink, CAM; van Daele, PLA; van Meer, MPA; van Thiel, RJ, 2018)	0.69
" We recommend combined therapy with albendazole and prednisolone, with consideration for increased steroid dosing in severe cases."	( Severe CNS angiostrongyliasis in a young marine: a case report and literature review. Bavaro, M; Cathey, M; Fortin Ensign, S; Larson, D; McAuliffe, L; Mukaigawara, M; Narita, M; Ohkusu, K; Quast, T; Volk, C; Yetto, J, 2019)	0.76
" Clinical benefit was assessed in all patients and among subgroups with a baseline blood eosinophil count of less than 150 cells/μL, baseline OGC dosage of greater than 20 mg/d, or weight of greater than 85 kg."	( Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. Akuthota, P; Bradford, ES; Brown, J; Cid, MC; Gleich, GJ; Jayne, D; Khoury, P; Langford, CA; Mallett, S; Merkel, PA; Moosig, F; Specks, U; Steinfeld, J; Wechsler, ME; Weller, PF; Yancey, SW, 2019)	0.51
" The dosage of prednisolone was gradually decreased as liver function improved."	( Acute onset of autoimmune hepatitis with sinusoidal and central vein endotheliitis, and marked involvement of activated dendritic cells: A case report. Obu, M; Oda, M; Okada, T; Uematsu, T; Yamazaki, H; Yokomori, H, 2018)	0.83
" Within three years, all polyps had disappeared and the steroid therapy was finished while the dosage of mesalazine was reduced in a stepwise fashion."	( Case report of patient with a Cronkhite-Canada syndrome: sustained remission after treatment with corticosteroids and mesalazine. Drebber, U; Kaufmann, T; Kütting, F; Mertens, J; Nierhoff, D; Schulte, S; Steffen, HM; Töx, U, 2019)	0.51
" A 74-year-old man without a history of autoimmune diseases received nivolumab at a dosage of 3 mg/kg once every 2 weeks for the treatment of stage IIIB squamous cell carcinoma."	( [Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment]. Fujii, R; Imai, Y; Okazaki, K; Tanaka, M; Uchitani, K, 2019)	0.51
"The range of CsA dosage was 50-200 mg/day, and mean CsA dose was 102."	( Low-dose cyclosporine for active lupus nephritis: a dose titration approach. Angthararak, S; Kitumnuaypong, T; Pichaiwong, W; Sumethkul, K, 2019)	0.51
" While on maintenance dosing of oral valacyclovir, he experienced reactivation in the form of bilateral vasculitis, which was successfully managed once restarting therapeutic oral dosing."	( Case Report: Varicella-zoster Encephalitis with Acute Retinal Necrosis and Oculomotor Nerve Palsy. Quan, SC; Skondra, D, 2019)	0.51
" AI patients need to adjust GC dosage in response to stressful events and illness in order to prevent life-threatening adrenal crisis (AC)."	( Daily adjustment of glucocorticoids by patients with adrenal insufficiency. Badenhoop, K; Beuschlein, F; Kienitz, T; Maison, N; Mayr, B; Meyer, G; Quinkler, M; Schöfl, C, 2019)	0.51
" Twenty four patients, which contained 18 PMR and 6 RS3PE syndrome, were treated with initial dosages of 10-20 mg per day oral prednisolone, and the dosage of prednisolone was then tapered."	( Predictive factors associated with the therapeutic response in patients with polymyalgia rheumatica and remitting seronegative symmetrical synovitis with pitting edema syndrome. Inaba, K; Kawahito, K; Kawaminami, S; Kondo, K; Miyatake, A; Nakanishi, Y; Okura, Y; Suzuki, Y; Tabata, R; Tani, K; Umetani, K; Yamaguchi, H; Yuasa, S, 2019)	0.72
" His clinical condition did not improve, therefore, we increased the dosage of prednisolone to 40 mg/day; however, his rash gradually expanded with papules and plaques."	( A case of neutrophilic dermatosis with Daisuke, N; Endo, Y; Furukawa, K; Ichinose, K; Igawa, T; Iwamoto, N; Kawakami, A; Kawashiri, SY; Koga, T; Koike, Y; Nakamura, H; Okamoto, M; Origuchi, T; Otsuka, M; Shimizu, T; Sumiyoshi, R; Takatani, A; Tamai, M; Tsuji, S, 2019)	0.74
" We estimated dose-response risks of infection for this population in England."	( Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. Keeley, A; Mallen, C; Morgan, AW; Pujades-Rodriguez, M; Wu, J, 2019)	0.51
" Statistically significant, albeit clinically irrelevant, increases in blood glucose and N-terminal pro-B-type natriuretic peptide concentrations were observed between baseline and the prednisolone pharmacokinetic steady state (7 days after initiation) only when the 2-mg/kg dosage was administered."	( Clinicopathologic, hemodynamic, and echocardiographic effects of short-term oral administration of anti-inflammatory doses of prednisolone to systemically normal cats. Berger, DJ; Khelik, IA; Mochel, JP; Palerme, JS; Seo, YJ; Ward, JL; Ware, WA, 2019)	0.91
" Demographic and clinical features including age, gender, House-Brackmann Facial Nerve Grading System House-Brackmann Grading Scale (HBGS) grade at admission and follow-up, and the dosage and onset of steroid treatment were reviewed."	( Prognostic Factors Associated With Recovery in Children With Bell's Palsy. Karatoprak, E; Yilmaz, S, 2019)	0.51
" Eculizumab was administered at a dosage of 900 mg/wk for the first month and 1200 mg every 2 weeks thereafter."	( Renal Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Single Center Experience. Alpay, N; Ozçelik, U, 2019)	0.51
"Total and free plasma prednisolone measurements correlated poorly with saliva measurements; however, correlation improved when concentrations early in the dosing interval were excluded."	( Prednisolone Concentrations in Plasma (Total and Unbound) and Saliva of Adult Kidney Transplant Recipients. Brooks, E; Isbel, NM; McWhinney, B; Staatz, CE; Tett, SE, 2019)	2.27
" The patient groups later developing hypothyroidism did not differ in age, BMI, pre-treatment TSH levels or initial dosage of prednisolone treatment."	( Long-term Outcome of Subacute Thyroiditis. Diederich, S; Görges, J; Janssen, OE; Keck, C; Müller-Wieland, D; Ulrich, J, 2020)	0.76
" Prednisolone dosage was increased to 1 mg/kg/day, and the subsequent taper was performed slowly over the course of 10 weeks."	( Drug reaction with eosinophilia and systemic symptoms syndrome in a patient taking lamotrigine. Dória, MDC; Lameiras, C; Mendes Lopes, M; Ornelas, É, 2019)	1.42
"Randomised-controlled trials (RCTs) comparing difluprednate and prednisolone acetate regardless of the dosing regimen used."	( Difluprednate versus Prednisolone Acetate after Cataract Surgery: a Systematic Review and Meta-Analysis. Basiony, A; KhalafAllah, MT; Salama, A, 2019)	1.07
" The lower dosage of oral prednisolone was a significant risk factor compared with higher dosage when used."	( Oral steroid decreases the progression of joint destruction of large joints in the lower extremities in rheumatoid arthritis. Azukizawa, M; Doi, K; Hashimoto, M; Ito, H; Matsuda, S; Mimori, T; Murakami, K; Murata, K; Nishitani, K; Okahata, A; Saito, M; Tanaka, M; Tomizawa, T, 2019)	0.81
" DWIBS makes it possible to adjust the medicine dosage while confirming the therapeutic effects and will likely be a useful method for monitoring IgG4-related disease."	( Clinical Utility of Diffusion-weighted Whole-body Magnetic Resonance Imaging with Background Body Signal Suppression for Assessing and Monitoring IgG4-related Disease. Kawakami, H; Kazatani, T; Kono, Y; Matsuoka, H; Miyoshi, T; Oshita, A; Suzuki, M, 2020)	0.56
" Survey items evaluated PCP preferred oral glucocorticoid and dosing regimen for children with acute asthma exacerbations, provider- and patient-level factors contributing to glucocorticoid preferences, and perception of glucocorticoid regimens in terms of treatment failure, resolution of symptoms and adherence."	( Primary care provider preferences for glucocorticoid management of acute asthma exacerbations in children. Hoch, H; Mistry, RD; Moran, E; Navanandan, N; Smith, H, 2021)	0.62
" Using linear regression and a negative binomial model, genetic variant association with three endpoints (accrued duration of remission, average oral glucocorticoid dose, and frequency of relapse) was tested in 61 EGPA subjects dosed with mepolizumab from MIRRA, a phase 3 trial."	( Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis. Condreay, LD; Ghosh, S; Parham, LR; Qu, XA; Raby, BA; Steinfeld, J; Wechsler, ME; Yancey, SW, 2020)	0.56
" One trial (27 participants) found that HC and DXA treatment suppressed 17 OHP and androstenedione more than PD treatment after six weeks and a further trial (eight participants) reported no difference in 17 OHP between the five different dosing schedules of HC at between four and six weeks."	( Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia. Krishan, A; Ng, SM; Stepien, KM, 2020)	0.56
" However, chronic use of topical corticosteroids dosed at <3 drops daily seemed to be associated with a lower risk of cataract development relative to eyes receiving higher doses over follow-up in the setting of suppressed uveitis."	( Risk of Cataract Development among Children with Juvenile Idiopathic Arthritis-Related Uveitis Treated with Topical Corticosteroids. Dunn, JP; Jabs, DA; Thorne, JE; Woreta, FA, 2020)	0.56
" Forty-five days after prednisolone therapy, partial remission of nephrotic syndrome and decrease of serum creatinine were achieved while peritoneal dialysis dosage had decreased."	( Eosinophilic peritonitis and nephrotic syndrome in Kimura's disease: a case report and literature review : Eosinophilic peritonitis in Kimura's disease. Dong, J; Nong, L; Song, D; Wang, S; Wang, Z; Xu, D; Yang, Z; Yu, B; Zhou, F, 2020)	0.87
" We also comment on suggested dosing for patients who usually take modified release hydrocortisone or prednisolone."	( ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency. Arlt, W; Baldeweg, SE; Pearce, SHS; Simpson, HL, 2020)	0.77
" Cumulative effects were seen for the 6 diseases studied, but dose-response effects were not found for daily dose."	( Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. Mebrahtu, TF; Morgan, AW; Pujades-Rodriguez, M; Stewart, PM; West, RM, 2020)	0.56
" However, albeit strong recommendations, the treatment protocol is based on low-quality evidence and high-quality clinical trials are lacking with respect to the optimal initiation dosage and usage of corticosteroid."	( Comparison of the therapeutic effects of 15 mg and 30 mg initial dosage of prednisolone daily in patients with subacute thyroiditis: protocol for a multicenter, randomized, open, parallel control study. Chen, R; Gao, B; Gao, L; Jia, A; Jiang, Y; Jiao, Y; Jing, X; Shang, L; Wei, J; Xu, J; Xu, S; Xu, W; Zhang, J, 2020)	0.79
" A total of 90 adult patients diagnosed with SAT who present moderate to severe pain or fail to respond to full doses of NSAIDs will be randomly assigned with a 1:1 ratio to the low initial PSL dosage group (15 mg daily) and standard initial PSL dosage group (30 mg daily)."	( Comparison of the therapeutic effects of 15 mg and 30 mg initial dosage of prednisolone daily in patients with subacute thyroiditis: protocol for a multicenter, randomized, open, parallel control study. Chen, R; Gao, B; Gao, L; Jia, A; Jiang, Y; Jiao, Y; Jing, X; Shang, L; Wei, J; Xu, J; Xu, S; Xu, W; Zhang, J, 2020)	0.79
" Based on pharmacokinetic-pharmacodynamic models, TNFα dose-response relationships for AZD9567 and prednisolone were established."	( Estimation of Equipotent Doses for Anti-Inflammatory Effects of Prednisolone and AZD9567, an Oral Selective Nonsteroidal Glucocorticoid Receptor Modulator. Almquist, J; Eriksson, UG; Hegelund Myrbäck, T; Leander, J; Prothon, S; Sadiq, MW, 2020)	1.01
"In immune-mediated inflammatory diseases, there is a lack of -estimates of glucocorticoid dose-response diabetes risk that consider changes in prescribed dose over time and disease activity."	( Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: a population-based cohort analysis. Mackie, SL; Pujades-Rodriguez, M; Wu, J, 2020)	0.56
" For the treatment of COVID-19 pneumonia, systemic and in-depth investigation is needed to determine the timing and dosage of glucocorticoids needed to inhibit overwhelming inflammatory response and not the protective immune response to COVID-19 pneumonia."	( Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience. Hu, Y; Hu, Z; Li, L; Peng, P; Wang, T; Wang, X; Zhang, Z, 2020)	0.56
" Mesalazine at 4,000 mg/day and prednisolone at 60 mg/day were started, and the prednisolone dosage was thereafter gradually reduced and switched to golimumab."	( Multiple Cerebral Infarction Associated with Cerebral Vasculitis in a Patient with Ulcerative Colitis. Dohi, O; Hasegawa, D; Hirose, R; Inoue, K; Ishikawa, T; Itoh, Y; Kamada, K; Konishi, H; Naito, Y; Takagi, T; Uchiyama, K; Yasuda, T; Yoshida, N, 2021)	0.9
"The median period of subject observation following the first RTX dosing was 34 months (cumulative RTX dose: 400 - 1,400 mg)."	( Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab. Adachi, H; Fujii, A; Fujimoto, K; Furuichi, K; Kagaya, Y; Kumano, S; Matsuura, T; Nomura, K; Okada, K; Okino, K; Tsuruyama, Y; Yamazaki, K; Yokoyama, H, 2021)	0.62
" Higher prednisolone dosage and PDAI-score were positively correlated with CTLA4 and FCGR3A expressions after 3 months, respectively (P-value = ."	( Investigating expression pattern of eight immune-related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: Potential roles of CTLA4 and FCGR3A genes expression in outcomes of rituximab therapy. Abbasi, M; Balali, M; Balighi, K; Daneshpazhooh, M; Elikaei Behjati, S; Karami, F; Mahmoudi, H; Masoudi, J; Modarressi, MH; Salehi Farid, A; Tavakolpour, S, 2020)	0.99
" An abbreviated profile within the first 4 hours after PL dosing provides a good prediction of PL exposure in renal Tx recipients."	( Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients. Andersen, AM; Åsberg, A; Bergan, S; Bjerre, A; Gustavsen, MT; Midtvedt, K; Skauby, RH; Vethe, NT, 2021)	2.06
" However, a fall in FeNO following supervised inhaled corticosteroid dosing could indicate previous poor adherence."	( Assessment of adherence to corticosteroids in asthma by drug monitoring or fractional exhaled nitric oxide: A literature review. Alahmadi, F; Fowler, SJ; Keevil, B; Niven, R; Peel, A, 2021)	0.62
" In order to improve immunosuppression and decrease dosage and duration of glucocorticoid treatment, a second immunosuppressive drug is commonly used in most of the immune-mediated diseases."	( Combination of Prednisolone and Azathioprine for Steroid-Responsive Meningitis-Arteritis Treatment in Dogs. Cauzinille, L; Giraud, L; Girod, M, 2021)	0.97
" The freeze-drying method was used to convert the SLP suspension into a solid dosage form for buccal delivery by using mucoadhesive polymers."	( Effects of Mucoadhesive Polymers on Released Particles and Drug Release in Solid Lipid Particle-Based Buccal Tablets. Phan, TTH; Tran, PHL; Tran, TTD, 2021)	0.62
" Les chats ont initialement été évalués au moment du recrutement et puis à huit semaines avec des radiographies thoraciques, lavage bronchoalvéolaire, tests de fonction pulmonaire et dosage de la fructosamine."	( Treatment of naturally occurring asthma with inhaled fluticasone or oral prednisolone: A randomized pilot trial. Bain, P; Egan, A; Knoll, J; Oura, TJ; Rozanski, EA; Sharp, CR; Verschoor-Kirss, M, 2021)	0.85
" Corticosteroids are inexpensive and promising drugs for relapse prevention in NMOSD, but few studies have analysed the efficacy of corticosteroids in NMOSD, especially regarding the appropriate dosing and tapering regimens."	( Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Akaishi, T; Aoki, M; Fujihara, K; Kuroda, H; Misu, T; Nakashima, I; Nishiyama, S; Takahashi, T; Takai, Y, 2021)	0.84
" Recently, corticosteroid dosing to treat relapses has been questioned, with data suggesting lower doses may be as effective."	( Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome. Christian, MT; Maxted, AP, 2022)	0.72
"001), and average oral dosage of >7."	( Pneumocystis Jirovecii Pneumonia in Systemic Lupus Erythematosus: A Nationwide Cohort Study in Taiwan. Chang, YS; Chen, WS; Huang, YF; Lai, CC; Li, TH; Tsao, YP; Wang, WH, 2022)	0.72
" The side-effects of oral steroids require careful consideration and further studies are needed to ascertain appropriate dosage and treatment duration."	( Short-term Oral Steroids Significantly Improves Chronic Rhinosinusitis Without Nasal Polyps. Chao, J; Cildir, G; De Silva, AP; Lopez, A; Pant, H; Sarah, AH; Schembri, MA; Tumes, DJ; Yip, KH, 2021)	0.62
" In this dosage range they promote osteoporosis, diabetes and hyperglycemia as well as cardiovascular events and infections, thereby contributing to an excess mortality."	( [Safety aspects of the treatment with glucocorticoids for rheumatoid arthritis]. Keyßer, G, 2021)	0.62
" Four trials included European cohorts using dosing schedules according to the regimens studied."	( Steroid treatment for the first episode of childhood nephrotic syndrome: comparison of the 8 and 12 weeks regimen using an individual patient data meta-analysis. Dorresteijn, EM; Schijvens, AM; Schreuder, MF; Teeninga, N; Teerenstra, S; Webb, NJ, 2021)	0.62
" Our investigations excluded other possible causes for deranged LFTs and there was no improvement of same despite reduced dosing of potentially hepatotoxic medications."	( Prednisolone: role in amoxicillin-clavulanate-induced cholestatic liver injury. Chigozie, R; Khan, I; Lee, MQ; O'Mara, G, 2021)	2.06
" The corticosteroid dosage that is effective against inflammatory disorders depends on the pathological background of autoimmune diseases; however, owing to limited clinical evidence, the dosage has been empirically determined in routine medical practice."	( [Corticosteroid Therapy in Patients with Autoimmune Diseases of the Central Nervous System]. Matsushita, T, 2021)	0.62
" Patients aged 18 years or older with previously untreated asymptomatic or mildly symptomatic mCRPC who had progressive disease and Eastern Collaborative Oncology Group performance status of 0 or 1 were randomly assigned (1:1; permuted block method) to receive ipatasertib (400 mg once daily orally) plus abiraterone (1000 mg once daily orally) and prednisolone (5 mg twice a day orally) or placebo plus abiraterone and prednisolone (with the same dosing schedule)."	( Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Alekseev, B; Alves, GV; Atduev, V; Borre, M; Bournakis, E; Bracarda, S; Buchschacher, GL; Chen, G; Chi, KN; Corrales, L; de Bono, JS; Gafanov, R; Gallo, J; Garcia, J; Hanover, J; Harle-Yge, ML; Massard, C; Matsubara, N; Olmos, D; Parnis, F; Puente, J; Sandhu, S; Sternberg, CN; Stroyakovskiy, D; Sweeney, C; Wongchenko, MJ, 2021)	1.07
" Therefore, the dosage of PSL was increased to 65 mg once daily."	( [A Case of Penile Pyoderma Gangrenosum Treated by Urethrocutaneostomy without Penectomy]. Hatano, S; Ishitoya, S; Kanematsu, A; Mizuno, K; Nishikawa, N; Ogura, K; Takada, H; Takao, N; Tsuchihashi, K, 2021)	0.62
"To investigate the relationship between real life glucocorticoid (GC) dosing and relapse rates in patients with new onset GCA in a single centre."	( Glucocorticoid dosing and relapses in giant cell arteritis-a single centre cohort study. Aringer, M; Felten, L; Leuchten, N, 2022)	0.72
" This study aimed to use meta-analysis methods to identify the appropriate dosage of prednisolone with the lowest recurrence rate in the treatment of patients with SAGT."	( Identifying the Lowest Effective Initial Dose of Prednisolone for the Treatment of Subacute Granulomatous Thyroiditis: A Systematic Review and Meta-Analysis. Aletaha, A; Fathi, M; Hadavi, M; Haghighat, S; Jouybari, L; Nourani, F; Roudsari, SB; Soltani, A, 2022)	1.2
"According to the results of this meta-analysis, 15 to 20 mg/day of prednisolone is the most effective dosage with the lowest recurrence rate in the treatment of subacute Granulomatous thyroiditis."	( Identifying the Lowest Effective Initial Dose of Prednisolone for the Treatment of Subacute Granulomatous Thyroiditis: A Systematic Review and Meta-Analysis. Aletaha, A; Fathi, M; Hadavi, M; Haghighat, S; Jouybari, L; Nourani, F; Roudsari, SB; Soltani, A, 2022)	1.21
" First, clinical symptoms improved as the dosage of prednisolone increased."	( A suspected case of a multiple autoimmune syndrome in a poodle dog. Bae, S; Jin, Y; Lim, D; Oh, T; Son, Y, 2022)	0.97
"OCS users (n=30 352) had, compared with nonusers (n=121 408), an increased risk of all outcomes with evident dose-response relationships starting at cumulative doses of ≤500 mg (prednisolone-equivalent)."	( Low-dose oral corticosteroids in asthma associates with increased morbidity and mortality. Andersen, JH; Davidsen, JR; Henriksen, DP; Madsen, H; Pottegård, A; Skov, IR, 2022)	0.91
" During the course of the study, patients were given standard treatment and an oral dose of 500 mg of RECOVEREEZ FORTE™ thrice daily, or standard of care and oral Prednisolone in tapered dosage (control group)."	( Anti-inflammatory response of cardamom extract and prediction of therapeutic window in COVID-19 patients by assessing inflammatory markers using RT-PCR. Hynse, A; Mandlecha, A; Shakeeb, N; Varkey, P, 2022)	0.92
" The purpose of this study is to investigate whether the combination of Lactobacillus rhamnosus GG (LGG) with prednisolone could reduce the dosage of glucocorticoid in controlling airway inflammation in a murine model for allergic asthma."	( Effect of combination treatment with Lactobacillus rhamnosus and corticosteroid in reducing airway inflammation in a mouse asthma model. Ko, JL; Lue, KH; Sun, HL; Voo, PY; Wu, CT, 2022)	0.93
"LGG may reduce the dosage of prednisolone and thus may be beneficial in the treatment of asthma."	( Effect of combination treatment with Lactobacillus rhamnosus and corticosteroid in reducing airway inflammation in a mouse asthma model. Ko, JL; Lue, KH; Sun, HL; Voo, PY; Wu, CT, 2022)	1.01
"The presentation of 3D printing in drug innovation especially focuses on the advancement of patient-centered dosage forms based on the structural design."	( A Recent Review On 3D-Printing: Scope and Challenges with Special Focus on Pharmaceutical Field. Doolaanea, AA; Kumar, M; Mandal, UK; Singh, S, 2022)	0.72
" Relative dosage was estimated as a weight-based, prednisolone-equivalent dose."	( The absolute risk of incident type 2 diabetes following exposure to systemic corticosteroids in selected steroid-related and phenotypic groups. Adamsson Eryd, S; Ambery, P; Astbury, C; Berni, E; Brown, MN; Currie, CJ; Heywood, B; Hunt, P; Jenkins-Jones, S, 2022)	0.97
"Corticosteroid exposure increased the risk of incident type 2 diabetes, and there was evidence of both a dose-response and a duration response."	( The absolute risk of incident type 2 diabetes following exposure to systemic corticosteroids in selected steroid-related and phenotypic groups. Adamsson Eryd, S; Ambery, P; Astbury, C; Berni, E; Brown, MN; Currie, CJ; Heywood, B; Hunt, P; Jenkins-Jones, S, 2022)	0.72
"Mepolizumab inhibits IL-5 activity and reduces exacerbation frequency and maintenance oral corticosteroid (OCS) dosage in patients with severe eosinophilic asthma (SEA)."	( Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma-A Randomized, Placebo-Controlled Crossover Trial (MAPLE). Borg, K; Bradding, P; Brightling, CE; Busby, J; Chaudhuri, R; Diver, SE; Heaney, LG; McDowell, JP; Pavord, ID; Shepherd, M; Shrimanker, R; Yang, F, 2022)	0.72
" The first 125 mg of methylprednisolone (mPSL) for 3 days was intravenous, after which it was switched to oral prednisolone (PSL) therapy and the dosage was gradually reduced."	( Posterior scleritis with choroidal detachments and periaortitis associated with IgG4-related disease: A case report. Kadoya, M; Koizumi, K; Kondo, M; Kubo, A; Mase, Y; Masuda, K; Matsumoto, A; Sotozono, C, 2022)	1.02
" These patients were divided into four treatment groups based on corticosteroid dosage and use of an antiviral agent."	( Benefits of High-Dose Corticosteroid and Antiviral Agent Combination Therapy in the Treatment of House-Brackman Grade VI Ramsay Hunt Syndrome. Abe, Y; Furukawa, T; Goto, T; Hull, M; Ito, T; Kakehata, S; Kubota, T; Sugiyama, M, 2022)	0.72
" No dose-response relationship between ICS use and SES could be identified."	( Socioeconomic status is associated with healthcare seeking behaviour and disease burden in young adults with asthma - A nationwide cohort study. Backer, V; Håkansson, KEJ; Ulrik, CS, )	0.13
" At the time points that prednisolone dosage was higher, higher levels of ALT, but no difference in AST levels was noted."	( Prevalence and management of chronic hepatitis B in pemphigus and pemphigoid patients: New evidence for the safety of rituximab. Aryanian, Z; Balighi, K; Daneshpazhooh, M; Hatami, P; Mahmoudi, H; Mohseniafshar, Z; Soori, T; Tahooneban, A; Tavakolpour, S, 2022)	1.02
"Reduction of the hydroxychloroquine (HCQ) dosage is recommended in systemic lupus erythematosus (SLE) patients with renal impairment, but a pharmacokinetics (PK) study of patients with renal impairment has not yet been performed."	( Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment. Furudate, S; Hashiguchi, M; Nagai, Y; Ohshima, M; Setoguchi, K; Shimada, K; Shimizu, M; Yokogawa, N, 2023)	0.91
"From the PK perspective, a dosage reduction is unnecessary in SLE patients with impaired renal function."	( Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment. Furudate, S; Hashiguchi, M; Nagai, Y; Ohshima, M; Setoguchi, K; Shimada, K; Shimizu, M; Yokogawa, N, 2023)	0.91
" The lack of a robust evidence base to guide the use of plasma exchange and glucocorticoid dosing contributes to variation in practice and suboptimal outcomes."	( Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT. Brettell, EA; Brezina, B; Broadhurst, E; Casian, A; Clark, W; de Zoysa, J; Flossmann, O; Fujimoto, S; Girard, L; Gregorini, G; Harper, L; Hawley, C; Ito-Ihara, T; Ives, N; Jarrett, H; Jayne, D; Jones, R; Khalidi, N; Levin, A; Mazzetti, A; McAlear, CA; Mehta, S; Merkel, PA; Pagnoux, C; Peh, CA; Puéchal, X; Pusey, CD; Reidlinger, D; Smyth, L; Specks, U; Szpirt, W; Wald, R; Walsh, M; Wheatley, K, 2022)	0.72
" Patients were randomised in a two-by-two factorial design to receive either adjunctive plasma exchange or no plasma exchange, and either a reduced or a standard glucocorticoid dosing regimen."	( Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT. Brettell, EA; Brezina, B; Broadhurst, E; Casian, A; Clark, W; de Zoysa, J; Flossmann, O; Fujimoto, S; Girard, L; Gregorini, G; Harper, L; Hawley, C; Ito-Ihara, T; Ives, N; Jarrett, H; Jayne, D; Jones, R; Khalidi, N; Levin, A; Mazzetti, A; McAlear, CA; Mehta, S; Merkel, PA; Pagnoux, C; Peh, CA; Puéchal, X; Pusey, CD; Reidlinger, D; Smyth, L; Specks, U; Szpirt, W; Wald, R; Walsh, M; Wheatley, K, 2022)	0.72
" All patients received the same glucocorticoid dosing from 6 to 12 months."	( Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT. Brettell, EA; Brezina, B; Broadhurst, E; Casian, A; Clark, W; de Zoysa, J; Flossmann, O; Fujimoto, S; Girard, L; Gregorini, G; Harper, L; Hawley, C; Ito-Ihara, T; Ives, N; Jarrett, H; Jayne, D; Jones, R; Khalidi, N; Levin, A; Mazzetti, A; McAlear, CA; Mehta, S; Merkel, PA; Pagnoux, C; Peh, CA; Puéchal, X; Pusey, CD; Reidlinger, D; Smyth, L; Specks, U; Szpirt, W; Wald, R; Walsh, M; Wheatley, K, 2022)	0.72
" A health-economic analysis of data collected in this study to examine the impact of both plasma exchange and reduced glucocorticoid dosing is planned to address the utility of plasma exchange for reducing early end-stage renal disease rates."	( Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT. Brettell, EA; Brezina, B; Broadhurst, E; Casian, A; Clark, W; de Zoysa, J; Flossmann, O; Fujimoto, S; Girard, L; Gregorini, G; Harper, L; Hawley, C; Ito-Ihara, T; Ives, N; Jarrett, H; Jayne, D; Jones, R; Khalidi, N; Levin, A; Mazzetti, A; McAlear, CA; Mehta, S; Merkel, PA; Pagnoux, C; Peh, CA; Puéchal, X; Pusey, CD; Reidlinger, D; Smyth, L; Specks, U; Szpirt, W; Wald, R; Walsh, M; Wheatley, K, 2022)	0.72
" In particular, no biomarkers have been identified to help determine dosing in a particular patient, although this is one of the goals of the biomarker plan of this study."	( Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT. Brettell, EA; Brezina, B; Broadhurst, E; Casian, A; Clark, W; de Zoysa, J; Flossmann, O; Fujimoto, S; Girard, L; Gregorini, G; Harper, L; Hawley, C; Ito-Ihara, T; Ives, N; Jarrett, H; Jayne, D; Jones, R; Khalidi, N; Levin, A; Mazzetti, A; McAlear, CA; Mehta, S; Merkel, PA; Pagnoux, C; Peh, CA; Puéchal, X; Pusey, CD; Reidlinger, D; Smyth, L; Specks, U; Szpirt, W; Wald, R; Walsh, M; Wheatley, K, 2022)	0.72
" Treatment was started with 30 mg of prednisolone, and the dosage was gradually decreased."	( [A Case of Unilateral Interstitial Lung Disease in a Patient Treated with Oxaliplatin, 5-Fluorouracil, and Leucovorin]. Aisaki, K; Aoki, K; Doumoto, Y; Funatsu, K; Hosaka, M; Kimura, T; Kobori, S; Minoshima, K; Ushiku, H; Wakabayashi, M; Yoshida, H, 2022)	0.99
" A phase II selection design will be used to determine hdroxychloroquine's efficacy, using prednisolone dosage and Birmingham Vasculitis Activity Score as a measure of disease activity."	( The HAVEN study-hydroxychloroquine in ANCA vasculitis evaluation-a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan. Arnold, L; Beckley-Hoelscher, N; Cape, A; Casian, A; D'Cruz, D; Douiri, A; Galloway, J; Jayne, D; John, S; Kim, S; Learoyd, AE; Luqmani, R; Morton, N; Nel, L; Reid, F; Sangle, S; Shivapatham, D, 2023)	1.13
" Six patients (35%) experienced a prolonged reduction of intraretinal fluid when the dosage was reduced to once daily."	( POTENTIAL TREATMENT FOR PERIPAPILLARY PACHYCHOROID SYNDROME. Behar-Cohen, F; Fernández-Avellaneda, P; Martinez Ciriano, JP; Pothof, AB; Yzer, S, 2023)	0.91
" We also followed the clinical indicators (absolute eosinophil counts, CRP and IgE levels, BVAS, Vascular Damage Index (VDI)) and daily prednisolone dosage at the EGPA diagnosis, at the mepolizumab induction and at the survey."	( Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan. Hashiramoto, A; Yamane, T, 2023)	1.11
" Adverse events were noted regardless of starting dosage or regimen."	( Perception and usage of short-term prednisone and prednisolone in dogs. Gober, M; Hillier, A, 2023)	1.16
" The mean dosage of oral prednisolone and mizoribine showed no differences among the three age groups."	( Demographics and treatment of patients with primary membranoproliferative glomerulonephritis in Japan using a national registry of clinical personal records. Isaka, Y; Kimura, T; Nakagawa, N; Narita, I; Sakate, R, 2023)	1.21
" Optimizing prednisone (and prednisolone) dosing by measuring their concentrations and calculating their pharmacokinetic parameters will allow for personalized treatments for patients, producing more effective and safer treatments for GVHD."	( Simultaneous Determination of Prednisone and Prednisolone in Serum by Turbulent Flow Liquid Chromatography-Tandem Mass Spectrometry. Carlow, DC; Schofield, RC; Scordo, M; Shah, G, 2024)	2